,PageNo,Text
0,page_0,"&OLQ LFDO 6WXG\ 3URWRFRO $0XOWLFHQWHU5DQGRPL]HG'RXEOH%OLQG3ODFHER&RQWUROOHG6WX G\WR(YDOXDWH WKH(IILFDF\6DIHW\ DQG7ROHUDELOLW\RI5LVSHULGRQH([WHQGHG 5HOHDVH,QMHFWDEOH 6XVSHQVLRQ 79 IRU6XEFXWDQHRXV8VHDV0DLQWHQDQFH7UHDWPHQW LQ $GXOW DQG$GROHVFHQW3DWLHQWV:LWK6FKL]RSKUHQLD 6WXG\1XPEHU79&16 1&7 3URWRFRO ZLWK $PHQGPHQW  $SSURYDO 'DWH  $SULO"
1,page_1,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 1 Clinical Study Protocol with Amendment 03 Study Number TV46000 -CNS -30072 A Multicenter, Randomized, Double -Blind, Placebo- Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended -Release Injectable Suspension (TV- 46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients with Schizophrenia A Randomized, Double -Blind, Placebo- Controlled Study on Efficacy, Safety, an d Tolerability of TV -46000 in Adults and Adolescents with Schizophrenia A Study to Test if TV -46000 is Effective for Maintenance Treatment of Schizophrenia (The RISE Study â€“ The RIsperidone Subcutaneous E xtended -release Study) Efficacy, Safety, and Tolera bility Study (Phase 3) IND number: 124384; NDA number: 213586; BLA number: Not applicable; EudraCT number: 2018 -001619- 65 EMA Decision number of Pediatric Investigation Plan: Not applicable Article 45 or 46 of 1901/2006 does not apply Protocol Amendment 03 Approval Date: 19 April 2020 Protocol Approval Date: 14 December 2017 Sponsor Teva Branded Pharmaceutical Products R&D, Inc. 145 Brandywine Parkway West Chester, Pennsylvania 19380 United States of America Information regarding clinical laboratories and other departments and institutions is found in Appendix A COVID -19 pandemic -related operational upd ates are provided in Appendix N This clinical study will be conducted in accordance with current Good Clinical Practice (GCP) as directed by the provisions of the International Council for Harmonisation (ICH); United States (US) Code of Federal Regulations (CFR), and European Union (EU) Directives and Regulations (as applicable in the region of the study); national country legislation; and the spon sorâ€™s Standard Operating Procedures (SOPs). Confidentiality Statement This document contains confidential and proprietary information (including confidential commercial information pursuant to 21CFRÂ§20.61) and is a confidential communication of Teva Brande d Pharmaceutical products R&D, Inc and/or its affiliates. The recipient agrees that no information contained herein may be published or disclosed without written approval from the sponsor. Â© 2020 Teva Branded Pharmaceutical Products R&D, Inc. All rights re served."
2,page_2,Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 2AMENDMENT HISTORY The protocol for Stud y TV46000 -CNS -30072 (original protocol dated 14 December 2017) has been amended and reissued as follows: Global Amendment 03 19 April 2020 (863 patients enrolled to date) The management of study activities dur ing the COVID -19 pandemic are detailed in Appendix N. The following sections are affected: Section 3.1. General Study Design and Study Schematic Diagram; Section 3.5. Schedule of Study Procedures and Assessments; Section 5.1.1. Test I nvestigational Medicinal Product; Section 5.1.2. Placebo Investigational Medicinal Product; Table 4. Investigational Medicinal Products Used in the Study ; Section 5.2.1. Storage and Security ; Section 5.2.3. Accountability ; Section 5.9. Randomization and Blinding; Section 6. Assessment of Efficacy ; Section 7. Assessment of Safety ; Section 7.4. Clinical L aboratory Tests; Section 7.6. Vital Signs; Section 7.7. Electrocardiograph y; Section 8.1. Pharmacokinetic Assessment Section 9.5.4.2. Sensitivity Anal ysis; Section 10. Quality Control and Quality Assurance; Appendix C. Quality Control and Quality Assurance; Appendix F. L ost to Follow -Up; Administrative Letter 03 09 February 2020
3,page_3,Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 3Global Amendment 02 with Revision 0116 October 2019 (649 patients enrolled to date) Global Amendment 02 02 September 2019 (584 patients enrolled to date) Letter of Clarification 02 27 June 2019 Global Amendment 01 06 December 2018 (184 patients enrolled to date) Letter of Clarification 01 26 June 2018 Local Amendment 01 for Bulgaria28May 2018 (6patients enrolled to date) Protocol with Revision 01 15 February 2018 (0patients enrolled to date) The Summary of Changes to the Protocol includes the corresponding reason/justification for each change and is provided in Section 16.
4,page_4,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 4INVESTIGATOR AGREEMENT Original Protocol Dated 14December 2017 Clinical Study Protocol with Amendment 03 IND number: 124384; NDA number: 213586; BLA number: Not applicable; EudraCT number: 2018 -001619- 65 EMA Decision number of Pediatric Investigation Plan: Not applica ble Article 45 or 46 of 1901/2006 does not apply A Multicenter, Randomized, Double -Blind, Placebo- Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended -Release Injectable Suspension (TV- 46000) for Subcutaneous Use as M aintenance Treatment in Adult and Adolescent Patients with Schizophrenia (The RISE Study â€“ The RIsperidone Subcutaneous E xtended -release Study) Principal Investigator: Title: Address of Investigational Center: Tel: I have read the Protocol Amendment 03 and agree that it contains all necessary details for carrying out this study . I am qualified by education, experience, and training to conduct this clinical research stud y. The signature below constitutes agreement with this protocol and attac hments, and provides assurance that this study will be conducted according to all stipulations of the protocol, including all statements regarding confidentiality , and according to national or local legal and regulatory requirements and applicable regulati ons and guidelines. I will make available the protocol and all information on the investigational medicinal product (IMP) that were furnished to me by the sponsor to all phy sicians and other study personnel reporting to me who participate in this study and will discuss this material with them to ensure that they are fully informed regarding the IMP and the conduct of the study . I agree to keep records on all patient information, investigational medicinal products (IMP) shipment and return forms, and all other information collected during the study , in accordance with national and local Good Clinical Practice (GCP) regulations as well as all other national and international laws and regulations. Principal Investigator Signature Date"
5,page_5,Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 5SPONSOR PROTOCOL APP ROVA L
6,page_6,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 6COORDINATING INVESTIGATOR AGREEMENT Original Protocol Dated 14December 2017 Clinical Study Protocol with Amendment 03 IND number: 124384; NDA number: 213586; BLA number: Not applicable; EudraCT number: 2018 -001619- 65 EMA Decision number of Pediatric Investigation Plan: Not applicable Article 45 or 46 of 1901/2006 does not apply A Multicenter, Randomized, Double -Blind, Placebo- Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended -Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients with Schizophrenia (The RISE Study â€“The RIsperidone Subcutaneous E xtended -release Study) I have read the Protocol Amendment 03 and agree that it contains all necessary details for carrying out this study . I am qualified by education, experience, and training to conduct this clinical research stud y. The signature below constitutes agreement with this protocol and attachments, and provides assurance that this study will be conducted according to all stipulations of the protocol, including all statements regarding confidentiality , and according to national and local legal and regulatory requiremen ts and applicable regulations and guidelines. I will make available the protocol and all information on the investigational medicinal product (IMP) that were furnished to me by the sponsor to all phy sicians and other study personnel reporting to me who par ticipate in this study and will discuss this material with them to ensure that they are fully informed regarding the IMP and the conduct of the study . I agree to keep records on patient information, I MPs shipment and return forms, and other information col lected during the stud y, in accordance with m y responsibilities under the function of the coordinating investigator and in accordance with national and local Good Clinical Practice (GCP) regulations as well as all other national and international laws and regulations. In addition, I will assume the responsibility of the coordinating investigator according to a separate contract. Coordinating Investigator: Title: Address of Investigational Center: Tel: E-mail: Coordinating Investigator Signature Date Executed signature pages are maintained within the Trial Master File."
7,page_7,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 7CLINICAL STUDY PROTOCOL SYNOPSIS Study TV46000- CNS -30072 Title of Study: A Multicenter, Randomized, Double -Blind, Placebo -Controlled Study to Evaluate the Efficacy , Safety , and Tolerability of Risperidone Extended -Release Injectable Suspension (TV- 46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients with Schizophrenia (The RI SE Study â€“The RIsperidone Subcutaneous Extended -release Study ) Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. Investigational New Drug (IND) Number: 124384 New Drug Application (NDA) Number: 213586 Biological License Application (BLA) Number: Not applicable EudraCT Number: 2018 -001619-65 EMA Decision number of Pediatric Investigation Plan: Not applicable Article 45 or 46 of 1901/2006 does not apply Name of Test Investigational Medicinal Product (IMP): Risperidone extended -release injectable suspension (TV-46000) for subcutaneous (sc) use EudraVigilance (EV) code for the IMP, if applicable: SUB10335MIG Type of the Study: Efficacy , Safet y, and Tolerability Study (Phase 3) Indication: Maintenance treatment of schizophrenia in patients currentl y treated with oral antipsy chotics Is this study conducted to investigate the New Use of an approved, marketed product? No Number of Investigational Centers Planned: Approximately 80 Countries Planned: The study is planned to be conducted in North America and Bulgaria. Planned Study Period: Q2 2018 to Q4 2020 Number of Patients Planned (total): The total number of patients planned to be enrolled into Stage 1 is approximately 860 adults (18 y ears of age and above), to achieve approximately 520 adults randomized to Stage 2. As an event -driven study , it may be possible to randomize more than 520 adult patients, as long as Stage 2 of the study ends when the number of events among adults reaches at least 90 (see Sample Size Rationale ). Adolescent patients will only be enrolled in the US; any enrolled adolescents will be in addition to the aforementioned total. Study Population: Male and female patients, 13 to 65 years of age at screening, who have a confirmed diagnosis of schizophrenia, are clinically stable, and are eligible for risperidone treatment."
8,page_8,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 8Primary and Secondary Objectives and Endpoints Objectives Endpoints The primary objective of this study is to evaluate the efficacy of TV -46000 during maintenance treatment in adult patients with schizophrenia.The primary efficacy endpoint is time to impending relapse. Relapse is defined as 1 or more of the following items: ï‚·Clinical Global I mpression â€“Improvement (CGI -I) of â‰¥5 (greater than or equal to minimally worse, ie, minimally worse, much worse or very much worse), AND ï€­an increase of an y of the following individual Positive and Negative S yndrome Scale (PANSS) items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of >4 with an absolute increase of â‰¥2 on that spe cific item since randomization, OR ï€­an increase in an y of the following 4 individual PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of >4 and an absolute increase of â‰¥4 on the combine d score of these 4 PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content) since randomization; ï‚·hospitalization due to worsening of ps ychotic s ymptoms (including partial hospitalization programs), exclu ding hospitalization for psy chosocial reasons ï‚·Clinical Global I mpression -Severit y of Suicidality (CGI -SS) of 4 (severel y suicidal) or 5 ( attempted suicide ) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2 ï‚·violent behavior resulting in clinicall y significant self - injury , injury to another person, or propert y damage A key secondary objective of this study is to evaluate the efficacy of TV -46000 during maintenance treatment in the total population (adults and adolescents) and in adolescent patients with schizophrenia.Key secondary endpoints are: ï‚·time to impending relapse (as defined under the primary objective) in the total population (adults and adolescents) ï‚·impending relapse rate at week 24 ï‚·percentage of patients who maintain stability at endpoint ï‚·percentage of patients achieving remission at endpoint ï‚·observed rate of impending relapse at endpoint ï‚·Drug Attitudes Inventory 10- item version (adult patients only) ï‚·Schizophrenia Quality of L ife Scale (SQLS) (adult patien ts only) ï‚·time to impending relapse in adolescent patients with schizophrenia"
9,page_9,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 9Objectives Endpoints A secondary objective of this study is to evaluate the safet y and tolerability of TV -46000 in the total population .The safet y variables include adverse events, extrapyramidal symptoms (EPS), risk of suicide events, depression sy mptoms, injection pain and other injection site reactions (local tolerability ), vital signs, laboratory tests, phy sical examination, electrocardiogram (ECG) measurements, bod y weight, rescue medication u se, time to all -cause discontinuation, all- cause discontinuation rates and discontinuation rates due to adverse events (tolerabilit y), and the following rating scales: ï‚·Abnormal Involuntary Movement Scale (AIMS) ï‚·Simpson -Angus Scale (SAS) ï‚·Barnes Akathisia Rating Scale (BARS) ï‚·Columbia Suicide Severity Rating Scale (C -SSRS) ï‚·Calgary Depression Scale for Schizophrenia (CDSS) ï‚·CGI-SS A secondary objective of this study is to evaluate the pharmacokinetics (PK) of oral risperidone and TV -46000 after administration of multiple doses in adults, adolescents, and the total population.The pharmacokinetic endpoints are the plasma concentrations of risperidone, 9 -OH-risperidone, and total active moiety (sum of risperidone and 9 -OH-risperidone)."
10,page_10,Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 Objectives Endpoints .
11,page_11,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 11Objectives Endpoints General Study Design: This is a double -blind, randomized, relapse prevention study comparing a therapeutic dose of TV -46000 sc (every month [q1m] and every 2 months [q2m]) with placebo sc (q1m) in a 1:1:1 ratio."
12,page_12,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 12Patients will undergo screening procedures/assessments within 30 day s before the start of Stage 1. They should have had a diagnosis of schizophrenia for >1 year (diagnosis must be reconfirmed b y Structured Clinical I nterview for DSM -5 [SCI D-5]) and have be en generall y responsive to antipsy chotics in the past y ear based on investigator judgement (and discussions with family members, caregivers, or healthcare professionals as applicable). Patients should also have had â‰¥1 episode of relapse in the last 24 mont hs. Patients will provide informed consent or assent, as applicable, at the screening visit. For adolescent patients, it is mandatory that a parent/caregiver accompanies the patient to each visit and serves as a reliable informant. It is recommended that a caregiver is identified for each adult patient. L ocal requirements should be followed. The caregiver may be contacted in case of loss of contact with the patient or to provide additional information about the patient, if needed. Patients can be accompanie d by caregivers to visits. Stage 1: Oral conversion and stabilization stage (12 weeks). Patients not alread y on oral risperidone or injectable risperidone ( RISPERDAL CONSTA, Janssen Pharmaceuticals, US PI ) and on an y antips ychotic (other than clozapine), and who can benefit from conversion to oral risperidone based on the investigatorâ€™s judgement, will be converted to oral risperidone (2to5mg/day ) to ensure that they tolerate risperidone and that the doses are adequate to tr eat their positive sy mptoms. Adolescent patients will receive a maximal dose of 4 mg/day . Patients who are already on risperidone but can still benefit from the study based on the investigator's judgement will also undergo the oral stabilization stage. Open-label oral risperidone (2 to 5mg/day ) will be used to stabilize patients to the treatments (the dose will be based on clinical judgement). Patients will come to the clinic for 4 visits (weeks -12, -10, - 8, and -4) for dose adjustments; however, additional visits may be required for dose adjustments. Patients will be assessed b y . Additionally , telephone contacts will take place at weeks -6 and -2, or more frequently if required in the judgement of th e investigator. Stability on risperidone, while also adequately controlling for s ymptoms of schizophrenia, will be assessed at baseline and is defined as meeting all of the following criteria for at least 4 consecutive weeks prior to the baseline visit: ï‚·outpatient status ï‚· ï‚· ï‚· ï‚· Blood samples for plasma drug concentration will be collected during the in - clinic visits (besides screening) and adverse event inquiry will be performed at all visits and telephone calls/teleconferences (TCs)."
13,page_13,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 13If a patient withdraws from the study prior to the randomization visit (Visit 6), the CRF for the patient's last visit will be marked as ""Not Continuing"" and the reason for discontinuat ion will be recorded. No extra testing or procedures will be required in addition to the regular visits. Stage 2: Double- blind maintenance stage (variable in duration) . Stabilized patients (see definition above) will be randomized to receive TV -46000 q1m s c injections, TV -46000 q2m sc injections, or placebo q1m sc injections in a 1:1:1 ratio. Patients that require a stabilization dose below 2 mg/day will not be randomized in the study . Also, as a precautionary measure, adolescent patients that will require a stabilization dose of more than 4 mg during the stabilization stage will not be randomized. Patients in the TV- 46000 groups will receive a dose of TV -46000 (q1m or q2m) that is equivalent to the oral dose on which they were stabilized in Stage 1. The max imal dose administered to adult patients will be equivalent to an oral risperidone dose of 5 mg/day , and the maximal dose administered to adolescents will be equivalent to 4 mg/day . Patients randomized to TV -46000 q1m or placebo sc will receive an sc injection of TV -46000 or placebo, respectivel y, at baseline and every 4 weeks (q4w) thereafter. Patients randomized to TV -46000 q2m will receive a TV -46000 injection at baseline and every 8 weeks (q8w) thereafter and a placebo sc injection 4 weeks after baseline and q8w thereafter to ensure blinding of the doses and durations of the TV- 46000 injections and the placebo injections. The study will continue on an outpatient basis, and telephone contacts will take place weekl y between clinic visits. I f, in the judgment of the investigator, the patient is likely to relapse or pose a danger to himself/herself or others, that patient may be invited for an unscheduled visit and/or hospitalized if ne eded, and treatment with the study drug may be discontinued. Per definition, an exacerbation in sy mptoms during Stage 1 cannot be defined as a relapse event, since relapse events can only occur following stabilization and randomization. Randomized patients, who relapse or meet 1 or more of the withdrawal criteria should be invited to perform the Earl y Termination (ET) visit as soon as possible, within 4 weeks of the last injection. Patients who remain relapse -free when the study is terminated should be in vited to perform the End -of- Treatment (EoT) visit within 4 weeks of the last injection. Therefore, a patient is considered a study completer if he or she experienced impending relapse or remained relapse -free at the time of study termination. During the conduct of this study , an Independent Data Monitoring Committee (IDMC) will review accumulating unblinded safety and pharmacokinetic data on a regular basis, as detailed in the IDMC charter, to ensure the continuing safety of the study patients and study conduct issues. The specific details regarding the IDMC sessions will be outlined in the I DMC charter. Brief Summary of Study Design for the Trial Registry(s): The purpose of the study is to evaluate the efficacy , safety , and tolerability of different dose r egimens of TV -46000 administered sc as compared to placebo during maintenance treatment in adult and adolescent patients with schizophrenia. The study will include male and female patients, 13 to 65 years of age at screening, who have a confirmed diagnosis of schizophrenia, are clinically stable, and are eligible for risperidone treatment. Patients will be randomized to receive doses of TV - 46000 q1m, TV -46000 q2m, or placebo q1m sc injections in a 1:1:1 ratio. Patients randomized to TV-46000 q1m or placebo will receive an sc injection of TV- 46000 or placebo, respectivel y, at baseline and q4w thereafter. Patients randomized to TV- 46000 q2m will receive a TV -46000 sc injection at baseline and q8w thereafter and a placebo sc injection 4 weeks after baseline and q8w thereafter to ensure blinding of the doses and durations of the TV -46000 injections and the"
14,page_14,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 14placebo injections. The doses of TV -46000 will be equivalent to 2 to 5 mg/day of oral risperidone. The primary efficacy endpoint is time to impending relapse, which will be measured by CGI -I, PANSS, and CGI- SS scores, hospitalization due to worsening of psy chotic s ymptoms, or violent behavior. The duration of patient participation in the study will include up to 4 weeks of screening, 12 weeks of the oral convers ion/stabilization stage, and a double -blind maintenance stage. The double -blind maintenance stage will be variable in duration, with patients continuing until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criter ia; or remain relapse -free at the time of study termination. Patients will subsequently complete all end -of-study assessments. When the study ends, eligible patients may be offered the opportunity to enter the TV46000 -CNS -30078 extension study to assess th e long -term safet y and tolerability of extended -release risperidone . If they choose to enter the extension study , they will not need to complete the follow- up/exit visits in this study . For all other patients, there will be 2follow -up/exit visits that will take place at 4 weeks and 8 weeks after the last dosing visit. During the follow -up/exit period, patients will be treated according to the investigatorâ€™s judgement. Method of Randomization and Blinding: Patients will be randomized to receive doses of TV-46000 q1m sc injection, TV -46000 q2m sc injection, or placebo q1m sc injection in a 1:1:1 ratio. Randomization will be stratified b y gender (male or female) and the dose of oral risperidone on which the patient was stabilized during Stage 1 (2/3, 4, or 5 m g). The doses of TV-46000 will be equivalent to 2 to 5 mg/day of oral risperidone ( equivalent to the oral dose on which the patient was stabilized in Stage 1) . As a precautionary measure, adolescent patients that will require a stabilization dose of more t han 4 mg during the stabilization stage will not be randomized. Patients randomized to TV -46000 q1m or placebo sc will receive an sc injection of TV-46000 or placebo, respectively , at baseline and q4w thereafter. Patients randomized to TV - 46000 q2m will re ceive a TV -46000 sc injection at baseline and q8w thereafter and a placebo sc injection 4 weeks after baseline and q8w thereafter to ensure blinding of the doses and durations of the TV -46000 injections and the placebo injections . Patients and investigators will remain blinded to the identity of the treatment administered to each patient. Due to the differences between the TV -46000 product and placebo, an unblinded nurse, not associated with rating the patient (including assessment of the injection site if needed) and independent from the study team, will be required at each site to administer the drug . Additional measures to mitigate the risk of unblinding will include: ï‚·the unblinded nurse will in a room separated from the patient; ï‚·the unblinded nurse will wrap a blinding film (so that the original appearance is masked) around the barrel of the syringe; ï‚·to maintain the patient blind, a cover will be used over the inj ection site during treatment administration; ï‚·the unblinded nurse will administer the injection to the patient. The sponsorâ€™s clinical personnel (and delegates) involved in the study will be blinded to the identity of the IMPs until the database is locked for final anal ysis and the IMP assignment is known."
15,page_15,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 15In the event of an emergency (ie, where knowledge of the study drug assignment is needed to make treatment decisions for the patient), the treatment group and dose to which the patient has been allocated can be determined by accessing the I nteractive Response Technology (IRT) system. Pharmacokinetic sample anal ysis and drug concentration calculations will be performed during the course of the study . . Investigational Medicinal Products: Dose, Pharmaceutical Form, Route of Administration, and Administration Rate Test IMP: In general, TV -46000 will b e administered in the abdomen (except as indicated below), b y sc injection at intervals of q1m or q2m, at a dose equivalent to oral risperidone 2 to 5 mg/day per the conversion table below. Patients that will require a stabilization dose below 2 mg/day will not be randomized in the study . The maximal dose administered to adult patients will be equivalent to an oral risperidone dose of 5 mg/day , and the maximal dose administered to adolescents will be equivalent to 4 mg/day . As a precautionary measure, adole scent patients that will require a stabilization dose of more than 4 mg during the stabilization stage will not be randomized. Several investigational centers may be selected by the sponsor (based on the centersâ€™ capabilities, sponsor's considerations, and prior clinical experience with injectable medication) for injection of study drug in the back of the upper arm, instead of the abdomen, to all or some of the enrolled patients at these sites (approximately 20% of the study patient population). Conversion Table Between Oral Risperidone and TV -46000 Doses Frequency of TV- 46000 AdministrationOral Risperidone Doses and Corresponding TV -46000 Doses 2 mg/day 3 mg/day 4 mg/day 5 mg/day (Adults Only) The injection site that is chosen for an individual patient should remain consistent throughout the study . If the chosen site is the arm, the injection will be administered in an alternating manner between the right arm and the left. If the chosen site is the abdomen, the injection will be administered in an alternating manner to the right and to the left of the umbilicus. Further details will be provided in the dosing manual."
16,page_16,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 16Reference IMP: None Placebo IMP: Investigational Medicinal Products Used in the Study IMP nam e Test IMP Placebo IMP Trade name and INN, if applicable, or company -assigned numberTV-46000; risperidone extended - release injectable suspension for sc administrationTV-46000 placebo Form ulation sterile extended -release injectable productsterile extended release injectable product Storage conditions Unit dose strength(s)/dosage level(s) Treatm ent Dosing volume (mL) Further dosing instructions are detailed in the pharmacy manual."
17,page_17,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 17IMP nam e Test IMP Placebo IMP Route of administration sc injection in abdomen or upper arm (per investigational center in which the patient is enrolled) ; the injection site that is chosen for an individual patient should remain consistent throughout the study.sc injection in abdomen or upper arm(per investigational center in which the patient is enrolled) ; the injection site that is chosen for an individual patient should remain consistent throughout the study. Dosing instructions q1m or q2m injections per the patientâ€™s assigned treatment group. The injection w ill be administered by an unblinded independent nurseq1m injections per the patientâ€™s assigned treatment group. The injection w ill be administered by an unblinded independent nurse Packaging Manufacturer . Duration of Patient Participation and Maximal Exposure to IMP: The duration of patient participation in the study will include up to 4 weeks of screening, 12 weeks of the oral conversion/stabilization stage, and a double -blind maintenance stage. Patients are expected to participate in the stud y for its entire duration, and undergo the scheduled visits and assessments as detailed in the protocol. The double -blind maintenance stage will be variable in duration, with patients continuing until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse -free at the time of study termination . When the study ends, eligible patients may be offered the opportunity to enter the long-term TV46000- CNS -30078 extension study to assess the safet y and tolerability of extended -release risperidone . If patients choose to enter the extension stud y, they will not need to complete the follow -up/exit visits in this study . For all other patients (ie, patients who experience a relapse event, meet 1 or more of the stud y discontinuation or withdrawal criteria, or do not consent to join the extension study), there will be 2 follow -up/exit visits that will take place at 4 weeks and 8 weeks after the last dosing visit. During the follow -up/exit period, patients will be treated according to the investigatorâ€™s judgement. Study Duration: Approximately 30 months , from Q2 2018 (first patient in) to Q4 2020 (last patient out). End of Study: End of study is defined as the date when the last patient in Stage 2 has completed all efficacy and safety assessments at the final visit per protocol."
18,page_18,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 18Plans for Treatment or C are after the Patient has Ended Participation in the Study: In case the patient is withdrawn from this study , no further treatment is planned by the sponsor after the patient completes their participation in this study . Patients will be advised to return to their primary physician for additional treatment. Patients may be treated in the meantime per investigator judgment and instruction as applicable. When the study ends, eligible patients may be offered the opportunity to enter the long- term TV46000- CNS -30078 extension study to assess the long -term safet y and tolerability of extended- release risperidone. This extension study is bey ond the scope of this protocol, and a separate protocol was issued for it. Inclusion Criteria: Patients may be enrolled in this study only if they meet all of the following criteria: a.The patient has a diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM- 5) for >1 year (diagnosis must be reconfirmed b y SCID-5) and has had â‰¥1 episode of relapse in the last 24 months. b.The patient has been responsive to an antipsy chotic treatment (other than clozapine) in the past y ear based on investigator judgement (and discussions with family members, caregivers, or healthcare pr ofessionals as applicable). c.[Revision 1] The patient has provided written informed consent and is competent to do so. For adolescent patients, written informed consent has been provided by each patientâ€™s parent or legal guardian, and written assent has be en provided b y each patient. d. The patient, in the investigatorâ€™s judgment, requires chronic treatment with an antipsy chotic medication. e.The patient, in the investigatorâ€™s judgment, can benefit from participation in this study . f.The patient is able to unders tand the nature of the study and follow protocol requirements, including the prescribed dosage regimens, tablet ingestion, sc depot injection, and discontinuation of prohibited concomitant medications ; can read and understand the written word in order to c omplete patient -reported outcomes measures; and can be reliably rated on assessment scales. g.The patient has a PANSS total score lower than 100 at screening. h. The patient has a stable place of residence for the previous 3 months before screening, and changes in residence are not anticipated over the course of study participation. i.The patient has no significant life events (such as pending loss of housing, family status change, long travel abroad, surgery , etc) that could affect study outcomes expected throughout the period of study participation. j.[Revision 1]The patient is a male or female of an y ethnic origin, 13 through 65 years of age at screening."
19,page_19,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 19k.[Revision 2] The patient has a bod y mass index between 18.0 and 38.0 kg/m2, inclusive, at screening. l.The patie nt is in adequate health as determined by medical and ps ychiatric history , medical examination, ECG, serum chemistry , hematology , urinal ysis, and serology . m.Women of childbearing potential and sexually -active adolescents must agree not to try to become preg nant, and, unless they have exclusively same -sex partners, must agree to use a highl y effective method of contraception, and to continue use of this method beginning 1 month before the first administration of study drug and for the duration of the study and for 120 day s after the last injection of study drug. Highl y effective methods of contraception include: ï€­Combined estrogen and progestogen hormonal contraception (oral, intravaginal, transdermal) associated with inhibition of ovulation; these should be initiated at least 1 month before the first dose of IMP. ï€­Progestogen -only hormonal contraception (oral, inje ctable, implantable) associated with inhibition of ovulation; these should be initiated at least 1 month before the first dose of IMP. ï€­Intrauterine device and intrauterine hormone -releasing s ystem; these need to be in place at least 2 months before screeni ng. ï€­Bilateral tubal occlusion ï€­Vasectomized partner provided that he is the sole sexual partner and has received medical assessment of the surgical process ï€­Sexual abstinence is only considered a highl y effective method if defined as refraining from heterosexual intercourse in the defined period. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lif estyle of the patient. n.The patient, if adult or adolescent male, is surgically sterile, or, if capable of producing offspring, has exclusively same -sex partners or is currently using an approved method of birth control and agrees to the continued use of th is method for the duration of the stud y (and for 120 days after the last dose of study drug). Male patients with sex partners who are women of childbearing potential must use condoms even if surgically sterile. In addition, male patients may not donate spe rm for the duration of the study and for 120 day s after taking the study drug . o.The patient must be willing and able to compl y with study restrictions and willing to return to the investigational center for the required visits throughout the duration of the study period, including follow- up procedures and assessments as specified in this protocol. Randomization Criteria: The following criteria are randomization criteria and must be fulfilled at the baseline visit before randomization, in addition to other relevant inclusion criteria:"
20,page_20,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 20p.The patient has not experienced mental or ph ysical deterioration, which prevents participation in the study per investigator judgement. q. The patient has demonstrated good compliance in following protocol requirements during Stag e 1. ï€­If the investigator or the sponsor determines that the patient was not in compliance with the study protocol, the case will be evaluated on a case -by-case basis, and the investigator and the sponsor will determine whether the patient will be randomize d in the double -blind period (Stage 2). r.The patient has been stabilized per the following criteria for at least 4 consecutive weeks prior to the baseline visit: ï‚·outpatient status ï‚·PANSS total score â‰¤80 ï‚·minimal presence of specific psy chotic sy mptoms on the PANSS, as measured b y a score of â‰¤4 on each of the following items: conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual thought content ï‚·CGI-S score â‰¤4 (moderately ill) ï‚·CGI-SS score â‰¤2 (mildly suicidal) on Part 1 and â‰¤5 (minimally worsened) on Part2 Exclusion Criteria: Patients will not be enrolled/randomized in this study if they meet any of the following criteria: a.The patient has a current clinically significant DSM -5 diagnosis other than schizophrenia, including schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnestic or other cognitive disorders, or borderline, paranoid, histrionic, schizoty pal, schizoid, or antisocial personalit y disorder. b.The patient is currently on cl ozapine or has received electroconvulsive therapy in the last 12 months. c.The patient has a history of epileps y or seizures, neuroleptic malignant s yndrome, clinically significant tardive dy skinesia, or other medical condition that would expose the patient to undue risk. d.[Revision 1] The patient has a positive serology for human immunodeficiency virus (HIV) -1, HIV -2, hepatitis B surface antigen, and/or hepatitis C. I f serology is positive for hepatitis C but the RNA test is negative, and the patient has no h istory of liver disease, enrollment will be considered following discussion between the investigator and the medical monitor as needed. e.The patient currently has or has a history of known hypersensitivity to risperidone or any of the excipients of TV -46000 or the oral formulation of risperidone used in the stabilization phase. f.The patient has a substance use disorder, including alcohol and benzodiazepines but excluding nicotine and caffeine."
21,page_21,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 21g.The patient has a significant risk of violent behavior based on the patientâ€™s medical history or investigatorâ€™s judgement. h.The patient has a significant risk of committing suicide based on the patientâ€™s medical history or investigatorâ€™s judgement and/or the C- SSRS (lifetime). Patients with a C-SSRS (current) positive r esponse to suicidal ideation items 3, 4, or 5 are not eligible. i.The patient has previously participated in a Teva -sponsored clinical study with TV-46000. j.The patient has a clinically significant deviation from normal in the phy sical examination. k.The patien t has clinicall y significant findings in biochemistry , hematology , ECG, or urinaly sis results. ï€­If the patient has a prolonged QTcF interval (defined as a QTcF interval of >450 msec for males and >470 msec for females) at screening or baseline , calculated as the mean of the triplicate ECG measurements, eligibility will be decided on a case-by-case basis following discussion between the investigator and the sponsor. l.The patient has an y clinically significant uncontrolled medical condition (treated or untrea ted). The investigator may discuss with the medical monitor as needed. m.The patient is a pregnant or lactating female. n.The patient has an y disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal s urgery ). o.The patient has an y other disease or condition that, in the opinion of the investigator, would make participation not in the best interest of the patient or that could prevent, limit, or confound the protocol- specified assessments. p.The patient has used an investigational drug within 3 months prior to screening or has participated in a non -drug clinical trial within 30 day s prior to screening. q.The patient is using or consuming the medications prohibited in this protocol. Statistical Considerations Sample Size Rationale: Median time to impending relapse was observed to be 7 months in the placebo group in a similarly designed study (Kane et al 2012). Assuming a similar placebo effect in this study , as well as a hazard ratio of 2.50 (placebo vs each TV- 46000 arm) and a randomization ratio of 1:1:1 (q1m:q2m:placebo) with 2 primary hypotheses to be tested (q1m vs placebo and q2m vs placebo) at a 2 -sided alpha of 0.050, the total number of events across treatment groups tha t will attain a statistical power of at least 90% to meet success criteria in both comparisons ( East 6 [Version 6.3] manual, 2014 ) is 90 relapse events. This number of events will need to be observed during Stage 2 of the stud y in the ITT analysis set (adult patients). The sample size rationale is based on the adult patients. There is no estimation of the sample size in the adolescent population, and their number is not known at this time."
22,page_22,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 22 Primary Efficacy Analysis: Time to impending relapse will be calculated as the earliest date the patient meets â‰¥1 of the impending relapse criteria minus the randomization date plus 1. Data from patients who did not relapse will be censored at the l ast valid assessment. Time to impending relapse for TV -46000 and placebo will be compared using the stratified log- rank test at the significance levels described (see Multiple Comparisons and Multiplicity) . Hazard ratios and their 2 -sided 95% confidence intervals (CIs) for TV -46000 q1m and q2m versus placebo will be anal yzed using a Cox proportional hazard model, with treatment and the aforementioned stratification variables as the factors (see Method of Randomization and Blinding) . Kaplan -Meier curves will be provided to present impending relapse rate data over time. The primary anal ysis will be conducted on the population of adult patients. Sensitivity Analysis: A sensitivity anal ysis will be conducted to assess the impact of large intervals between the pr evious assessment and the assessment at the time the first relapse was observed via the interval censoring method. Sensitivity anal ysis will also be conducted by tipping point anal ysis, that imputes time to relapse for dropouts (for reasons suspected to be related to relapse) with increasing risk to relapse, compared to similar patients in the same treatment group that continue treatment. The per -protocol anal ysis set will also be used to as a suplemental analysis to evaluate the primary efficacy variable. Details will be provided in the statistical analy sis plan. Key Secondary Efficacy Analysis 1: Time to impending relapse in adult and adolescent patients will be assessed similarly to the Primary Efficacy Analy sis. The Cox proportional hazard model will include patient age group (if applicable) along with treatment, and the aforementioned stratification variables as the factors. The details about the Ty pe-I statistical error control will be discussed in Multiple Compari sons and Multiplicity. Key Secondary Efficacy Analysis 2: Impending relapse rate at week 24 will be estimated using the Kaplan- Meier method and calculated as 1 minus the proportion of adult and adolescent patients free of impending relapse events at week 2 4. The Greenwood formula will be used to calculate standard errors for impending relapse rates at week 24, and the pooled standard errors will be used for h ypothesis testing using z statistics, assuming that the differences between TV - 46000 and placebo follow a normal distribution of large samples.Ty pe-I statistical error control will be discussed in Multiple Comparisons and Multiplicity. Key Secondary Efficacy Analysis 3: The anal yses of the proportion of patients who maintain stability at endpoint in Stag e 2 will be described in the statistical analy sis plan. Ty pe-I statistical error control will be discussed in Multiple Comparisons and Multiplicity. Key Secondary Efficacy Analysis 4: The anal yses of the proportion of patients achieving remission at endpoint in Stage 2 will be described in the statistical analy sis plan. Ty pe-I statistical error control will be discussed in Multiple Comparisons and Multiplicity."
23,page_23,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 23Key Secondary Efficacy Analysis 5: The observed impending relapse rates at endpoint will be compa red between groups using the Cochranâ€“Mantel â€“Haenszel (CMH) test adjusting for stratification variables. Type -I statistical error control will be discussed in Multiple Comparisons and Multiplicity. Key Secondary Efficacy Analysis 6: Change from baseline of DAI-10 at endpoint will be compared between groups using repeated measures ANCOVA . Type-I statistical control will be discussed in Multiple Comparisons and Multiplicity. Key Secondary Efficacy Analysis 7: Change from baseline of SQL S at endpoint will be compared between groups using repeated measures ANCOVA. Ty pe-I statistical control will be discussed in Multiple Comparisons and Multiplicity. Key Secondary Efficacy Analysis 8: Time to impending relapse in adolescent patients will be assessed if the numbe r of randomized adolescents will be at least 10, with clinically sufficient exposure. The method will be similar to the Primary Efficacy Analy sis. The details about the Type- I statistical error control will be discussed in Multiple Comparisons and Multipli city. In the event that prefilled sy ringes become available during the stud y, data relating to the ease of dosing administration will be listed. Multiple Comparisons and Multiplicity: At the final anal ysis after at least 90 relapse events, a fixed sequential (hierarchical) testing approach will be implemented. The first primary efficacy hypothesis comparing q1m to placebo will be tested with a 2 -sided alpha of 0.05; if significant, the second primary efficacy hypothesis comparing q2m to placebo will be tested with a 2 -sided alpha of 0.05. If the first primary hypothesis test fails to reach statistical significance, no further formal h ypothesis testing will be performed. Type-I error wil l be further controlled for the key secondary endpoints by employ ing the fixed sequential (hierarchical) approach to the secondary endpoints. Accordingl y, secondary endpoints will be anal yzed onl y if primary efficacy endpoints have a p- value less than or e qual to alpha of 0.05."
24,page_24,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 24For the key secondary endpoints, if the resulting 2- sided p- value from the first comparison is significant, then the next comparison of interest will be interpreted inferentially at the same alpha level. This process will continue either until all comparisons of interest are interpreted inferentiall y or until the point at which the resulting 2 -sided h ypothesis is insignificant at the same alpha level. At the point where a comparison is found to be insignificant, no further comparisons will be interpreted inferentially. Further details about the Ty pe-I statistical error control for the key secondary endpoints will be discussed in the statistical anal ysis plan. There will be no multiplicity control for all other exploratory efficacy endpoints, which will be tested at a nominal 5% level. Safety Analyses: Safety anal yses will be performed on the safety anal ysis set. All adverse events will be coded using the Medica l Dictionary for Regulatory Activities. Each patient will be counted only once in each preferred term or s ystem organ class category for the analyses of safet y. Summaries will be presented for all adverse events (overall and by severit y), including adverse events determined b y the investigator to be related to test IMP (ie, reasonable possibility defined as related or with missing relationship) (overall and by severit y), serious adverse events, and adverse events causing withdrawal from the stud y. Summaries will be presented b y treatment group. Patient listings of serious adverse events and adverse events leading to withdrawal will be presented. Changes in laboratory , ECG, and vital sign measurement data will be summarized descriptivel y. All values will be c ompared with predefined criteria to identify potentiall y clinically significant values or changes, and such values will be listed. The use of concomitant medications will be summarized by therapeutic class using descriptive statistics. Descriptive statistics for allowed rescue medications will be presented b y treatment group. Safety outcomes, including changes from baseline in EPS scale scores (BARS, AI MS, and SAS) and CDSS during Stage 2, will be presented using descriptive statistics by treatment group. Adjustment to stratification factors may be conducted as appropriate. The incidence of treatment -emergent adverse events related to EPS will be summarized by the following event categories: akathisia, dy skinesia, dystonia, parkinsonism, and tremor. The C-SSRS and CGI-SS will be used to assess the risk of suicide events during the study . Descriptive statistics will be presented b y treatment group. For continuous variables, descriptive statistics (n, mean, standard deviation, median, minimum, and maximum) wil l be provided for actual values and changes from baseline to each time point. For categorical variables, patient counts and percentages will be provided. If any patient dies during the study, a listing of deaths will be provided, and all relevant informati on will be discussed in the patient narrative included in the clinical study report. Safety data collected in Stage 1 will also be summarized using descriptive statistics in the enrolled patients set. Selected safet y data will also be presented b y site of injection (abdomen vs arm) and b y age group (adolescents [ages 13 -17] and adults [18 y ears of age and above]), as applicable."
25,page_25,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 25Separate summaries for adolescent patients may be presented separatel y for some anal yses, as applicable, and will be described in the Statistical Analy sis Plan. Tolerability Analysis: In case an adverse event related to an injection site reaction is reported, an assessment of the sc injection site (ie, local tolerability [skin at injection site] ) will be made. The presence and sever ity of ery thema, swelling, induration, and pain at the injection site may be assessed. All-cause discontinuation rates and discontinuation rates due to adverse events (dropout rates) will be calculated as the number of patients who withdrew earl y,and the number of patients who withdrew earl y due to adverse events, respectively , divided by the number of patients in each treatment group and will be presented using descriptive statistics. Time to all- cause discontinuation will be calculated as the discontinuation date minus the randomization date plus 1. Kaplan -Meier curves for the time to discontinuation as a result of all causes will be plotted . Separate summaries for adolescent patients might be presented separatel y for some anal yses, as applicable. Pharm acokinetic Analysis: Blood samples will be collected from all patients for quantitation of the plasma concentrations of risperidone, 9 -OH-risperidone, and total active moiety , at weeks -12, -10, - 8, and -4 in Stage 1, at baseline, every 4 weeks in Stage 2,and at the follow - up/exit visits. D uring Stage 2 of the stud y, blood samples for PK assessment will be taken within an hour prior to sc dose administration. During Stage 2, unscheduled pharmacokinetic samples will be aimed to be collected in the event of relapse as defined per the study â€™s relapse criteria, any serious adverse event, patient withdrawal, and/or the need for potential TV -46000 depot excision. Every effort should be made to obtain the additional pharmacokinetic sample at the closest time possible to the occurrence of the event. Drug concentrations over time [C(t)] reported by time (visit) and treatment (q1m, q2m, and oral) will be presented using descriptive statistics ( n, mean, standard deviation, median, minimum, geometric mean, and coefficient of variation). Additional pharmacokinetic parameters may be determined if data permits."
26,page_26,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 26In addition, the pharmacokinetics of TV- 46000 (and if data permits, also of oral risperidone) will be evaluated by using a population pharmacokinetics approach and reported separately from the main study report. Pharmacokinetic/Pharmacodynamic Analysis : Biomarker and Pharmacogenetics Analysis: Biomarker and pharmacogenetic anal ysis plans and results will be outlined in a separate document. Planned Interim Analyses: There will be no interim analy sis in this study ."
27,page_27,Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 27TABLE OF CONTENTS TITLE PAGE ...................................................................................................................................1 AMENDMENT HI STORY .............................................................................................................2 INVESTIGATOR AGREEMENT ...................................................................................................4 SPONSOR PROTOCOL APP ROVAL ...........................................................................................5 COORDINATING INVESTI GATOR AGREEMENT ...................................................................6 CLINICAL STUDY PROTO COL SYNOPSI S................................ ...............................................7 LIST OF ABBREVIATION S................................................................ ........................................34 1. INTRODUCTION AND BAC KGROUND INFORMATI ON..................................37 1.1. Introduction ................................................................ .................................................37 1.2. Findings from Nonclinical and Clinical Studies .........................................................38 1.2.1. Nonclinical Studies.....................................................................................................38 1.2.2. Clinical Studies ................................ ...........................................................................39 1.2.2.1. Clinical Pharmacology Studies ...................................................................................39 1.2.2.2. Clinical Safety and Efficacy Studies ..........................................................................40 1.3. Known and Potential Benefits and Risks to Patients..................................................41 1.3.1. Known and Potential Benefits and Risks of the Test Investigational Medicinal Product(s) ..................................................................................................41 1.3.2. Overall Benefit and Risk Assessment for This Study ................................................41 2. STUDY OBJECTIVES AND ENDPOINTS ..............................................................43 2.1. Primary and Secondary Study Objectives and Endpoints ..........................................43 2.2. .......................................................................45 3. STUDY DESIGN ................................................................ .......................................47 3.1. General Study Design and Study Schematic Diagram ...............................................47 3.2. Planned Number of Patients and Countries................................................................52 3.3. Justification for Study Design and Selection of Population .......................................52 3.4. Stopping Rules for the Study ................................ ......................................................53 3.5. Schedule of Study Procedures and Assessments ........................................................53 4. SELECTION AND WITHDR AWAL OF PATIENTS ..............................................65 4.1. Patient I nclusion Criteria ................................ ................................ ............................ 65 4.2. Patient Exclusion Criteria ................................ ................................ ........................... 67 4.3. Withdrawal Criteria and Procedures for the Patient................................ ................... 68 4.3.1. General Withdrawal Criteria .......................................................................................68
28,page_28,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 284.3.2. Study -Specific Patient Withdrawal Criteria and Procedures ......................................70 4.3.3. Pharmacokinetic Sampling in Case of Patient Withdrawal ........................................70 4.4. Replacement of Patients .............................................................................................71 4.5. Rescreening .................................................................................................................71 4.6. Screening Failure ........................................................................................................71 5. TREATMENTS ..........................................................................................................72 5.1. Investigational Medicinal Products Used in the Study ...............................................72 5.1.1. Test I nvestigational Medicinal Product ......................................................................72 5.1.1.1. Starting Dose and Dose Levels ...................................................................................72 5.1.1.2. Dose Modification and Dose Stratification ................................................................73 5.1.2. Placebo Investigational Medicinal Product ................................................................73 5.2. Preparation, Handling, Labeling, Storage, and Accountability for IMPs ...................75 5.2.1. Storage and Security ...................................................................................................75 5.2.2. Labeling ......................................................................................................................75 5.2.3. Accountability .............................................................................................................75 5.3. Justifi cation for Investigational Medicinal Products ..................................................76 5.3.1. Justification for Dose of Test I nvestigational Medicinal Product ..............................76 5.3.2. Justification for Use of Placebo Investigational Medicinal Product ..........................76 5.4. Other Medicinal Products/Non- Investigational Medicinal Products ..........................76 5.5. Treatment After the End of the Study .........................................................................77 5.6. Restrictions ................................................................ .................................................77 5.6.1. Activity .......................................................................................................................77 5.6.2. Specific Beverages ......................................................................................................77 5.6.3. Blood Donation................................................................ ...........................................78 5.7. Prior and Concomitant Medication or Therap y..........................................................78 5.8. Procedures for Monitoring Patient Compliance ................................ ......................... 79 5.9. Randomization and Blinding ......................................................................................80 5.10. Maintenance of Randomization and Blinding ............................................................81 5.10.1. Maintenance of Randomization ..................................................................................81 5.10.2. Blinding and Unblinding ............................................................................................81 5.10.3. Data Monitoring Committee .......................................................................................82 5.11. 82 6. ASSESSMENT OF EFFICA CY................................................................................83"
29,page_29,Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 296.1. Assessments of Efficacy .............................................................................................83 6.1.1. Clinical Global I mpression â€“Improvement (CGI -I)....................................................83 6.1.2. Positive and Negative Syndrome Scale (PANSS) ......................................................83 6.2. Other Assessments ......................................................................................................83 6.2.1. 83 6.2.2. Quality of Life Scales .................................................................................................83 6.2.2.1. .............................................................83 6.2.2.2. ................................84 6.2.3. 84 6.2.4. Personal and Social Performance Scale (PSP) ...........................................................84 6.2.5. Healthcare Resource Utilization .................................................................................84 6.2.6. Clinical Global I mpression of Severity ......................................................................85 7. ASSESSMENT OF SAFETY .....................................................................................86 7.1. Adverse Events ................................ ...........................................................................86 7.1.1. Definition of an Adverse Event ..................................................................................86 7.1.2. Recording and Reporting of Adverse Events .............................................................87 7.1.3. Severity of an Adverse Event .....................................................................................87 7.1.4. Relationship of an Adverse Event to the Investigational Medicinal Product .............88 7.1.5. Serious Adverse Events ..............................................................................................88 7.1.5.1. Definition of a Serious Adverse Event .......................................................................89 7.1.5.2. Expectedness ................................ ...............................................................................89 7.1.5.3. Reporting a Serious Adverse Event ............................................................................90 7.1.6. Protocol -Defined Adverse Events of Special Interest ................................................92 7.1.7. Protocol Deviations Because of an Adverse Event ....................................................92 7.2. Pregnancy ...................................................................................................................92 7.3. Medication Error and Special Situations Related to the I nvestigational Medicinal Products .....................................................................................................93 7.4. 95
30,page_30,Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 307.4.2.4. Prolactin......................................................................................................................95 7.5. Physical Examinations ................................................................................................95 7.6. Vital Signs ................................................................ ..................................................96 7.7. Electrocardiograph y....................................................................................................96 7.8. Assessment of Local Tolerability and Pain ................................................................96 7.8.1. Erythema and Edema Assessment ................................ ..............................................97 7.8.2. Induration and Nodule Assessment ............................................................................97 7.8.3. Injection Pain Intensity Assessment ...........................................................................97 7.9. Assessment of Suicidality...........................................................................................97 7.9.1. Columbia Suicide Severity Rating Scale (C -SSRS) ...................................................98 7.9.2. Clinical Global I mpression -Severit y of Suicidality ....................................................98 7.10. Study -Specific Assessments of Safet y........................................................................98 7.10.1. Abnormal Involuntary Movement Scale (AIMS) .......................................................98 7.10.2. Barnes Akathisia Rating Scale (BARS) .....................................................................99 7.10.3. Simpson -Angus Scale (SAS) ......................................................................................99 7.10.4. Calgary Depression Scale for Schizophrenia (CDSS) ................................................99 7.11. Other Assessments ................................................................ ......................................99 8. ASSESSMENT OF PHARMA COKINETICS/ PHARMACO DYNAM ICS/ BIOMARKERS/ PHARMACO GENOMICS ..........................................................101 8.1. Pharmacokinetic Assessment ....................................................................................101 8.2. Pharmacokinetic/Pharmacody namics Assessment ...................................................102 8.3. ...................................................................102 8.4. Pharmacogenetics .....................................................................................................102 9. STATI STICS ............................................................................................................103 9.1. Sample Size and Power Considerations ...................................................................103 9.2. Analy sis Sets ................................................................ .............................................103 9.2.1. Enrolled Patients Set.................................................................................................103 9.2.2. Intent -to-Treat Anal ysis Set ................................ ......................................................104 9.2.3. Extended I ntent -to-Treat Analy sis Set ......................................................................104 9.2.4. Per- Protocol Anal ysis Set .........................................................................................104 9.2.5. Safety Anal ysis Set ................................ ...................................................................104 9.2.6. Pharmacokinetics Analy sis Set .................................................................................104 9.3. Data Handling Conventions ......................................................................................104
31,page_31,Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 319.3.1. Handling Withdrawals and Missing Data.................................................................105 9.4. Study Population .......................................................................................................105 9.4.1. Pat ient Disposition ....................................................................................................105 9.4.2. Demographic and Baseline Characteristics ..............................................................105 9.5. Efficacy Anal ysis................................................................ ......................................105 9.5.1. Primary Endpoint ......................................................................................................105 9.5.2. K ey Secondary Endpoints .........................................................................................106 9.5.2.1. Time to I mpending Relapse in the eITT Anal ysis Set ..............................................106 9.5.2.2. Impending Relapse Rate at Week 24 ................................ ........................................106 9.5.2.3. Percentage of Patients Who Maintain Stability at Endpoint ....................................106 9.5.2.4. Percentage of Patients Achieving Remission at Endpoint ........................................107 9.5.2.5. Observed Rate of Impending Relapse at Endpoint ...................................................107 9.5.2.6. Drug Attitudes Inventory 10- item Version ............................................................... 107 9.5.2.7. Schizophrenia Quality of L ife Scale .........................................................................107 9.5.2.8. Time to I mpending Relapse in Adolescent Patients with Schizophrenia .................108 9.5.3. / 108 9.5.3.1. ................................ ................... 108 9.5.3.2. Healthcare Resource Utilization ...............................................................................108 9.5.3.3. ......................................108 9.5.3.4. CGI-I Score at Endpoint ...........................................................................................108 9.5.3.5. Personal and Social Performance Scale ....................................................................108 9.5.4. Planned Method of Analysis .....................................................................................108 9.5.4.1. Primary Efficacy Anal ysis........................................................................................108 9.5.4.2. Sensitivity Anal ysis..................................................................................................109 9.5.4.3. Subgroup Analy sis....................................................................................................109 9.5.4.4. Key Secondary Anal yses..........................................................................................109 9.5.4.5. Key Secondary Efficacy Analy sis 9.5.2.2 -9.5.2.7....................................................109 9.5.4.6. ................................ ..................................................110 9.6. Multiple Comparisons and Multiplicity ....................................................................110 9.7. Safety Anal ysis.........................................................................................................111 9.8. Tolerability Anal ysis................................................................................................112 9.9. Pharmacokinetic Analy sis........................................................................................113 9.10. Pharmacod ynamic Anal ysis......................................................................................113
32,page_32,Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 329.11. Pharmacokinetic/Pharmacody namic Anal ysis..........................................................113 9.12. Biomarker and Pharmacogenetics Anal ysis.............................................................113 9.13. Planned Interim Anal ysis..........................................................................................113 9.14. Reporting Deviations from the Statistical Plan ........................................................114 10. QUALITY CONTROL AND QUALITY ASSURANCE .......................................115 11. COMPLIANCE STATEMENT ................................................................................115 12. DATA MANAGEMENT AND RECOR D KEEPING ............................................115 13. FINANCING AND INSURA NCE ...........................................................................116 14. PUBLICATION POLICY ........................................................................................116 15. REFERE NCES .........................................................................................................117 16. SUMMARY OF CHANGES ....................................................................................120 16.1. Global Amendment 03 (Dated 19 April 2020) .........................................................120 16.2. Administrative L etter 03 (Dated 09 February 2020) ................................................131 16.3. Global Amendment 02 with Revision 01 (Dated 16 October 2019) ........................133 16.4. Global Protocol Amendment 02 (Dated 02 September 2019)..................................143 16.5. Letter of Clarification 02 (27 June 2019) .................................................................165 16.6. Global Protocol Amendment 01 (Dated 06 December 2018) ..................................167 16.7. Letter of Clarification 01 (26 June 2018) .................................................................210 16.8. Local Amendment 01 for Bulgaria (Dated 28 May 2018) .......................................212 16.9. Protocol with Revision 01 (Dated 15 February 2018) ..............................................216 ................................ .......................................................................217 APPENDIX B.STUDY PROCEDURES AND ASSESSMENTS BY VISIT .........................219 APPENDIX C.QUALITY CONTROL AND QUALITY ASSURANCE ..............................229 APPENDIX D. ETHI CS................................................................ ...........................................231 APPENDIX E.BIRTH CONTROL METHOD S AND PREGNANCY TESTING .................233 APPENDIX F.LOST TO FOLLOW -UP.................................................................................235 APPENDIX G. LIST OF PROHIBITED M EDICATIONS .....................................................236 APPENDIX H. ................................ ...........................................238 APPENDIX I. ...............................................239 APPENDIX J.PHARMACOGENETIC ASSE SSMENTS ......................................................240 APPENDIX K. PRODUCT COMPLAINTS............................................................................241 APPENDIX L.DATA MANAGEMENT AND RECORD KEEPING ....................................243
33,page_33,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 33APPENDIX M. PUBLICATION POLICY ..............................................................................246 APPENDIX N. MANAGEMENT OF STUDY ACTIVITIES DURI NG CO VID-19 .............247 LIST OF TABLES Table 1: ...................................................................................................................54 Table 2: TV46000 -CNS -30072 (RISE) Study Procedures and Assessments (In -Clinic Visits and Telephone Contacts) â€“ Baseline, Double -Blind Maintenance Stage (Stage 2), End of Treatment/Earl y Termination and Follow -Up......................58 Table 3: Conversion Table Between Oral Risperidone and TV -46000 Doses .........................73 Table 4: Investigational Medicinal Products Used in the Study ...............................................74 Table 5: Other Medicinal Products Used in the Study .............................................................77 Table 6: The Relationship of an Adverse Event to the IMP .....................................................88 Table 7: Clinical L aboratory Tests ...........................................................................................94 Table 8: Questions for Unblinded Nurses Administering Study Drug to Patients (for use of prefilled sy ringes only ) ..................................................................................100 Table 9: List of Prohibited Medications Affecting C ytochrome P450 ...................................236 LIST OF FIGURES Figure 1: Overall Study Schematic Diagram ................................ .............................................50"
34,page_34,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 34LIST OF ABBREVIATION S Abbreviation Term Î²-HCG Beta human chorionic gonadotropin ADR averse drug reaction AIMS Abnorm al Involuntary Movement Scale ALT alanine aminotransferase ANCOVA analysis of covariance ANOVA analysis of variance AST aspartate aminotransferase BARS Barnes Akathisia Rating Scale CA competent authority CDMS clinical data management system CDSS Calgary Depression Scale for Schizophrenia CFR Code of Federal Regulations (USA) CGI-I Clinical Global Impression â€“Improvement CGI-S Clinical Global Impression of Severity CGI-SS Clinical Global Impression -Severity of Suicidality CI confidence interval CMH Cochran â€“Mantel â€“Haenszel COVID -19 Coronavirus disease 2019 CRF case report form (refers to any media used to collect study data [ie, paper or electronic]) CRO contract research organization CSR clinical study report C-SSRS Columbia Suicide Severity Rating Scale C(t) concentrations of drug over time [C(t)] reported by time (visit) and treatment"
35,page_35,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 35Abbreviation Term CYP cytochrome P450 DAI-10 Drug Attitudes Inventory 10 -item version DSM -5 Diagnostic and Statistical Manual of Mental Disorders, 5thEdition ECG electrocardiogram/electrocardiography EOS end of study EOT end of treatment EPS extrapyramidal symptoms EQ-5D-5L 5-Level EuroQol Five Dimensions Questionnaire ER emergency room ET early termination FDA Food and Drug Administration FSH Follicle stimulating hormone GCP Good Clinical Practice GLP Good Laboratory Practice GPSP Global Patient Safety and Pharmacovigilance HIV human immunodeficiency virus IB Investigatorâ€™s Brochure ICF informed consent form ICH International Council for Harmonisation IDMC Independent Data Monitoring Committee IEC Independent Ethics Committee im intramuscular IMP investigational medicinal product IRB Institutional Review Board IRT Interactive Response Technology ITT intent -to-treat LAI long-acting injectable LOCF last observation carried forward LSO local safety officer NDA New Drug Application NOAEL no observed adverse effect level NPRS Numeric Pain Rating Scale OTC over-the-counter"
36,page_36,Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 36Abbreviation Term PANSS Positive and Negative Syndrome Scale PI prescribing information PK pharmacokinetic(s) PP per-protocol PSP Personal and Social Performance Scale q1m every month q2m every 2 months q3m every 3 months q4w every 4 weeks q8w every 8 weeks RNA ribonucleic acid RO receptor occupancy RSI reference safety information SAS Simpson -Angus Scale sc subcutaneous SCID -5 Structured Clinical Interview for DSM -5 SmPC Summary of Product Characteristics SOP Standard Operating Procedure SQLS Schizophrenia Quality of Life Scale SUSAR suspected unexpected serious adverse reaction TC telephone call/teleconference ULN upper limit of normal US United States (of America) US FDA United States Food and Drug Administration VC videoconference vs versus
37,page_37,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 371. INTRODUCTION AND BACKGROUND INFORMATION 1.1. Introduction Schizophrenia is a severely debilitating ps ychotic disorder characterized by positive sy mptoms (eg, delusions, hallucinations, and grossl y disorganized or catatonic behavior) and negative symptoms (eg, affective flattening, alogia, and avoliti on (New York State Office of Mental Health 2011 , Stefan and Travis 2002 ]). Cognitive deficits are common; they include impairment of executive functioning and attention, as well as difficulties wi th short- and long -term memory . The worldwide lifetime morbidity risk of the disorder is about 1% across diverse geographic, cultural, and socio -economic regions. Since, in most patients, the disease follows a chronic course with long -lasting impairment, long- term treatment with antipsy chotic agents is usually required. Noncompliance and high discontinuation rates are particularl y problematic in patients with schizophrenia. Premature discontinuation of antipsy chotic drug therap y is a common phenomenon; in t he Clinical Antipsy chotic Trials of Intervention Effectiveness study , 74% of patients discontinued their antipsy chotic drug within 18 months due to either poor tolerability or lack of efficacy . Even among patients who do not explicitly discontinue drug the rapy, nonadherence to long -term oral medication regimen is one of the most significant therapeutic issues in the therap y of schizophrenia and related disorders. As a result, many of these patients do not experience the full benefit of antips ychotic drug th erapy and suffer frequent relapses or exacerbations that require rehospitalization, often in the context of psy chiatric emergency (Rainer 2008 ). Thus, the use of a long -acting injectable (LAI) antipsy chotic agent may increase compliance in patients with schizophrenia ( Barnes and Curson 1994, Hughes 2007, Keith and Kane 2003 , Walburn et al 2001 ). In addition, r ecent evidence suggests that earl y use of LAI risperidone might carry advantages for clinical outcomes in patients with schizophrenia, further supported by neuroimaging ( Subotnik et al 2015 ). The underl ying disease mechanisms and initial approach to the diagnosis and treatment of schizophrenia in adolescent patients aged 13 to 17 y ears and adult patients 18 y ears of age and older is essentially the same. Schizophrenia in children and adolescents is accepted to be clinically and biologically similar to adult -onset schizophrenia, but with some differences in the presentation of the s ymptoms, relative frequency of core ps ychotic s ymptoms (eg, auditory hallucinations, delusions, thought disorder), neurocognitive impairments, psy chop hysiological abnormalities, and the presence of structural brain abnormalities ( Asarnow et al 1995 , Bo and Haahr 2016 , Rapoport et al 2005). Pediatric patients displa y a more severe clinical prognosis and a greater neurodegenerative trajectory , and can be less responsive to treatment compared to patients with adult- onset schizophrenia ( Bo and Haahr 2016 ). Children and adolescents who are diagnosed with schizophrenia display high stability with regard to the phenoty pical expression of the disorder into adulthood ( Hollis 2000 ). Studies of neurops ychological functions and brain structure in patients with schizophr enia have shown the same degenerative patterns, regardless of the patientâ€™s age at the onset of the disorder ( Weinberger and Harrison 2011). The sponsor is developing a risperidone extended- release injectable suspension for su bcutaneous (sc) use that will deliver therapeutic levels of risperidone over intervals of 1 month (TV -46000 every month [q1m]) or 2 months (TV -46000 every 2 months [q2m]) to patients with"
38,page_38,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 38schizophrenia. TV-46000 is a new formulation of risperidone that uses this technology ; the product is referred to as TV -46000 q1m and TV -46000 q2m to designate t he 1-and 2 -month duration products, respectivel y. There are 4 possible TV -46000 dose strengths for each duration product, comparable to 2, 3, 4, and 5 mg/day of oral risperidone.The sponsor will provide a the dose will be comparable to the oral risperidone dose on which the patient will be stabilized. The critical importance of optimal compliance with prescribed antipsy chotic regimens has been repeatedly and convincingl y demonstrated in patients with schizophrenia. Adherence increases the likelihood of positive outcomes in all aspects o f a patientâ€™s life including better s ymptom control, reduced risk of relapse and rehospitalization, and improved quality of life as well as social and occupational functioning. Despite their proven effectiveness, poor adherence to prescribed antipsy chotic regimens remains the most important driver of suboptimal clinical outcomes in patients with schizophrenia ( Birnbaum and Sharif 2008). The rationale for developing q1m and q2m risperidone products is to improve patient complian ce and to offer greater convenience to the patient through a reduction in clinic visits in comparison to other risperidone products currentl y on the market. I t is intended that therapeutic concentrations will be reached within 24 hours of injection. I t is anticipated that these advantages will reduce the rate of relapse and concomitant impact on patientsâ€™ well -being and healthcare costs. The purpose of the study is to compare the safet y and efficacy of different durations of TV - 46000 administered sc versus placebo. In addition, there is a paucity of data in relation to L AI use in children and adolescents with serious mental illness and existing reports have substantial methodological limitations ( Lytle et al 2017). Enrollment of adolescents in this study will provide data for evaluating the efficacy , safet y and tolerability of TV -46000 in this patient population. Refer to the current Investigatorâ€™s Brochure (IB) for detailed information on the background, pharmaceutical particulars, nonclinical, and clinical experience with TV -46000. 1.2. Findings from Nonclinical and Clinical Studies 1.2.1. Nonclinical Studies The nonclinical pharmacology and toxicology of risperidone have been well established for oral and intramuscular (im) administration both in vitro and in vivo. Nonclinical studies evaluating genotoxicity , carcinogenicity , chronic toxicology , and reproductive and developmental toxicology of risperidone are publicl y available in p ublished literature or prescribing information (PI) of approved oral or im risperidone products."
39,page_39,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 39Injection of TV -46000 sc to rats and dogs elicited pharmacological signs t ypical of risperidone. In rats onl y, transient stress -related signs were detected in some of the animals. Pathological findings could be divided into sy stemic pharmacologically related changes Local reaction in rats and dogs was a typical foreign bod y local absorptive reaction. Residual fibrotic capsules at the sites of injection were still evident after injection in but their size showed a trend toward reduction. I n 3 single -dose pharmacokinetic and local tolerance non -Good Laboratory Practice (GL P) studies in minipigs, TV-46000 was administered as a single dose . In these studies, the sc lesions were milder than in rats or dogs; however, 2 cases of generalized ery thema . Both cases were non- life-threatening, and 1 was self-limited. In single -dose GL P toxicology studies in both rats and dogs, a no observed adverse effect level (NOAEL), and therefore, a margin of safet y, could not be determined under the experimental conditions of the studies performed because expected adverse reactions related to the pharmacological actions of risperidone were noted at all dose levels. Si milarly , a NOAEL (and therefore, a margin of safety ) could not be determined in the multiple dose toxicity study in dogs because of decreased size and weight of male and female reproductive organs that were observed at all tested dose levels of the study drug. These changes are known risperidone pharmacological effects. Overall, TV -46000 and its vehicle were well tolerated locall y and s ystematically in rats, dogs, and minipigs at all doses tested. The mutagenic potential o f the in TV -46000 was tested in a GL P Ames test, and no increase in frequency of revertants was noted. To summarize, nonclinical studies reported b y Teva evaluated TV-46000 administered by sc injection. Subsequent clinical investigations have demonstrated that this formulation is more suited to a 1-month and 2- month dosing interval; however, the nonclinical data that have been generated are still relevant for the ongoing clinical development program. 1.2.2. Clinical Studies 1.2.2.1. Clinical Pharmacology Studies The stud y found that TV- 46000, administered at sub -therapeutic , was safe and well tolerated when administered as an sc injection to either the posterior upper arm or the abdomen."
40,page_40,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 40 to evaluate the safet y, tolerabilit y, and pharmacokinetics of TV -46000 in patien ts with schizophrenia or schizoaffective disorder was also completed. A total of 96 patients with schizophrenia or schizoaffective disorder were allocated into 8 sequential cohorts of 12 patients each. Stud y participants were clinically stable patients who are currentl y on antips ychotic treatment of oral risperidone. The stud y included 5 single -dose cohorts and 2 multiple -dose cohorts . In addition, interchangeability of inject ion site was assessed via administration of a similar dose to the abdomen and to the upper arm. 1.2.2.2. Clinical Safety and Efficacy Studies As of October 2017, the safet y and efficacy of oral risperidone have been evaluated in clinical studies in a total of 9803 adult and pediatric patients exposed to 1 or more doses of risperidone for up to 3 y ears, including a total of 2687 patients who received oral risperidone in double blind, placebo-controlled studies. The most common adverse events (reported in â‰¥5% of risper idone treated patients and with a frequency twice that of placebo) were parkinsonism, akathisia, dystonia, tremor, sedation, dizziness, anxiety , blurred vision, nausea, vomiting, upper abdominal pain, stomach discomfort, dy spepsia, diarrhea, salivary hypersecretion, constipation, dry mouth, increased appetite, increased weight, fatigue, rash, nasal congestion, upper respiratory tract infection, nasophary ngitis, and phary ngolary ngeal pain (see RISPERIDONE tablets, Teva Pharmaceuticals, US PI )."
41,page_41,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 41The safet y and efficacy of risperidone LAI (RISPERDALÂ®CONSTAÂ®, Janssen Pharmaceuticals) have been evaluated in clinical studies in a total of 2392 patients exposed to 1 or more doses of risperidone for up to 4 years, including a t otal of 332 patients who were treated with risperidone LAI while participating in a 12 -week, double -blind, placebo- controlled study . The most common adverse drug reactions (ADRs) in patients with schizophrenia (â‰¥5% of risperidone treated patien ts) were headache, parkinsonism, dizziness, akathisia, fatigue, constipation, dy spepsia, sedation, weight increased, pain in extremity , and dry mouth (see RISPERDAL CONSTA, Janssen Pharmaceuticals, US PI ). Limited efficacy data for TV -46000 in patients are available. Furthermore, human safet y data on TV-46000 are also limited; to date, doses up to have been tested. However, the safet y profile is expected to be generall y similar to that of risperidone LAI. To date, the on ly new safet y signals that were identified in the TV- 46000 Phase 1 program were some ty pes of injection site reactions such as injection site pain, ery thema, induration, pruritus, and swelling. The majorit y of these adverse events were mild to moderate in severity and resolved quickly . 1.3. Known and Potential Benefits and Risks to Patients 1.3.1. Known and Potential Benefits and Risks of the Test Investigational Medicinal Product(s) Experience with TV -46000 in humans is limited, and there are onl y limited data on ADR s associated with this formulation. However, the safety profile of the active ingredient, risperidone, given in a different long -acting parenteral formulation has been well characterized. The licensed risperidone long -acting injection, RI PERDAL CONSTA, is generally well tolerated. The most commonly reported ADRs include insomnia, anxiety , headache, upper respiratory tract infection, parkinsonism, and depression. The occurrence of ADRs appears to be dose -related. Injection of TV-46000 is expected to result i n less pain than the conventional (oil -based) antipsy chotic im depot injections. Additional information regarding benefits and risks to patients can be found in the IB . Based on the limited data from the clinical program, injection site ery thema, injection site edema, injection site pain, and injection site nodules appear to be ADRs of TV -46000. In summary , the benefit and risk assessment of TV-46000 is favorable following review of the available data. Additional safet y information on TV -46000, including RS I, is presented in the TV-46000 IB. 1.3.2. Overall Benefit and Risk Assessment for This Study In completed clinical studies, oral and im administration of risperidone demonstrated superiorit y over placebo in assessments such as Brief Psy chiatric Rating Scale, Sca le for the Assessment of Negative S ymptoms, and Positive and Negative Sy ndrome Scale (PANSS). This superiority was generall y dose dependent, with oral doses ranging from 2 to 16 mg/day on a once per day or twice per day schedule. On a longer term, risperidone treatment resulted in a significantly longer time to relapse over a 2 -year period compared to treatment with an active comparator. Intramuscular (im) risperidone was generall y well tolerated over the dose range of . The most common adverse events in clinical studies ( â‰¥5% of risperidone treated patients and with a frequency twice that of placebo) were parkinsonism, akathisia, dy stonia, tremor, sedation,"
42,page_42,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 42dizziness, anxiety , blurred vision, nausea, vomiting, upper abdominal pain, stomach disco mfort, dyspepsia, diarrhea, salivary hypersecretion, constipation, dry mouth, increased appetite, increased weight, fatigue, rash, nasal congestion, upper respiratory tract infection, nasophary ngitis, and phary ngolary ngeal pain. The most common ADRs in cli nical studies of risperidone LAI in patients with schizophrenia ( â‰¥5% of risperidone treated patients) were headache, parkinsonism, dizziness, akathisia, fatigue, constipation, dy spepsia, sedation, weight increased, pain in extremity , and dry mouth. Based on the extensive safet y and efficacy database for oral and im risperidone, and preliminary findings from the TV -46000 clinical development program thus far, the sponsor anticipates a favorable risk- benefit profile for administration of an extended -release suspension of risperidone for sc injection in adult patients with schizophrenia. To date, the onl y new safet y signals that were identified in the TV -46000 Phase 1 program were some t ypes of injection site reactions (see Section 1.2.2.2). They have not significantl y impacted TV -46000â€™s benefit -risk profile nor have they presented a significant burden to the patients."
43,page_43,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 432. STUDY OBJECTIVES AND ENDPOINTS 2.1. Primary and Secondary Study Objectives and Endpoints The primary and secondary study objectives and endpoints are: Objectives Endpoints The primary objective of this study is to evaluate the efficacy of TV -46000 during maintenance treatment in adult patients with schizophrenia.The primary efficacy endpoint is time to impending relapse. Relapse is defined as 1 or more of the following items: ï‚·Clinical Global I mpression â€“Improvement (CGI -I) of â‰¥5 (greater than or equal to minimally worse, ie, minimally worse, much worse or very much worse), AND ï€­an increase of any of the following individual Positive and Negative S yndrome Scale (PANSS) items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a sc ore of >4 with an absolute increase of â‰¥2 on that specific item since randomization, OR ï€­an increase in an y of the following 4 individual PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a scor e of >4 and an absolute increase of â‰¥4 on the combined score of these 4 PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content) since randomization ï‚·hospitalization due to worsening of ps ychotic s ymptoms (including partial hospitalization programs), excluding hospitalization for psy chosocial reasons ï‚·Clinical Global I mpression -Severit y of Suicidality (CGI -SS) of 4 (severel y suicidal) or 5 ( attempted suicide ) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2 ï‚·violent behavior resulting in clinicall y significant self -injury , injury to another person, or propert y damage A key secondary objective of this study is to evaluate the efficacy of TV -46000 during maintenance treatment in a total population (adults and adolescents) and in adolescent patients with schizophrenia.Key secondary endpoints are: ï‚·time to impending relapse (as defined under the primary objective) in the total population (adults and adolescents) ï‚·impending relapse rate at w eek 24 ï‚·percentage of patients who maintain stability at endpoint ï‚·percentage of patients achieving remission at endpoint ï‚·observed rate of impending relapse at endpoint ï‚·Drug Attitudes Inventory 10- item version ( adult patients only) ï‚·Schizophrenia Quality of Life Scale (SQLS) ( adult patients"
44,page_44,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 44Objectives Endpoints only) ï‚·time to impending relapse in adolescent patients with schizophrenia A secondary objective of this study is to evaluate the safet y and tolerability of TV -46000 in the total population .The safety variables include adverse events, extrapy ramidal symptoms (EPS), risk of suicide events, depression sy mptoms, injection pain and other injection site reactions (local tolerability ), vital signs, laboratory tests, phy sical examination, electrocardiogram (ECG) measure ments, body weight, rescue medication use, time to all-cause discontinuation, all- cause discontinuation rates and discontinuation rates due to adverse events (tolerabilit y), and the following rating scales: ï‚·Abnormal Involuntary Movement Scale (AIMS) ï‚·Simpso n-Angus Scale ï‚·Barnes Akathisia Rating Scale ï‚·Columbia Suicide Severity Rating Scale (C -SSRS) ï‚·Calgary Depression Scale for Schizophrenia (CDSS) ï‚·CGI-SS A secondary objective of this study is to evaluate the pharmacokinetics of oral risperidone and TV -46000 after administration of multiple doses in adults, adolecsents, and the total population .ï‚·The pharmacokinetic endpoints are the plasma concentrations of risperidone, 9 -OH-risperidone, and total active moiety (sum of risperidone and 9- OH-risperidone). Justification of Primary Endpoint The primary endpoint of the study is time to impending relapse compared with placebo. Time to impending relapse is a well -accepted endpoint for the evaluation of efficacy during maintenance therap y with antips ychotics."
45,page_45,Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 452.2.
46,page_46,Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 46Objectives Endpoints
47,page_47,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 473. STUDY DESIGN 3.1. General S tudy Design and Study Schematic Diagram This is a double -blind, randomized, relapse prevention study comparing a therapeutic dose of TV-46000 sc q1m and q2m with placebo sc (q1m) in a 1:1:1 ratio. Patients will undergo screening procedures/assessments within 30 day s before the start of Stage 1. They should have had a diagnosis of schizophrenia for >1 year (diagnosis must be reconfirmed b y Structured Clinical I nterview for DSM -5 [SCI D-5]) and have been generall y responsive to antipsy chotics in the past y ear based on investigator judgment (and discussions with family members, caregivers, or healthcare professionals as applicable). Patients should also have had â‰¥1 episode of relapse in the last 24 months. Patients will provide informed consent or assent, as applicable, at the screening visit. For adolescent patients, it is mandatory that a parent/caregiver accompanies the patient to each visit and serves as a reliable informant. It is recommended that a caregiver is identified for each adult patient. L ocal requirements should be followed. The caregiver may be contacted in case of loss of contact with the patient or to provide additional information about the patient, if needed. Patients can be accompanied by caregivers to visits. Stage 1: Oral conversion and stabilization stage (12 weeks). Patients not alread y on oral risperidone or injectable risperidone ( RISPERDAL CONSTA, Janssen Pharmaceuticals, US PI ) and on an y antips ychotic (other than clozapine), and who can benefit from conversion to oral risperidone based on the investigatorâ€™s judgement, will be converted to oral risperidone (2to5mg/day ) to ensure that they tolerate risperidone and that the doses are adequate to treat their positive sy mptoms. Patients who are alread y on risperidone but can still benefit from the study based on the investigator's judgement will also undergo the oral stabilization stage. Open - label oral risperidone (2 to 5 mg/day ) will be used to stabilize patients to the treatments (the dose will be base d on clinical judgement). Adolescent patients will receive a maximal dose of 4 mg/day . Patients will come to the clinic for 4 visits (weeks -12, -10, - 8, and -4) for dose adjustments ( Table 1); however, additional visits may be required for dose adjustments. Patients will be assessed b y PANSS, Clinical Global Impression of Severit y (CGI -S), Abnormal Involuntary Movement Scale (AIMS), Barnes Akathisia Rat ing Scale (BARS), Simpson -Angus Scale (SAS), Columbia Suicide Severit y Rating Scale (C -SSRS), Calgary Depression Scale for Schizophrenia (CDSS), and Clinical Global I mpression -Severity of Suicidality (CGI -SS). Additionally , telephone contacts will take pla ce at weeks - 6 and -2, or more frequentl y if required in the judgement of the investigator (see Table 1for more details)."
48,page_48,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 48ï‚· Blood samples for plasma drug concentration will be collected during the in -clinic visits (besides screening) and adverse event inquiry will be performed at all visits and telephone calls/teleconferences (TCs). If a patient withdraws from the study prior to the randomization visit (Visit 6), the CRF for the patient's last visit will be marked as ""Not Continuing"" and the reason for discontinuation will be recorded. No extra testing or procedures will be required in addition to the regular visits. Stage 2: Double-blind maintenance stage (variable in duration). Stabilized patients (see definition above) will be randomized to receive TV -46000 q1m sc injections, TV -46000 q2m sc injections, or placebo q1m sc injections in a 1:1:1 ratio. Patients that require a stabiliza tion dose below 2 mg/day will not be randomized in the study . Also, as a precautionary measure, adolescent patients that will require a stabilization dose of more than 4 mg during the stabilization stage will not be randomized. Patients in the TV -46000 gro ups will receive a dose of TV -46000 (q1m or q2m) that is equivalent to the oral dose on which they were stabilized in Stage 1. The maximal dose administered to adult patients will be equivalent to an oral risperidone dose of 5 mg/day, and the maximal dose administered to adolescents will be equivalent to 4 mg/day. Patients randomized to TV-46000 q1m or placebo sc will receive an sc injection of TV- 46000 or placebo , respectively , at baseline and every 4 weeks (q4w) thereafter. Patients randomized to TV -46000 q2m will receive a TV -46000 injection at baseline and every 8 weeks (q8w) thereafter, and a placebo sc injection 4 weeks after baseline and q8w thereafter, to ensure blinding of the doses and durations of the TV -46000 injections and the placebo injections . The study will continue on an outpatient basis ( Table 2 ), and telephone contacts will take place weekl y between clinic visits. I f, in the judgment of the investigator, the patient is likely to relapse or pose a danger to himself/herself or others, that patient may be invited for an unscheduled visit and/or hospitalized if needed, and treatment with the study drug may be discontinued. During Stage 2, unscheduled pharmacokinetic samples will be aimed to be collected in the event of relapse as defined per the study â€™s relapse criteria, any serious adverse event, patient withdrawal, and/or the need for potential TV- 46000 depot excision. Every effort should be made to obtain the additional pharmacokinetic sample at the closest time possible to the occurrence of the event. The duration of patient participation in the study will include up to 4 weeks of screening, 12weeks of the oral conversion/stabilization stage, and a double -blind maintenance stage. The double -blind maintenance stage will be variable in duration, with patients continuing until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria ; or"
49,page_49,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 49remain relapse -free during the double -blind phase until the study is terminated because at least 90 relapse events are recorded in the study adult population. Per definition, an exacerbation in sy mptoms during Stage 1 cannot be defined as a relapse e vent, since relapse events can only occur following stabilization and randomization. Randomized patients who relapse or meet 1 or more of the withdrawal criteria should be invited to perform the Earl y Termination (ET) visit as soon as possible, within 4 weeks of the last injection. Patients who remain relapse -free when the study is terminated should be invited to perform the End -of- Treatment visit within 4 weeks of the last injection. Therefore, a patient is considered a study completer if he or she exper ienced impending relapse or remained relapse- free at the time of study termination. Patients will subsequently complete all end -of-study assessments. When the study ends, eligible patients may be offered the opportunity to enter the TV46000- CNS -30078 exten sion study to assess the long- term safety and tolerability of extended -release risperidone. This extension study is bey ond the scope of this protocol, and a separate protocol was issued for it. I f patients choose to enter the extension study , they will not need to complete the follow- up/exit visits in this study . For all other patients (ie, patients who experience a relapse event, meet 1 or more of the stud y discontinuation or withdrawal criteria, or do not consent to join the extension study ), there will be 2 follow -up/exit visits that will take place at 4 weeks and 8 weeks after the last dosing visit. During the follow -up/exit period, patients will be treated according to the investigatorâ€™s judgement. End of study is defined as the date when the last patie nt in Stage 2 has completed all efficacy and safet y assessments at the final visit per protocol. The study duration will be approximately 30 months, from Q2 2018 (first patient in) to Q4 2020 (last patient out). During the conduct of this study , an Indepe ndent Data Monitoring Committee (IDMC) will review accumulating unblinded safet y and PK data on a regular basis to ensure the continuing safet y of the stud y patients and study conduct issues (see Section 5.10.3 ). For COVID -19 updates, refer to Appendix N. The study schematic diagram is presente d in Figure 1."
50,page_50,Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 50Figure 1: Overall Study Schematic Diagram
51,page_51,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 51aAdolescent patients will receive doses equivalent to 2 -4 mg/day oral risperidone. Patients that will require a stabilization dose below 2 mg/day will not be randomized in the study. bWith the exception of the screening visit, pharmacokinetic samples will be collected at each in -clinic visit. c dPatients randomized to the TV- 46000 q1m or q2m sc groups in Stage 2 w ill receive TV -46000 sc at doses equivalent to the 2 to 5 mg/day dose of oral risperidone on which they were stabilized during Stage 1. Adolescent patients will receive a maximal TV -46000 dose equinvalent to 4 mg/day oral risperidone. eWhen the study ends, eligible patients may be offered the opportunity to enter the TV46000 -CNS -30078 extension study to assess the long -term safety and tolerability of extended -release risperidone . This extension study is beyond the scope of this protocol and is detailed in a separate protocol. If patients choose to enter the extension study, they will not need to complete the follow -up/exit visits in this study. fFor patients who experience a relapse event, meet 1 or more of the study discontinuation or w ithdrawal criteria, or do not consent to join the extension study, there will be 2 follow -up/exit visits that will take place 4 w eeks and 8 w eeks after the last dosing visit. BL = baseline; EoS=end of study; EoT = end of treatment; FU = Follow Up; PK = pharmacokinetics; q1m=every month; q2m=every 2 months; sc=subcutaneous; TC â€“telephone call/teleconference; Wk = week."
52,page_52,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 523.2. Planned Number of Patients and Countries Approximately 1260 patients will be screened to achieve enrollment of approximately 860 adult patients in Stage 1, including approximately 70 adult patients in Bulgaria. The number of randomized adult patients in Stage 2 is planned to be approximately 520, including approximately 55 adult patients in Bulgaria. Details on the definition of evaluable patients and determination of the sample size are giv en in Section 9.1. Adolescent patients will only be enrolled in the US; any enrolled adolescents will be in addition to the aforementioned total. The study is planned to be conducted in approximately 80 investigational centers in North America and Bulgaria. 3.3. Justification for Study Design and Selection of Population Long -term use of antipsychotic agents has been shown to be effective in preventing rel apse in patients with schizophrenia, but carries the risk of side effects (including weight gain, hypergly cemia/diabetes, and metabolic s yndrome) and must be justified for each new agent or new formulation. Therefore, the sponsor is conducting a scientific ally valid study that supports the use of TV -46000 at the proposed clinical dosage regimen. Moreover, the drug class of LAI at ypical antipsy chotics has not been studied extensively in children or adolescents ( Lytle et al 2017). Although compliance in children and adolescents treated with antips ychotics is substantially higher than in adults, ranging from approximately 74% to 88% ( Pogge et al 2005, Yazdi et al 2008 ), LAIs may be considered for patients with confirmed schizophrenia and with risk factors for medication non -adherence: history of non - adherence, severe s ymptoms, comorbid substance use, cognitive impairment, ambivalence or negative attitudes towards medication, and poor insight ( Ferrin et al 2016 ).In the Pediatric Study Antipsy chotic LAIs are viewed as maintenance therap y in stable patients with schizophrenia, but they are not currentl y approved for treatment of acute sy mptoms. Thus, the population for this study consists of adult and adolescent patients with chronic schizophrenia and excludes patients with acute disease. Onl y patients who have been stabilized on oral therap y with risperidone will be randomized i nto the double -blind maintenance stage of the stud y."
53,page_53,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 533.4. Stopping Rules for the Study There are no formal rules for early termination of this study . During the conduct of the study , serious adverse events will be reviewed ( Section 7.1.5.3.1 ) as they are reported from the investigational centers to identify safet y concerns. The study may be terminated by the sponsor for any reason at any time. For example, the sponsor should terminate the study in the event of: ï‚·new toxicological or pharmacological findings or safet y issues invalidate the earlier positive benefit -risk assessment ï‚·discontinuation of the development of the investigational medicinal product (IMP) 3.5. For COVID -19 updates, refer to Appendix N."
54,page_54,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS-30072 54Table 1:TV46000- CNS -30072 (RISE) Study Procedures and Assessments (In -Clinic Visits and Telephone Contacts) â€“ Pre-Treatment Period (Screening and Stage 1) Study Period Pre- treat ment Period N/A Screening Stage 1: Oral Conversion and Stabilization Stagea Unscheduled Visit Visit number V1 V2 V3b V4 V4a V5 V5a Time point Procedures and assessments Wk -16 Wk -12 Wk -10 Wk -8 Wk -6 Wk -4c Wk -2 As deemed necessary by the investigatord Allowed tim e window +4 weeks Â±3 days N/A In-Clinic Visit X X X X X X Telephone Calle, fX X Informed consent (and assent, as applicable) X Medical and psychiatric history X SCID -5 X Prior medication history X Inclusion and exclusion criteria X Clinical laboratory testsg, hX X Virology and thyroid screening testsiX Urine drug screen X Concomitant medication inquiry X X X X X X Full physical examination, including weight XjX Vital signs measurementkX X X X X X 12-lead ECGlX FSH TestmX Serum Î² -HCG test for women of childbearing potentialX"
55,page_55,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS-30072 55Study Period Pre-treat ment Period N/A Screening Stage 1: Oral Conversion and Stabilization Stagea Unscheduled Visit Visit number V1 V2 V3b V4 V4a V5 V5a Time point Procedures and assessments Wk -16 Wk -12 Wk -10 Wk -8 Wk -6 Wk -4c Wk -2 As deemed necessary by the investigatord Allowed tim e window +4 weeks Â±3 days N/A In-Clinic Visit X X X X X X Telephone Calle, fX X Urine Î² -HCG test for women of childbearing potentialX X X X Inquiry about pregnancy status (for women of childbearing potential)X X PANSS X X X X X X CGI-S X X X X X CGI-SS X X X X X CGI-InX X X X AIMS X X X X X BARS X X X X X SAS X X X X X C-SSRS X X X X X X X X PSP (in adult patients only) X SQLS (in adult patients only) X EQ-5D-5L (in adult patients only) X CDSS X X X X X Healthcare resource utilization X DAI-10 (in adult patients only) X"
56,page_56,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS-30072 56Study Period Pre-treat ment Period N/A Screening Stage 1: Oral Conversion and Stabilization Stagea Unscheduled Visit Visit number V1 V2 V3b V4 V4a V5 V5a Time point Procedures and assessments Wk -16 Wk -12 Wk -10 Wk -8 Wk -6 Wk -4c Wk -2 As deemed necessary by the investigatord Allowed tim e window +4 weeks Â±3 days N/A In-Clinic Visit X X X X X X Telephone Calle, fX X Blood samples for plasma drug concentrationoX X X X Oral risperidone dispensing (For qd intake)pX X X X Dosage review and adjustment X X X X Adverse event inquiry (including SAE reporting) X X X X X X X X Inquiry regarding alcohol consumption/illicit drug use X X X X X X X X Brief set of clinical questions to detect psychotic symptomsq X X aIf a patient withdraws from the study prior to the randomization visit (Visit 6), the CRF for the patient's last visit will be marked as ""Not Continuing"" and the reason for discontinuation will be recorded. No extra testing or procedures w ill be required in addition to the regular visit s. bVisits 3 through 5a should be scheduled relative to Visit 2 (and not relative to screening). For example, Visit 3 should be scheduled 2 w eeks (+/ -3 day s) after Visit 2, regardless of when the screening visit took place. cPatients whose symptoms have stabilized at this visit will be required to meet the specified stability criteria for at least 4 consecutive weeks, until the baseline visit at which they will be assessed. dOther procedures may be performed at the discretion of the investigator. In addition, to reduce patient burden and to avoid unnecessary data collection, the investigator will have discretion in determining whether the procedures which are currently marked as mandatory actually need to be performed during the unscheduled visit in the case that: (i) the unscheduled visit is one of multiple in-clinic visits, that are deemed necessary in close proximity (2 or more visits within 1 week), and(ii) when the visit is for administrative purposes (eg, reconsenting) or clinical reasons (eg, repeat laboratory sample collection for reasons unrelated to an adver se event or impending/current relapse), and notdue to a potential relapse or a change in the patient's medical status per clinical judgement. eTelephone contact w ill occur at w eek - 6 and w eek -2 in the oral conversion and stabilization stage (Stage 1) (or more frequently if required in the judgement of the investigator). These contacts will be referred to by the previous visit number and a letter (for example, the telephone c ontacts that take place 2 w eeks after visit 4 w ill be referred to as â€œvisit 4aâ€)."
57,page_57,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS-30072 57fEach contact will include inquiries about injection site pain, suicidal ideation and behavior, adverse events, alcohol consum ption, and pregnancy status (for women of childbearing potential). Patients will also be asked a brief set of clinical questions in order to detect psychotic symptoms (see relevant assessment). gClinical laboratory tests (serum chemistry, hematology, and urinalysis) may also be performed at any time if clinically indica ted. hGlom erular Filtration Rate (GFR) will be calculated based on plasma creatinine levels, weight, gender and age using the Cockcroft -Gault equation. iIncludes HIV, HBsAg, hepatitis C antibody, TSH, T3, and T4. jHeight will be measured at the screening visit only. kVital sign measurements will include blood pressure [systolic/diastolic], respiratory rate, tympanic temperature, and pulse. lAt screening, ECG measurements will be done in triplicate. The mean of the 3 measurements will be used to determine study eli gibility. mThe FSH test will only be performed for women with no menses for 12 months in order to confirm postmenopausal status. nCGI-I during Stage 1 will be relative to screening. oDuring the in -clinic visits in Stage 1, if possible, the blood samples for PK assessment should be taken within an hour prior to dosing. In any case, the hour of the last dose taken prior to collection of the p harmacokinetic sample will be recorded on the CRF. pPatients will be advised to take the oral risperidone at approximately the same hour every day (morning or evening, at their convenience). The hour of the last dose taken prior to collection of the pharmacokinetic sample w ill be recorded on the CRF. qThe specific questions asked will be at the discretion of the investigator. A list of suggested questions will be provided to the investigator. Psychiatric adverse events or suspicion of a psychiatric deterioration as a result of the telephone contact will trigger an invitation of the pat ient to an unscheduled visit where psychiatric scales will be administered to rule out an impending relapse at the discretion of the investigator. Î²-HCG=beta human chorionic gonadotropin; AIMS=Abnormal Involuntary Movement Scale; BARS=Barnes Akathisia Rating Scale; CDSS=Calgary Depression Scale for Schizop hrenia; CGI -I=Clinical Global Impression -Improvement; CGI -S=Clinical Global Impression of Severity; CGI -SS=Clinical Global Impression - Severity of Suicidality; CRF = case report form; C -SSRS=Columbia Suicide Severity Rating Scale; DAI -10=Drug Attitudes Inve ntory 10 -item version; EQ-5D-5L=5-Level EuroQol Five Dimensions Questionnaire; ET=early termination; FSH=follicle stimulating hormone; FU=follow -up; HbsAg=hepatitis B surface antigen; HIV=human immunodeficiency virus; NPRS=Numeric Pain Rating Scale; PANSS= Positive and Negative Syndrome Scale; PK = pharmacokinetics; PSP=Personal and Social Performance Scale; qd=every day; SAE=serious adverse event; SAS=Simpson -Angus Scale; SCID -5=Structured Clinical Interview for DSM -5; SQLS=Schizophrenia Quality of Life Scale; T3=triiodothyronine; T4=thyroxine; TSH=thyroid stimulating hormone; V = Visit; Wk=week."
58,page_58,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS-30072 58Table 2: TV46000- CNS -30072 (RISE) Study Procedures and Assessments (In -Clinic Visits and Telephone Contacts) â€“ Baseline, Double -Blind Maintenance Stage (Stage 2), End of Treatment/Early Termination and Follow -Up Study Period Double -Blind Maintenance Stagea Follow -Up N/A BL Stage 2: Relapse Prevention BL The 24 -weekseries from Visit 7 to Visit 12c repeats (Visits 13 -18c, 19 -24c, etc) until patient completion, relapse or early termination.End of Treat ment (EoT)/Early Termination (ET) VisitExitb Unscheduled Visitc Visit number V6 V6a, 6b, 6cV7 V7a, 7b, 7cV8 V8a, 8b, 8cV9 V9a, 9b, 9c, V10 V10a, 10b, 10c V11 V11a, 11b, 11c V12 V12a, 12b, 12c FU1 FU2 As deemed necessary by the investigatorTime point Procedures and assessments Day1 Wk 1-3 Wk 4 Wk 5-7Wk 8 Wk 9-11Wk 12 Wk 13- 15Wk 16Wk 17-19Wk 20 Wk 21 -23Wk 24Wk 25-274 Wks after last dosing visit 8 Wks after last dosing visit (EoS) Allowed tim e window Â±3 days Â±3 days N/A In-Clinic Visit X X X X X X X X X X X Telephone Calld, eX X X X X X X Inclusion and exclusion criteriaXf Clinical laboratory testsg, h X X X X X X X Urine drug screen X X Concomitant medication inquiryX X X XX X X XX XX Fully physical examination, including weightXX X X Vital signs measurementiX X X X X X X X X X X 12-lead ECGjX X X X XkX X Serum Î² -HCG test for women of childbearing potentialX X X"
59,page_59,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS-30072 59Study Period Double -Blind Maintenance Stagea Follow -Up N/A BL Stage 2: Relapse Prevention BL The 24 -weekseries from Visit 7 to Visit 12c repeats (Visits 13 -18c, 19 -24c, etc) until patient completion, relapse or early termination.End of Treat ment (EoT)/Early Termination (ET) VisitExitb Unscheduled Visitc Visit number V6 V6a, 6b, 6cV7 V7a, 7b, 7cV8 V8a, 8b, 8cV9 V9a, 9b, 9c, V10 V10a, 10b, 10c V11 V11a, 11b, 11c V12 V12a, 12b, 12c FU1 FU2 As deemed necessary by the investigatorTime point Procedures and assessments Day1 Wk 1-3 Wk 4 Wk 5-7Wk 8 Wk 9-11Wk 12 Wk 13- 15Wk 16Wk 17-19Wk 20 Wk 21 -23Wk 24Wk 25-274 Wks after last dosing visit 8 Wks after last dosing visit (EoS) Allowed tim e window Â±3 days Â±3 days N/A In-Clinic Visit X X X X X X X X X X X Telephone Calld, eX X X X X X X Urine Î² -HCG test for women of childbearing potentiallX X X X X X X X Inquiry about pregnancy status (for women of childbearing potential)X X X XX X X PANSS X X X X X X X X X X X CGI-S X X X X X X X X X X CGI-SS X X X X X X X X X X CGI-ImX X X X X X X X X AIMS X X X X X X X X X X BARS X X X X X X X X X X SAS X X X X X X X X X X C-SSRS X X X X X X X X X X X X X X X X X X PSP (in adult patients only)X X Xn X XX"
60,page_60,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS-30072 60Study Period Double -Blind Maintenance Stagea Follow -Up N/A BL Stage 2: Relapse Prevention BL The 24 -weekseries from Visit 7 to Visit 12c repeats (Visits 13 -18c, 19 -24c, etc) until patient completion, relapse or early termination.End of Treat ment (EoT)/Early Termination (ET) VisitExitb Unscheduled Visitc Visit number V6 V6a, 6b, 6cV7 V7a, 7b, 7cV8 V8a, 8b, 8cV9 V9a, 9b, 9c, V10 V10a, 10b, 10c V11 V11a, 11b, 11c V12 V12a, 12b, 12c FU1 FU2 As deemed necessary by the investigatorTime point Procedures and assessments Day1 Wk 1-3 Wk 4 Wk 5-7Wk 8 Wk 9-11Wk 12 Wk 13- 15Wk 16Wk 17-19Wk 20 Wk 21 -23Wk 24Wk 25-274 Wks after last dosing visit 8 Wks after last dosing visit (EoS) Allowed tim e window Â±3 days Â±3 days N/A In-Clinic Visit X X X X X X X X X X X Telephone Calld, eX X X X X X X SQLS (in adult patients only)X X Xn X XX EQ-5D-5L (in adult patients only)X XXn X XX CDSS X X X X X X X X X X Healthcare resource utilizationX Xn X XX DAI-10 (in adult patients only)X X X Blood sample for pharmacogenetic analysisXo Blood sample for biomarker analysisp X X X X Blood samples for plasma drug concentrationq X X X XX X X XX X Xr"
61,page_61,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS-30072 61Study Period Double -Blind Maintenance Stagea Follow -Up N/A BL Stage 2: Relapse Prevention BL The 24 -weekseries from Visit 7 to Visit 12c repeats (Visits 13 -18c, 19 -24c, etc) until patient completion, relapse or early termination.End of Treat ment (EoT)/Early Termination (ET) VisitExitb Unscheduled Visitc Visit number V6 V6a, 6b, 6cV7 V7a, 7b, 7cV8 V8a, 8b, 8cV9 V9a, 9b, 9c, V10 V10a, 10b, 10c V11 V11a, 11b, 11c V12 V12a, 12b, 12c FU1 FU2 As deemed necessary by the investigatorTime point Procedures and assessments Day1 Wk 1-3 Wk 4 Wk 5-7Wk 8 Wk 9-11Wk 12 Wk 13- 15Wk 16Wk 17-19Wk 20 Wk 21 -23Wk 24Wk 25-274 Wks after last dosing visit 8 Wks after last dosing visit (EoS) Allowed tim e window Â±3 days Â±3 days N/A In-Clinic Visit X X X X X X X X X X X Telephone Calld, eX X X X X X X Blood samples for plasma drug concentration (Adolescents only)Xs Assessment of stability Xt Randomization X Placebo sc administrationuX X X X X X X Xv TV-46000 q1m sc administrationu X X X XX X X Xv TV-46000 q2m sc administrationu, w X XX X Xv Questions to assess ease of study drug administrationxX X X Adverse event inquiry (including SAE reporting, injection site -related events including pain)yX X X X X X X X X X X X X X X X X X"
62,page_62,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS-30072 62Study Period Double -Blind Maintenance Stagea Follow -Up N/A BL Stage 2: Relapse Prevention BL The 24 -weekseries from Visit 7 to Visit 12c repeats (Visits 13 -18c, 19 -24c, etc) until patient completion, relapse or early termination.End of Treat ment (EoT)/Early Termination (ET) VisitExitb Unscheduled Visitc Visit number V6 V6a, 6b, 6cV7 V7a, 7b, 7cV8 V8a, 8b, 8cV9 V9a, 9b, 9c, V10 V10a, 10b, 10c V11 V11a, 11b, 11c V12 V12a, 12b, 12c FU1 FU2 As deemed necessary by the investigatorTime point Procedures and assessments Day1 Wk 1-3 Wk 4 Wk 5-7Wk 8 Wk 9-11Wk 12 Wk 13- 15Wk 16Wk 17-19Wk 20 Wk 21 -23Wk 24Wk 25-274 Wks after last dosing visit 8 Wks after last dosing visit (EoS) Allowed tim e window Â±3 days Â±3 days N/A In-Clinic Visit X X X X X X X X X X X Telephone Calld, eX X X X X X X Inquiry regarding alcohol consumption/illicit drug use X X X X X X X X X X X X X X X X X X Brief set of clinical questions to detect psychotic symptomszX X X XX X X aThe double -blind maintenance stage will be variable in duration, with patients continuing until they experience a relapse event and comp lete all end -of-study assessments; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse -free during the double -blind phase until the study is terminated because at least 90 relapse events are recorded in the study in the ITT analysis set. Patient s will continue study visits and assessments as shown in the table (ie, the same assessments performed at visits Visits 7 and 8 will be repeated at visits Visits 9 and 10, respectively). How ever, note that functional measures (PSP, SQLS, and EQ -5D-5L) and the healthcare resource utilization will be performed every 12 w eeks. bWhen the study ends, eligible patients may be offered the opportunity to enter TV46000 -CNS- 30078, the long -term safety and tolerability extension study. This extension study is beyond the scope of this protocol and is detailed in a separate protocol . If the patients choose to enter the extension study, they will not need to complete the follow -up/exit visits in this study. All other patients (ie, patients who experience a relapse event, meet 1 or more of the study discontinuation or withdrawal criteria, or do not consent to join the extension study), will undergo these 2 follow -up/exit visits. During the follow -up/exit period p atients will be treated according to the investigatorâ€™s judgement. cOther procedures may be performed at the discretion of the investigator. In addition, to reduce patient burden and to avoid u nnecessary data collection, the investigator will have discretion in determining whether the procedures which are currently marked as mandatory actually need to be performed during the unscheduled visit in the case that: (i) the unscheduled visit is one of multiple in-clinic visits, that are deemed necessary in close proximity (2 or more visits"
63,page_63,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS-30072 63within 1 week), and(ii) when the visit is for administrative purposes (eg, reconsenting) or clinical reasons (eg, repeat laboratory sample collection for reasons unrelated to an adverse event or impending/current relapse), and notdue to a potential relapse or a change in the pat ient's medical status per clinical judgement . dTelephone contacts will occur weekly between clinic visits in the double -blind maintenance stage (Stage 2). These contacts will be referred to by the previous visit number and a letter (for example, the telephone contacts that take place 1, 2, and 3 w eeks after Visit 6 will be referr ed to as â€œVisit 6a,â€ â€œVisit 6b,â€ and â€œVisit 6c,â€ respectively). eEach contact will include inquiries about injection site pain, suicidal ideation and behavior, adverse events, alcohol consum ption, and pregnancy status (for women of childbearing potential). Patients will also be asked a brief set of clinical q uestions in order to detect psychotic symptoms (see relevant assessment). fPatient must meet randomization criteria in addition to other relevant inclusion criteria before randomization. gClinical laboratory tests (serum chemistry, hematology, and urinalysis) may also be performed at any time if clinically indic ated. hGlom erular Filtration Rate (GFR) will be calculated based on plasma creatinine levels, weight, gender and age using the Cockcroft -Gault equation. iVital sign measurements will include blood pressure [systolic/diastolic], respiratory rate, tympanic temperature, and pulse. jAt baseline, measurements will be done in triplicate. The mean of the 3 measurements will be used to determine study eli gibility. Single measurements will be performed at all other in -clinic visits. kDuring the EoT visit, if in the judgment of the investigator the patient will not roll over into the extension stu dy or w ill not come to one or both of the follow -up visits â€“an ECG should be performed. lUrine Î² HCG (dipstick) test will be performed at all visits where study drug is administered (prior to study drug administration). A negative result must be obtained before study study drug is administered. mCGI-I during Stage 2 will be relative to the baseline visit. nAs of Visit 9, inclusive, this assessment will be conducted every 12 weeks thereafter (Visits 12, 15, 18, and so on). oA blood sample for pharmacogenetic analysis will be collected at baseline or any visit thereafter, unless the patient declines testing or local regulations prohibit testing. pBlood for biomarker analyses will be collected as follows: 6 mL for serum, 6 mL for plasma, and 2.5 mL for PAXgene RNA, unless the patient declines testing or local regulations prohibit testing . qBlood samples for PK assessment will be taken within an h our prior to dosing. rDuring Stage 2, unscheduled pharmacokinetic samples will be aimed to be collected in the event of relapse as defined per the studyâ€™s relapse criteria, any serious adverse e vent, patient withdrawal, and/or the need for potential TV -46000 depot excision. Every effort should be made to obtain the additional pharmacokinetic sample at the closest time possible to the occurrence of the event. sAnother pharmacokinetic sample w ill be collected from adolescent patients at a supplementary in -clinic visit at Week 14 (2 Weeks after Visit 9). If it is not possible to take the sample at this visit, it may be taken 2 w eeks after another in -clinic visit. Tw o additional samples, 3 weeks and 1 w eek post -injection, respectively, may be taken at the sponsor's discretion. tStability is defined as meeting all of the following criteria for at least for 4 consecutive weeks prior to the baseline visit: outpatient status; PANSS total score â‰¤80; minimal presence of specific psychotic symptoms on the PANSS, as measured by a score of â‰¤4 on each of the following item s: conceptual disor ganization, suspiciousness, hallucinatory behavior, and unusual thought content; Clinical Global Impression of Severity (CGI -S) score â‰¤4 (moderately ill); and CGI -SS score â‰¤2 (mildly suicidal) on Part 1 and â‰¤5 (minimally worsened) on Part 2. uStudy drug will be administered per the patientâ€™s assigned treatment group. vApplicable only for EoT visit (ie, not ET). If in the judgment of th e investigator, the patient w ill not roll over into the extension study or w ill not come to one or both of the follow -up visits â€“ a dose of study drug should not be given in this EoT/ET EoT visit."
64,page_64,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS-30072 64wPatients randomized to the TV -46000 q2m group will receive a TV -46000 injection at the baseline visit and q8w thereafter and a placebo sc injection 4 w eeks after baseline and q8w thereafter to ensure blinding. xIn the event that prefilled syringes become available during the study, this will be completed by the unblinded nurse who adm inisters the study drug to the patients following the first 3 injections to each patient. yInjection site pain and other injection site reactions will only be assessed during Stage 2 of the study, in which the sc inj ections are administered. Pain may be assessed periodically using th e NPRS until resolution. zThe specific questions asked will be at the discretion of the investigator. A list of suggested questions will be provided to the investigator. Psychiatric adverse even ts or suspicion of a psychiatric deterioration as a result of the telephone contact will trigger an invitation of the patient to an unscheduled visit where psychiatric scales will be administered to rule out an impending relapse at the discretion of the in vestigator. Î²-HCG=beta human chorionic gonadotropin; AIMS=Abnormal Involuntary Movement Scale; BARS=Barnes Akathisia Rating Scale; CDSS=Calgary Depression Scale for Schizophrenia; CGI -I=Clinical Global Impression -Improvement; CGI -S=Clinical Global Impress ion of Severity; CGI -SS=Clinical Global Impression - Severity of Suicidality; C -SSRS=Columbia Suicide Severity Rating Scale; DAI -10=Drug Attitudes Inventory 10 -item version; ECG = electrocardiography; EQ-5D-5L=5-Level EuroQol Five Dimensions Questionnaire; E oS=end of study ;EoT=end of treatment; ET=early termination;FU=follow -up; NPRS=Numeric Pain Rating Scale; PANSS=Positive and Negative Syndrome Scale; PSP=Personal and Social Performance Scale; q1m = once monthly; q2m = every 2 months; q8w = every 8 weeks; RNA = ribonucleic acid; SAE=serious adverse event; SAS=Simpson -Angus Scale; sc=subcutaneous;; SQLS=Schizophrenia Quality of Life Scale; V = Visit; Wk= week."
65,page_65,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 654. SELECTION AND WITHDR AWA L OF PATIENTS Prospective waivers (exceptions) from study inclusion and exclusion criteria to allow patients to be randomized/enrolled are not granted b y Teva ( Appendix C). 4.1. Patient Inclusion Criteria Patients may be enrolled in this study only if they meet all of the following criteria: a.The patient has a diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, 5thEdition (DSM -5) for >1 year (diagnosis must be reconfirmed b y SCID-5) and has had â‰¥1 episode of relapse in the last 24 months. b.The patient has been respo nsive to an antipsy chotic treatment (other than clozapine) in the past y ear based on investigator judgement (and discussions with family members, caregivers or healthcare professionals as applicable). c.[Revision 1] The patient has provided written informed consent and is competent to do so. For adolescent patients, written informed consent has been provided by each patientâ€™s parent or legal guardian, and written assent has been provided b y each patient. d. The patient, in the investigatorâ€™s judgment, requires chronic treatment with an antipsy chotic medication. e.The patient, in the investigatorâ€™s judgment, can benefit from participation in this study . f.The patient is able to understand the nature of the study and follow protocol requirements, including the prescri bed dosage regimens, tablet ingestion , sc depot injection, and discontinuation of prohibited concomitant medications; can read and understand the written word in order to complete patient -reported outcomes measures; and can be reliably rated on assessment scales. g.The patient has a PANSS total score lower than 100 at screening. h. The patient has a stable place of residence for the previous 3 months before screening, and changes in residence are not anticipated over the course of study participation. i.The patien t has no significant life events (such as pending loss of housing, family status change, long travel abroad, surgery , etc) that could affect study outcomes expected throughout the period of stud y participation. j.[Revision 1] The patient is a male or female of any ethnic origin, 13 through 65 y ears of age at screening. k.[Revision 2] The patient has a bod y mass index between 18.0 and 38.0 kg/m2, inclusive at screening."
66,page_66,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 66l.The patient is in adequate health as determined b y medical and ps ychiatric history , medical examination, electrocardiogram (ECG), serum chemistry , hematology , urinaly sis, and serology . m.[Revision 1] Women of childbearing potential (see Appendix E) and sexually -active female adolescents must agree not to try to become pregnant, and, unless they have exclusively same -sex partners, must agree to use a highl y effective method of contraception, and agree to continue use of this method beginning 1 month before the first administration of study drugs and for the duration of the study and for 120 days after the last injection of study drug. Highly effective methods of contraception include: ï€­Combined estrogen and progestogen hormonal contraception (or al, intravaginal, transdermal) associated with inhibition of ovulation; these should be initiated at least 1 month before the first dose of IMP. ï€­Progestogen -only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation ; these should be initiated at least 1 month before the first dose of IMP. ï€­Intrauterine device and intrauterine hormone-releasing s ystem; these need to be in place at least 2 months before screening. ï€­Bilateral tubal occlusion ï€­Vasectomized partner provided that he is the sole sexual partner and has received medical assessment of the surgical process ï€­Sexual abstinence is only considered a highl y effective method if defined as refraining from heterosexual intercourse in the defined period. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifesty le of the patient. n.[Revision 1] The patient, if adult or adolescent male, is surgically sterile, or, if capable of producing offspri ng, has exclusively same -sex partners or is currently using an approved method of birth control and agrees to the continued use of this method for the duration of the study (and for 120 day s after the last dose of study drug). Male patients with sex partne rs who are women of childbearing potential (see Appendix E) must use condoms even if surgically sterile. In addition, male patients may not donate sperm for the duration of the study and for 120 days after taking the stud y drug. o.The patient must be willing and able to compl y with study restrictions and willing to return to the investigational center for the required visits throughout the duration of the study period, including follow- up procedures and assessments as specified in this protocol. Randomization Criteria: The following criteria are randomization criteria and must be fulfilled at the baseline visit before randomization in addition to other relevant inclusion criteria:"
67,page_67,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 67p.The patient has not experienced mental or ph ysical deterioration, which prevents participation in the study per investigator judgement. q. The patient has demonstrated good compliance in following protocol requirements during Sta ge 1. ï€­If the investigator or the sponsor determines that the patient was not in compliance with the study protocol, the case will be evaluated on a case -by-case basis, and the investigator and the sponsor will determine whether the patient will be randomiz ed in the double -blind period (Stage 2). r.The patient has been stabilized per the following criteria for at least 4 consecutive weeks prior to the baseline visit: ï‚·outpatient status ï‚·PANSS total score â‰¤80 ï‚·minimal presence of specific psy chotic sy mptoms on the PANSS, as measured b y a score of â‰¤4 on each of the following items: conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual thought content ï‚·CGI-S score â‰¤4 (moderately ill) ï‚·CGI-SS score â‰¤2 (mildly suicidal) on Part 1 and â‰¤5 (minimally worsened) on Part2 4.2. Patient Exclusion Criteria Patients will not be enrolled/randomized in this study if they meet any of the following criteria: a.The patient has a current clinically significant DSM- 5 diagnosis other than schizophrenia, including sch izoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnestic or other cognitive disorders, or borderline, paranoid, histrionic, schizoty pal, schizoid, or antisocial personalit y disorder. b.The patient is currently on cloza pine or has received electroconvulsive therapy in the last 12 months. c.The patient has a history of epileps y or seizures, neuroleptic malignant s yndrome, clinically significant tardive dy skinesia, or other medical condition that would expose the patient to undue risk. d.[Revision 1] The patient has a positive serology for human immunodeficiency virus (HIV) -1, HIV -2, hepatitis B surface antigen, and/or hepatitis C. I f serology is positive for hepatitis C but the RNA test is negative, and the patient has no hist ory of liver disease, enrollment will be considered following discussion between the investigator and the medical monitor as needed. e.The patient currently has or has a history of known hypersensitivity to risperidone or any of the excipients of TV -46000 or the oral formulation of risperidone used in the stabilization phase."
68,page_68,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 68f.The patient has a substance use disorder, including alcohol and benzodiazepines but excluding nicotine and caffeine. g.The patient has a significant risk of violent behavior based on the p atientâ€™s medical history or investigatorâ€™s judgement. h.The patient has a significant risk of committing suicide based on the patientâ€™s medical history or investigatorâ€™s judgement and/or the C- SSRS (lifetime). Patients with a C-SSRS (current) positive respo nse to suicidal ideation items 3, 4, or 5 are not eligible. i.The patient has previously participated in a Teva -sponsored clinical study with TV-46000. j.The patient has a clinically significant deviation from normal in the phy sical examination. k.The patient has clinicall y significant findings in biochemistry , hematology , ECG, or urinaly sis results. ï€­If the patient has a prolonged QTcF interval (defined as a QTcF interval of >450 msec for males and >470 msec for females) at screening or baseline, c alculated as the mean of the triplicate ECG measurements, eligibility will be decided on a case-by- case basis following discussion between the investigator and the sponsor. l.The patient has an y clinically significant uncontrolled medical condition (treated or untreated). The investigator may discuss with the medical monitor as needed. m.The patient is a pregnant or lactating female. n.The patient has an y disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastroint estinal surgery ). o.The patient has an y other disease or condition that, in the opinion of the investigator, would make participation not in the best interest of the patient or that could prevent, limit, or confound the protocol- specified assessments. p.The pa tient has used an investigational drug within 3 months prior to screening or has participated in a non -drug clinical trial within 30 day s prior to screening. q.The patient is using or consuming the medications prohibited in this protocol. 4.3. Withdrawal Criteria and Procedures for the Patient 4.3.1. General Withdrawal Criteria Patients are expected to participate in the stud y for its entire duration, and perform the scheduled visits and procedures. Each patient is free to withdraw from the study or discontinue treatment with I MP at an y time, without prejudice to their continued care but every effort should be undertaken to determine the reason for discontinuation."
69,page_69,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 69Every effort should be made to ensu re patients comply with study visits and procedures as detailed in the protocol. Patients must be withdrawn from the study if an y of the following events occur: 1. The patient withdraws consent or requests discontinuation from the IMP or withdrawal from the s tudy for any reason. 2. The patient develops an illness that would interfere with his or her continued participation. 3.The patient is noncompliant with the study procedures and assessments or administration of I MPs in the opinion of the investigator. 4.The patie nt takes prohibited concomitant medications as defined in this protocol. 5.A female patient has a confirmation of pregnancy during the study from a positive pregnancy test. 6.The sponsor requests withdrawal of the patient. 7. Patient experiences an adverse event or other medical condition which indicates to the investigator that continued participation is not in the best interest of the patient. Patients should be treated with standard of care after withdrawal from or termination of the study as appropriate. Alter natively , if the opportunity is available and the patient is eligible, the patient may be offered the option to participate in TV46000 -CNS -30078, the long- term safet y and tolerability extension study . See Appendix Ffor information regarding how the study will define and address lost to follow -up patients to help limit the amount and impact of missing data. If the reason for withdrawal from the stud y or discontinuation from IMP is an adverse event and/or clinicall y significant abnormal laboratory test result, monitoring will be continued as applicable (eg, until the event has resolved or stabilized, until the patient is referred to the care of a healthcare professional, or until a determination of a cause unrelated to the IMP or study procedure is made). The specific event or test result (including repeated test results, as applicable) must be recorded both on the source documentation and in the case report form (CRF); both the adverse events page and the relevant page of the CRF will be completed at that time. The patient will be monitored as applicable (eg, until the event has resolved or stabilized, until the patient is referred to the care of a healthcare professional, or until a determination of a cause unrelated to the test IMP or study procedure is made). The investigator must inform the study contact person as soon as possible of each patient who is bein g considered for withdrawal due to adverse events. Additional reports must be provided when requested. If a patient is withdrawn from the study for multiple reasons that include also adverse events, the relevant page of the CRF should indicate that the wit hdrawal was related to an adverse event. An exception to this requirement will be the occurrence of an adverse event that in the opinion of the investigator is not severe enough to warrant discontinuation but that requires the use of a prohibited medicatio n, thereb y requiring discontinuation of the patient. In such a case, the reason for discontinuation would be â€œneed to take a prohibited medicationâ€, not the adverse event."
70,page_70,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 70In the case of patients lost to follow -up, attempts to contact the patient must be made and documented in the patientâ€™s medical records and transcribed to the CRF. All assessments should be performed according to the protocol on the last day the patient takes IMP, or as soon as possible thereafter. 4.3.2. Study -Specific Patient Withdrawal Criter ia and Procedures 1.The patient withdraws consent to continue in the study for any reason. Every effort should be undertaken to identify the reason for discontinuation. 2. A serious or intolerable adverse event develops that necessitates discontinuation at the discretion of the investigator. 3. The investigator believes continued participation is not in the best interest of the patient. 4.The investigator believes that the patient has not adhered to the stud y procedures or restrictions. A protocol deviation occurs th at, in the opinion of the investigator, warrants discontinuation from the study . 5.A patient requires concomitant medication that may interfere with the pharmacokinetics of the study drug. 6.A patient relapses, as defined by the study â€™s relapse criteria (Section 9.5.1). 7.A patient demonstrates a significant clinical deterioration that cannot be managed with rescue medication, as judged b y the investigator based on an y relevant history or observation made b y the investigative site, including rating scales. 8.A patient has a mean increase of â‰¥30 ms from baseline in triplicate QTcF (interval corrected for heart rate using Fridericiaâ€™s formula) values at an y visi t, pending discussion between the sponsor and the investigator. 9. A patient exhibits an event of possible drug- induced liver injury that requires immediate study treatment cessation and is defined as follows: ï€­alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >8 times the upper limit of normal (ULN) ï€­ALT or AST >5Ã—ULN for more than 2 weeks ï€­ALT or AST >3Ã—ULN and total bilirubin level >2Ã—ULN or international normalized ratio >1.5 ï€­ALT or AST >3Ã—ULN with the appearance of fatigue, nausea, vomi ting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%) 4.3.3. Pharmacokinetic Sampling in Case of Patient Withdrawal Note: Withdrawal under the above criteria (see Section 4.3.2 ) will be discussed by the investigator and the sponsor. For patients who withdraw from the study , every effort will be made to follow safet y after withdrawal, including pharmacokinetic sampling when ap plicable,"
71,page_71,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 71unless consent is withdrawn. For pharmacokinetics , the sample date and time will be recorded both on the source documentation and the CRF. If a patient is withdrawn from the study or there is an occurrence of a serious adverse event that in the j udgement of the investigator would be best managed b y immediate cessation of treatment, the possibility to excise the depot should be discussed with the sponsor to draw on learnings of this procedure gained during pre -clinical studies. In this case, 2 cons ecutive pharmacokinetic samples will be obtained: 1 immediately before the excision procedure, and 1 several hours after the procedure and prior to patient discharge. Additional pharmacokinetic samples may be obtained if judged to be required b y the sponso r. The sample date and time as well as the date and time of the excision procedure will be recorded both on the source documentation and the CRF. 4.4. Replacement of Patients A patient who is randomized but does not complete all treatment periods will not be r eplaced with another eligible patient. 4.5. Rescreening A patient who is screened but not enrolled, eg, because enrollment inclusion and exclusion criteria were not met or enrollment did not occur within the specified window, may be considered for screening aga in if, eg, there is a change in the patientâ€™s medical condition or a modification of study inclusion and exclusion criteria. Patients may have individual parameters retested at the discretion of both the investigator and the sponsor . Patients may be rescre ened once if the repeated values for the laboratory , vital sign, or ECG screening criteria are within acceptable limits as judged by the investigator or if repeated values show normalization of the out- of-range values, but their initial screening period ha s expired. If the patient is rescreened, an informed consent form (I CF) will need to be resigned. 4.6. Screening Failure Screening failures are defined as participants who consent to participate in the clinical study but are not subsequently enrolled in the stu dy. Minimal information must be obtained, including but not limited to demography , screening failure details, eligibility criteria, and any serious adverse events."
72,page_72,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 725. TREA TMENTS 5.1. Investigational Medicinal Products Used in the Study Investigational medicinal product is defined as the test I MP ( Table 4). 5.1.1. Test Investigational Medicinal Product TV-46000 will be supplied as a read y-to-use, extended -release inje ctable product in a single- use . For COVID - 19 updates, refer to Appendix N. 5.1.1.1. Starting Dose and Dose Levels In general, TV -46000 will be administered to patients in the abdomen (except as indicated below) b y sc injection, at intervals of q1m or q2m, at a dose equivalent to oral risperidone 2 to 5 mg/day on which they were stabilized in Stage 1, per the conversion table below ( Table 3). The maximal dose administered will be equivalent to an oral risperidone dose of 5 mg/day . Patients that require a stabilization dose below 2 mg/day will not be randomize d in the study . Also, as a precautionary measure, adolescent patients that will require a stabilization dose of more than 4 mg during the stabilization stage will not be randomized. Several investigational centers may be selected by the sponsor (based on the centersâ€™ capabilities, sponsor's considerations, and prior clinical experience with injectable medication) for injection of study drug into the back of the upper arm, instead of the abdomen, to all or some of the enrolled patients at these sites (appro ximately 20% of the study patient population)."
73,page_73,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 73Table 3: Conversion Table Between Oral Risperidone and TV- 46000 Doses Frequency of TV-46000 AdministrationOral Risperidone Doses and Corresponding TV -46000 Doses 2 mg/day 3 mg/day 4 mg/day 5 mg/day (Adults Only) The injection site that is chosen for an individual patient should remain consistent throughout the study . If the chosen site is the arm, the injection will be administered in an alternating manner between the right arm and the left. If the chosen site is the abdomen, the injection will be administerd in an alternating manner to the right and to the left of the umbilicus. Further details will be provided in the dosing manual. 5.1.1.2. Dose Modification and Dose Stratification The dose of test IMP will not be modifie d for a given patient during the study . 5.1.2. Placebo Investigational Medicinal Product TV-46000 placebo is available as an extended- release injectable product Additional details about sc injection administration can be found in the study manual. For COVID -19 updates, refer to Appendix N."
74,page_74,Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 74
75,page_75,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 755.2. Preparation, Handling, Labeling, Storage, and Accountability for IMPs 5.2.1. Storage and Security The investigator or designee must confirm appropriate temperature conditions have been maintained for all medicinal products re ceived, and any discrepancies must be reported and resolved before their use. The IMPs (TV -46000 and TV -46000 placebo) must be stored according to the storage conditions specified on the label and must be securel y locked and kept in the outer carton until use. For COVID -19 updates, refer to Appendix N. 5.2.2. Labeling Supplies of I MPs will be labeled a ccording to the current International Council for Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and Good Manufacturing Practice and will include any locall y required statements. I f necessary , labels will be translated into the local langua ge. 5.2.3. Accountability Each IMP shipment will include a packing slip listing the contents of the shipment and any applicable forms. The investigator is responsible for ensuring that deliveries of IMPs and other study materials from the sponsor are correctly received, recorded, handled, and stored safely and properl y in accordance with the Code of Federal Regulations (CFR) or national and local regulations, and are used in accordance with this protocol. Only patients enrolled in the study may receive IMPs, and only authorized staff at each investigational center may suppl y or administer IMPs. All I MPs must be stored in a secure, environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions or appropriate instructions with access limited to the investigator and authorized staff at each investigational center. The investigator, institution, or the head of the medical institution (where applicable) is responsible for IMP accountability , reconciliation, and record maintenance (ie, receipt, reconciliation, and final disposition records). A record of IMP accountability (ie, IMP and other study materials received, used, retained, returned, or destro yed) must be prepared and signed by the principal investigator or designee, with an account given for any discrepancies. All test or placebo IMP supplies (used, partially - used and unused) will be returned to the sponsor or its designee according to local and national regulations and the siteâ€™s standard operating procedur es (SOPs), following written authorization from the sponsor."
76,page_76,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 76The sponsorâ€™s monitor will review all relevant drug -related information for accountability purposes prior to an y drug destruction. Documented evidence of destruction should be made available to the sponsor and/or its designees. The investigator, pharmacist, or drug administrator must verify that no TV -46000 drug supplies remain in the study centersâ€™ possession at the end of the study . For COVID -19 updates, refer to Appendix N. 5.3. 5.3.2. Justification for Use of Placebo Investigational Medicinal Product The US FDA requires a placebo -controlled study to demonstrate the efficacy and safet y of TV- 46000 for the maintenance treatment of patients with chronic schizophrenia. Whi le it has been demonstrated that regular use of antipsy chotics reduces the rate of relapses, treatment compliance is poor, which is often related to side effects. It is considered justified to treat patients with placebo after they have been stabilized on oral active treatment. Patients who experience a relapse will discontinue study drug and may be treated using standard of care. 5.4. Other Medicinal Products/Non -Investigational Medicinal Products In the US, oral risperidone for stabilization ( Table 5) will be a commercial product supplied by the study center. In Bulgaria, oral risperidone for stabilization ( Table 5 ) will be a commercial product supplied centrally b y the sponsor. The brand name of the oral risperidone supplied will be recorded on the source documentation."
77,page_77,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 77Oral risperidone is to be stored acc ording to the manufacturerâ€™s Summary of Product Characteristics (SmPC) . Note that oral risperidone is mandated for use in this study; however, for the purposes of this study , it is not considered an IMP. Table 5: Other Medicinal Products Used in the Study Medicinal product nam e Stabilization Trade name and INN, if applicable, or company -assigned numberrisperidone Form ulation tablets, oral solution, or orally disintegrating tabletsa Unit dose strength(s)/dosage level(s) multiple strengths commercially available Route of administration oral; self -administered by patient Dosing instructions 2 to 5 mg/day Packaging various (commercial product) Manufacturer various (commercial product) aThe brand name of the oral risperidone supplied w ill be recorded on the source documentation. INN=international nonproprietary n ame. 5.5. Treatment After the End of the Study In case the patient is withdrawn from this study , no further treatment is planned by the sponsor after the patient completes their participation in this study . Patients will be advised to return to their primary physician for additional treatment. Patients may be treated in the meantime per investigator judgment and instruction as applicable. When the study ends, eligible patients may be offered the opportunity to enter the TV46000- CNS -30078 extension study to asses s the long -term safet y and tolerability of extended -release risperidone. This extension study is bey ond the scope of this protocol, and a separate protocol was issued for it. 5.6. Restrictions Patients will be required to comply with the following restrictions: 5.6.1. Activity There are no specific restrictions in this study regarding normal daily activities, unless otherwise advised b y the investigator. 5.6.2. Specific Beverages Patients should not consume excessive amounts of alcoholic beverages, defined as more than 2 units per day (1 unit=1/2 pint [8 ounces] of beer, 1 small glass [5 ounces] of wine or 1 measure of spirits) during the course of the stud y, including the follow -up/exit period. Patient should be advised regarding potential risk of drowsiness, dizziness and ot her side effects of alcohol on risperidone treatment."
78,page_78,Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 785.6.3. Blood Donation Patients may not donate blood from 30 day s prior to the first I MP administration until 6 months after the last I MP administration. 5.7.
79,page_79,Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 79 5.8.
80,page_80,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 80If the investigator or the sponsor determines that the patient is not in compliance with the study protocol, the investigator and the sponsor should determine whether the patient should be withdrawn from the study. 5.9. Randomization and Blinding Patients will be randomized to rec eive doses of TV -46000 q1m sc injection, TV -46000 q2m sc injection, or placebo q1m sc injection in a 1:1:1 ratio. Randomization will be stratified b y gender (male or female) and the dose of oral risperidone on which the patient was stabilized during Stage 1 (2/3, 4, or 5 mg). The doses of TV -46000 will be equivalent to 2 to 5 mg/day of oral risperidone ( equivalent to the oral dose on which the patient was stabilized in Stage 1 ). Patients randomized to TV- 46000 q1m or placebo sc will receive an sc injection of TV -46000 or placebo, respectivel y, at baseline and q4w thereafter. Patients randomized to TV- 46000 q2m will receive a TV -46000 injection at baseline and q8w thereafter and a placebo sc injection 4 weeks after baseline and q8w thereafter to ensure blindi ng of the doses and durations of the TV - 46000 injections and the placebo injections. Patients and investigators will remain blinded to the identity of the treatment administered to each patient. Due to the differences between the TV -46000 product and place bo,an unblinded nurse, not associated with rating the patient (including assessment of the injection site if needed) and independent from the study team, will be required at each site to administer the study drug. Patients will be randomly assigned to treatment groups by means of a c omputer -generated randomization list. The randomization list will be assigned to the relevant treatment groups through a qualified service provider (eg, via the Interactive Response Technology [IRT] sy stem). The generation of the randomization list and man agement of the IRT s ystem will be done by a qualified service provider under the oversight of the responsible function at Teva. The specifications for randomization will be under the responsibility and oversight of Teva Global Statistics. The sponsorâ€™s cli nical personnel (and delegates) involved in the study will be blinded to the identity of the IMPs until the database is locked for final anal ysis, and t he IMP assignment is known. However, if a prioritized sample analy sis is needed, bioanalytical and IDMC clinical pharmacology representatives are unblinded. In the event of an emergency (ie, where knowledge of the study drug assignment is needed to make treatment decisions for the patient), the treatment group and dose to which the patient has been allocated can be determined by accessing the I RT s ystem. All investigational centers will"
81,page_81,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 81be provided with details on how to access the s ystem for code breaking at the start of the study . The Medical Monitor or equivalent should be notified following unblinding. Any unblinding of the IMP performed by the investigator must be recorded in the source documents. The pharmacist at each investigational center who will dispense the I MPs will know the I MP assignments for each patient. I n addition, up to 2 other individuals from each investigational center will know the IMP assignments to provide quality assurance and oversight in their preparation and administration, as necessary . These individuals will not be involved in conduct of an y study procedures and assessment of an yadverse events and should not discuss the medication assignment or appearance with others (except for the unblinded nurse administering the medication). For COVID -19 updates, refer to Appendix N. 5.10. Maintenance of Randomization and Blinding 5.10.1. Maintenance of Randomization Patient randomization codes will be maintained in a secure location at the service provider contracted to generate the codes. At the time of analy sis (after the end of study ), after receiving unblinding request from Teva statistician, the service provider will provide the unblinded I MP assignment according to the processes defined in the relevant SOP. 5.10.2. Blinding and Unblinding Pharmacokinetic data will be assessed during the study . Personnel responsible for bioanal ysis will be provided with the randomization code in order to facilitate the analysis. However, the personnel responsible for bioanaly sis will not have access to clinical safet y and efficacy data and will provide unblinded pharmacokinetic concentration data to the unblinded statistician for provisio n to the I DMC members for review, and to a pharmacometrics modeler, independent of the study team, for update of the population pharmacokinetic model. In addition, the modeler may receive other relevant patient information to update the model (such as demo graph y, certain clinical laboratory results, etc). The detailed process of data delivery to the IDMC will be described in the IDMC charter. The detailed process of pharmacokinetic analy sis during the course of the stud y will be described in the pharmacokin eticanaly sis plan. The pharmacokinetic concentrations and modeling results will not be available to the sponsorâ€™s study team until unblinding of study . For information about personnel who may be aware of IMP assignments (including an unblinded nurse and an unblinded pharmacist), see Section 5.9. These individuals will not be involved in conduct of an y stud y procedures or assessment of any adverse e vents . In case of a serious adverse event, pregnancy , or in cases when knowledge of the IMP assignment is needed to make treatment decisions, the investigator may unblind the patientâ€™s IMP assignment as deemed necessary , mainl y in emergency situations. Individual randomization codes, indicating the IMP assignment for each randomized patient, will be available to the investigator(s) or pharmacist(s) at each investigational center via the IRT, both via telephone and internet. Breaking of the treatment code can alway s be performed b y the investigator without prior approval by the sponsor; however, the sponsor should be notified following the breaking of the treatment code. The patient's IMP assignment should not be revealed to the sponsor."
82,page_82,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 82When a blind is broken, the patient will be withdrawn from the study , and the event will be recorded on the CRF. The circumstances leading to the breaking of the code should be fully documented in the investigatorâ€™s study files and in the patientâ€™s source documentation. Assignment of IMP should not be recorded in an y study documents or source document. In blinded studies, for an adverse event defined as a suspected unexpected serious adverse reaction (SUSAR) (ie, reasonable possibility ; see Section 7.1.4), the Global Patient Safety and Pharmacovigilance (GPSP) team may independently request that the blind code be broken (on a case-by-case basis) to comply with regulatory require ments. The report will be provided in an unblinded manner for regulatory submission. If this occurs, blinding will be maintained for the investigator and for other personnel involved in the conduct of the stud y, and anal ysis and reporting of the data. 5.10.3. Data Monitoring Committee During the conduct of this study there will be an IDMC that will review accumulating unblinded safet y and pharmacokinetic data on a regular basis (as detailed in the IDMC charter) to ensure the continuing safet y of the study patients and an y study conduct issues. The IDMC will be composed of independent physicians with expertise in the relevant therapeutic field and other relevant experts, such as a statistician and a pharmacokinetic specialist. The IDMC chairperson will communicate with the sponsor in regard to issues resulting from the conduct and clinical aspects of the study . The sponsor will work closel y with the committee to provide the necessary data for review. The IDMC will provide recommendations about modify ing, stopping, o r continuing the study . The conduct and specific details regarding the IDMC sessions will be outlined in the IDMC charter. 5.11."
83,page_83,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 836. ASSESSMENT OF EFFICA CY For each assessment, where applicable, every effort should be made to retain the same rater for each patient throughout the course of the stud y, except under exceptional circumstances. For COVID -19 updates, refer to Appendix N. 6.1. Assessments of Efficacy 6.1.1. Clinical Global Impression â€“ Improvement (CGI -I) The Clinical Global I mpression â€“Improvement (CGI -I) scale permits a global evaluation of the patientâ€™s improvement in sy mptoms overall. The CGI -I scale rates the patientâ€™s impro vement relative to his or her s ymptoms on a 7- point scale ranging from 1 (very much improved) to 7 (very much worse) ( Guy 1976a ). The CGI -I will be administered b y the investigator/trained rater at all visits during the stud y (except for the screening and baseline visits). 6.1.2. Positive and Negative Syndrome Scale (PANSS) The PANSS ( Kay et al 1987) is a 30 -item instrument used in patients with schizophrenia to identify the presence and severit y of ps ychopathology symptoms, the relationship of these symptoms to one another, and the global psy chopathology . Each item is scored on a 7 -point scale ranging from 1 (absent) to 7 (extreme). The positive sy mptom scale includes 7 items with a maximum score of 49; t he negative s ymptom scale includes 7 items with a maximum score of 49; and the general ps ychopathology scale includes 16 items with a maximum score of 112. The PANSS will be administered b y the investigator at screening and all visits during the study. 6.2. Other Assessments 6.2.1. Structured Clinical Interview for DSM -5 (SCID -5) The SCI D-5 is a semi -structured interview guide for making DSM -5 diagnoses. I t will be administered at screening by a clinician or trained mental health professional that is familiar with the DSM -5 classification and diagnostic criteria. The SCI D-5 can be used to ensure that the major DSM -5 diagnoses are sy stematically evaluated and that all of the stud y patients have s ymptoms that meet the DSM- 5 criteria for inclusion and exclusion and to char acterize a study population in terms of current and previous psy chiatric diagnoses ( First et al 2015 ). 6.2.2. Quality of Life Scales 6.2.2.1. Schizophrenia Quality of Life Scale (SQLS) SQL S will be administered to adult patients only at the time points specified in Table 1and Table 2, and is used to capture quality of life. The 33- item measure yields 3 subscale scores:"
84,page_84,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 84psychosocial, motivation/energy , and s ymptoms/side effects ( Wilkinson et al 2000 ). Higher scores on the scales indicate worse quality of life. 6.2.2.2. 5-Level EuroQol Five Dimensions Questionnaire (EQ- 5D-5L) The 5 -Level EuroQol Five Dimensions Questionnaire (EQ-5D- 5L) will be administered to adult patients only at the time points specified in Table 1andTable 2 , and is a standardized questionnaire that assesses overall state of health. The EQ-5D- 5L consists of 2 parts. In Part 1, patients rate their health state in 5 domains (mobility , self - care, usual activities, pain/discomfort, and mood) using a scale of 1 to 5, where 1 = no problems, 2 = slight problems, 3 = moderate problems, 4 = severe problems, and 5 = extreme problems. In Part 2, patients rate their health state on a 100 -mm visual analog scale; a rating of 0 represents the worst imaginable health state, and a rating of 100 represents the best imaginable health state ( EuroQol Group 1990, Rabin and de Charro 2001 ). 6.2.3. Drug Attitudes Inventory 10- item Version (DAI -10) The Drug Attitudes Inventory 10-item version (DAI -10) will be administered to adult patients only at the time points specified in Table 1andTable 2, and measures subjective responses and attitudes toward maintenance of antipsy chotic drug therapy that may affect compliance. There are 2 versi ons: the DAI -10 and the DAI -30, which track very closel y (r=0.93), and onl y the shorter DAI -10 will be used. The DAI -10 consists of 10 items covering 3 domains (subjective positive, subjective negative, and attitude toward medication), although only a sing le composite score is computed ( Hogan et al 1983, Nielsen et al 2012 ). A positive total score indicates a compliant response and a negative score indicates a non- compliant response. 6.2.4. Personal and S ocial Performance Scale (PSP) The Personal and Social Performance Scale (PSP) will be administered to adult patients only at the time points specified in Table 1andTable 2,and is a clinician -rated instrument that measures personal and social functioning in patients with schizophrenia ( Morosini et al 2000 ). The PSPis a 100-point si ngle- item rating scale, divided into 10 equal intervals. The score is based on the assessment of patientâ€™s functioning in 4 categories: 1) socially useful activities; 2) personal and social relationships; 3) self -care; and 4) disturbing and aggressive beha viors. Higher scores represent better personal and social functioning, with ratings from 91 to 100 indicating more than adequate functioning, while scores under 30 indicating functioning so poor that intensive supervision is required. 6.2.5. Healthcare Resource U tilization Healthcare resource utilization will be assessed for both adult and adolescent patients approximately every 3 months (at the time points specified in Table 1andTable 2) for hospitalizations, emergency room (ER) visits, and outpatient visits (ie, not including protocol - mandated outpatient visits). Hospitalizations will be assessed as the percentage of patients with hospitalizations over the past 4 weeks, associated length of stay , and the number of hospitalizations among patients who were hospitalized. I n addition, the percentage of patient s with ER visits and number of ER visits over the past 4 weeks and the percentage of patients with outpatient visits and number of outpatient visits over the past 4 weeks will be evaluated."
85,page_85,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 85This should be completed by the site investigator/coordinator through patient interviews. and where possible, verification against medical records should be performed. The famil y member or caregiver may also need to provide input. 6.2.6. Clinical Global Impression of Severity The CGI -S scale was developed to rate the severity of a patientâ€™s condition on a 7 -point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients; Guy 1976a ). The CGI -S will be administered by the investigator/trained rater at all in- clinic vis its."
86,page_86,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 867. ASSESSMENT OF SAFETY In this stud y, safety will be assessed b y qualified study personnel by evaluating the reported adverse events, clinical laboratory test results, vital sign measurements, ECG findings, phy sical examination findings (including bod y weight measurements), use of concomitant medication, and local injection site tolerance . Additional assessments of safet y of specific interest to the use of medicinal products in schizophrenia include assessments of suicidality , depression, and abnormal movements (eg, tardive d yskinesia, akathisia, and parkinsonism). For COVID -19 updates, refer to Appendix N. 7.1. Adverse Events 7.1.1. Definition of an Adverse Eve nt Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can, therefore, be an y unfavorab le and unintended ph ysical sign, s ymptom, or laboratory parameter that develops or worsens in severit y during the course of thisstudy , or significant worsening of the disease under study , or of any concurrent disease, whether or not considered related to the IMP. A new condition or the worsening of a pre- existing condition will be considered an adverse event. Stable chronic conditions (such as arthritis) that are present before stud y entry and do not worsen during thisstudy will not be considered adverse events. Accordingl y, an adverse event can include an y of the following: ï‚·intercurrent illnesses ï‚·physical injuries ï‚·events possibly related to concomitant medication ï‚·significant worsening (change in nature, severit y, or f requency ) of the disease under study or other pre- existing conditions ï‚·drug interactions ï‚·events occurring during diagnostic procedures or during an y washout phase of this study ï‚·laboratory or diagnostic test abnormalities that result in the withdrawal of the patient from the study , are associated with clinical signs and sy mptoms or a serious adverse event, require medical treatment or further diagnostic work- up, or are considered b y the investigator to be clinically significant. (Note: Abnormal laboratory or diagnostic test results at the screening visit that preclude a patient from entering the stud y or receiving stud y treatment are not considered adverse events.)"
87,page_87,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 87Worsening of the disease under study , schizophrenia, will be assessed using PANSS and should be recorded as an adverse event onl y if the presentation or outcome is more severe than would normally be expected from the normal course of the disease in a particular patient. A relapse event, defined per one of the criteria listed (see primary endpoint definition in Section 2.1), will not be automatically classified as an adverse event unless specificall y judged as such by the investigator. 7.1.2. Recor ding and Reporting of Adverse Events For recording of adverse event, the study period is defined for each patient as the time period from signature of the ICF to the end of the follow -up period. The follow -up period of recording of adverse events is define d as 120days after the last dose of IMP. The period for reporting treatment -emergent adverse events is defined as the period after the first dose of IMP is administered and until 120days after the last dose of IMP. All adverse events that occur during th e defined study period must be recorded both on the source documentation and the CRF, regardless of the severit y of the event or judged relationship to the I MP. For serious adverse events, the serious adverse event form must be completed, and the serious a dverse event must be reported immediately (Section 7.1.5.3.1). The investigator does not need to activel y monitor patients for adverse events after the defined period. At each contact with the patient, the investigator or designee must question the patient about adverse events b y asking an open- ended question such as â€œHave y ou had any unusual sy mptoms or medical problems since the last visit? If yes, please describe.â€ All reported or observed signs and sy mptoms will be recorded individually , except when considered manifestations of a medical condition or disease state. A precise diagnosis will be recorded whenever possible. When such a diagnosis is mad e, all related signs, symptoms, and an y test findings will be recorded collectively as a single diagnosis on the CRF and, if it is a serious adverse event, on the serious adverse event form. The clinical course of each adverse event will be monitored at suitable intervals until resolved, stabilized, or returned to baseline; or until the patient is referred for continued care to a healthcare professional; or until a determination of a cause unrelated to the IMP or stud y procedure is made. The onset and end d ates, duration (in case of adverse event duration of less than 24 hours), action taken regarding IMP, treatment administered, and outcome for each adverse event must be recorded both on the source documentation and the CRF. The relationship of each adverse event to IMP and study procedures, and the severit y and seriousness of each adverse event, as judged b y the investigator, must be recorded as described below. Further details are given in the Safety Monitoring Plan. 7.1.3. Severity of an Adverse Event The severi ty of each adverse event must be recorded as 1 of the following: Mild: No limitation of usual activities"
88,page_88,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 88Moderate: Some limitation of usual activities Severe: Inability to carry out usual activities 7.1.4. Relationship of an Adverse Event to the Investigational M edicinal Product The relationship of an adverse event to the IMP is characterized as follows: Table 6: The Relationship of an Adverse Event to the IMP Term Definition Clarification No reasonable possibility (not related)This category applies to adverse events that, after careful consideration, are clearly due to extraneous causes (disease, environment, etc) or to adverse events that, after careful medical consideration at the time they are evaluated, are judged t o be unrelated to the IMP.The relationship of an adverse event may be considered â€œno reasonable possibilityâ€ if it is clearly due to extraneous causes or if at least 2 of the following apply: ï‚·It does not follow a reasonable temporal sequence from the admi nistration of the IMP. ï‚·It could readily have been produced by the patientâ€™s clinical state, environmental or toxic factors, or other modes of therapy administered to the patient. ï‚·It does not follow a known pattern of response to the IMP. ï‚·It does not reappear or worsen when the IMP is re-administered. Reasonable possibility (related)This category applies to adverse events for which, after careful medical consideration at the time they are evaluated, a connection with the administration of IMP cannot be ruled out with certainty.The relationship of an adverse event may be considered â€œreasonable possibilityâ€ if at least 2 of the following apply: ï‚·It follows a reasonable temporal sequence from administration of the IMP. ï‚·It cannot be reasonably explained by t he known characteristics of the patientâ€™s clinical state, environmental or toxic factors, or other modes of therapy administered to the patient. ï‚·It disappears or decreases on cessation or reduction in dose. There are important exceptions when an adverse ev ent does not disappear after discontinuation of the IMP, yet an IMP relationship clearly exists. ï‚·It follows a known pattern of response to the IMP. IMP=investigational medicinal product. 7.1.5. Serious Adverse Events For recording of serious adverse events, the study period is defined for each patient as that time period from signature of the I CF to the end of the follow -up period. Serious adverse events occurring in a patient after the end of the follow -up period should be reported to the sponsor if the investigator becomes aware of them, following the procedures described in Section 7.1.5.3.1. A relapse event, defined per one of the criteria listed (see p rimary endpoint definition in Section 2.1), will not be automatically classified as a serious adverse event unless specificall y judged as such b y the investigator."
89,page_89,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 897.1.5.1. Definition of a Serious Adverse Event A serious adverse event is an adverse event occurring at an y dose that results in any of the following outcomes or actions: ï‚·results in death ï‚·is life -threatening adverse event (ie, the patient was at risk of death at the time of the event); it does not refer to an event which h ypothetically might have caused death if it were more severe ï‚·requires inpatient hospitalization or prolongation of existing hospitalization, which means that hospital inpatient a dmission or prolongation of hospital stay were required for treatment of an adverse event, or that they occurred as a consequence of the event Hospitalizations scheduled before the patient signed the ICF will not be considered serious adverse events, unles s there was worsening of the pre -existing condition during the patientâ€™s participation in this study . ï‚·results in persistent or significant disability /incapacity (refers to a substantial disruption of oneâ€™s ability to conduct normal life functions) ï‚·is a congenital anomal y/birth defect ï‚·an important medical event that may not result in death, be life -threatening, or require hospitalization, but may jeopardize the patient and may require medical intervention to prevent 1 of the outcomes listed in this definition Examples of such events are intensive treatment in an ER or at home for allergic bronchospasm; blood dy scrasias or convulsions that do not result in hospitalization; or the development of drug dependency or drug abuse. Note: Any suspected transmission of an infectious agent via a medicinal product is considered an important medical event . All occurrences of possible drug -induced liver injury that meet Hy â€™s law criteria, defined as al l of the below, must be reported by the investigator to the sponsor as a serious adverse event: ï‚·ALT or AST increase of >3Ã— the ULN ï‚·total bilirubin increase of >2Ã— ULN ï‚·absence of initial findings of cholestasis (ie, no substantial increase of alkaline phosphatase) An adverse event that does not meet an y of the criteria for serio usness listed above will be regarded as a nonserious adverse event. 7.1.5.2. Expectedness A serious adverse event that is not included in the Adverse Reaction section of the relevant RSI by its specificit y, severity, outcome, or frequency is considered an unexpecte d adverse event. The RSI for this study is the RSI section of the current version of the IB for TV -46000. For the purpose of SUSAR reporting, the version of the RSI at the time of occurrence of the SUSAR applies."
90,page_90,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 90A serious adverse event that is not included in the Listing of Adverse Reactions in the RSI by its specificit y, severity, outcome, or frequency is considered an unexpected adverse event. The sponsorâ€™s GPSP team will determine the expectedness for all serious adverse events. 7.1.5.3. Reporting a Serio us Adverse Event 7.1.5.3.1. Investigator Responsibility To satisfy regulatory requirements, a ll serious adverse events that occur during the study , regardless of judged relationship to administration of the IMP, must be reported to the sponsor by the investigator. Th e event must be reported within 24 hours of when the investigator learns about it. Completing the serious adverse event form and reporting the event must not be delay ed, even if not all the information is available. The investigator does not need to active ly monitor patients for adverse events once this study has ended. Serious adverse events occurring to a patient after the last administration of I MP of that patient has ended should be reported to the sponsor if the investigator becomes aware of them . The serious adverse event form should be sent to the local safet y officer (LSO) or designee (a contract research organization [CRO] in a country without a sponsor L SO) (contact information is in the Clinical Study Personnel Contact Information section); the L SO will forward the report to the sponsorâ€™s GPSP team. The following information should be provided to record the event accurately and completel y: ï‚·study number ï‚·investigator and investigational center identification ï‚·patient number ï‚·onset date and detailed description of adverse event ï‚·investigatorâ€™s assessment of the relationship of the adverse event to the IMP (no reasonable possibility and reasonable possibility ) Additional information includes: ï‚·age and sex of patient ï‚·date of first dose of IMP ï‚·date and amount of last administered dose of IMP ï‚·action taken ï‚·outcome, if known ï‚·severit y ï‚·explanation of assessment of relatedness ï‚·concomitant medication (including doses, routes of administration, and regimens) and treatment of the event ï‚·pertinent laboratory or other diagnostic test data"
91,page_91,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 91ï‚·medical history ï‚·results of dechallenge/rechallenge, if known ï‚·for an adverse event resulting in death ï€­cause of death (whether or not the death was related to I MP) ï€­autopsy findings (if available) Each report of a serious adverse event will be reviewed and evaluated by the investigator and the sponsor to assess the nature of the event and the relationship of the event to the I MP, study procedures, and to underlying disease. Additional information (follow -up) about an y serious adverse event unavailable at the initial reporting should be forwarde d by the investigator within 24 hours of when it becomes known to the same address as the initial report. For all countries, the sponsorâ€™s GPSP team will distribute the Council for International Organizations of Medical Sciences form/Extensible Markup Lang uage file to the L SO/CRO for submission to the competent authorities (CAs), Independent Ethics Committee/Institutional Review Boards (IEC/IRBs), and investigators, according to regulations. The investigator must ensure that the IEC/IRB is also informed of the event, in accordance with national and local regulations. For double -blind studies, blinding will be maintained for all study personnel except the unblinded nurse. Therefore, in case of a SUSAR, only the LSO/CRO will receive the unblinded report for re gulatory submission; the others will receive a blinded report. 7.1.5.3.2. Sponsor Responsibility If a serious unexpected adverse event is believed to be related to the IMP or study procedures, the sponsor will take appropriate steps to notify all investigators partic ipating in sponsored clinical studies of IMP and the appropriate CAs (and IEC/I RB, as appropriate). In addition to notify ing the investigators and CAs (and IEC/IRB, as appropriate), other action may be required, including the following: ï‚·altering existing r esearch by modify ing the protocol ï‚·discontinuing or suspending the stud y ï‚·modify ing the existing consent form and informing all study participants of new findings ï‚·modify ing listings of expected toxicities to include adverse events newl y identified as related to IMP"
92,page_92,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 927.1.6. Protocol -Defined Adverse Events of Special Interest No protocol -defined adverse events of special interest were identified for this study . 7.1.7. Protocol Deviations Because of an Adverse Event If a patient experiences an adverse event or medical emergenc y, deviations from the protocol may be allowed on a case -by-case basis. To ensure patient safety , after the event has stabilized or treatment has been administered (or both), the investigator or other phy sician in attendance must contact the ph ysician iden tified in the Clinical Study Personnel Contact Information section of this protocol as soon as possible to discuss the situation. The investigator, in consultation with the sponsor, will decide whether the patient should continue to participate in the stud y. 7.2. Pregnancy Any female patient becoming pregnant during the study will discontinue IMP. All pregnancies of women participating in the study and female partners of men participating in the study , if applicable, that occur during the study , or within at lea st 120 day s after the end of study , are to be reported immediately to the individual identified in the Clinical Study Personnel Contact I nformation section of this protocol, and the investigator must provide the sponsor (LSO/CRO) with the completed pregnancy form. The process for reporting a pregnancy is the same as that for reporting a serious adverse event but using the pregnancy form (Section 7.1.5.3). The investigator is not required to report patients who are found to be pregnant between screening and baseline, provided no protocol- related procedures were applied. All female patients (or female partners of men participating in the study ) who become pregnant will be monitored for the outcome of the pregnancy (including spontaneous, elective, or voluntary abortion) .If the pregnancy continues to term, the outcome (health of the infant up to 8weeks of age), including details of birth and presenc e or absence of any birth defect, congenital abnormalities, or maternal and newborn complications, will be reported to the sponsor. Any complication of pregnancy during the study and any complication of pregnancy that the investigator becomes aware of afte r withdrawal from the study will be reported as an adverse event or serious adverse event, as appropriate. Since there is lack of data on human teratogenicity, genotoxicity , fetotoxicity , or spermatoxicity for this I MP, female partners of men participating in the study who become pregnant will be asked to sign an ICF and will be monitored for the outcome of the pregnancy (including spontaneous, elective, or voluntary abortion) . If the pregnancy continues to term, the outcome (health of the infant up to 8 weeks of age), including details of birth and presence or absence of any birth defect, congenital abnormalities, or maternal and newborn complications, will be reported to the sponsor. Any complication of pregnancy during the study and any complication of pr egnancy that the investigator becomes aware of after withdrawal from the study will be reported as an adverse event or serious adverse event, as appropriate. If the pregnancy in the woman participating in the study and/or the female partners of men partici pating in the stud y does not continue to term, 1 of the following actions will be taken: ï‚·For a spontaneous abortion, report as a serious adverse event."
93,page_93,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 93ï‚·For an elective abortion due to developmental anomalies, report as a serious adverse event. ï‚·For an elect ive abortion notdue to developmental anomalies, report on the pregnancy form; do not report as an adverse event. 7.3. Medication Error and Special Situations Related to the Investigational Medicinal Products Any administration of IMP that is not in accordance with the study protocol should be reported as a deviation in the patientâ€™s source documents, regardless of whether or not an adverse event occurs as a result. The following are t ypes of medication errors and special situations: 1.Medication error: An y uninte ntional error in the prescribing, dispensing, or administration of a medicinal product while in the control of the healthcare professional, patient, or consumer. 2.Overdose: Administration of a quantity of a medicinal product given per administration or cumu latively , which is above the maximum recommended dose according to the authorized product information. Clinical judgment should alway s be applied. An y dose of IMP (whether the test IMP, reference IMP, or placebo I MP), whether taken intentionally or unintentionall y, in excess of that prescribed must be immediately reported to the sponsor. 3.Misuse: Situations where the I MP is intentionally and inappropriately used not in accordance with the authorized product information. 4. Abuse: Persistent or sporadic, intenti onal excessive use of IMP, which is accompanied by harmful phy sical or psy chological effects. 5.Off-label use: Situations where an IMP is intentionally used for a medical purpose not in accordance with the authorized product information. 6.Occupational exposure: Exposure to an I MP, as a result of oneâ€™s professional or non-professional occupation. 7. Breastfeeding: Suspected adverse reactions, which occur in infants, following exposure to a medicinal product from breast milk. 7.4. Clinical Laboratory Tests All cl inical laboratory test results outside of the reference range will be judged by the investigator as belonging to 1 of the following categories: ï‚·abnormal and not clinically significant ï‚·abnormal and clinically significant"
94,page_94,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 94Table 7: For COVID -19 updates, refer to Appendix N. 7.4.1. Table 7."
95,page_95,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 95 7.5. Physical Examinations Full phy sical examinations, including height (to be obtained at the screening visit only ) and weight, will be performed at the time points detailed in Table 1and Table 2. The full phy sical examination will consist of examining the following body systems: cardiovascular, respiratory , abdominal, skin, neurological, and musculoskeletal sy stems. The ph ysical examination will also include examination of general appearance, including head, eyes, ears, nose, and throat; chest;"
96,page_96,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 96abdomen; skin; ly mph nodes; and extremities. Body weight and ty mpanic temperature will be measured at each visit. Systolic and diastolic blood pressure and pulse rate will be measured with the patient in a seated position. Any physical examination finding that is judged by the investigator as clinicall y significant (except at the screening visit) will be considered an adver se event, recorded on the CRF, and monitored as described in Section 7.1.2. 7.6. Vital Signs Vital signs (blood pressure [sy stolic/diastolic] , respirator y rate, t ympanic temperature, and pulse) will be measured at the time points detailed in Table 1andTable 2. All vital sign results outside of the reference ranges will be judged b y the investigator as belonging to 1 of the following categories: ï‚·abnormal and not clinically significant ï‚·abnormal and clinically significant Before blood pressure and pulse are measured, the patient must rest in a supine or seated position for at least 5 minutes. (The same position and arm should be used each time vital signs are measured for a given patient.) Forany abn ormal vital sign value, the measurement should be repeated as soon as possible. Any vital sign value that is judged by the investigator as clinically significant will be recorded both on the source documentation and on the CRF as an adverse event, and will be monitored as described in Section 7.1.2. For COVID -19 updates, refer to Appendix N. 7.7. Electrocardiography A standard 12- lead ECG will be recorded at the time points detailed in Table 1andTable 2 . Triplicate measurements will be performed at screening and baseline and single measurements at all other in -clinic visits. A qualified phy sician at a central diagnostic center will be interpreting the ECG. All ECG results outside of the reference ranges will be judged by the investigator as belonging to 1 of the following catego ries: ï‚·abnormal and not clinically significant ï‚·abnormal and clinically significant Any ECG finding that is judged by the investigator as clinicall y significant (except at the screening visit) will be considered an adverse event, recorded on the source docu mentation and in the CRF, and monitored as described in Section 7.1.2. For COVID -19 updates, refer to Appendix N. 7.8. Assessment of Local Tolerability and Pain In case an adverse event related to an injection site reaction is reported, an assessment of the sc injection site (ie, local tolerability [skin at injection site]) will be made. The presence and severit y of ery thema, swelling, induration, and pain at the injection site may be assessed using the scales below as applicable."
97,page_97,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 977.8.1. Erythema and Edema Assessment Scoring of ery thema and edema will be done using 5 -point scales: Erythema: ï‚·None = 0 ï‚·Very slight = 1 ï‚·Well defined = 2 ï‚·Moderate to severe = 3 ï‚·Severe = 4 Edema: ï‚·None = 0 ï‚·Very slight = 1 ï‚·Slight = 2 ï‚·Moderate = 3 ï‚·Severe = 4 7.8.2. Induration and Nodule Assessment The presence and size (length and width) of an y palpable induration/nodules at the injection site will be assessed and recorded. Scoring of nodules will be done using a 4 -point scale: ï‚·No induration/nodule = 0 ï‚·Discernible induration/small nodule <0.5 cm = 1 ï‚·Marked induration/medium size nodule of 0.5 to 1 cm = 2 ï‚·Severe induration/significant size nodule >1 cm = 3 7.8.3. Injection Pain Intensity Assessment In case an adverse event related to an injection site reaction is reported, intensity of injection pain will be assessed b y patients using an 11- point NPRS (0 [no pain] to 10 mm [worst pain]) (Williamson and Hoggart 2005 ). Pain measurement will be evaluated during visits and telephone calls until resolution. The exact timing will be captured in the source documentation. 7.9. Assessment of Suicidality Risperidone is considered to be central nervous system- active. In addition, the re is an increased risk of suicide attempt in patients with schizophrenia or bipolar disorder. The sponsor considers it important to monitor for such events before and during this clinical stud y. Risperidone is considered to be an at ypical antipsychotic me dicinal product. Although risperidone or other similar medicinal products in this class are not known to be associated with"
98,page_98,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 98an increased risk of suicidal thinking or behavior when given to patients with schizophrenia, the sponsor considers it important to monitor for such events before or during this clinical study . The study population being administered TV -46000 or placebo should be monitored appropriatel y and observed closel y for suicidal ideation and behavior or any other unusual changes in behavior. Co nsideration should be given to discontinuing the test I MP in participants who experience signs of suicidal ideation or behavior. Families and caregivers of participants being treated with test I MP should be instructed to monitor participants for the emergence of unusual changes in behavior, as well as the emergence of suicidal ideation and behavior, and to report such sy mptoms immediately to the study investigator. Baseline assessment of suicidal ideation and behavior and treatment -emergent suicidal ideatio n and behavior will be assessed during the study using the C -SSRS and CGI -SS scale. 7.9.1. Columbia Suicide Severity Rating Scale (C -SSRS) The C -SSRS is a semi structured interview that captures the occurrence, severity , and frequency of suicide -related thoughts and behaviors ( Posner et al 2011). The interview and rating for the C -SSRS will be conducted by a rater specificall y trained to rate the scale (per the minimum requirements outlined b y the scale author), regardless of educatio n level, who has appropriate clinical trial experience with C-SSRS administration, after review and approval by the Teva clinical project ph ysician or designee. There are required items that address suicidal ideation and potential additional items related to intensity of ideation and suicidal behavior if there are any positive responses to a required item. The C -SSRS uses dichotomous scales (ie, y es or no), Likert scales, and text or narrative to further describe the thoughts or behaviors. The C -SSRS will b e administered at screening (baseline/screening version) and all post-screening visits (â€œsince last visitâ€ version) during the stud y, as well as during phone contacts (â€œsince last visitâ€ version). 7.9.2. Clinical Global Impression -Severity of Suicidality The CGI -SS scale provides an overall clinician- rated assessment of the risk of suicidality (Lindenmay er et al 2003 ). The CGI -SS consists of a 5 -point scale in Part 1 ranging from 1 (not at all suicidal) to 5 (attempted suicide) and a 7-point scale in Part 2 ranging from 1 (very much improved) to 7 (very much worse). The CGI -SS will be assessed at screening and all visits during the study . 7.10. Study -Specific Assessments of Safety 7.10.1. Abnormal Involuntary Movement Scale (AIMS) The AIMS will be performed at the time points specified in Table 1and Table 2 . The AIMS scores the occurrence of tardive d yskinesia in patients receiving neuroleptic medications ( Guy 1976b). The AIMS is a 14- item scale that includes assess ments of orofacial movements, extremity and truncal dy skinesia, examinerâ€™s judgment of global severit y, subjective measures of awareness of movements and distress, and a yes/no assessment of problems concerning teeth and/or dentures. Higher scores indicate greater severity of the condition."
99,page_99,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 997.10.2. Barnes Akathisia Rating Scale (BARS) The BARS will be performed at the time points specified in Table 1andTable 2. The BARS is an instrument that assesses the severit y of drug -induced akathisia ( Barnes 1989). The BARS includes 3 items for rating objective restless movements, subjective restlessness, and an y subjective distress associated with akathisia that are scored on a 4 -point scale of 0 to 3, and summed y ielding a total scored ranging from 0 to 9. The BARS also includes a global c linical assessment of severity scored on a scale of 0 to 5. Higher scores are indicative of greater severit y of akathisia. 7.10.3. Simpson -Angus Scale (SAS) The SAS will be performed at the time points specified in Table 1and Table 2. The SAS is a 10- item instrument for the assessment of neuroleptic- induced parkinsonism ( Simpson and Angus 1970 ). The items on the scale include measurements of hypokinesia, rigidity , glabellar reflex, tremor, and salivation. Each item is rated on a 5- point scale (0 to 4), with a higher score indicating greater severity of s ymptoms. The mean score is calculated by adding the individual item scores and dividing by 10. 7.10.4. Calgary Depression Scale for Schizophrenia (CDSS) The CDSS will be performed at the time points specified in Table 1and Table 2. The CDSS is specificall y designed to assess the level of depression separate from the positive, negative, and EPS in schizophrenia ( Addin gton et al 1993 ). This clinician -administered instrument consists of 9 items, each rated on a 4 -point scale from 0 (absent) to 3 (severe). 7.11. Other Assessments"
100,page_100,Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 100Table 8:
101,page_101,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 1018. ASSESSMENT OF PHARMA COKINETICS/ PHARMACODYNAM ICS/ BIOMARKERS/ PHARMACOGENOMICS 8.1. For COVID -19 updates, refer to Appendix N."
102,page_102,Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 1028.2. 8.3. . 8.4. Pharmacogenetics The final list of genes to be evaluated will be det ermined at the time of anal ysis to be able to account for the most current research. The planned pharmacogenetic anal ysis and results of other potential genetic factors will be detailed in a separate document that will encompass the latest scientific advan ces related to this evaluation.
103,page_103,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 1039. STATISTICS This section describes the statistical anal ysis as foreseen at the time of planning the study . Changes, additions, and further details about the analy ses will be described in the statistical analysis plan. After f inalization of the statistical analy sis plan, an y additional analy ses or changes to analy ses that may be required will be fully disclosed in the clinical study report (CSR). 9.1. 9.2. Analysis Sets 9.2.1. Enrol led Patients Set The enrolled patients set will include all patients who have met stud y eligibility requirements for Stage 1 and received oral risperidone."
104,page_104,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 1049.2.2. Intent -to-Treat Analysis Set The intent -to-treat (ITT) anal ysis set will include adult patients ran domized to the double -blind maintenance stage (Stage 2), regardless if they have received treatment or not. I n the ITT analysis set, treatment will be assigned based on the treatment to which patients were randomized, regardless of which treatment they actually received. The purpose of the primary anal yses is to estimate the effect of randomized treatment only , omitting any effect of additional treatment that may be administered after discontinuation of the randomized treatment. Accordingl y, the ITT anal ysis set complies with while -on-treatment strategy1that will be taken with regard to the intercurrent event of treatment discontinuation, with censoring at this intercurrent event. Thi s study estimand will be the difference in time to relapse (survival) under the treatment to which the patient was initially randomized until last treatment or earl y termination of all adult patients who were successfully stabilized on oral risperidone at a daily dose range of 2 mg to 5 mg. 9.2.3. Extended Intent -to-Treat Analysis Set The extended intent -to-treat (eITT) anal ysis set will include all patients (adults and adolescents) randomized to the double -blind maintenance stage (Stage 2), regardless if they have received treatment or not. In the eITT anal ysis set, treatment will be assigned based on the treatment to which patients were randomized, regardless of which treatment they actually received. 9.2.4. Per-Protocol Analysis Set The per -protocol (PP) analy sis set will include all patients in the I TT anal ysis set who have no major protocol deviations. I n this analy sis set, treatment will be assigned based on the treatment patients actuall y received. The PP analysis set will be discussed before unblinding and finding s will be documented in the study data review document. 9.2.5. Safety Analysis Set The safet y analysis set will include all randomized patients who receive â‰¥1 dose of study treatment or placebo in the double -blind maintenance stage (Stage 2). In the safet y analysis set, treatment will be assigned based on the treatment patients actuall y received, regardless of the treatment to which they were randomized, unless otherwise specified. 9.2.6. Pharmacokinetics Analysis Set The pharmacokinetics analy sis set will include all patients from the safety analy sis set who also have â‰¥1 plasma concentration measured. 9.3. Data Handling Conventions For all variables, onl y those observed data from the patients will be used in the statistical analyses, ie, there is no plan to estimate mis sing data, unless otherwise specified. Data from 1ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guidance on statistical principles for clinical t rials. EMA/CHMP/ICH/436221/2017. European Medicines Agency. 30 August 2017."
105,page_105,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 105patients who did not relapse will be censored at the last valid relapse assessment date. Detailed data imputation rules will be described in the statistical anal ysis plan. 9.3.1. Handling Withdrawals and Missing Da ta Missing data will not be imputed, unless otherwise specified. 9.4. Study Population The eITT anal ysis set (Section 9.2.3 ) will be used for all study population summaries of the double -blind treatment stage unless otherwise specified. Summaries will be presented b y treatment group and for all patients. If the n umber of adolescents permits, summaries will also be presented b y age subgroup.The primary anal ysis will be conducted on the ITT anal ysis set (Section 9.2.2) , and the eITT analysis set (Section 9.2.3 ) will be used for analy sis of the key secondary endpoints unless otherwise specified. The anal ysisset on which anal ysis for other endpoints will be conducted will be specified on a case- by-case basis. The enrolled patients set (Section 9.2.1) will be used for data summaries before the double -blind treatment stage. 9.4.1. Patient Disposition Data from patients screened and enrolled in Stage 1; patients who were enrolled in Stage 1 but not randomized for the double - blind stage and reason for not randomized; patients who were randomized; patients who were randomized but not treated; patients in the ITT patients in the eITT , PP, safet y, and pharmacokinetics analysis sets; patients who completed the study ; and patients who withdrew from the study will be summarized using descriptive statistics. Data from patients who withdrew from the study will also be summarized by reason for withdrawal using descriptive statistics. Adolescent patient disposition may be summarized separately , if applicable. 9.4.2. Demographic and Baseline Characteristics Patient demographic and baseline characteristics, including medical history, prior medications and therapies, and ECG findings, will be summarized using the descriptive statistics. For continuous variables, descriptive statistics (number [n], mean, standard deviation, median, minimum, and maximum) will be provided. For categorical variables, patient counts and percentages will be provided. Categories for missing data will be presented if necessary . The ITT anal ysis set, the eITT a nalysis set, and the eITT subset of adolescents will be used for the summaries, as applicable. 9.5. Efficacy Analysis 9.5.1. Primary Endpoint The primary efficacy endpoint is time to impending relapse. Patients meeting an y 1 or more of the below impending relapse cri teria are considered relapsed. Relapse is defined as 1 or more of the following items: ï‚·CGI-I of â‰¥5 (greater than or equal to minimally worse, ie, minimally worse, much worse or very much worse ) AND"
106,page_106,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 106ï€­an increase of any of the following individual PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of >4 with an absolute increase of â‰¥2 on that specific item since randomization, OR ï€­an increase in an y of the following 4 individual PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of >4 and an absolute increase of â‰¥4 on the combined score of these 4 PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousne ss, and unusual thought content) since randomization ï‚·hospitalization due to worsening of ps ychotic s ymptoms (including partial hospitalization programs), excluding hospitalization for ps ychosocial reasons ï‚·CGI-SS of 4 (severel y suicidal) or 5 ( attempted sui cide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2 ï‚·violent behavior resulting in clinicall y significant self -injury , injury to another person, or propert y damage. Time to impending relapse will be calculated as the earliest date the pat ient meets â‰¥1 of the impending relapse criteria minus the randomization date plus 1. The absolute increase of the combined score of the 4 PANSS items is the sum of the increases of those scores (ignoring the decreases). 9.5.2. Key Secondary Endpoints The eITT analysis set (Section 9.2.3) will be used for all summaries in this section, unless otherwise specified. For the endpoints that are evaluted onl y in the adult population, the analy sis will be conducted on the ITT anal ysis set. The key secondary endpoints are listed in Section 2.1and described in detail below. 9.5.2.1. Time to Impending Relapse in the eITT Analysis Set Time to impending relapse using the same definition and primary anal ysis that is described in Section 9.5.1 using the eITT anal ysis will be employ ed. 9.5.2.2. Impending Relapse Rate at Week 24 This rate will be estimated using the Kaplan -Meier method. 9.5.2.3. Percentage of Patients Who Maintain Stability at Endpoint Stability is defined as meeting all of the following criteria for at least 4 consecutive weeks: outpatient status; PANSS total score â‰¤80; minimal presence of specific ps ychotic symptoms on the PANSS, as measured by a score of â‰¤4 on each of the following items: conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual thought content; CGI -S score â‰¤4 (moderatel y ill); and CGI -SS score â‰¤2 (mildly suicidal) on Part 1 and â‰¤5 (minimally worsened) on Part 2."
107,page_107,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 107The percentage will be calculated as the number of patients who m aintained stability at endpoint divided by the number of eITT patients that adhere to treatment for at least 4 weeks or experienced relapse in the given treatment group. This analy sis estimates the treatment effect of randomized treatment on patient's stability once the patient adheres to treatment long enough until the last treatment. The use of eITT anal ysis complies with while on treatment estimand and will be comprised of the difference in proportions under the treatment to which the patient was ini tially randomized of all patients who were successfully stabilized on oral risperidone at a daily dose range of 2 mg to 5 mg. Accordingl y, this estimand addresses the clinical question to what extent patients improve their chances to maintain stability once they start the treatmen t if the patient adheres to the treatment long enough. 9.5.2.4. Percentage of Patients Achieving Remission at Endpoint Positive sy mptom, negative sy mptom, and overall sy mptom remission will be examined and are defined b y Andreasen et al ( 2005) including severity and duration criteria. All remission criteria can be derived from PANSS items. For overall s ymptom remission, the patient must not relapse during the study and in addition, over a period of at least 6 months preceding the endpoint, maintain scores of â‰¤3 on each of the 8 specific PANSS items: P1 (delusions), G9 (unusual thought content), P3 (hallucinatory behavior), P2 (conceptual disorganization), G5 (mannerisms/posturing), N1 (blunted affect), N4(social withdrawal), and N6 (lack of spontaneity). The percentage will be calculated as the number of patients who achieved remission at endpoint divided by the number of eITT patients that adhere at least 6 months or experienced relapse in the given treatment g roup. This analy sis estimates the treatment effect of randomized treatment on patient's remission once the patient adheres to treatment long enough until the last treatment. The use of eITT anal ysis complies with the while on treatment estimand, and will b e comprised of the difference in proportions under the treatment to which the patient was initially randomized of all patients who were successfully stabilized on oral risperidone at a daily dose range of 2 mg to 5 mg. Accordingl y, this estimand addresses the clinical question to what extent patients improve their chances to achieve remission once they start the treatment if the patient adheres to the treatment long enough. 9.5.2.5. Observed Rate of Impending Relapse at Endpoint Observed rate of impending relapse wi ll be calculated as the number of patients who relapsed by endpoint divided by the number of patients in each treatment group. 9.5.2.6. Drug Attitudes Inventory 10- item Version The change from baseline to endpoint in total score will be calculated. 9.5.2.7. Schizophrenia Qu ality of Life Scale The change from baseline to endpoint in total score will be calculated."
108,page_108,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 1089.5.2.8. Time to Impending Relapse in Adolescent Patients with Schizophrenia Time to impending relapse using the same definition and primary anal ysis that was described in Section 9.5.1 will be used on the eITT anal ysisset using adolescent patients alone. This assessment of time to impending relapse in adolescent patients is pending randomization of at least 10 adolescent patients with clinically sufficient exposure. 9.5.3.1. 9.5.3.2. Healthcare Resource Utilization The percentage of patients who were hospitalized, number of hospitalizations, and length of hospital stay (number of day s); percentage of patients who had ER visits and number of ER visits; and percentage of patients who had outpatient visits and number of outpatient visits will be calculated. 9.5.3.3. Change in PANSS Total Score from Baseline to Endpoint Thechange from baseline to endpoint in total score will be calculated. 9.5.3.4. CGI -I Score at Endpoint CGI-I at endpoint will be anal yzed. 9.5.3.5. Personal and Social Performance Scale The change from baseline to endpoint in total scor e will be calculated. 9.5.4. Planned Method of Analysis The ITT anal ysis set (Section 9.2.2 ) will be used for all efficacy anal yses. Summaries will be presented b y treatment group. Analy sis that will be conducted on the eITT anal ysis set or on the adolescent patient subset of the eITT will be described below, as applicable. 9.5.4.1. Primary Efficacy Analysis Time to impending relapse will be calculated as the earliest date the patient meets â‰¥1 of the impending relapse criteria minus the randomization date plus 1. Data from patients who did not relapse will be censored at the last valid assessment. Time to impending relapse for TV -46000 and placebo will be compa red using the stratified log-rank test at significance levels described in Section 9.6. Hazard ratios and their 2 -sided 95% confidence intervals (CI s) for TV -46000 q1m"
109,page_109,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 109and q2m versus placebo will be anal yzed using a Cox proportional hazard model, with treatment and stratification variables as the factors, as described in Section 5.9. Kaplan -Meier curves will be provided to present impending relapse rate data over time. 9.5.4.2. Sensitivity Analysis A sensitivity anal ysis will be conducted to assess the impact of large intervals between the previous as sessment and the assessment at the time the first relapse was observed via the interval censoring method. Sensitivity anal ysis will also be conducted by tipping point analy sis that imputes time to relapse for dropouts (for reasons suspected to be related t o relapse) with increasing risk to relapse compared to similar patients in the same treatment group that continue treatment . The PP analy sis set will also be used as supplemental anal ysis to evaluate the primary efficacy variable. Details will be provided in the statistical anal ysis plan. Senstivity anal ysis will be conducted on the ITT analy sis set. For COVID -19 updates, refer to Appendix N. 9.5.4.3. Subgroup Analysis Additional subgroup analy sis for the primary endpoint, including region, will be described in the statistical analy sis plan. 9.5.4.4. Key Secondary Analyses The fixed sequential (hie rarchical) Strategy (FDA 2017 ) will be used to control the overall Ty pe- I statistical error in the study for both primary and secondary efficacy endpoints. The key secondary endpoints will be anal yzed in a pooled manner for q1 m and q2m. The details about the Type-I statistical error control for the key secondary endpoints will be discussed in the statistical analysis plan. 9.5.4.4.1. Time to Event Key Secondary Analysis For the key secondary endpoint discussed in Section 9.5.2.1 , time to impending relapse in adult and adolescent patients will be assessed similarly to the Primary Efficacy Analy sis using the eITT Anal ysis Set (Section 9.2.2). The Cox proportional hazard model will include patient age group (if applicable) along with treatment, and the aforementioned stratification variables as the factors. For the key secondary endpoint discussed in Section 9.5.2.8 , time to impending relapse in adolescent patients will be assessed if the number of randomized patients will be at least 10 with clinically sufficient exposure. The method will be similar to the Primary Efficacy Anal ysis, but will use the adolescent patients subset. Ty pe-I statistical error control will be discussed in Multiple Comparisons and Multiplicity . 9.5.4.5. Key Sec ondary Efficacy Analysis 9.5.2.2 -9.5.2.7 Impending relapse rate at week 24 will be estimated using the Kaplan -Meier method and calculated as 1 minus the proportion of patients free of impending relapse events at week 24. The Greenwood formula will be used to calculate standard errors for impending relapse rates at week"
110,page_110,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 11024, and the pooled standard errors will be used for hy pothesis testing using z -statistics, assuming that the differences between TV -46000 and placebo follow a normal distribution of large samples. Two-sided 95% CIs of the differences will also be calculated. The observed impending relapse rates at endpoint will be compared between groups using the Cochran â€“Mantel â€“Haenszel (CMH) test adjusting for stratification variables. The anal yses of the proportion of patients who maintain stability at endpoint and the proportion of patients achieving remission at endpoint in Stage 2 will be described in the statistical anal ysis plan. Change from baseline of DAI -10 and SQLS total score, will be anal yzed using an anal ysis of covariance (ANCOVA) method, with treatment and stratification variables as factors and baseline (score at the end of Stage 1) as a covariate. Additional details regarding the anay sis will be documented in the statisti cal analysis plan. The eITT anal ysis set (Section 9.2.3 ) will be used for all summaries in this section, unless otherwise specified.Ty pe-I statistical error control will be discussed in Multiple Comparisons and Multiplicity . 9.6. Multiple Comparisons and Multiplicity , a fixed sequential (hierarchical) testing approach will be implemented. If the resulting first p-value of the primary efficacy hypothesis test comparing q1m to placebo is found to be significant at 0.05 alpha, then the second primary efficacy hypothesis (q2m vs. placebo) will be interpreted inferentiall y at the same alpha level of"
111,page_111,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 1110.05. If the first primary hypothesis fails to reach significance no further formal hypothesis testing will be performed. Type-I error will be further controlled for the key secondary endpoints by employ ing fixed sequential (hierarchical) testing strategy within each endpoints family (primary endpoints and key secondary endpoints). Secondary endpoints will be anal yzed in a pooled manner for the treatment groups if the two primary endpoints are foun d to be significant. Further details about the Ty pe-I statistical error control will be discussed in the statistical analy sis plan. A fixed -sequence (hierarchical) testing procedure will be implemented to control the Ty pe-I error rate . The sequence of the secondary endpoints comparisons will be as follows: 1.Time to impending relapse in the eITT anal ysis set 2.Impending relapse rate at week 24 3.Percentage of patients who maintain stability at endpoint 4. Percentage of patients achieving remission at endpoint 5.Obse rved rate of impending relapse at endpoint 6.DAI-10 change from baseline to endpoint 7.SQL S change from baseline to endpoint 8.Time to impending relapse in adolescent patients with schizophrenia If the first comparison is found to be significant, then the next comparison of interest will be interpreted inferentiall y at the same alpha level. This process will continue either until all comparisons were tested inferentiall y or until the point at whic h the resulting 2 -sided test is insignificant at the same alpha level. . Any p- value associated with these comparisons will be considered as nominal p -value and will not be used for inference. 9.7. Safety Analysis Safety anal yses will be performed on the s afety analy sis set (Section 9.2.5). Safety assessments and time points are provided in Table 1and Table 2. All adverse events will be coded using the Medical Dictionary for Regulatory Activities. Each patient will be counted only once in each preferred term or s ystem organ class category for the analyses of safet y. Summaries will be presented for all adverse events (overall and by severit y), including adverse events determined b y the investigator to be related to test IMP (ie, reasonable possibility ; see Section 7.1.4) (defined as related or with missing relationship) (overall and b y severit y), serious adverse events, and adverse events causing withdrawal from the study . Summaries will be pre sented by treatment group. Patient listings of serious adverse events and adverse events leading to withdrawal will be presented."
112,page_112,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 112Changes in laboratory , ECG, and vital sign measurement data will be summarized descriptivel y. All values will be compared with predefined criteria to identify potentiall y clinically significant values or changes, and such values will be listed. The use of concomitant medications will be summarized by therapeutic class using descriptive statistics. Descriptive statistics for allowed rescue medications (see Section 5.7) will be presented b y treatment group. Safety outcomes, including changes from baseline in EPS scale scores (BARS, AI MS, and SAS) and CDSS during Stage 2, will be presented using descriptive statistics by treatment group. Adjustment to stratification factors may be conducted as appropriate. The incidence of treatment -emergent adverse events related to EPS will be summarized by the following event categories: akathisia, dy skinesia, dy stonia, p arkinsonism, and tremor. The C-SSRS and CGI -SS will be used to assess the risk of suicide events during the study . Descriptive statistics will be presented b y treatment group. For continuous variables, descriptive statistics (n, mean, standard deviation, m edian, minimum, and maximum) will be provided for actual values and changes from baseline to each time point. For categorical variables, patient counts and percentages will be provided. If any patient dies during the study, a listing of deaths will be prov ided, and all relevant information will be discussed in the patient narrative included in the CSR. Safety data collected in Stage 1 will also be summarized using descriptive statistics in the enrolled patients set. Selected safet y data will also be present ed by site of injection (abdomen vs arm) and b y age group (adolescents [ages 13 -17] and adults [18 y ears of age and above]), as applicable . Separate summaries for adolescent patients may be presented separatel y for some anal yses, as applicable, and will be described in the Statistical Analy sis Plan. 9.8. Tolerability Analysis In case an adverse event related to an injection site reaction is reported, an assessment of the sc injection site (ie, local tolerability [skin at injection site] ) will be made. The presen ce and severit y of ery thema, swelling, induration, and pain at the injection site may be assessed using the scales described in Section 7.8as appl icable. All-cause discontinuation rates and discontinuation rates due to adverse events (dropout rates) will be calculated as the number of patients who withdrew earl y for all reasons, and the number of patients who withdrew earl y due to adverse events, r espectivel y, divided by number of patients in each treatment group, and will be presented using descriptive statistics. Time to all- cause discontinuation will be calculated as the discontinuation date minus the randomization date plus 1. Kaplan -Meier curve s for the time to discontinuation as a result of all causes will be plotted. Separate summaries for adolescent patients might be presented separatel y for some anal yses, as applicable, and will be described in the Statistical Analy sis Plan."
113,page_113,Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 1139.9. 9.11. Pharmacok inetic/Pharmacodynamic Analysis . 9.13. Planned Interim Analysis There will be no interim anal ysis in this study .
114,page_114,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 1149.14. Reporting Deviations from the Statistical Plan Deviations from the statistical plan, along with the reasons for the deviations, will be described in protocol amendments, the statistical analy sis plan, the CSR, or any combination of these, as appropriate, and in accordance with applicable national, local, and regional requirements and regulations."
115,page_115,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 11510. QUALITY CONTROL AND QUALITY ASSURANCE Refer to Appendix Cfor information regarding quality control and quality assurance. This includes information about protocol amendments, deviations, responsibilities of the i nvestigator to study personnel, study monitoring, and audit and inspection. For COVID -19 updates, refer to Appendix N. Refer to Appendix Kfor the definition of a clinical product complaint and investigator responsibilities in the management of a clinical product complaint. 11. COMPLIANCE STATEMENT This study will be conducted in full accordance with the I CH Harmonised Tripartite Guideline, Guideline for GCP E6 and any applicable national and local laws and regulations (eg, Title 21 Code of Federal Regulations [21CFR] Parts 11, 50, 54, 56, 312, and 314, Directive 2001/20/EC of the Eu ropean Parliament and of the Council on the approximation of the laws, regulations, and administrative provisions of the Member States relating to the implementation of GCP in the conduct of clinical st udies on medicinal products for human use). Any episode of noncompliance will be documented. The investigator is responsible for performing the clinical study in accordance with this protocol and the applicable GCP guidelines referenced above for collectin g, recording, and reporting the data accurately and properly . Agreement of the investigator to conduct and administer this clinical study in accordance with the protocol will be documented in separate clinical study agreements with the sponsor and other fo rms, as required by national CAs in the country where each investigational center is located. The investigator is responsible for ensuring the privacy , health, and welfare of the patients during and after the clinical study and must ensure that trained personnel are immediatel y available in the event of a medical emergency . The investigator and the involved clinical study personnel must be familiar with the background and requirements of the study and with the properties of the IMPs as described in the IB o r PI. The principal investigator at each investigational center has the overall responsibility for the conduct and administration of the clinical study at that investigational center and for contacts with study management, with the I EC/IRB, and with CAs. See Appendix Dfor the ethics expectations of informed consent, CAs and IEC/I RB, confidentiality regarding study patients, and requirements for registration of the clinical study . 12. DATA MANAGEMENT AND RECORD KEEPING See Appendix Lfor information regarding data management and record keeping. This includes direct access to source data and documents, dat a collection, data quality control, and archiving of CRFs and source documents."
116,page_116,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 11613. FINANCING AND INSURA NCE A separate clinical stud y agreement, including a study budget, will be signed between each principal investigator and the sponsor (or the CRO designated by the sponsor) before the IMP is delivered. The patients in this clinical study are insured in accordance with applicable legal provisions. The policy coverage is subject to the full policy terms, conditions, extensions, and exclusions. Excluded from the insurance coverage are damages to health and worsening of previous existing disease that would have occurred or continued if the patient had not taken part in the clinical study . The policy of Clinical Trials I nsurance will be provided to the investigational centers b y the sponsor. For covered clinical studies (see 21CFR54), the investigator will provide the sponsor with financial information required to complete FDA 3454 form. Each investigator will notify the sponsor of an y relevant changes during the co nduct of the study and for 1 year after the study has been completed. 14. PUBLICA TION POLICY See Appendix Mfor information regarding the publication policy."
117,page_117,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 11715. REFERENCES Addington D, Addington J, Maticka -Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psy chiatry Suppl. 1993 Dec;(22):39 -44. Andreasen NC, Carpenter WT, Kane JM, L asser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psy chiatry 2005;62:441-9. Asarnow R, Brown W, Strandburg R. Children with a schizophrenic disorder: neurobehavioral studies. Eur Arch Ps ychiatry Clin Neurosci. 1995;245:70 - 9. Barnes TR. A rating scale for drug -induced akathisia. Br J Psy chiatry . 1989 May ;154:672 -6. Barnes TR, Curson DA. Long- term depot antips ychotics. A risk-be nefit assessment. Drug Saf 1994;10:464 -79. Birnbaum M, Sharif Z. Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER. Patient Prefer Adherence. 2008;2:233- 40. Bo S, Haahr UH. Earl y-onset psy chosis and child and adolescent schizophrenia. Scandinavian J Child Adolescent Psy chiatry and Psy chology 2016;4(1):1 -3. EAST 6 (Version 6.3) manual, Cy tel Statistical Software & Services, C ytel Inc. Volume 10, Page 1931, 11Jul2014. EuroQol Group. EuroQol --a new facil ity for the measurement of health -related quality of life. Health Policy 1990;16:199 â€“208. FDA. Multiple Endpoints in Clinical Trials. Guidance for Industry . January 2017. Ferrin M, Gosney H, Marconi A, Rey JM. Using antipsy chotic medication for the treatme nt of schizophrenia in children and adolescents. In Rey JM (ed), I ACAPAP e -Textbook of Child and Adolescent Mental Health. Geneva: International Association for Child and Adolescent Psychiatry and Allied Professions 2016. First MB, Williams JBW, Karg RS, S pitzer RL . Structured Clinical Interview for DSM -5 Disorders, Clinical Trials Version (SCID-5- CT). Arlington, VA. American Psy chiatric Association, 2015. Guy W. ECDEU Assessment Manual for Ps ychopharmacology (revised). Rockville (Maryland): US Department o f Health, Education, and Welfare; Public Health service; Alcohol, Drug Abuse, and Mental Health Administration; National Institute of Mental Health, Psy chopharmacology Research Branch, 1976a;218 -22. Guy WA. Abnormal Involuntary Movement Scale (AIMS). In: E CDEU Assessment Manual for Psychopharmacology . Washington, D.C; 1976b:534 -7. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity . Psy chological medicine. 1983;13(1):177- 183. Hollis C. Adult outcomes of child -and adolescent -onset schizophrenia: diagnostic stability and predictive validity . Am J Psy chiatry 2000;157(10):1652-9."
118,page_118,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 118Hughes DA. Estimation of the impact of non -compliance on pharmacokinetics: an anal ysis of the influence of dosing regimens. British J Clin Pharm 2007;65:871-8. Kane JM, Sanchez R, Perry PP, Jin N, Johnson BR, Forbes RA, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52 -week, multicenter, randomized , double -blind, placebo -controlled study . J Clin Psy chiatry 2012;73(5):617 -24. Kay SR, Fiszbein A, Opler LA. The positive and negative s yndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261- 76. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psy chiatry 2003;64:1308-15. Lindenmay er JP, Czobor P, Alphs L , Nathan AM, Anand R, Islam Z. et al. The InterSePT scale for suicidal thinking reliability and validity . Schizophr Res. 2003;63(1â€“2):161 â€“70. Lytle S, McVo y M, Sajatovic M. L ong-acting injectable antips ychotics in children and adolescents. J Child Adolesc Psy chopharmacol. 2017;27(1):2-9. Morosini PL , Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM -IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psy chiatr Scand. 2000 Apr;101(4):323 - 9. New York State Office of Mental Health. Schizophrenia. June 2011. 16 pages. Nielsen RE, L indstrom E, Nielsen J, L evander S. DAI -10 is as good as DAI - 30 in schizophrenia. Eur Neurops ychopharmacol. 2012;22(10):747- 750. Perkovic MN, Erjavec GN, Strac DS, Uzun S, Kozumplik O, Pivac N. Theranostic Biomarkers for Schizophrenia . Int J Mol Sci. 2017;18(4). pii: E733. Pogge DL, Singer MB, Harvey PD. Rates and predictors of adherence with aty pical antipsy chotic medication: a follow -up study of adolescent inpatients. J Child Adolesc Psychopharmacol. 2005;15(6):901 -12. Posner K, Brow n GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psy chiatry 2011;168(12):1266-77. Rabin R, de Charro F. EQ -5D: a measure of health status from the EuroQol Group. Ann Med. 2001 Jul;33(5):337-43. Rainer MK. Risperidone long -acting injection: a review of its long term safety and efficacy . Neurops ychiatr Dis Treat 2008;4(5):919 -27. Rapoport J, Addington A, Frangou S. The neurodevelopmental model of schizophrenia: what can very early onset cases tell us? Curr Psy chiatry Rep. 2005;7:81 â€“2. RISPERDAL CONSTA (risperidone) LONG ACTING INJECTION. US Prescribing Information. Janssen Pharmaceuticals, Inc., 2014. RISPERIDONE tablets USP for oral use. US Prescribing Information. Teva Pharmaceuticals USA, I nc., 2014."
119,page_119,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 119Simpson GM, Angus JWS. A rating scale for extrapy ramidal side effects. Acta Psy chiatr Scand 1970;212:11 -9. Stefan M, Travis M. An atlas of schizo phrenia. London: The Parthenon Publishing Group, 2002. Subotnik KL , Casaus LR, Ventura J, L uo JS, Hellemann GS, Gretchen -Doorly D, et al. Long - acting injectable risperidone for relapse prevention and control of breakthrough s ymptoms after a recent first episode of schizophrenia. A randomized clinical trial. JAMA Psy chiatry 2015;72(8):822 -9. Walburn J, Gray R, Gournay K, Quraishi S, David AS. Sy stematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psy chiatry 2001;179:300- 7. Weinberger D, Harrison PJ (Eds.) Schizophrenia. 3rd ed. Hoboken, NJ: Wiley -Blackwell;2011. Wilkinson G, Hesdon B, Wild D, Cookson R, Farina C, Sharma V, et al. Self- report quality of life measure for people with schizophrenia: the SQLS. Br J Psy chiatry 2000;177:42 -46. Williamson A, Hoggart B. Pain: A review of three commonly used pain rating scales. J Clin Nurs 2005;14(7):798- 804. Yazdi K, Unterlass G, Kemmler G, et al. Factors influencing adherence in children and adolescents treated with antipsy chotics or antidepressants. Prim Care Companion J Clin Psychiatry 2008;10(2):160 -1."
120,page_120,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV4 6000- CNS -30072 12016. SUMMARY OF CHANGES 16.1. Global Amendment 03 (Dated 19 April 2020) The primary reason for this amendment is to rescind the previous interim analy ses strategy , and to perform the final s tatistical anal ysis of the study data when at least 90 relapse events are observed, without an y interim anal ysis. The original assumptions for sample size determination in the initial protocol were as follows: ï‚·a placebo effect (namel y, median time to impe nding relapse of 7 months in the placebo group) similar to that observed in a similarl y-designed study (Kane et al 2012) ; ï‚·a hazard ratio of 1.82 (placebo vs TV -46000 for both dosing regimens); ï‚·a randomization ratio of 1:1:1 (q1m:q2m:placebo), with 2 primary h ypotheses to be tested (q1m vs placebo and q2m vs placebo) at an overall 2- sided alpha of 0.050. As the study progressed, the preliminary study design assumptions were found to no longer hold as the pooled cumulative num ber of relapse events (across all treatment groups, due to blinding) was lower than anticipated, based on the above mentioned median time to relapse and hazard ratio. A stronger treatment effect, a longer time to relapse for the placebo group , and an incre ased early termination (ET) rate -either as single factors or in combination -may cause this decrease in the rate of observed events. Since Teva personnel and delegates are blinded to the treatment assignments, the precise underl ying reasons are not know n at this time. An earlier anal ysis will permit earlier completion of this double blind, placebo- controlled stud y (TV46000 -CNS - 30072) and earlier roll- over of patients into the ongoing TV46000- CNS - 30078 safet y extension study, in which all patients receiv e treatment with TV -46000. Additionally , COVID -19 pandemic -related operational updates were added to the study as a new appendix ( Appendix N). Administrative changes have been applied, including updating the Table of Contents. In addition to the reasons mentioned above, an earlier completion may be even more important now given the COVID -19 challenges. All major changes to the protocol body are listed below in the table, and are reflected in the synopsis, as applicable. Minor editorial changes (ty pos, punctuation, etc) have been made to the protocol (and protocol s ynopsis, as appropriate). Table 2(Study Procedures and Assessments) and Figure 1(Overall Study Schematic Diagram) have also been revised to reflect the changes described below."
121,page_121,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 121Original text with changes shown New wording Reason/Justification for change TITLE PAGE NDA number: Not applicable 213586 NDA number: 213586 New Drug Application number assigned. [Other section affected by this change: Investigator Agreement and Coordinating Investigator Agreement] Teva Branded Pharmaceutical Products R&D, Inc. 41 Moores Road 145 Brandywine Parkway Frazer, Pennsylvania 19355 West Chester, Pennsylvania 19380 United States of AmericaTeva Branded Pharmaceutical Products R&D, Inc. 145 Brandywine Parkway West Chester, Pennsylvania 19380 United States of AmericaPer Administrative Letter 03, new address following relocation of sponsor offices. CLINICAL STUDY PROTOCOL SYNOPSIS Sample Size Rationale: Median time to impending relapse w as observed to be 7 months in the placebo group in a similarly designed study (RISPERDAL CONSTA, Janssen Pharmaceuticals, US PI Kane et al 2012 ).Median time to impending relapse w as observed to be 7 months in the placebo group in a similarly designed study (Kane et al 2012).Correction. For consistency with Section 9.1. LIST OF ABBREVIATIONS See New wording column Added: COVID -19 = coronavirus d isease 2019 TC = telephone call/teleconference; VC= videoconferenceNewly -introduced abbreviations 1. INTRODUCTION AND BACKGROUND 1.1. Introduction ... Clarification and simplification."
122,page_122,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 122Original text with changes shown New wording Reason/Justification for change ...... 3. STUDY DESIGN 3.1. General Study Design and Study Schematic Diagram The study will continue on an outpatient basis ( Table 1 Table 2 ), and telephone contacts will take place weekly between clinic visits.The study will continue on an outpatient basis (Table 2), and telephone contacts will take place weekly between clinic visits.Correction. The double -blind maintenance stage will be variable in duration, with patients continuing until they experience a relapse event; meet 1 or more of the study discontinuation or w ithdrawal criteria; or remain relapse- free during the double -blind phase until the study is terminated for efficacy due to a successful interim analysis or because 207at least 90 relapse events are recorded in the study adult population. ... Patients who remain relapse -free when the study is terminated for efficacy due to a successful interim analysis or because 207 relapse events in adults are recorded in the study should be invited to perform the End -of-Treatment visit within 4 w eeks of the last injection.The double- blind maintenance stage will be variable in duration, with patients continuing until they experience a relapse event; meet 1 or more of the study discontinuation or w ithdrawal criteria; or remain relapse- free during the double -blind phase until the study is terminated because at least 90 relapse events are recorded in the study adult population. ... Patients who remain relapse -free when the study is terminated should be invited to perform the End -of-Treatment visit within 4 weeks of the last injectio n.There w ill be no interim analysis for efficacy in this study; the final analysis will be performed earlier due to the low event rate. Correction and simplification. The study duration will be approximately 30 months, from Q2 2018 (first patient in) t o Q4 2020 (last patient out). In case of a successful interim analysis, the study will be terminated earlier (see Section 9.6 ) The study duration will be approximately 30 months, from Q2 2018 (first patient in) to Q4 2020 (last patient out). There w ill be no interim analysis for efficacy in this study. See New wording columnFigure 1 (Overall Study Schematic Diagram) has been revised as described below : ï‚·Number of randomized patients was updated from ~417 to ~520; ï‚·Number of patients randomized to each tr eatment arm was updated from ~139 to ~173.Updated enrollment projections."
123,page_123,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 123Original text with changes shown New wording Reason/Justification for change 3.2. Planned Number of Patients and Countries Approximately 993 1260 patients will be screened to achieve enrollment of approximately 695 860adult patients in Stage 1, including approximately 67 70 adult patients in Bulgaria. The number of randomized adult patients in Stage 2 is planned to be approximately 417520, including approximately 40 55 adult patients in Bulgaria. Approximately 1260 pa tients will be screened to achieve enrollment of approximately 860adult patients in Stage 1, including approximately 70 adult patients in Bulgaria. The number of randomized adult patients in Stage 2 is planned to be approximately 520, including approximately 55adult patients in Bulgaria. Updated enrollment projections. 3.4. Stopping Rules for the Study There are no formal rules for early terminati on of this study. During the conduct of the study, serious adverse events will be reviewed ( Section 7.1.5.3.1 ) as they are reported from the investigational centers to identify safety concerns. The study may be terminated by the sponsor for any reason at any time. For example, the sponsor should terminate the study in the event of: ï‚·new toxicological or pharmacological findings or safety issues invalidate the earlier positive benefit -risk assessment ï‚·discontinuation of the development of the investigational medicinal product (IMP) Two formal interim analyses are planned in this study , when the number of events observed in the intent totreat (ITT) analysis set reach es 43.5% and 60% of the planned 207 relapse events (90 and 125 events in adult patients, respectively). An Independent Data Monitoring Committee (IDMC) w ill conduct the interim analysis to assess efficacy for all randomized patients . Results will need to demonstrate statistically significant effects in the prim ary analysis of the primary endpoint (at a significance level of 0.0101) for both risperidone treatment groups (q1m and q2m) at any of the interim analyses in order to stop the study early for success, as described in Section 9.6 . The IDMC could recommend to discontinue the study for ethical reasons, most notably continued exposure to placebo, if efficacy is established.There are no formal rules for early termination of this study. During the conduct of the study, serious adverse events will be reviewed ( Section 7.1.5.3.1 ) as they are reported from the investigational centers to identify safety concerns. The study may be terminated by the sponsor for any reason at any time. For example, the sponsor should terminate the study in the event of: ï‚·new toxicological or pharmacological findings or safet y issues invalidate the earlier positive benefit -risk assessment ï‚·discontinuation of the development of the investigational medicinal product (IMP)There w ill be no interim analysis for efficacy in this study."
124,page_124,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 124Original text with changes shown New wording Reason/Justification for change 3.5. Schedule of Study Procedures and Assessm ents Study procedures and assessments with their time points are presented in Table 1 and Table 2 .Study procedures and assessments with their time points are presented in Table 1 and Table 2.Correction. Table 2: TV46000 -CNS -30072 (RISE) Study Procedures and Assessments (In -Clinic Visits and Telephone Contacts) â€“Baseline, Double -Blind Maintenance Stage (Stage 2), End of Treatm ent/Early Termination and Follow -Up a. The double- blind maintenance stage will be variable in duration, with patients continuing until they experience a relapse event and complete all end -of-study assessments; meet 1 or more of the study discontinuation or withdraw al criteria; or remain relapse -free during the double- blind phase until the study is terminated for efficacy due to a successful interim analysis or because 207at least 90 relapse events are recorded in the study in the ITT analysis set . ..a. The double- blind maintenance stage will be variable in duration, with patients continuing until they experience a relaps e event and complete all end -of-study assessments; meet 1 or more of the study discontinuation or withdraw al criteria; or remain relapse -free during the double- blind phase until the study is terminated because at least 90 relapse events are recorded in the study in the ITT analysis set. ...There w ill be no interim analysis for efficacy in this study; the final analysis will be performed earlier due to the low event rate. 5. TREATMENTS 5.10.1. Maintenance of Random ization Patient randomization codes will be maintained in a secure location at the service provider contracted to generate the codes. At the time of analysis (after the end of study or at each interim analysis ), after receiving unblinding request from Teva statist ician, the service provider will provide the unblinded IMP assignment according to the processes defined in the relevant SOP. The codes w ill be provided to an independent statistician who will perform the interim analyses.Patient randomization codes will be m aintained in a secure location at the service provider contracted to generate the codes. At the time of analysis (after the end of study) , after receiving unblinding request from Teva statistician, the service provider will provide the unblinded IMP assignment according to the processes defined in the relevant SOP. There w ill be no interim analysis for efficacy in this study. 5.10.3. Data Monitoring Committee During the conduct of this study there will be an IDMC that w ill review accumulating unblinded safety and pharmacokinetic data on a regular basis (as detailed in the IDMC charter) to ensure the continuing safety of the study patients and any study conduct issues. The IDMC w ill perform up to 2 formal interim analyses for efficacy in this study (when the number of events observed reaches 43% and 60% of the planned 207 relapse events in the ITT analysis set [Section 3.4 ]). The second interim analysis will be performed if at least one of the p values of the 2 primary comparisons is above 0.0101 at the first interim analysis. During the conduct of this study there will be an IDMC that w ill review accumulating unblinded safety and pharmacokinetic data on a regular basis (as detailed in the IDMC charter) to ensure the continuing safety of the study patients and any study conduct issues. The IDMC w ill be composed of independent physicians with expertise in the relevant therapeutic field and other relevant experts, such as a statistician and a pharmacokinetic specialist. ... There w ill be no interim analysis for efficacy in this study."
125,page_125,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 125Original text with changes shown New wording Reason/Justification for change The IDMC w ill be composed of independent physicians with expertise in the relevant therapeutic field and other relevant experts, such as a statistician and a pharmacokinetic specialist. ... 5.11."
126,page_126,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 126Original text with changes shown New wording Reason/Justification for change 9.4. Study Population The eITT analysis set (Section 9.2.3) w ill be used for all study population summaries of the double- blind treatment stage unless otherwise specified. Summaries will be presented by treatment group and for all patients. If the number of adolescents permits, summaries will also be presented by age subgroup.The primary analysis wil l be conducted on the ITT analysis set (Section 9.2.2), and the eITT analysis set (Section 9.2.3) will be used for analysis of the key secondary endpoints unless otherwise specified the first key secondary endpoint will be conducted on the complete eITT an alysis set (Section 9.2.3) and the second key secondary will be conducted on the adolescent subset of the eITT analysis set, if the number of adolescents permits . The analysis set on which analysis for other endpoints will be conducted w ill be specified on a case - by-case basis. The enrolled patients set (Section 9.2.1) w ill be used for data summaries before the double -blind treatment stage.The eITT analysis set (Section 9.2.3) w ill be used for all study population summaries of the double- blind treatment st age unless otherwise specified. Summaries will be presented by treatment group and for all patients. If the number of adolescents permits, summaries will also be presented by age subgroup.The primary analysis will be conducted on the ITT analysis set (Sec tion 9.2.2), and the eITT analysis set (Section 9.2.3) will be used for analysis of the key secondary endpoints unless otherwise specified. The analysis set on which analysis for other endpoints will be conducted will be specified on a case -by-case basis. The enrolled patients set (Section 9.2.1) will be used for data summaries before the double -blind treatment stage.Correction."
127,page_127,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 127Original text with changes shown New wording Reason/Justification for change 9.4.2. Dem ographic and Baseline Characteristics The ITT analysis set, the eITT analysis set, and the eITT subset of adolescents will be used for the summaries, as applicable . The ITT analysis set, the eITT analysis set, and the eITT subset of adolescents will be used for the summaries, as applicable.Clarification. 9.5.2. Key Secondary Endpoints ... The key secondary endpoints are comprised of endpoints that correspond to the 2 key secondary objectives described listed in Section 2.1 and described in detail below .... The key secondary endpoints are listed in Section 2.1and described in detail below .Correction. 9.5.4. Planned Method of Analysis The ITT analysis set (Section 9.2.2) will be used for all efficacy analyses. Summaries will be presented by treatment group. Analysis that will be conducted on the eITT analysis set or on the adolescent patient subset of the eITT w ill be described below , as applicable.The ITT analysis set (Section 9.2.2) will be used for all efficacy analyses. Summaries will be presented by treatment group. Analysis that will be conducted on the eITT analysis set or on the adolescent patient subset of the eITT w ill be described below , as applicable.Clarification. 9.5.4.4.1. Time to Event Key Secondary Analysis For the key secondary endpoint sdiscussed in Section 9.5.2.1,time to impending relapse in adult and adolescent patients will be assessed similarly to the Primary Efficacy Analysis using the eITT Analysis Set (Section 9.2.2).For the key secondary endpoint discussed in Section 9.5.2.1,ti me to impending relapse in adult and adolescent patients will be assessed similarly to the Primary Efficacy Analysis using the eITT Analysis Set (Section 9.2.2).Correction of typo. 9.6. Multiple Com parisons and Multiplicity There w ill be up to 2 formal interim analyses when the number of events observed reaches 43.5% and 60% of the planned 207 relapse events (90 and 125 events, respectively) in the ITT analysis set. At the first interim analysis, both primary efficacy tests will be tested at a 2 sided alpha of 0.0101. If both tests are significant at the first interim analysis, the study will be stopped early. If only 1 primary efficacy test (or none) is significant at the first interim analysis, the study will continue until the second interim analysis. If both tests are significant at the second interim analysis, the study will be stopped early. If only 1 primary efficacy test (or none) is significant at this interim analysis, the study will continue until 207 relapse events are observed. At the final analysis after 207at least 90 relapse events, a fixed At the final analysis after at least 90 relapse events, a fixed sequential (hierarchical) testing approach w ill be implemented. If the resulting first p-value of the primary e fficacy hypothesis test comparing q1m to placebo is found to be significant at 0.05 alpha, then the second primary efficacy hypothesis (q2m vs. placebo) w ill be interpreted inferentially at the same alpha level of 0.05. If the first primary hypothesis fail s to reach significance no further formal hypothesis testing will be performed. ...There w ill be no interim analysis for efficacy in this study; the final analysis will be performed earlier due to the low event rate."
128,page_128,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 128Original text with changes shown New wording Reason/Justification for change sequential (hierarchical) testing approach w ill be implemented. If the resulting first p-value of the primary efficacy hypothesis test comparing q1m to placebo is found to be significant at 0.0418 0.05 alpha, then the second primary efficacy hypothesis (q2m vs. placebo) will be interpreted inferentially at the same alpha level of 0.0418 0.05. If the first primary hypothesis fails to reach significance no further formal hypothesis testing will be performed. This procedure w ill adequately control overall type 1 error for a 2sided alpha of 0.05 accounting for the interim analyses. The nominal alphas of 0.0101 at each interim analysis and 0.0418 at the final analysis were calculated using EAST 6 softw are, as described in the EAST 6 manual (East 6 [Version 6.3] manual, 2014 ). ... 9.13. Planned Interim Analysis There w ill be no interim analysis in this study. There w ill be up to 2 formal interim analyses when the number of events observed in the ITT analysis set reaches 43.5% and 60% of the planned 207 relapse events (90 and 125 events in adult patients, respect ively). Results will need to demonstrate statistically significant effects in the primary analysis of the primary endpoint (at a significance level of 0.0101) for both risperidone treatment groups (q1m and q2m) at any of the interim analyses in order to st op the study early for success as described in Section 9.6 .If success criteria was not met [ie, if only 1 primary efficacy test (or none) is significant] at the first interim analysis (at 90 relapse events), the study will continue to the second interim analysis (at 125 relapse events). If only 1 primary efficacy test (or none) is significant at this interim analysis, (ie, if none of the interim analyses demonstrate success), the study will continue until 207 relapse events are reached. An IDMC will condu ct the interim analyses to assess efficacy for all randomized patients. An IDMC charter w ill be developed for the interim analyses. Procedures will be taken to ensure the There w ill be no interim analysis in this study. Deleted since text is no longer relevant; no interim analysis for efficacy will be performed. TheIDMC is described in Section 5.10.3. of the protocol."
129,page_129,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 129Original text with changes shown New wording Reason/Justification for change integrity of the study follows the IDMC charter. The IDMC could recommend to discontinue the study for ethical reasons, most notably continued exposure to placebo, if efficacy is established. APPENDIX A. CLINICAL LABORATORIES AND OTHER DEPARTMENTS AND INSTITUTIONS Sponsorâ€™s Medical Expert/Contact Point designated by the Sponsor for Further Information on the Study Teva Branded Pharmaceutical Products R&D, Inc. Tel: + Cell: + Email: Sponsorâ€™s Medical Expert/Contact Point designated by the Sponsor for Further Information on the Study Teva Branded Pharmaceutical Products R&D, Inc. Tel: Cell: Email: Per Administrative Letter 03, updated to reflect change of responsibilities at Teva. APPENDIX B. STUDY PROCEDURES AND ASSESSMENTS BY VISIT Note in Section g Stage 2: Early Termination (ET) Visit/End -of-Treatm ent Visit (EoT): Note: The double -blind maintenance stage will be variable in duration, with patients continuing until they experience a relapse event and complete all end -of-study assessments; meet 1 or more of the study discontinuation or withdraw al criteria; or remain relaps e-free at the time of study termination during the double blind phase until the study is terminated for efficacy due to a successful interim analysis or because 207 relapse events are recorded in the study in the ITT analysis set.Note in Section g Stage 2: Early Termination (ET) Visit/End -of-Treatm ent Visit (EoT): Note: The double -blind maintenance stage will be variable in duration, with patients continuing until they experience a relapse event and complete all end -of-study assessments; meet 1 or more of the study discontinuation or withdraw al criteria; or remain relapse -free at the time of study termination. There w ill be no interim analysis for efficacy in this study; the final analysis will be performed earlier due to the low event rate. Note in Section c Stage 2: Relapse Prevention (Visit 6a, Week 1Â±3days; Visit 6b, Week 2Â±3 days; and Visit 6c, Week 3Â±3days [Telephone Contacts]) (Visit 7a, Week 5Â±3days; Visit 7b, Week 6Â±3 days; and Visit 7c, Week 7Â±3 days [Telephone Contacts], 8a -8c, 9a -9c, etc.) Note: Telephone contacts will occur weekly betw een in -clinic visits during the double- blind maintenance stage (Stage 2) (see Table 1 Table 2 ).Note in Section c Stage 2: Relapse Prevention (Visit 6a, Week 1Â±3days; Visit 6b, Week 2Â±3 days; and Visit 6c, We ek 3Â±3days [Telephone Contacts]) (Visit 7a, Week 5Â±3days; Visit 7b, Week 6Â±3 days; and Visit 7c, Week 7Â±3 days [Telephone Contacts], 8a -8c, 9a -9c, etc.) Note: Telephone contacts will occur weekly betw een in -clinic visits during the double- blind maintenan ce stage (Stage 2) (see Table 2 ).Correction. APPENDIX G. LIST OF PROHIBITED MEDICATIONS (Other sections affected by this change: Section 5.7) ... In addition to those listed above, medications that may be expected to significantly interfere w ith the metabolism or ... In addition to those listed above, medications that may be expected to significantly interfere w ith the metabolism or Clarification due to COVID -19 pandemic."
130,page_130,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 130Original text with changes shown New wording Reason/Justification for change excretion of risperidone and/or 9 -OH risperidone, may be associated with a significant drug interaction with risperidone, or may pose a si gnificant risk to patientsâ€™ participation in the study (eg, chloroquine, which is a QTc prolongator) are prohibited.excretion of risp eridone and/or 9 -OH risperidone, may be associated with a significant drug interaction with risperidone, or may pose a significant risk to patientsâ€™ participation in the study (eg, chloroquine, which is a QTc prolongator) are prohibited. APPENDIX N. MANAGEMENT OF STUDY ACTIVITIES DURING COVID -19 New appendix and text. Additional text too numerous to include in this table; refer to Appendix Nof this protocol.Updated to manage study conduct during the COVID -19 pandemic. Section 3.1. General Study Design and Study Schematic Diagram ; Section 3.5. Schedule of Study Procedures and Assessments; Sec tion 5.1.1. Test Investigational Medicinal Product; Section 5.1.2. Placebo Investigational Medicinal Product; Table 4. Investigatio nal Medicinal Products Used in the Study; Section 5.2.1. Storage and Security; Section 5.2.3. Accountability; Section 5.9. Randomization and Blinding; Section 6. Assessment of Efficacy; Section 7. Assessment of Safety; 7.4. Clinical Laboratory Tests; 7.6. Vital Signs; 7.7. Electrocardiography; Section 8.1. Pharm acokinetic Assessment; Section 9.5.4.2. Sensitivity Analysis; Section 10.Quality Control and Quality Assurance; Appendix C. Quality Control and Quality Assurance; Appendix F. Lost to Follow Up SeeNew wording column. For COVID -19 updates, refer to Appendix N. Updated sections to cross - reference the addition of Appendix N."
131,page_131,Placebo -Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000 -CNS -30072 13116.2. Administrative Letter 03 (Dated 09 February 2020)
132,page_132,Placebo -Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000 -CNS -30072
133,page_133,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 13316.3. Global Amendment 02 with Revision 01 (Dated 16 October 2019) The primary reason for this revision of Global Amendment 02 is to reorganize the statistical analyses with the introduction of the fixed sequential (hierarch y) method to control the Ty pe-I error for the primary analy ses in the final anal ysis and a reconsideration and hierarchy of the key secondary endpoints. A comparison table showing the changes from Global Amendment 02 to Global Amendment 02 with Revision 01 with is provided below. Previous text is presented in the column titled ""Original text with chang es shown"", and the revised or new text is presented in the column titled ""new wording."" Revised or new text is shown in bold italics and deleted text is shown in strike - through. The revisions listed below have been made to the protocol (and protocol s ynop sis, as appropriate) and are considered significant by the Teva Authorized Representative. These changes are unlikely to affect the safet y or rights (ph ysical or mental integrit y) of the subjects in this clinical study or the scientific value of the clinic al study . Also, to adhere with current Teva standards, some formatting and editing changes have been made."
134,page_134,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 134Original text with changes shown New wording Reason/Justification for change TITLE PAGE (Other sections affected by this change: Header, Investigator Agreement; Coordinating Investigator Agreem ent) Clinical Study Protocol with Amendm ent 02 with Revision 01Clinical Study Protocol Amendment 02 with Revision 01 To denote the new global amendment with revision AMENDMENT HISTORY The protocol for Study TV46000 -CNS -30072 (original protocol dated 14 December 2017) has been amended and reissued as follows: Global Amendment 02 with Revision 0116 October 2019 (649 patients enrolled to date) Global Amendment 0202 September 2019 (584 patients enrolled to date) Letter of Clarification 0227 June 2019 Global Amendment 0106 December 2018 (184 patients enrolled to date) â€¦ â€¦ The Summary of Changes to the Protocol includes the corresponding reason/justification for each change and is provided in Section 16.The protocol for Study TV46000 -CNS -30072 (original protocol dated 14 December 2017) has been amended and reissued as follows: Global Amendment 02 with Revision 0116 October 2019 (649 patients enrolled to date) Global Amendment 0202 September 2019 (584 patients enrolled to date) Letter of Clarification 0227 June 2019 Global Amendment 0106 December 2018 (184 patients enrolled to date) â€¦ â€¦ The Summary of Changes to the Protocol includes the corresponding reason/justification for each change and is provided in Section 16.This page w as updated with the details of the documents issued since the last amendment 2. STUDY OBJECTIVES AND ENDPOINTS 2.1.Prim ary and Secondary Study Objectives and Endpoints ( Other sections affected by this change: Clinical Study Protocol Synopsis) TheA key secondary objective of this study is to evaluate the efficacy of TV -46000 during maintenance treatment in a total population (adults and adolescents) and in adolescent patients with schizophrenia.Akey secondary objective of this study is to evaluate the efficacy of TV -4600 0 during maintenance treatment in a total population (adults and adolescents) and in adolescent patients with schizophrenia.Correction ThekKey secondary endpoints are: 1time to impending relapse (as defined under the Key secondary endpoints are: ï‚·time to impending relapse (as defined under the Revision and reorgarnization to the"
135,page_135,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 135Original text with changes shown New wording Reason/Justification for change primary objective) in the total po pulation (adults and adolescents) ,and impending relapse rate at week 24 percentage of patients who maintain stability at endpoint percentage of patients achieving remission at endpoint observed rate of impending relapse at endpoint Drug Attitudes Inventory 10 -item version (adult patients only) Schizophrenia Quality of Life Scale (SQLS) (adult patients only) 2time to impending relapse in adolescent patients with schizophrenia. NOTE: The assessment of time to impending relapse in adolescent patients is pending randomization of at least 10 adolescent patients with clinically sufficient exposure.primary objective) in the total population (adults and adolescents) ï‚·impending rel apse rate at week 24 ï‚·percentage of patients who maintain stability at endpoint ï‚·percentage of patients achieving remission at endpoint ï‚·observed rate of impending relapse at endpoint ï‚·Drug Attitudes Inventory 10 -item version ( adult patients only ) ï‚·Schizop hrenia Quality of Life Scale (SQLS) ( adult patients only ) ï‚·time to impending relapse in adolescent patients with schizophreniasecondary endpoints A secondary objective of this study is to evaluate the specific efficacy parameters of TV46000 in the total population beyond the measures of the primary objective.Not applicable Correction due to moving the endpoints up to key secondary endpoints Secondary efficacy endpoints are as follows: ï‚·impending relapse rate at week 24 ï‚·observed rate of impending relapse at endpoint ï‚·percentage of patients who maintain stability at endpoint (Section 9.5.3.3) percentage of patients achieving remission at endpoint (Section 9.5.3.4) Not applicable Correction (now included under the key secondary endpoints ) The follow ing quality of life and healthcare resource utilization measures will be assessed: ï‚·Schizophrenia Quality of Life scale (adult patients only) ï‚·5-Level EuroQol Five Dimensions Questionnaire (adult patients only) ï‚·Drug Attitudes Inventory 10 item version (adult patients only) ...The follow ing quality of life and healthcare resource utilization measures will be assessed: ï‚·5-Level EuroQol Five Dimensions Questionnaire (adult patients only) ...Correction (now included under the key secondary endpoints )"
136,page_136,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 136Original text with changes shown New wording Reason/Justification for change 9.5. EFFICACY ANALYSIS 9.5.2. Key Secondary Endpoints The key secondary endpoints are: 1time to impending relapse (as defined under the primary objective) in the eITT analysis set, and 2time to impending relapse in adolescent patients with schizophrenia. NOTE: The assessment of time to impending relapse in adolescent patients is pending randomization of at least 10 adolescent patients with clinically sufficient exposure. The eITT analysis set (Section 9.2. 3) will be used for al l summaries in this section, unless otherwise specified. For the endpoints that are evaluted only in the adult population, the analysis will be conducted on the ITT analysis set. The key secondary endpoints are comprised of endpoints that correspond to the 2 key secondary objectives described inThe eITT analysis set (Section 9.2.3) w ill be used for all summaries in this section, unless otherwise specified. For the endpoints that are evaluted only in the adult population, the analysis will be c onducted on the ITT analysis set. The key secondary endpoints are comprised of endpoints that correspond to the 2 key secondary objectives described in Section 2.1.Revision and reorganization to the section 9.5.2. The section numbers will be updated accor dingly."
137,page_137,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 137Original text with changes shown New wording Reason/Justification for change Section 2.1. 9.5.2.1. Tim e to Impending Relapse in the eITT Analyses Set Not applicable Time to impending relapse using the same definition and primary analysis that is described in section 9.5.1 using the eITT analysis will be employed. New section added, included in the key secondary endpoints 9.5.2.2 Im pending Relapse Rate at Week 24 This rate w ill be estimated using the Kaplan -Meier method This rate w ill be estimated using the Kaplan -Meier method Reorganization of the section (now included under the key secondary endpoints) 9.5.2.3. Percentage of Patients Who Maintain Stability at Endpoint The percentage w ill be calculated as the number of patients who maintained stability at endpoint divided by the number of eITT patients that adhere to treatment for at least 4 weeks or experienced relapse in the given treatment group. This analysis estimates the treatment effect of randomized treatment on patient's stability once the patient adheres to treatment long enough until the last treatment. The use of eITT analysis complies with while on treatment estimand and will be comprised of the difference in proportions under the treatment to which the patient was initially randomized of all patients who were successfully stabilized on oral risperidone at a daily dose range of 2 mg to 5 mg. Accordingly, this estimand addresses the clinical question to what extent patients improve their chances to maintain stability once they start the treatment if the patient adheres to the treatment long enough.The percentage w ill be calculated as the number of patients who maintained stability at endpoint divided by the number of eITT patients that adhere to treatment for at least 4 weeks or experienced relapse in the given treatment group. This analysis estimates the treatment effect of randomized treatment on patient's stability once the patient adheres to treatment long enough until the last treatment. The use of eITT analysis complies with while on treatment estimand and will be comprised of the diffe rence in proportions under the treatment to which the patient was initially randomized of all patients who were successfully stabilized on oral risperidone at a daily dose range of 2 mg to 5 mg. Accordingly, this estimand addresses the clinical question to what extent patients improve their chances to maintain stability once they start the treatment if the patient adheres to the treatment long enough.Revision and reorganization to the section 9.5.2.4. Percentage of Patients Achieving Remission at Endpoint For overall symptom remission, the patient must not relapse during the study and in addition, over a period of at least 6months preceding the endpoint, maintain scores of â‰¤3 on each of the 8 specific PANSS items: P1 (delusions), G9 (unusual thought content), P3 (hallucinatory behavior), P2 (conceptual disorganization), G5 (mannerisms/posturing), N1 (blunted affect), N4 (social w ithdraw al), and N6 (lack of spontaneity). For overall symptom remission, the patient must not relapse during the study and in addition, over a period of at least 6months preceding the endpoint, maintain scores of â‰¤3 on each of the 8 specific PANSS items: P1 (delusions), G9 (unusual thought content), P3 (hallucinatory behavior), P2 (conceptual disorganization), G5 (mannerisms/pos turing), N1 (blunted affect), N4 (social w ithdraw al), and N6 (lack of spontaneity). Revision and reorganization of the section"
138,page_138,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 138Original text with changes shown New wording Reason/Justification for change The percentage will be calculated as the number of patients who achieved remission at endpoint divided by the number of eITT patients that adhere at least 6 months or experienced relapse in the given treatment group. This analysis estimates the treatment effect of randomized treatment on patient's remission once the patient adheres to treatment long enough until the last treatment. The use of eITT analysis complies with the while on treatment estimand, and will be comprised of the difference in proportions under the treatment to which the patient was initially randomized of all patients who were successfully stabilized on oral risperidone at a daily dose range of 2 mg to 5 mg. Accordingly, this estimand addresses the clinical question to what extent patients improve their chan ces to achieve remission once they start the treatment if the patient adheres to the treatment long enough. The analysis will be detailed in the statistical analysis plan.The percentage w ill be calculated as the number of patients who achieved remission at endpoint divided by the number of eITT patients that adhere at least 6 months or experienced relapse in the given treatment group. This analysis estimates the treatment effect of randomized treatment on patient's remission once the patient adheres to treatment long enough until the last treatment. The use of eITT analysis complies wit h the while on treatment estimand, and will be comprised of the difference in proportions under the treatment to which the patient was initially randomized of all patients who were successfully stabilized on oral risperidone at a daily dose range of 2 mg t o 5 mg. Accordingly, this estimand addresses the clinical question to w hat extent patients improve their chances to achieve remission once they start the treatment if the patient adheres to the treatment long enough. 9.5.2.5. Observed Rate of Impending Relapse at Endpoint Observed rate of impending relapse w ill be calculated as the number of patients who relapsed by endpoint divided by the number of patients in each treatment group .Observed rate of impending relapse w ill be calculated as the number of patients who relapsed by endpoint divided by the number of patients in each treatment group .Reorganization of the section (now included under the key secondary endpoints) 9.5.2.6. Dru g Attitudes Inventory 10 -item Version The change from baseline to endpoint in total score w ill be calculatedThe change from baseline to endpoint in total score w ill be calculatedReorganization of the section (now included under the key secondary endpoints) 9.5.2.7.Schizophrenia Quality of Life Scale The change from baseline to endpoint in total score w ill be calculatedThe change from baseline to endpoint in total score w ill be calculatedReorganization of the section (now included under the key secondary endpoints)"
139,page_139,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 139Original text with changes shown New wording Reason/Justification for change 9.5.2.8. Tim e to Impending Relapse in aAdolescent Patients with Schizophrenia Not applicable Time to impending relapse using the same definition and primary analysis that was described in section 9.5.1 w ill be used on the eITT analysis set using adolescent patients alone. This assessment of time to impending relapse in adolescent patients is pending randomization of at least 10 adolescent patients with clinically sufficient exposure.New section added, included in the key secondary endpoints 9.5.4.2. Sensitivity Analyses The PP analysis set will also be used as supplemental analysis to evaluate the primary efficacy variable. Details will be provided in the statistical analysis plan. Senstivity analysis will be conducted on the ITT analysis set.The PP analysis set will also be used as supplemental analysis to evaluate the primary efficacy variab le. Details will be provided in the statistical analysis plan. Senstivity analysis will be conducted on the ITT analysis set.Clarification to the sensitivity analyses 9.5.4.4. Key Secondary Analyses The fixed sequential (hierarchical) Strategy (FDA 2017) will be used to control the overall Type- I statstical error in the study for both primary and secondary efficacy endpoints. The key secondary endpoints will be analyzed in a pooled manner for q1m and q2m. The details about the Type- I statistical error control for the key secondary endpoints will be discussed in the statistical analysis plan.The fixed sequential (hierarchical) Strategy (FDA 2017) w ill be used to control the overall T ype-I statstical error in the study for both primary and secondary efficacy endpoints. The key secondary endpoints will be analyzed in a pooled manner for q1m and q2m. The details about the T ype-I statistical error control for the key secondary endpoints will be discussed in the statistical analysis plan.New text added 9.5.4.4.1. Time to Event Key Secondary Analyses Time to Event Key Secondary Analyses 1 Time to Event Key Secondary Analyses Correction to the title For the key secondary endpoints discussed in Section 9.5.2.1 ,Ttime to impending relapse in adult and adolescent patients will be assessed similarly to the Primary Efficacy Analysis using the eITT Analysis Set (Section 9.2.2). The Cox proportional hazard model w ill include patient age group (if applicable) along w ith treatment, and the aforementioned stratification variables as the factors. The details about the Type I statistical error control w ill be discussed in Section 9.6 . For the key secondary endpoint discussed in Section 9.5.2.8 ,Ttime to impending relapse in adolescent patients will be assessed if the number of randomized patients will be at least 10 with clinically sufficient exposure. The method w ill be similar to the Primary Efficacy Analysis, but will use the For the key secondary endpoints discussed in Section 9.5.2.1, time to impending relapse in adult and adolescent patients will be assessed similarly to the Primary Efficacy Analysis using the eITT Analysis Set (Section 9.2.2). The Cox proportional hazard model will include patient age group (if applic able) along with treatment, and the aforementioned stratification variables as the factors. For the key secondary endpoint discussed in Section 9.5.2.8, time to impending relapse in adolescent patients will be assessed if the number of randomized patients will be at least 10 with clinically sufficient exposure. The method w ill be similar to the Primary Efficacy Analysis, but will use the adolescent patients subset .Type-I statistical error control w ill be discussed Clarification to the key secondary analysis"
140,page_140,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 140Original text with changes shown New wording Reason/Justification for change adolescent patients subset .The details about the Type I statistical error control will be discussed in Section 9.6. Multiple Comparisons and Multiplicity.in Multiple Comparisons and Multiplicity. 9.5.4.5. Key Secondary Efficacy Analysis 9.5.2.2 -9.5.2.7 KeySecondary Efficacy Analysis 9.5.2.2 -9.5.2.7 Key Secondary Efficacy Analysis 9.5.2.2 -9.5.2.7 Correction to the title Impending relapse rate at week 24will be estimated using the Kaplan -Meier method and calculated as 1 minus the proportion of patients free of impending relapse events at week 24. The Greenw ood formula will be used to calculate standard errors for impending relapse rates at week 24, and the pooled standard errors will be used for hypothesis testing using z -statistics, assuming that the differences betw een TV -46000 and placebo follow a norm al distribution of large samples. The tests will be conducted at a nominal 2 sided alpha of 0.05 .Impending relapse rate at week 24 will be estimated using the Kaplan -Meier method and calculated as 1 minus the proportion of patients free of impending relapse events at week 24. The Greenw ood formula will be used to calculate standard errors for impending relapse rates at week 24, and the pooled standard errors will be used for hypothesis testing using z -statistics, assuming that the differences betw een TV -46000 and placebo follow a norm al distribution of large samples.Change due to the implementation of the hierarchy Change from baseline of DAI -10 and SQLS total score, will be analyzed using an analysis of covariance (ANCOVA) method, with treatment and stratification variables as factors and baseline (score at the end of Stage 1) as a covariate. Additional details regarding the analysis will be documented in the statistical analysis plan.Change from baseline of DAI -10 and SQLS total score, will be analyzed using an analysis of covariance (ANCOVA) method, with treatment and stratification variables as factors and baseline (score at the end of Stage 1) as a covariate. Additional details rega rding the analysis will be documented in the statistical analysis plan. New text added The eITT analysis set (Section 9.2 .3) will be used for all summaries in this section, unless otherwise specified. Type -I statistical error control will be discussed i n Multiple Comparisons and Multiplicity.The eITT analysis set (Section 9.2.3) w ill be used for all summaries in this section, unless otherwise specified. Type-I statistical error control will be discussed in Multiple Com parisons and Multiplicity.Change added 9.6 Multiple Com parisons and Multiplicity If both tests are significant at the first interim analysis, the study will be stopped early . If only 1 primary efficacy test (or none) is significant at the first interim analysis, the study will continue until the second interim analysis. If both tests are significant at the second interim analysis, the study will be stopped early â€¦If both tests are significant at the first interim analysis, the study will be stopped early. If only 1 primary efficacy test (or none) is significant at the first interim analysis, the study will c ontinue until the second interim analysis. If both tests are significant at the second interim analysis, the study will be stopped early â€¦Clarifiication and correction to the multiple Com parisons and Multiplicity methodology for the primary analyses"
141,page_141,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 141Original text with changes shown New wording Reason/Justification for change At the fina l analysis after 207 events, a fixed sequential (hierarchical) testing approach will be implemented .If the resulting first p-value of the both primary efficacy tests hypothesis test comparing q1m to placebo will be conducted with 2 sided is found to be significant at alphas of 0.0418 alpha, then the second primary efficacy hypothesis (q2m vs. placebo) will be interpreted inferentially at the same alpha level of 0.0418 if 1 primary efficacy test is not significant at a 2sided alpha of 0.0418 , the other w ill be tested at a 2 sided alpha of 0.0418 divided by 2. If the first primary hypothesis fails to reach significance no further formal hypothesis testing will be performed. This procedure w ill adequately control overall Type -Ierror for a 2-sided alpha o f 0.05 accounting for the interim analyses . The nominal alphas of 0.0101 at each interim analysis and 0.0418 at the final analysis were calculated using EAST 6 software, as described in the EAST 6 manual ( East 6 [Version 6.3] manual, 2014) . Type-I error w ill be further controlled for the 2key secondary endpoints by employing thefixed sequential ( hierarchical ) testing strategy within each endpoints family (primary endpoints and key secondary endpoints) approach , Secondary endpoint s#1will be analyzed in a pooled manner only in case the 2 for the treatment groups if the two primary endpoints are found to be primary efficacy endpoints have significant. p values less than or equal to alpha of 0.0418 . In that case, key secondary endpoint #1 will be te sted for the 2 dosing regimens using the same approach. Namely, tests for the 2 dosing regimens will be conducted with 2 sided alphas of 0.0418; if one of the comparisons for the key secondary endpoint #1 is not significant at a 2 sided alpha of 0.0418, th e other will be tested at a 2 sided alpha of 0.0418 divided by 2. Further details about the Type- I statistical error control will be discussed in the statistical analysis plan. A fixed -sequence (hierarchical) testing procedure will be implemented to contro l the Type- I error rate . The sequence of the secondary endpoints comparisons will be as follows If secondary endpoint #1 is successful on both dosing regimens At the final analysis after 207 events, a fixed sequential (hierarchical) testing approach will be implemented. If th e resulting first p-value of the primary efficacy hypothesis test comparing q1m to placebo is found to be significant at 0.0418 alpha, then the second prim ary efficacy hypothesis (q2m vs. placebo) w ill be interpreted inferentially at the same alpha level of 0.0418. If the first primary hypothesis fails to reach significance no further formal hypothesis testing will be performed. This procedure w ill adequately control overall Type -I error for a 2-sided alpha of 0.05 accounting for the interim analyses. The nominal alphas of 0.0101 at each interim analysis and 0.0418 at the final analysis were calculated using EAST 6 softw are, as described in the EAST 6 manual (East 6 [Version 6.3] manual, 2014) . Type-I error w ill be further controlled for the key secondary endpoints by employing fixed sequential (hierarchical) testing strategy within each endpoints family (primary endpoints and key secondary endpoints). Secondary endpoints will be analyzed in a pooled manner for the treatment groups if the two primary endpoin ts found to be significant. Further details about the Type-I statistical error control will be discussed in the statistical analysis plan. A fixed -sequence (hierarchical) testing procedure w ill be implemented to control the T ype-I error rate. The sequence of the secondary endpoints comparisons will be as follows: 1.Time to impending relapse in the eITT analysis set 2.Impending relapse rate at week 24 3.Percentage of patients who maintain stability at endpoint 4.Percentage of patients achieving remission at endpoint 5.Observed rate of impending relapse at endpoint 6.DAI-10 change from baseline to endpoint 7.SQLS change from baseline to endpoint 8.Time to im pending relapse in adolescent patients with schizophrenia If the first comparison is found to be significant, then the next comparison of interest will be interpreted inferentially at the"
142,page_142,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 142Original text with changes shown New wording Reason/Justification for change against placebo, and there are at least 10 adolescent patients in the study with clinically suffi cient exposure, then the 2 dosing regimens in the adolescent study population will be tested against placebo in the same way as described for the primary efficacy endpoint and key secondary endpoint #1. 1.Time to impending relapse in the eITT analysis set 2.Impending relapse rate at week 24 3.Percentage of patients who maintain stability at endpoint 4.Percentage of patients achieving remission at endpoint 5.Observed rate of impending relapse at endpoint 6.DAI-10 change from baseline to endpoint 7.SQLS change from basel ine to endpoint 8.Time to impending relapse in adolescent patients with schizophrenia If the first comparison is found to be significant, then the next comparison of interest will be interpreted inferentially at the same alpha level. This process will contin ue either until all comparisons were tested inferentially or until the point at which the resulting 2 -sided is insignificant at the same alpha level. ny p-value associated with these comparisons will be considered as nominal p -value and will not be used for inference. There w ill be no multiplicity control for all other exploratory efficacy endpoints (secondary or exploratory) , which will be tested at a nominal 5% level.same alpha level. This process w ill continue either until all compar isons were tested inferentially or until the point at which the resulting 2 -sided is insignificant at the same alpha level ny p-value associated with these comparisons will be considered as nominal p -value and w ill not be used for inference. There w ill be no multiplicity control for all other exploratory efficacy endpoints , which will be tested at a nominal 5% level. REFERENCES Not applicable FDA, Multiple Endpoints in Clinical Trials. Guidance for Industry. DRAFT GUIDANCE. January 2017Reference added"
143,page_143,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 14316.4. Global Protocol Amendment 02 (Dated 02 September 2019) The primary reason for this global amendment is to revise the number of relapse events at which the formal, pre -specified interim analy sis will be conducted. In addition to the originally - planned, single interim analy sis that was to be conducted when 125 relapse events were observed, the Sponsor now plans to also conduct an earlier i nterim anal ysis when 90 relapse events are reached. Since the study 's initiation, the rate of observed relapse events (pooled across all treatment groups due to blinding) is lower than expected. This may be due to a longer median time to relapse than assumed for the placebo group, or a higher hazard ratio than assumed during the study planning. An earlier anal ysis, if successful, will allow the Sponsor to stop this double - blind, placebo -controlled study and roll the patients over earlier into the long term TV46000 - CNS -30078 extension study (in which all patients receive treatment with TV -46000) without affecting the statistical power of the stud y,while maintaining control of the ty pe-I error. Patients randomized to the q1m or q2m treatment arms in the RI SE study will continue on their assigned treatment regimen in the extension study , and patients randomized to the placebo arm in the RISE study will be re -randomized in a 1:1 manner to the q1m or q2m treatment arms in the extension study . These changes to th e statistical methodology are unlikely to affect the safety (phy sical or mental integrit y) or rights of the patients in this clinical Phase 3 study, the secondary endpoints of the study or the studyâ€™s scientific value, since the focus on the impending time to relapse as the primary endpoint is maintained, as well as the originally -planned time points for the interim and final anal ysis, and the overall control of t ype-I error using the same principles and methodology originall y used for the study . Moreover, from an ethical perspective, adding an earlier interim analysis will enable patients on placebo to receive effective treatment earlier, if the treatment is found to be effective.The technical details of the planned statistical anal ysis of the study data wi ll be provided in the Statistical Anal ysis Plan. Further clarifications and changes related to stud y conduct were also implemented in this amendment. These include (but are not limited to) prolongation of study duration ( although in case of a successful interim analy sis, the study will be terminated earlier), change of inclusion criterion k to omit the BMI percentile limitation, updates to the planned number of enrolled patients per updated projections, clarification of procedures to be performed during uns cheduled visits (per Clarification Letter 02 dated 27 June 2019) and clarification regarding highl y effective birth control methods (see Appendix E) and some administrative details (see Appendix A). The revisions listed below have been made to the protocol (and protocol s ynopsis, as appropria te) and are not considered significant by the Teva Authorized Representative. The study schema ( Figure 1), Table 1(Screening and Stage 1) , Table 2(Stage 2 and Follow- Up) and the corresponding footnotes, have been revised to reflect the changes described below. A comparison table showing the changes from Global Amendment 01 to Global Amend ment 02 is provided below. Previous text is presented in the column titled ""Original text with changes shown"", and the revised or new text is presented in the column titled ""new wording."" Revised or new text is shown in bold italics and deleted text is sho wn in strike -through. Also, to adhere with current Teva standards, some formatting and editing changes have been made."
144,page_144,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 144Changes to the Protocol Original text with changes shown New wording Reason/Justification for change TITLE PAGE (Other sections affected by this change: Investigator Agreem ent; Coordinating Investigator Agreement) Clinical Study Protocol with Am endm ent 0102Clinical Study Protocol with Am endm ent 02 To denote the new global amendment. AMENDMENT HISTORY AMENDMENT HISTORY The protocol for Study TV46000 -CNS -30072 (original protocol dated 14 December 2017) has been amended and reissued as follows: Global Amendment 0202 September 2019 (584 patients enrolled to date) Letter of Clarification 0227 June 2019 Global Amendment 0106 December 2018 (184 patients enrolled to date) â€¦ â€¦ The Summary of Changes to the Protocol includes the corresponding reason/justification for each change and is provided in Section 16.AMENDMENT HISTORY The protocol for Study TV46000 -CNS -30072 (original protocol dated 14 December 2017) has been amended and reissued as follows: Global Amendment 0202 September 2019 (584 patients enrolled to date) Letter of Clarification 0227 June 2019 Global Amendment 0106 December 2018 (184 patients enrolled to date) â€¦ â€¦ The Summary of Changes to the Protocol includes the corresponding reason/justification for each change and is provided in Section 16.This page w as updated with the details of the documents issued since the last amendment. SPONSOR PROTOCOL APPROVAL Sponsorâ€™s Authorized Representative Vice President Therapeutic Area Head, Neurology and Psychiatry, Specialty Clinical DevelopmentSponsorâ€™s Authorized Representative Vice President Therapeutic Area Head, Neurology and Psychiatry, Specialty Clinical DevelopmentThis reflects a change in responsibilities at Teva. 1. INTRODUCTION AND BACKGROUND INFORMATION 1.2.2.1 Clinical Pharm acology Studies A Phase 1 single and multiple ascending dose study (TV46000 -SAD -10055) to evaluate the safety, tolerability, and A Phase 1 single and multiple ascending dose study (TV46000 -SAD -10055) to evaluate the safety, Text updated to reflect completion of the 10055 study and final results"
145,page_145,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 145Original text with changes shown New wording Reason/Justification for change pharmacokine tics of TV -46000 in patients with schizophrenia or schizoaffective disorder is ongoing was also completed . â€¦ A preliminary The comparison of different sites of injection of a single sc dose administered in the abdomen versus the upper arm, suggests indicated thatthere are no clinically therapeutically relevant differences in exposure and that either the abdomen or upper arm could be used for sc injection without significantly altering the controlled -release drug delivery of risperidone . tolerability, and pharmacokinetics of TV -46000 in patients with schizophrenia or schizoaffective disorder was also completed. â€¦ The comparison of different sites of injection of a single sc dose administered in the abdomen versus the upper arm indicated that there are no therapeutically relevant differences in exposure and that either the abdomen or upper arm could be used for sc injection without significantly altering the controlled - release drug delivery of risperidone .(CSR issued 21 December 2018) . 3.STUDY DESIGN 3.1. General Study Design and Study Schematic Diagram â€¦ The double -blind maintenance stage will be variable in duration, with patients continuing until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse- free during the double - blind phase until the study is terminated for efficacy at the due to a successful interim analysis or because 207 relapse events are recorded in the study adult population. â€¦ Patients who remain relapse -free when the study is terminated for efficacy at the due to a successf ulinterim analysis or because 207 relapse events in adults are recorded in the study should be invited to perform the End -of-Treatment visit within 4 weeks of the last injection. â€¦ Patients will subsequently complete all end -of-study assessments. When the study ends, eligible patients may be offered the opportunity to enter anthe TV46000 -CNS- 30078 extension study to assess the long -term safety and tolerability of extended -release risperidone. This extension study is beyond the scope of this protocol .,Aand a separate protocol willwas issued for the extension study as applicable it. â€¦ The study duration will be approximately 1830months, from â€¦ The double -blind maintenance stage will be variable in duration, with patients continuing until they experience a relapse event; meet 1 or more of the study discontinuation or w ithdrawal criteria; or rem ain relapse- free during the double -blind phase until the study is terminated for efficacy due to a successful interim analysis or because 207 relapse events are recorded in the study adult population. â€¦ Patients who remain relapse -free when the study is terminated for efficacydue to a successful interim analysis or because 207 relapse events in adults are recorded in the study should be invited to perform the End-of-Treatm ent visit within 4 w eeks of the last injection. â€¦ Patients will subsequently complete all end- of-study assessments. When the study ends, eligible patients may be offered the opportunity to enter the TV46000 - CNS -30078 extension study to assess the long -term safety and tolerability of extended -release risperidone. This extension study is beyo nd the scope of this protocol, and a separate protocol w as issued for it.Clarification following the addition of an earlier interim analysis. Updated to the expected duration of the full study (207 relapse events) per the current projections. The number of the safety extension study was add ed."
146,page_146,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 146Original text with changes shown New wording Reason/Justification for change Q2 2018 (first patient in) to Q4 2019 2020 (last patient out ). In case of a successful interim analysis, the study will be terminated earlier ( see Section 9.6 ). â€¦â€¦ The study duration will be approximately 30 months, from Q2 2018 (first patient in) to Q4 2020 (last patient out). In case of a successful interim analysis, the study will be termi nated earlier ( see Section 9.6 ) â€¦ The number of the safety extension study was added to the study schema. e When the study ends, eligible patients may be offered the opportunity to enter antheTV46000 -CNS- 30078 extension study to assess the long -term safety and tolerability of extended -release risperidone . This extension study is beyond the scope of this protocol and will be isdetailed in a separate protocol as applicable. If patients choose to enter the extension study, they will not need to complete the follow -up/exit visits in this study. e When the study ends, eligible patients may be offered the opportunity to enter theTV46000 -CNS- 30078 extension study to assess the long-term safety and tolerability of extended -release risperidone . This extension study is beyond the scope of this protocol and is detailed in a separate protocol. If patients choose to enter the extension study, they w ill not need to complete the follow -up/exit visits in this study.The protocol for the 30078 extension study was issued, and its number was therefore implemented. 3.2. Planned Number of Patients and Countries Approximately 795993 patients will be screened to achieve enrollment of approximately 596695 adult patients in Stage 1, including approximately 5767adult patients in Bulgaria.Approximately 993 patients will be screened to achieve enrollment of approximately 695 adult patients in Stage 1, including approximately 67 adult patients in Bulgaria.Corrected per updated enrollment projections and screen failure rate."
147,page_147,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 147Original text with changes shown New wording Reason/Justification for change 3.4. Stopping Rules for the Study One Two formal interim analysis analyses will be conducted are planned in this study , when the number of events observed in the intent -to-treat (ITT) analysis set (reach es43.5% and 60% of the planned 207 relapse events (90 and 125 events in adult patients, respectively ). An Independent Data Monitoring Committee (IDMC) will conduct t he interim analysis to assess efficacy for all randomized patients. Results will need to demonstrate statistically significant effects in the prim ary analysis of the primary endpoint (at a significance level of 0.0101) for both risperidone treatment groups (q1m and q2m), at any of the interim analyses in order to stop the study early for success ,as described in Section 9.6. The IDMC could recommend to discontinue the study for ethical reasons, most notably continued exposure to placebo, if efficacy is established.Two formal interim analyses are planned in this study, when the number of events observed in the intent -to- treat (ITT) analysis set reach es 43.5% and 60% of the planned 207 relapse events (90 and 125 events in adult patients, respectively). An Ind ependent Data Monitoring Committee (IDMC) will conduct the interim analysis to assess efficacy for all randomized patients. Results will need to demonstrate statistically significant effects in the prim ary analysis of the primary endpoint (at a significanc e level of 0.0101) for both risperidone treatment groups (q1m and q2m) at any of the interim analyses in order to stop the study early for success, as described in Section 9.6. The IDMC could recommend to discontinue the study for ethical reasons, most not ably continued exposure to placebo, if efficacy is established.Revised due to the addition of another, earlier interim analysis. 3.5. Schedule of Study Procedures and Assessments Table 1: d. Other procedures may be performed at the discretion of the investigator. In addition, to reduce patient burden and to avoid unnecessary data collection, the investigator will have discretion in determining whether the procedures which are currently mark ed as mandatory actually need to be performed during the unscheduled visit in the case that: (i) the unscheduled visit is one of multiple in-clinic visits, that are deemed necessary in close proximity (2 or more visits within 1 week), and (ii) when the vis it is for administrative purposes (eg, reconsenting) or clinical reasons (eg, repeat laboratory sample collection for reasons unrelated to an adverse event or impending/current relapse), and notdue to a potential relapse or a change in the patient's medic al status per clinical judgement .d. Other procedures may be performed at the discretion of the investigator. In addition, to reduce patient burden and to avoid unnecessary data collection, the investigator will have discretion in determining whether the procedures which are currently marked as mandatory actually need to be performed during the unscheduled visit in the case that: (i) the unscheduled visit is one of multiple in-clinic visits, that are deemed necessary in close proximity (2 or more visits within 1 week), and(ii) when the visit is for administrative purposes (eg, reconsenting) or clinical reasons (eg, repeat laboratory sample collection for reasons unrelated to an adverse event or impending/current relapse), and notdue to a potential relapse or a change in the patient's medical status per clinical judgement . Clarification regarding procedures to be performed during unscheduled visits, per Letter of Clarification 02. q.The specific questions asked w ill be at the discretion of the investigator. This Alist of suggested questions are detailed in the study manual will be provided to the investigator . q.The specific questions asked w illbe at the discretion of the investigator. A list of suggested questions will be provided to the investigator. Psychiatric adverse events Corrected since there is no study manual; the list was provided to the investigators and is also available"
148,page_148,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 148Original text with changes shown New wording Reason/Justification for change Psychiatric adverse events or suspicion of a psychiatric deterioration as a result of the telephone contact will trigger an invitation of the patient to an unscheduled visit where psychiatric scales will be administered to rule out an impending relapse at the discretion of the investigator. or suspicion of a psychiatric deterioration as a result of the telephone contact will trigger an invitation of the patient to an unscheduled visit where psychiatric scales will be administered to rule out an impending relapse at the discretion of the investigator.vis the study portal. Table 2: a. The double -blind maintenance stage will be variable in duration, with patients continuing until they experience a relapse event and complete all end -of-study assessments; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse- free during the double -blind phase until the study is terminated for efficacy at the due to a successful interim analysis or because 207 relapse events are recorded in the study in the ITT analysis set. â€¦a. The doubl e-blind maintenance stage will be variable in duration, with patients continuing until they experience a relapse event and complete all end -of- study assessments; meet 1 or more of the study discontinuation or w ithdrawal criteria; or remain relapse- free dur ing the double -blind phase until the study is terminated for efficacy due to a successful interim analysis or because 207 relapse events are recorded in the study in the ITT analysis set. ...Revised due to the addition of another, earlier interim analysi s. b. When the study ends, eligible patients may be offered the opportunity to enter aTV46000 -CNS- 30078, the long-term safety and tolerability extension study. This extension study is beyond the scope of this protocol and is detailed in a separate protocol . If the patients choose to enter the extension study, they will not need to complete the follow - up/exit visits in this study. All other patients (ie, patients who experience a relapse event, meet 1 or more of the study discontinuation or w ithdrawa l criteria, or do not consent to join the extension study), will undergo these 2 follow -up/exit visits. During the follow -up/exit period patients will be treated according to the investigatorâ€™s judgement. b. When the study ends, eligible patients may be offered the opportunity to enter TV46000 -CNS -30078, the long -term safety and tolerability extension study. This extension study is beyond the scope of this protocol and is detailed in a separate protocol. If the patients choose to enter the extension study, they will not need to complete the follow -up/exit visits in this study. All other patients (ie, patients who experience a relapse event, meet 1 or more of the study discontinuation or w ithdrawal criteria, or do not consent to join the extension study), wi ll undergo these 2 follow -up/exit visits. During the follow -up/exit period patients will be treated according to the investigatorâ€™s judgement.Nam e of the extension study added. c. Other procedures may be performed at the discretion of the investigator. In addition, to reduce patient burden and to avoid unnecessary data collection, the investigator will have discretion in determining whether the procedures which are currently marked as mandatory actually need to be performed during the unscheduled visit in the case that: (i) the unscheduled visit is one of multiple in-clinic visits, that are deemed necessary in close proximity (2 or more visits c. Other procedures may be performed at the discretion of the investigator. In addition, to reduce patient burden and to avoid unnecessary data collection, the investigator will have discretion in determining whether the procedures which are currently marked as mandatory actually need to be performed during the unscheduled visit i n the case that: (i) the unscheduled visit is one of multiple in-clinic visits, that are Clarification regarding procedures to be performed during unscheduled visits, per Letter of Clarification 02."
149,page_149,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 149Original text with changes shown New wording Reason/Justification for change within 1 week), and (ii) when the visit is for administrative purposes (eg, reconsenting) or clinical reasons (eg, repeat laboratory sample collection for reasons unrelated to an adverse event or impending/current relapse), and notdue to a potential relapse or a change in the patient's medical status per clinical judgement . deemed necessary in close proximity (2 or more visits within 1 week), and(ii) when the visit is for administrative purposes (eg, reconsenting) or clinical reasons (eg , repeat laboratory sample collection for reasons unrelated to an adverse event or impending/current relapse), and notdue to a potential relapse or a change in the patient's medical status per clinical judgement . p. Blood for biomarker analyses will be collected as follows: 6 mL for serum, 6 mL for plasma, and 2.5 mL for PAXgene RNA , unless the patient declines testing or local regulations prohi bit testing .p. Blood for biomarker analyses will be collected as follows: 6 mL for serum, 6 mL for plasma, and 2.5 mL for PAXgene RNA, unless the patient declines testing or local regulations prohibit testing .Clarification. z. The specific questions ask ed w ill be at the discretion of the investigator. This Alist of suggested questions are detailed in the study manual. will be provided to the investigator Psychiatric adverse events or suspicion of a psychiatric deterioration as a result of the telephone contact will trigger an invitation of the patient to an unscheduled visit where psychiatric scales will be administered to rule out an impending relapse at the discretion of the investigator.z. The specific questions asked w ill be at the discretion of the investigator. A list of suggested questions will be provided to the investigator . Psychiatric adverse events or suspicion of a psychiatric deterioration as a result of the telephone contact w ill trigger an invitation of the patient to an unscheduled visit where psychiatric scales will be administered to rule out an impending relapse at the discretion of the investigator.Corrected since there is no study manual; the list was provided to the investigators and is also available vis the study portal. 4. SELE CTION AND WITHDRAWAL OF PATIENTS 4.1. Patient Inclusion Criteria k. [Revision 12] The patient has a body mass index between 18.0 and 38.0 kg/m2, inclusive at screening. For adolescent patients, the BMI should be at least in the 50th percentile for age and gender and must not exceed 38.0 kg/m2.k. [Revision 2] The patient has a body mass index betw een 18.0 and 38.0 kg/m2, inclusive at screening. This limitation was removed to encourage enrollment of otherwise eligible adolescents. 4.3.1.General Withdra wal Criteria â€¦ Patients should be treated w ith standard of care after withdrawal from or termination of the study as appropriate. Alternatively, if the opportunity is available and the patient is eligible, the patient may be offered the option to particip ate in aTV46000 -CNS- 30078 , the long-term safety and tolerability extension study . â€¦â€¦ Patients should be treated w ith standard of care after withdrawal from or termination of the study as appropriate. Alternatively, if the opportunity is available and the patient is eligible, the patient may be offered the option to participate in TV46000 -CNS - 30078 , the long -term safety and tolerability extension study . â€¦Nam e of the extension study added."
150,page_150,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 150Original text with changes shown New wording Reason/Justification for change 5. TREATMENTS 5.1.2. Place bo Investigational Medicinal Product TV-46000 placebo is available as an extended -release Correct ion; w ording on PFS added for consistency with the packaging description in the Table of Investigational Medicinal Products Used in the Study. Table 4: Investigational Medicinal Products Used in the Study Clarification; dose should also be marked as Adults Only, since this dose is comparable to 5mg oral risperidone for the TV - 46000 q1m product. Correction; dose has been marked as Adults Only for consistency with the protocol synopsis. 5.5. Treatm ent After the End of the Study â€¦ When the study ends, eligible patients may be offered t he opportunity to enter anthe TV46000 -CNS- 30078 extension study to assess the long -term safety and tolerability of extended -release risperidone. This extension study is beyond the scope of this protocol . A, and a separate protocol willwas issued for the extension study as applicable it.â€¦ When the study ends, eligible patients may be offered the opportunity to enter the TV46000 -CNS- 30078 extension study to assess the long -term safety and tolerability of extended -release risperidone. This extension study is beyond the scope of this protocol, and a separate protocol w as issued for it.Nam e of the extension study added. 5.7. Prior and Concom itant Medication or Therapy"
151,page_151,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 151Original text with changes shown New wording Reason/Justification for change â€¦ In general, a Antidepressants, antipsychotics (other than study drug), and mood stabiliz ers will not be permitted as concomitant medications. However, some antidepressants and mood stabilizers (including the CYP2D6 inhibitors fluoxetine, paroxetine , and duloxetine ) will be permitted if the patient is on a stable dose for at least 3 months prior to screening. No dose changes or new administrations of these drugs will be permitted during the study. If these are required as rescue medications, this should lead to a consideration of discontinuation from the study due to exacerbation or relapse.â€¦ In general, antidepressants, antipsychotics (other than study drug), and mood stabilizers w ill not be permitted as concomitant medications. How ever, some antidepressants and mood stabilizers (including the CYP2D6 inhibitors fluoxetine, paroxetine , and duloxetine ) will be permitted if the patient is on a stable dose for at least 3 months prior to screening. No dose changes or new administrations of these drugs will be permitted during the study. If these are required as rescue medications, this should lea d to a consideration of discontinuation from the study due to exacerbation or relapse.Clarification that exceptions are allow ed for some antidepressants under the conditions listed. 5.10.1. Maintenance of Random ization Patient randomization codes will be maintained in a secure location at the service provider contracted to generate the codes. At the time of analysis (after the end of study or at each interim analysis) , after receiving unblinding request from Teva statist ician, the service provider w ill provide the unblinded IMP assignment according to the processes defined in the relevant SOP. The codes w ill be provided to an independent statistician who will perform antheinterim analysis analyses . Patient randomizatio n codes will be maintained in a secure location at the service provider contracted to generate the codes. At the time of analysis (after the end of study or at each interim analysis) , after receiving unblinding request from Teva statistician, the service provider will provide the unblinded IMP assignment according to the processes defined in the relevant SOP. The codes w ill be provided to an independent statistician who will perform the interim analyses.Clarification. 5.10.3. Data Monitoring Committee â€¦ The IDMC w ill perform 1 up to 2 formal interim analysis analyses offorefficacy in this study (when the number of events observed reaches 43.5% and 60% of the planned 207 relapse events in the ITT analysis set [Section 3.4]). The second interim analysis w ill be performed if at least one of the p -values of the 2 primary comparisons is above 0.0101 at the first interim analysis. â€¦â€¦ The IDMC w ill perform up to 2 formal interim analyses for efficacy in this study (when the number of events observed reaches 43.5% and 60% of the planned 207 relapse events in the ITT analysis set [Section 3.4]). The second interim analysis will be perform ed if at least one of the p -values of the 2 primary comparisons is above 0.0101 at the first interim analysis. â€¦Revised due to the addition of another, earlier interim analysis. 8. ASSESSMENT OF PHARMACOKINETICS/PHARMACODYNAMICS/BIOMARKERS/PHARMACOGENOM ICS 8.3."
152,page_152,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 152Original text with changes shown New wording Reason/Justification for change with a known or hypothesized role in schizophrenia or response to antipsychotic medications , unless the patient declines testing or local regul ations prohibit testing .biomarkers with a known or hypothesized role in schizophrenia or response to antipsychotic medications, unless the patient declines testing or local regulations prohibit testing . 9. ."
153,page_153,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 153Original text with changes shown New wording Reason/Justification for change used, the p -value for the other comparison (the significant comparison), should be significant at a 2 -sided alpha/2 level. Assuming the above , a to tal of 207 relapse events will need to be observed during Stage 2 of the study forin the ITT analysis set (adult patients) in the 3 treatment groups (combined) in order to have a statistical power or approximately attain 90% power (East 6 [Version 6.3] man ual, 2014 ). The sample size rationale is based on the adult patients. There is no estimation of the sample size in the adolescent population, and their number is not known at this time. Assuming an accrual time of 6 months and a maximal treatment duration during the double -blind stage of approximately 13 months, approximately 139 adult patients will need to be randomized to each treatment group for a total of 417 adult patients randomized. Assuming that 30% 40% of the patients enrolled in Stage 1 w ill not b e randomized to the double- blind phase (Stage 2), a total of 596approximately 695 adult patients will need to be enrolled into Stage 1. As an event -driven study, depending on the actual recruitment rate and percentage of patients who are enrolled in Stage 1 and are randomized to Stage 2, it may be possible to randomize more than 417 adult patients, as long as Stage 2 of the study ends due to a successful interim analysis or when the number of relapse events in the ITT analysis set reaches 207.Assuming an accrual time of 6 months and a maximal treatment duration during the double- blind stage of approximately 13 months, approx imately 139 adult patients will need to be randomized to each treatment group for a total of 417 adult patients randomized. Assuming that 40% of the patients enrolled in Stage 1 will not be randomized to the double -blind phase (Stage 2), a total of approxi mately 695 adult patients will need to be enrolled into Stage 1. As an event -driven study, depending on the actual recruitment rate and percentage of patients who are enrolled in Stage 1 and are randomized to Stage 2, it may be possible to randomize more than 417 adult patients, as long as Stage 2 of the study ends due to a successful interim analysis or when the number of relapse events in the ITT analysis set reaches 207. 9.2.2. Intent -to-Treat Analysis Set The intent -to-treat (ITT) analysis set will include adult patients randomized to the double- blind maintenance stage (Stage 2), regardless if they have received treatment or not. In the ITT analysis set, treatment will be assigned based on the treatment to which patients were randomized, regardless of which treatment they actually received. The purpose of the prim ary analyses is to estimate the effect of randomized treatment only, omitting any effect of additional treatment that may be administered after discontinuation of the randomized treatment. Accordingly, the ITT analysis set complies with while -on-treatment strategy1that will be taken with regard to the intercurrent The intent -to-treat (ITT) analysis set will include adult patients randomized to the double -blind maintenance stage (St age 2), regardless if they have received treatment or not. In the ITT analysis set, treatment will be assigned based on the treatment to which patients were randomized, regardless of which treatment they actually received. The purpose of the primary analy ses is to estimate the effect of randomized treatment only, omitting any effect of additional treatment that may be administered after discontinuation of the randomized treatment. Accordingly, the ITT analysis set complies with while -Per ICH guidance the description of the estima nd was included for clarification and elaboration of the previous ITT definition. The citation of the guidance was added as a footnote."
154,page_154,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 154Original text with changes shown New wording Reason/Justification for change event of treatment discontinuation, with censoring at this intercurrent event. This study estimand will be the difference in time to relapse (survival) under the treatment to which the patient was initially randomized until last treatment or early termination of all adult patients who were successfully stabilized on oral risperidone at a daily dose range of 2 mg to 5 mg. 1ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical t rials to the guidance on statistical principles for clinical trials. EMA/CHMP/ICH/436221/2017. European Medicines Agency. 30 August 2017on-treatment strategy1that will be taken with regard to the intercurrent event of treatment discontinuation, with censoring at this intercurrent event. This study estimand will be the difference in time to relapse (survival) under the treatment to which the patient was initial ly randomized until last treatment or early termination of all adult patients who were successfully stabilized on oral risperidone at a daily dose range of 2 mg to 5 mg. 1ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guidance on statistical principles for clinical trials. EMA/CHMP/ICH/436221/2017. European Medicines Agency. 30 August 2017 9.4. Study Population The eITT analysis set (Section 9.3) (Section 9.2.3) will be used for all study population summaries of the double -blind treatment stage unless otherwise specified. Summaries will be presented by treatment group and for all patients. If the number of adolescents permits, summaries will also be presented by age subgroup. The primary analysis will be conducted on the ITT analysis set (Section 9.2.2) , the first key secondary endpoint will be conducted on the complete eITT analysis set (Section 9.2.3) and the second key secondary will be conducted on the adolescent subset of the eITT analysis set , if the number of adolescents permits . The analysis set on which analysis for other endpoints endpoints will be conducted will be specified on a case -by-case basis. The enrolled patients set (Section 9.2.1) will be used for data summaries before the double -blind treatment stage.The eITT analysis set (Section 9.2.3) will be used for all study population summaries of the double -blind treatment stage unless otherwise specified. Summaries will be presented by treatment grou p and for all patients. If the number of adolescents permits, summaries will also be presented by age subgroup. The primary analysis will be conducted on the ITT analysis set (Section 9.2.2), the first key secondary endpoint will be conducted on the comple te eITT analysis set (Section 9.2.3) and the second key secondary will be conducted on the adolescent subset of the eITT analysis set, if the number of adolescents permits. The analysis set on which analysis for other endpoints will be conducted will be sp ecified on a case -by-case basis. The enrolled patients set (Section 9.2.1) w ill be used for data summaries before the double -blind treatment stage.Correction of cross -link to correct sub-section. Clarification regarding data analysis and presentation. 9.5.1. Prim ary Endpoint â€¦ Time to impending relapse will be calculated as the earliest date the patient meets â‰¥1 of the impending relapse criteria minus the randomization date plus 1. â€¦ Time to impending relapse will be calculated as the earliest date the patient meets â‰¥1 of the impending relapse criteria minus the randomization date plus 1. Clarification regarding the absolute increase of the combined score defined in the primary endpoint."
155,page_155,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 155Original text with changes shown New wording Reason/Justification for change The absolute increase of the combined score of the 4 PANSS items is th e sum of the increases of those scores (ignoring the decreases).The absolute increase of the c ombined score of the 4 PANSS items is the sum of the increases of those scores (ignoring the decreases). 9.5.5.2. Sensitivity Analysis A sensitivity analysis will be conducted to assess the impact of large intervals between the previous assessment and the assessment when at the time the first relapse was observed via the interval censoring method. Sensitivity analysis will also be conduct ed by classifying dropouts tipping point analysis that imputes time to relapse for dropouts (for reasons other than suspected to be related to relapse) as relapse events instead of censoring with increasing risk to relapse, compared to similar patients in the same treatment group that continue treatment. The PP analysis set will also be used to assess evaluate the primary efficacy variable. Details will be provided in the statistical analysis plan. Senstivity analysis will be conducted on the ITT analysis s et.A sensitivity analysis will be conducted to assess the impact of large intervals between the previous assessment and the assessment at the time the first relapse w as observed via the interval censoring method. Sensitivity analysis will also be conducte d by tipping point analysis that imputes time to relapse for dropouts (for reasons suspected to be related to relapse) w ith increasing risk to relapse, compared to similar patients in the same treatment group that continue treatment. The PP analysis set w ill also be used to evaluate the primary efficacy variable. Details will be provided in the statistical analysis plan. Senstivity analysis will be conducted on the ITT analysis set.Correction of the former methodology; the current methodology is tipping p oint analysis. Correction in terminology. 9.6. Multiple Com parisons and Multiplicity There will be 1up to 2 forma l interim analysis analyses when the number of events observed reaches 43.5% and 60% of the planned 207 relapse events ( 90 and 125 events , respectively ) in the ITT analysis set. At this the first interim analysis, both primary efficacy tests will be tested at a 2 -sided alpha of 0.0101. If both tests are significant at the first interim analysis, the study maywill be stopped. If only 1 primary efficacy test (or none) is significant at the first interim analysis, the study will continue until the second interim analysis. If both tests are significant at the second interim analysis, the study will be stopped. If only 1 primary efficacy test (or n one) is significant at this interim analysis, the study will continue until 207 required number of relapse events are observed At the final analysis, both primary efficacy tests will be conducted with 2 -sided alphas of 0.0464 0.0418 ; if 1 primary efficacy test is not significant at a 2 -sided alpha of 0.0464 0.0418 , the other w ill be tested at a 2 -sided alpha of 0.0464 0.0418 divided by 2. This procedure w ill adequately control overall type 1 error for a 2-sided alpha of 0.05. The nominal alphas of 0.0101 at theThere w ill be up to 2 formal interim analyses when the number of events observed reaches 43.5% and 60% of the planned 207 relapse events (90 and 125 events, respectively) in the ITT analysis set. At the first interim analysis, both primary efficacy tests will be tested at a 2-sided alpha of 0.0101. If both tests are significant at the first interim analysis, the s tudy will be stopped. If only 1 primary efficacy test (or none) is significant at the first interim analysis, the study will continue until the second interim analysis. If both tests are significant at the second interim analysis, the study will be stopped . If only 1 primary efficacy test (or none) is significant at this interim analysis, the study will continue until 207 relapse events are observed At the final analysis, both primary efficacy tests will be conducted with 2 -sided alphas of 0.0418; if 1 pri mary efficacy test is not significant at a 2 -sided alpha of 0.0418, the other w ill be tested at a 2 -sided alpha of 0.0418 divided by 2. This procedure w ill adequately control overall type 1 Clarification following addition of a 2ndinterim analysis."
156,page_156,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 156Original text with changes shown New wording Reason/Justification for change each interim analysis and 0.0464 0.0418 at the final analysis were calculated using EAST 6 software as described in the EAST 6 manual (East 6 [Version 6.3] manual, 2014). Type-I error w ill be further controlled for the 2 key secondary endpoints by em ploying the hierarchical approach. Secondary endpoint #1 w ill be analyzed only in case the 2 primary efficacy endpoints have p -values less than or equal to alpha of 0.0464 0.0418 . In that case, key secondary endpoint #1 w ill be tested for the 2 dosing regimens using the same approach. Nam ely, tests for the 2 dosing regimens will be conducted with 2-sided alphas of 0.0464 0.0418 ; if one of the comparisons for the key secondary endp oint #1 is not significant at a 2 -sided alpha of 0.0464 0.0418 , the other will be tested at a 2 -sided alpha of 0.0464 0.0418 divided by 2. â€¦error for a 2 -sided alpha of 0.05. The nominal alphas of 0.0101 a t each interim analysis and 0.0418 at the final analysis were calculated using EAST 6 software as described in the EAST 6 manual ( East 6 [Version 6.3] manual, 2014 ). Type-I error w ill be further controlled for the 2 key secondary endpoints by employing the hierarchical approach. Secondary endpoint #1 w ill be analyzed only in case the 2 primary efficacy endpoints have p -values less than or equal to alpha of 0.0418. In that case, key secondary endpoint #1 will be tested for the 2 dosing regimens using the sam e approach. Namely, tests for the 2 dosing regimens will be conducted with 2 -sided alphas of 0.0418; if one of the comparisons for the key secondary endpoint #1 is not significant at a 2 -sided alpha of 0.0418, the other w ill be tested at a 2 -sided alpha of 0.0418 divided by 2. â€¦ 9.7. Safety Analysis Safety assessments and time points are provided in Table 1 and Table 2 .Safety assessments and time points are provided in Table 1 and Table 2.Correction; addition of cross -link to other Table of Assessments. 9.13. Planned Interim Analysis There will be 1up to 2 formal interim analysis analyses when the number of events observed in the ITT analysis set reaches 43.5% and 60% of the planned 207 relapse events ( 90 and 125 events in adult patients , respectively). Results will need to demonstrate statistically significant effects in the primary analysis of the primary endpoint (at a significance level of 0.0101) for both risperidone treatment group s (q1m and q2m) at any of the interim analyses in order to stop the study early for success as described in Section 9.5.5. 29.6. Ifsuccess criteria was not met [ie,if only 1 primary efficacy test (or none) is significant] at the first interim analysis (at 90 relapse events), the study will continue to the second interim analysis (at 125 relapse events). If only 1 primary efficacy test (or none) is significant at this interim analysis, (ie, if none of the interim analyses demonstrate There will be up to 2 formal interim analyses when the number of events observed in the ITT analysis set reaches 43.5% and 60% of the planned 207 relapse events ( 90 and 125 events in adult patients , respectively ). Results will need to demonstrate statistically significant effects in the primary analysis of the primary endpoint (at a significance level of 0.0101) for both risperidone treatment groups (q1m and q2m) at any of the interim analyses in order to stop the study early for success as described in Section 9.6. If success criteria was not met [ie,if only 1 primary efficacy test (or none) is significant] at the first interim analysis (at 90 relapse events), the study will continue to the second interim analysis (at 125 relapse events). If only 1 primary Revised due to the addition of another, earlier interim analysis. Re-organization of section text for clarification. Correction of cross -link to correct section of protocol."
157,page_157,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 157Original text with changes shown New wording Reason/Justification for change success), the study will continue until 207 relapse events are reached. An IDMC will conduct the interim analysis analyses to assess efficacy for all randomized patients. An IDMC charter will be developed for the interim analyses. Procedures will be taken to ensure the integ rity of the study thatfollow sthe IDMC charter. Results will need to demonstrate statistically significant effects in the primary analysis of the primary endpoint (at a significance level of 0.0101for both risperidone treatment groups (q1m and q2m) ) as described in Section 9.5.5.2 . The IDMC could recommend to discontinue the study for ethical reasons, most notably continued exposure to placebo, if efficacy is established.efficacy test (or n one) is significant at this interim analysis, (ie, if none of the interim analyses demonstrate success), the study will continue until 207 relapse events are reached. An IDMC will conduct the interim analyses to assess efficacy for all randomized patients . An IDMC charter will be developed for the interim analyses. Procedures will be taken to ensure the integrity of the study follows the IDMC charter. The IDMC could recommend to discontinue the study for ethical reasons, most notably continued exposure to placebo, if efficacy is established. APPENDIX A . CLINICAL LABORATORIES AND OTHER DEPARTMENTS AND INSTITUTIONS Sponsorâ€™s Authorized Representative Vice President, Therapeutic Area Head, Neurology and Psychiatry Specialty Clinical Development Teva Branded Pharmaceutical Products R&D, Inc. Tel: Email: Sponsorâ€™s Authorized Representative Vice President, Therapeutic Area Head, Neurology and Psychiatry Specialty Clinical Development Teva Branded Pharmaceutical Products R&D, Inc. Tel: Email: This reflects a change in responsibilities at Teva. Sponsorâ€™s Medical Expert/Contact Point designated by t he Sponsor for Further Information on the Study Senior Director, Global Clinical Development, Neuropsychiatry Teva Branded Pharmaceutical Products R&D, Inc. Tel: Cell: + Email: Sponsorâ€™s Medical Expert/Contact Point designated by the Sponsor for Further Inform ation on the Study Teva Branded Pharmaceutical Products R&D, Inc. Tel: Cell: Email: Eran Harary wasappointed as the Therapeutic Area Head, thus the title change as above. He remains the Sponsor's medical expert for the study. Medical Monitor s For US: Medical Director ICON PLC For US: Medical Director ICON PLC Addition of the contact details for the medical monitor for Bulgaria."
158,page_158,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 158Original text with changes shown New wording Reason/Justification for change Mobile: Email: For Bulgaria: Medical Director ICON PLC Mobile: + Email: Mobile: Email: For Bulgaria: Medical Director ICON PLC Mobile: Email: Rater Training for Clinical Scales and Utilization Measures Bracket Signant Health (formerly Bracket) 575 E. Sw edesford Road, Ste 200 Wayne, PA 19087 United StatesRater Training for Clinical Scales and Utilization Measures Signant Health (formerly Bracket ) 575 E. Sw edesford Road, Ste 200 Wayne, PA 19087 United StatesUpdate of vendor name following the merge between Bracket and CRF Health. Other contact information remains unchanged. Bioassay and Pharm acokinetic Sample Analysis Please refer to the study Trial Master File. Teva Pharmaceutical Works P. Ltd. Co. (TPW) Bioanalytical Laboratory Pallagi St. 13 Debrecen 4042 HungaryBioassay and Pharm acokinetic Sample Analysis Teva Pharmaceutical Works P. Ltd. Co. (TPW) Bioanal ytical Laboratory Pallagi St. 13 Debrecen 4042 HungaryUpdated with the details of the laboratory that will perform the analysis. APPENDIX B. STUDY PROCEDURES AND ASSESSMENTS BY VISIT b. Stage 1: Oral Conversion and Stabilization (Telephone Contacts [Visit 4a, Week -6Â±3 days and Visit 5a, Week -2Â±3days]) (Other sections affected by this change: c. Stage 2: Relapse Prevention [Telephone Contacts]). ... ï‚·brief set of clinical questions to detect psychotic symptoms â€“the specific questions asked will be at the discretion of the investigator. A list of suggested questions will be provided to the investigator.... ï‚·brief set of clinical questions to detect psychotic symptoms â€“the specific questions asked will be at the discretion of the investigator. A lis t of suggested questions will be provided to the investigator.Added for clarity and consistency with corresponding footnote inTable 1 and Table 2. Procedures During Double -blind Maintenance Stage Administration of Investigational Medicinal Product (Baseline [Visit 6, Day 1 Â±3 days]) (Other sections affected by this change: g. Early Term ination (ET) Visit/End -of-Treatm ent Visit (EoT); Follow -up/ Exit Period ... ï‚·blood sample for pharmacogenetic analysis , unless the patient declines testing or local r egulations prohibit testing.... ï‚·blood sample for pharmacogenetic analysis, unless the patient declines testing or local regulations prohibit testing.Added for clarity and consistency with corresponding footnotes in Table 2 and other protocol sections."
159,page_159,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 159Original text with changes shown New wording Reason/Justification for change ï‚·blood sample for biomarker analysis , unless the patient declines testing or local regulations prohibit testing. ---ï‚·blood sample for biomarker analysis, unless the patient declines testing or local regulations prohibit testing. ... g. Stage 2: Early Term ination (ET) Visit/End -of-Treatm ent Visit (EoT) Note: The double -blind maintenance stage will be variable in duration, with patients continuing until they experience a relapse event and complete all end -of-study assessments; meet 1 or more of the stu dy discontinuation or w ithdrawal criteria; or remain relapse- free during the double -blind phase until the study is terminated for efficacy at the due to a successful interim analysis or because 207 relapse events are recorded in the study in the ITT analys is set. Note: The double -blind maintenance stage will be variable in duration, with patients continuing until they experience a relapse event and complete all end -of- study assessments; meet 1 or more of the study discontinuation or w ithdrawal criteria; or remain relaps e-free during the double -blind phase until the study is terminated for efficacy due to a successful interim analysis or because 207 relapse events are recorded in the study in the ITT analysis set. Revised due to the addition of another, earlier interim a nalysis. Follow -up/Exit Period ( Follow -up Visit 1 [4 weeks after last dosing visit] and Follow -up Visit 2 [8 weeks after the last dosing visit, End -of-Study (EoS) Visit]) Note: Eligible patients who choose to enter the long term TV46000 -CNS- 30078 extens ion study will not need to complete the follow -up/exit visits in this study. Note: Eligible patients who choose to enter the long term TV46000 -CNS -30078 extension study will not need to complete the follow -up/exit visits in this study. Nam e of the extens ion study added. Unscheduled Visits â€¦ Procedures performed during unscheduled visits will include the following: ï‚·concomitant medication review; ï‚·inquiry about changes in use of alcohol and illicit drugs ï‚·vital sign measurements ï‚·adverse event inquiry (including serious adverse event reporting, injection site -related events including pain) ï‚·C-SSRS (""Since Last Visit"" version) (if visit scheduled to assess psychiatric adverse events) ï‚·PANSS and review of relapse criteria Other procedures may be performed a t the discretion of the investigator. In addition, to reduce patient burden and to avoid â€¦ Procedures performed during unscheduled visits will include the following: ï‚·concomitant medication review; ï‚·inquiry about changes in use of alcohol and illicit drugs ï‚·vital sign measurements ï‚·adverse event inquiry (including serious adverse event reporting, injection site -related events including pain) ï‚·C-SSRS (""Since Last Visit"" version) (if visit scheduled to assess psychiatric adverse events) ï‚·PANSS and review of relapse criteria Other procedures may be performed at the discretion of the investigator. In addition , to reduce patient burden and to avoid Clarification regarding procedures to be performed durin g unscheduled visits, per Letter of Clarification 02."
160,page_160,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 160Original text with changes shown New wording Reason/Justification for change unnecessary data collection, the investigator will have discretion in determining whether the aforementioned procedures (which are currently marked in Table 1 and Tabl e 2as mandatory) actually need to be performed during the unscheduled visit in the case that: (i) the unscheduled visit is one of multiple in-clinic visits, that are deemed necessary in close proximity (2 or more visits within 1 week), and (ii) when the visit is for administrative purposes (eg, reconsenting) or clinical reasons (eg, repeat laboratory sample collection for reasons unrelated to an adverse event or impending/current relapse), and notdue to a potential relapse or a change in th e patient's medical status per clinical judgement . Notwithstanding, it is hereby emphasized that the above refers only to unscheduled visits, and not to any other scheduled in -clinic visits or telephone contacts. â€¦unnecessary data collection, the investigator w ill have discretion in determining whether the aforementioned procedures (which are currently marked in Table 1 and Table 2 as mandatory) actually need to be performed during the unscheduled visit in the case that: (i) the unscheduled visit is one of multiple in -clinic visits, that are deemed necessary in close proximity (2 or more visits within 1 week), and (ii) when the vis it is for administrative purposes (eg, reconsenting) or clinical reasons (eg, repeat laboratory sample collection for reasons unrelated to an adverse event or impending/current relapse), and not due to a potential relapse or a change in the patient's medic al status per clinical judgement . Notw ithstanding, it is hereby emphasized that the above refers only to unscheduled visits, and not to any other scheduled in -clinic visits or telephone contacts. â€¦ APPENDIX E. BIRTH CONTROL METHODS AND PREGNANCY TESTING â€¦ Postm enopausal wom en are defined as : ï‚·1year postmenopausal (no menses for 12 months without an alternative medical cause plus an increased concentration of follicle stimulating hormone [FSH] of more than 35 U/L) in women not using hormonal contraception or hormonal replacement therapy â€¦ Description of different birth control m ethods Description of Hhighly effective birth control m ethods: Highly effective birth control methods are methods that can achieve a failure rate of less than 1% per year when used consistently and correctly are considered . Such methods include the following : ï‚·Com bined estrogen and progestogen hormonal contraception (o ral, intravaginal, transdermal) associated with inhibition of ovulation; these should be initiated at least 7 days (for IMPs without suspected teratogenicity/genotoxicity) and 1 month â€¦ Postm enopausal wom en are defined as: ï‚·1year postmenopausal (no menses for 12months without an alternative medical cause plus an increased concentration of follicle stimulating hormone [FSH] of more than 35 U/L) in women not using hormonal contraception or hormonal replacement therapy â€¦ Description of highly effective birth control methods: Highly effective birth control methods are methods that can achieve a failure rate of less than 1% per year when used consistently and correctly. Such methods include the following: ï‚·Com bined estrogen and progestogen hormonal contraception (oral, intravaginal, transdermal) associated with inhibition of ovulation; these Only highly effective birth control methods should be used in this study. Therefore, unnecessary information was deleted. The information provided in this appendix w as aligned with that in the 30078 protocol for consistency and in line with the Clinical Trials Facilitation Group (CTFG) document ""Recommendation related to contraception and pregnancy testing in clinical trials"" (Final Version, 2014 -09-15). The paragraphs on pregnancy tests in women of childbearing potential were deleted since the time points for pregnancy testing are defined in the protocol."
161,page_161,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 161Original text with changes shown New wording Reason/Justification for change (for IMPs potentially teratogenic/genotoxic) before the first dose of IM P. ï‚·Progestogen -only hormonal contraception (oral, injectable, implantable) associated w ith inhibition of ovulation; these should be initiated at least 7 days (for IMPs w ithout suspected teratogenicity/genotoxicity) and 1 month (for IMPs potentially teratog enic/genotoxic) before the first dose of IMP. ï‚·Intrauterine device and intrauterine hormone -releasing system need to be in place at least 2 months before screening. ï‚·Bilateral tubal occlusion ï‚·Vasectomized partner provided that he is the sole sexual partner a nd has received medical assessment of the surgical process ï‚·Sexual abstinence is only considered a highly effective method if defined as refraining from heterosexual intercourse in the defined period. The reliability of sexual abstinence needs to be evaluat ed in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. ï‚·Periodic abstinence (eg, calendar, ovulation, symptothermal, post -ovulation methods), declaration of abstinence for the duration of a study, and withdrawal are not acceptable methods of contraception (according to Medicines and Healthcare Products Regulatory Agency, MHRA). Acceptable birth control methods: Acceptable birth control methods that result in a failure rate of more than 1% per year include: progestogen only oral horm onal contraception for which the inhibition of ovulation is not the primary mode of action; male or female condom with or without spermicide; cap, diaphragm, or sponge with spermicide. The combination of male condom with either ca p, diaphragm, or sponge with spermicide (double barrier methods) are also considered acceptable but not highly effective methods of birth control. Unacceptable birth control methods:should be init iated at least 7 days (for IMPs without suspected teratogenicity/genotoxicity) and 1 month (for IMPs potentially teratogenic/genotoxic) before the first dose of IMP. ï‚·Progestogen -only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation; these should be initiated at least 7 days (for IMPs w ithout suspected teratogenicity/genotoxicity) and 1month (for IMPs potentially teratogenic/genotoxic) before the first dose of IMP. ï‚·Intrauterine device and intrauterine hormone - releasing system need to be in place at least 2months before screening. ï‚·Bilateral tubal occlusion ï‚·Vasectomized partner provided that he is the sole sexual partner and has received medical assessment of the surgical process ï‚·Sexual abstinence is only consider ed a highly effective method if defined as refraining from heterosexual intercourse in the defined period. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. ï‚·Periodic abstinence (eg, calendar, ovulation, symptothermal, post -ovulation methods), declaration of abstinence for the duration of a study, and withdraw al are notacceptable methods of contraception (according to Medicines and Healthcare Pro ducts Regulatory Agency, MHRA). Male contraception Male patients must always use a condom. â€¦ Pregnant fem ale partners of male study"
162,page_162,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 162Original text with changes shown New wording Reason/Justification for change Periodic abstinence (calendar, symptothermal, post ovulation methods), w ithdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method are not acceptable methods of contraception. Female condom and male condom should not be used together. Male contraception Male patients must always use a condom , except in cases of no genotoxicity; or no demonstrated or suspected human teratogenicity/fetotoxicity . â€¦ Contraception for fem ale partners of m ale study participants: Female partners (who are not pregnant) of male study participants must use contraception for non pregnant women of childbearing potential until the end of relevant systemic exposure in case of IMPs with genotoxicity or IMPs w ith no genotoxicity but demonstrated or suspected human teratogenicity/fetotoxicity. Pregnancy tests in wom en of childbearin g potential: 1.Conduct monthly pregnancy testing from first dose of IMP until last dose of IMP and additional 30 days in case the IMP does not have a marketing authorization and has suspected human teratogenicity/genotoxicity/fetotoxicity. Conduct monthly pregnancy testing and in case the IMP has a marketing authorization, if the IMP has a demonstrated or suspected human teratogenicity/genotoxicity/fetotoxicity according to Risk Safety Information. Shorter testing intervals are to be considered depending on drug dosing schedule. Consider additional pregnancy testing, but at least at the end of relevant systemic exposure, in case of possible human teratogenicity/fetotoxicity. This refers to IMPs, for which human data on pregnancies is limited or not available , there is no suspicion of human teratogenicity based on class effects or genotoxic potential, and nonclinical reproductive toxicity studies of relevance for early human pregnancy show positive findings that do not generate a strong suspicion of human teratogenicity/fetotoxicity. For IMPs w ith unlikely risk of human teratogenicity/fetotoxicity, additional pregnancy testing is participants: Male study participants must use condoms during intercourse if their female partners are pregnant."
163,page_163,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 163Original text with changes shown New wording Reason/Justification for change generally not necessary. This refers to IMPs for which assessment of the completed necessary nonclinical studies does not indicate te ratogenicity/fetotoxicity in early pregnancy and human data are not available or do not contradict these findings or there is already sufficient evidence for lack of risk based on human data. Pregnant fem ale partners of male study participants: Male study participants must use condoms during intercourse if their female partners are pregnant. . . All blood tubes will be labeled w ith the patient code number. If required by local regulations, following DNA extraction from the pharmacogenetic blood sample, the DNA sample will be labeled w ith a new code (ie, double coding).All blood tubes will be labeled w ith the patient code number .Correction; text relevant to PGx samples de leted from here and moved to Appendix J. APPENDIX J. PHARMACOGENETIC ASSESSMENTS A blood sample (6 mL) for pharmacogenetic assessment will be collected from all patients who signed the informed consent for pharmacogenetic assessments at the time point detailed in Table 2 , unless the patient declines testing or local regulations prohibit testing . All blood tubes will be labeled with the patient code number. If required by local regulations, following DNA extraction from the pharmacogenetic blood sample, the DNA sample will be A blood sample (6 mL) for pharmacogenetic assessment will be collected from all patients who signed th e informed consent for pharmacogenetic assessments at the time point detailed in Table 2 , unless the patient declines testing or local regulations prohibit testing. All blood tubes will be labeled with the patient code number . If required by local regulations, following DNA extraction from the pharmacogenetic Added for clarity and consistency with corresponding footnote in Table 2 and Section 8.4. Correction; relevant text moved here from Appendix I."
164,page_164,"Placebo- Controlled Study -Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 164Original text with changes shown New wording Reason/Justification for change labeled with a new code (ie, double coding). Genetic variabili ty in the metabolizer gene, cytochrome P450 2D6 (CYP2D6), w ill be evaluated for an association with drug concentrations of TV- 46000 and oral risperidone.blood sample, the DNA sample w ill be labeled with a new code (ie, double coding). Genetic variability in the metabolizer gene, cytochrome P450 2D6 (CYP2D6), will be evaluated for an association with drug concentrations of TV- 46000 and oral risperidone."
165,page_165,Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 16516.5. Letter of Clarification 02 (27 June 2019)
166,page_166,Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 166
167,page_167,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 16716.6. Global Protocol Amendment 01 (Dated 06 December 2018) The primary reason for this global amendment is to allow adolescent patients (aged 13 -17 years) to enroll in this clinical study and receive treatment with TV -46000, following regulatory interactions with FDA. To this end, assent to study procedures was in troduced, some inclusion criteria were modified and 2 new key secondary endpoints for data anal ysis were added. Clarifications regarding risperidone dosing and assessment of certain scales relevant to adolescent patients were also added. Further clarificat ions and changes related to study conduct were also implemented in this amendment. These include (but are not limited to) splitting the Table of Assessments into 2 separate tables (1 for each stage of the stud y) for clarity. The end -of-study (EoS)/Early Termination (ET) visit is now depicted as a separate visit, and the repeating 24- week visit window (ie, Visit 7- 12c, 13 -18c, etc) is depicted to better detail the assessments performed at the various visits. Other examples include: a urine pregnancy test was added to the baseline visit, specify ing which scales will only be performed in adult patients, and up to 3 additional pharmacokinetic samples will be collected from adolescents. In addition, the country -specific items introduced in the L ocal Amendment 01 for Bulgaria (dated 28 May 2018) and in the Clarification Letter (dated 26 June 2018) were implemented as applicable. The revisions listed below have been made to the protocol (and protocol s ynopsis, as appropriate) and are considered significant b y the Teva Authorized Representative. Table 1(Screening and Stage 1) , Table 2(Stage 2 and Follow- Up), the Overall Study Schematic Diagram, and the corresponding footnotes, have been revised to reflect changes described below. A comparison table showing the changes fr om the Protocol with Revision 01 to Amendment 01 is provided below. Previous text is presented in the column titled ""Original text with changes shown"", and the revised or new text is presented in the column titled ""new wording."" Revised or new text is show n in bold italics and deletions are shown in strike -through. Throughout the protocol, cross-references to both Table 1 and Table 2 were created for certain procedures and assessments as applicable. If this was the onl y change made to the section text, it is not depicted in the comparison table. Also, in order to adhere with current Teva standards, some formatting and editing changes have been made."
168,page_168,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 168Original text with changes shown New wording Reason/Justification for change TITLE PAGE (Other sections affected by this change: Investigator Agreem ent; Coordinating Investigator Agreement) Clinical Study Protocol with Amendment 01 Clinical Study Protocol with Am endm ent 01 To denote the global amendment. A Multicenter, Randomized, Double- Blind, Placebo - Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended -Release Injectable Suspension (TV -46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients with SchizophreniaA Multicenter, Randomized, Double- Blind, Placebo - Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended -Release Injectable Suspension (TV -46000) for Subcutaneous Use as Maintenance Treatment in A dult and Adolescent Patients with SchizophreniaTo reflect the introduction of the possibility to enroll adolescent patients in the study. A Randomized, Double- Blind, Placebo -Controlled Study on Efficacy, Safety, and Tolerability of TV- 46000 in Adults and Adolescents with SchizophreniaA Randomized, Double- Blind, Placebo -Controlled Study on Efficacy, Safety, and Tolerability of TV -46000 in Adults and Adolescents with SchizophreniaTo reflect the introduction of the possibility to enroll adolescent patients in the study. [Not applicable] (The RISE Study â€“The RIsperidone Subcutaneous Extended -release Study)Addition of study name to protocol. EudraCT number: Not applicable 2018 -001619 -65 EudraCT number: 2018 -001619 -65 Number added for study conduct in EU. PREFACE This Clinical Study Protocol with Revision 01 includes updates to the original protocol dated 14 December 2017.[Deleted] Preface deleted and moved to Section 16.4 as part of Summary Changes to protocol. AMENDMENT HISTORY [Not applicable] AMENDMENT HISTORY The protocol for Study TV46000 -CNS -30072 (original protocol dated 14 December 2017) has been amended and reissued as follows: Global Amendment 0106 December 2018 (184 patients enrolled to date) Letter of Clarification 0126 June 2018This page w as added in the amendment for tracking history."
169,page_169,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 169Original text with changes shown New wording Reason/Justification for change Local Amendment 01 for Bulgaria28May 2018 (6patients enrolled to date) Protocol with Revision 0115 February 2018 (0patients enrolled to date) The Summary of Changes to the Protocol includes the corresponding reason/justification for each change and is provided in Section 16. LIST OF ABBREVIATIONS [Not applicable] FSH = Follicle stimulating hormone Newly -added abbreviation. [Not applicable] SmPC = Summary of Product Characteristics Newly -added abbreviation. 1. INTRODUCTION AND BACKGROUND INFORMATION 1.1 Introduction [Not applicable] The underlying disease mechanisms and initial approach to the diagnosis and treatment of schizophrenia in adolescent patients aged 13 to 17 years and adult patients 18 years of age and older is essentially the same. Schizophrenia in children and adolescents is accepted to be clinically and biologically similar to adult -onset schizophrenia, but with some differences in the presentation of the symptoms, relative frequency of core psychotic symptoms (eg, auditory hallucinations, delusions, thought disorder), neurocognitive impairments, psychophysiological abnormalities, and the presence of structural brain abnormalities ( Asarnow et al 1995 , Bo and Haahr 201 6, Rapoport et al 2005 ). Pediatric patients display a more severe clinical prognosis and a greater neurodegenerative trajectory, and can be less responsive to treatment compared to patients with adult -onset schizophrenia ( Bo and Haahr 2016 ). Children and adolescents who are diagnosed with schizophrenia display high stability with regard to the phenotypical expression of the disorder into adulthood ( Hollis 2000 ). Studies of neuropsychological New text regarding schizophrenia in the pediatric population. Literature references added to reference list."
170,page_170,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 170Original text with changes shown New wording Reason/Justification for change functions and brain structure in patients with schizophrenia have shown the same degenerative patterns, regardless of the patientâ€™s age at the onset of the disorder ( Weinberger and Harrison 2011 ). The purpose of the study is to compare the safety and efficacy of different durations of TV- 46000 administered sc versus placebo. In addition, there is a paucity of data in relation to LAI use in children and adolescents with serious mental illness and exi sting reports have substantial methodological limitations (Lytle et al 2017). Enrollment of adolescents in this study will provide data for evaluating the efficacy, safety and tolerability of TV -46000 in this patient population.The purpose of the study is to com pare the safety and efficacy of different durations of TV- 46000 administered sc versus placebo. In addition, there is a paucity of data in relation to LAI use in children and adolescents with serious mental illness and existing reports have substantial methodological limitations ( Lytle et al 2017 ). Enrollment of adolescents in this study will provide data for evaluating the efficacy, safety and tolerability of TV -46000 in this patient population.Added justification for inclusion of adolescen ts in the study. 2. STUDY OBJECTIVES AND ENDPOINTS 2.1. Prim ary and Secondary Study Objectives and Endpoints [Not applicable] The key secondary objective of this study is to evaluate the efficacy of TV -46000 during maintenance treatment in a total popul ation (adults and adolescents) and in adolescent patients with schizophrenia . The key secondary endpoints are: 1. time to impending relapse (as defined under the primary objective) in the total population (adults and adolescents), and 2. time to impending relapse in adolescent patients with schizophrenia. NOTE: The assessment of time to impending relapse in adolescent patients is pending randomization of at least 10 adolescent patients with clinically sufficient exposure.Pursuant to inclusion of adolescent patients in the study, a secondary objective and tw o key secondary endpoints were added for analysis of study data. A secondary objective of this study is to evaluate the specific efficacy parameters of TV-46000 in the total population beyond the measures of the primary objective.A secondary objective of this study is to evaluate the specific efficacy parameters of TV-46000 in the total population beyond the measures of the primary objective.Clarification. A secondary objective of this study is to evaluate the safety and tolerability of TV -46000 in the total population .A secondary objective of this study is to evaluate the safety and tolerability of TV -46000 in the total population .Clarification."
171,page_171,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 171Original text with changes shown New wording Reason/Justification for change A secondary objective of this stud y is to evaluate the pharmacokinetics of oral risperidone and TV -46000 after administration of multiple doses in adults, adolescents, and the total population .A secondary objective of this study is to evaluate the pharmacokinetics of oral risperidone and TV-46000 after administration of multiple doses in adults, adolescents, and the total population .Clarification. ."
172,page_172,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 172Original text with changes shown New wording Reason/Justification for change 3.STUDY DESIGN 3.1. General Study Design and Study Schematic Diagram Patients will provide informed consent or assent, as applicable, at the screening visit. For adolescent patients, it is mandatory that a parent/caregiver accompanies the patient to each visit and serves as a reliable informant. It is r ecommended that a caregiver is identified for each adult patient. Local requirements should be followed. The caregiver may be contacted in case of loss of contact with the patient or to provide additional information about the patient, if needed. Patients can be accompanied by caregivers to visits. Open -label oral risperidone (2 to 5 mg/day) will be used to stabilize patients to the treatments (the dose w ill be based on clinical judgement). Adolescent patients will receive a maximal dose of 4 mg/day. If a patient withdraws from the study prior to the randomization visit (Visit 6), the CRF for the patient's last visit will be marked as ""Not Continuing"" and the reason for discontinuation will be recorded. No extra testing or procedures will be required in ad dition to the regular visits.Patients will provide informed consent or assent, as applicable, at the screening visit. For adolescent patients, it is mandatory that a parent/caregiver accompanies the patient to each visit and serves as a reliable informant. It is recommended that a caregiver is identified for each adult patient. Local requirements should be followed. The caregiver may be contacted i n case of loss of contact with the patient or to provide additional information about the patient, if needed. Patients can be accompanied by caregivers to visits. Open -label oral risperidone (2 to 5 mg/day) will be used to stabilize patients to the treatm ents (the dose w ill be based on clinical judgement). Adolescent patients will receive a maximal dose of 4 mg/day . If a patient withdraws from the study prior to the randomization visit (Visit 6), the CRF for the patient's last visit will be marked as ""Not Continuing"" and the reason for discontinuation will be recorded. No extra testing or procedures w ill be required in addition to the regular visits.Newly -added text pertaining to study conduct for adolescents: provision of assent, mandatory caregiver presence, maximal dose received. Clarification regarding other aspects of study conduct. Definition of study completers added. Sentence on unscheduled PK samples revised throughout the document to clarify that unscheduled PK samples do not need to be collected during Stage 1, and this is relevant only for Stage 2. The w ord ""potential"" w as removed from the safety extension study,"
173,page_173,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 173Original text with changes shown New wording Reason/Justification for change Stage 2: Double -blind maintenance stage (variable in duration). Stabilized patients (see definition above) will be randomized to receive TV -46000 q1m sc injections, TV- 46000 q2m sc injections, or placebo q1m sc injections in a 1:1:1 ratio. Patients that require a stabilization dose below 2 mg/day will not be randomized in the study. Also, as a precautionary measure, adolescent patients that wi ll require a stabilization dose of more than 4 mg during the stabilization stage will not be randomized. The maximal dose administered to adult patients will be equivalent to an oral risperidone dose of 5 mg/day , and the maximal dose administered to adol escents will be equivalent to 4 mg/day. During Stage 2, Uunscheduled pharmacokinetic samples will be aimed to be collected in the event of relapse as defined per the studyâ€™s relapse criteria, any serious adverse event, patient withdrawal, and/or the need for potential TV -46000 depot excision. Every effort should be made to obtain the additional pharmacokinetic sample at the closest time possible to the occurrence of the event . The double -blind maintenance stage will be variable in duration, with patients continuing until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse- free during the double - blind phase until the study is terminated for efficacy at the interim analysis or because 207 rel apse events are recorded in the ITT analysis set . Per definition, an exacerbation in symptoms during Stage 1 cannot be defined as a relapse event, since relapse events can only occur following stabilization and randomization. Randomized patients who rela pse or meet 1 or more of the withdrawal criteria should be invited to perform the Early Stage 2: Double -blind maintenance stage (variable in duration). Stabilized patients (see definition above ) will be randomized to receive TV -46000 q1m sc injections, TV- 46000 q2m sc injections, or placebo q1m sc injections in a 1:1:1 ratio. Patients that require a stabilization dose below 2 mg/day will not be randomized in the study. Also, as a precautionary m easure, adolescent patients that will require a stabilization dose of more than 4 mg during the stabilization stage will not be randomized. The maximal dose administered to adult patients will be equivalent to an oral risperidone dose of 5 mg/day, and the maximal dose administered to adolescents will be equivalent to 4 mg/day. During Stage 2, unscheduled pharmacokinetic samples will be aimed to be collected in the event of relapse as defined per the studyâ€™s relapse criteria, any serious adverse event, patient withdraw al, and/or the need for potential TV -46000 depot excision. Every effort should be made to obtain the additional pharmacokinetic sample at the closest time possible to the occurrence of the event The double -blind maintenance stage will be vari able in duration, with patients continuing until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse -free during the double- blind phase until the study is terminated for efficacy at the int erim analysis or because 207 relapse events are recorded in the ITT analysis set. Per definition, an exacerbation in symptoms during Stage 1 cannot be defined as a relapse event, since relapse events can only occur following stabilization and randomiz ation. Randomized p atients who relapse or meet 1 or more of the since preparations for it have begun."
174,page_174,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 174Original text with changes shown New wording Reason/Justification for change Termination (ET) visit as soon as possible, within 4 weeks of the last injection. Therefore, a patient is considered a study completer if he or she experienced impendin g relapse or remained relapse -free at the time of study termination. This potential extension study is beyond the scope of this protocol.withdrawal criteria should be invited to perform the Early Term ination (ET) visit as soon as possible, w ithin 4 w eeks of the last injection. Therefore, a patient is considered a study complete r if he or she experienced impending relapse or remained relapse -free at the time of study termination. This extension study is beyond the scope of this protocol. Figure 1: Overall Study Schem atic Diagram aAdolescent patients will receive doses equivalent to 2 -4 mg/day oral risperidone. Patients that will require a stabilization dose below 2 mg/day will not be randomized in the study. b With the exception of the screening visit, pharmacokinetic samples will be collected at each in -clinic visit. cAnother pharmacokinetic sample will be collected at Week 14 (2 w eeks after Visit 9) from adolescent patients only. It is highly preferable to collect the sample at Week 14. How ever, if this is not possible, it may be collected 2 Schema and footnotes revised to reflect dosing and pharmacok inetic sampling in the adolescent patient population. The w ord ""potential"" w as removed from the safety extension study, since preparations for it have begun."
175,page_175,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 175Original text with changes shown New wording Reason/Justification for change aAdolescent patients will receive doses equivalent to 2 -4 mg/day oral risperidone. Patients that will require a stabilization dose below 2 mg/day will not be randomized in the study. b With the exception of the screening visit, pharmacokinetic samples will be collected at each in -clinic visit. c Another pharmacokinetic sample will be collected at Week 14 (2 weeks after Visit 9) from adolescent patients only. It is highly preferable to collect the sample at Week 14. However, if this is not possible, it may be collected 2 weeks after another in -clinic visit. Up to 2 additional samples may also be collected from adolescent patients (3 weeks and 1 week post -injection, respectively) at the sponsor's discretion. dPatients randomized to the TV- 46000 q1m or q2m sc groups in Stage 2 w ill receive TV -46000 sc at doses equivalent to the 2 to 5 mg/day dose of oral risperidone on which they were stabilized during Stage 1. Adolescent patients will receive a maximal TV -46000 dose equinvalent to 4 mg/day oral risperidone. eWhen the study ends, eligible patients may be offered the opportunity to enter an extension study to assess the long -weeks after another in -clinic visit. Up to 2 additional samples may also be collected from adolescent patients (3 weeks and 1 w eek post -injection, respectively) at the sponsor's discretion. dPatients randomized to the TV- 46000 q1m or q2m sc groups in Stage 2 w ill receive TV -46000 sc at doses equivalent to the 2 to 5 mg/day dose of oral risperidone on which they were stabilized during Stage 1. Adolescent patients will receive a maximal TV -46000 dose equinvalent to 4 mg/day oral risperidone. eWhen the study ends, eligible patients may be offered the opportunity to enter an extension study to assess the long - term safety and tolerability. This extension study is beyond the scope of this protocol and will be detailed in a separate protocol as applicable. If patients choose to enter the extension study, they will not need to complete the follow - up/exit visits in this study. fFor patients who experience a relapse event, meet 1 or more of the study discontinuation or w ithdraw al criteria, or do not consent to join the extension study, there w ill be 2follow -up/exit visits that will take place 4 w eeks and 8 weeks after the last dosing visit."
176,page_176,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 176Original text with changes shown New wording Reason/Justification for change term safety and tolerability. This extension study is beyond the scope of this protocol and will be detailed in a separate protocol as applicable. If patients choose to enter the extension study, they will not need to complete the follow - up/exit visits in this study. fFor patients who experience a relapse event, meet 1 or more of the study discontinuation or w ithdrawal criteria, or do not consent to join the extension study, there will be 2 follow - up/exit visits that will take place 4 w eeks and 8 w eeks after the last dosing visit. 3.2. Planned Number of Patients and Countries Approximately 795 patients will be screened to achieve enrollment of approximately 596 patients in Stage 1 , including approximately 57 patients in Bulgaria . The number of randomized patients in Stage 2 is planned to be approximately 417, including approximately 40 patients in Bulgaria. Details on the d efinition of evaluable patients and determination of the sample size are given in Section 9.1. The study is planned to be conducted in approximately 80 investigational centers in North America and possibly other regions as well Bulgaria .Approximately 795 patients will be screened to achieve enrollment of approximately 596 patients in Stage 1, including approximately 57 patients in Bulgaria. The number of randomized patients in Stage 2 is planned to be approximately 417, including approximately 40 patients in Bulgaria. Details on the definition of evaluable patients and determination of the sample size are given in Section 9.1. The study is planned to be conducted in approximately 80 investigational centers in North America and Bulgaria.Information added regarding study projection in Bulgaria. 3.3. Justification for Study Design and Selection of Population [Not applicable] Moreover, the drug class of LAI atypical antipsychotics has not been studied extensively in children or adolescents (Lytle et al 201 7). Although compliance in children and adolescents treated with antipsychotics is substantially higher than in adults, ranging from approximately 74% to 88% ( Pogge et al 2005, Yazdi et al 2008 ), LAIs may be considered for patients with confirmed schizophr enia and with risk factors for medication non -adherence: history of non-adherence, severe symptoms, comorbid substance use, cognitive impairment, ambivalence or negative attitudes towards medication, and poor insight ( Ferrin et al 2016 ). In the Pediatric S tudy Plan submitted to FDA, a partial waiver was proposed for patients 0 to 12 years of age, since New text describ ing the justification of adolescent enrollment in the study."
177,page_177,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 177Original text with changes shown New wording Reason/Justification for change necessary studies in this age group w ould be impossible or highly impracticable, and the inclusion of adolescent patients (13 -17 years of age) in this Phase 3 program was proposed. The Agency concurred w ith these proposals. Non-clinical studies with TV -46000 in young and mature animals did not identify a particular concern for treatment of the targeted adolescent population aged 13 and above. Antipsychotic LAIs are viewed as maintenance therapy in stable patients with schizophrenia, but they are not currently approved for treatment of acute symptoms. Thus, the population for this stu dy consists of adult and adolescent patients with chronic schizophrenia and excludes patients with acute disease. Only patients who have been stabilized on oral therapy with risperidone will be randomized into the double- blind maintenance stage of the stud y.Antipsychotic LAIs are viewed as maintenance therapy in stable patients with schizophrenia, but they are not currently approved for treatment of acute symptoms. Thus, the population for this study consists of adult and adolescent patients with chronic s chizophrenia and excludes patients with acute disease. Only patients who have been stabilized on oral therapy with risperidone will be randomized into the double -blind maintenance stage of the study.Revision due to the option of adolescent enrollment in the study. 3.4. Stopping Rules for the Study One formal interim analysis will be conducted, when the number of events observed in the intent- to-treat (ITT) analysis set reach es60% of the planned 207 relapse events (125 events in adult patients).One for mal interim analysis will be conducted, when the number of events observed in the intent -to-treat (ITT) analysis set reach es60% of the planned 207 relapse events (125 events in adult patients).Clarification. 3.5. Schedule of Study Procedures and Assessm ents TV46000 -CNS -30072 Study Procedures and Assessments This w as previously Table 1; both stages of the study were depicted.The table w as split into 2 separate tables: Table 1 (In - Clinic Visits and Telephone Contacts) for the pre -treatment period (Stage 1), and Table 2 for the double -blind, maintenance stage (Stage 2). The row s corresponding to each stage are included in the relevant table. Footnotes which are relevant to both are included under each table. Only newly -added or revised row s and footnotes are denoted in this summary of changes.For further clarity, especially the assessments which are conducted at repeating time points. General Revisions to Table 1 (Stage 1): Revisions to Table 1 (Stage 1): Assent must be obtained from adolescent patients."
178,page_178,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 178Original text with changes shown New wording Reason/Justification for change Informed consent (and assent, as applicable) [Not applicable] [Not applicable] Adverse event inquiry (including SAE reporting, injection siterelated events including pain ) Informed consent (and assent, as applicable) FSH test added aseparate procedure at screening for women without mens es for the past 12 months. Addition of (adults patients only) to some assessments and procedures. Adverse event inquiry (including SAE reporting)Clarification regarding FSH testing. Clarification in which patients these assessments should be performed. Revised since there are no injections during Stage 1. [Not applicable] aIf a patient withdraws from the study prior to the randomization visit (Visit 6), the CRF for the patient's last visit will be marked as ""Not Continuing"" and the reason for discontinuation will be recorded. No extra testing or procedures w ill be required in addition to the regular visits. bVisits 3 through 5a should be scheduled relative to Visit 2 (and not relative to screening). For example, Visit 3 should be scheduled 2 w eeks (+/ -3 day s) after Visit 2, regardless of when the screening visit took place. mThe FSH test will only be performed for women with no menses for 12 months in order to confirm postmenopausal status. oDuring the in-clinic visits in Stage 1, if possible, the blood samples for PK assessment should be taken within an hour prior to dosing. In any case, the hour of the last dose taken prior to collection of the pharmacokinetic sample will be recorded on the CRF.Newly -added footnotes to Table 1. eTelephone contact will occur at w eek -6 and week -2 in the oral conversion and stabilization stage (Stage 1) (or more frequently if required in the judgement of the investigator). These contacts will be referred to by the pr evious visit number and a letter (for example, the telephone contacts that take place 1,2, and 3 weeks after visit 64will be referred to as â€œvisit 6a4aâ€ â€œvisit 6b,â€ and â€œvisit 6c,â€ respectively ).e Telephone contact w ill occur at w eek - 6 and week -2 in the oral conversion and stabilization stage (Stage 1) (or more frequently if required in the judgement of the investigator). These contacts will be referred to by the previous visit number and a letter (for example, the telephone contacts that take plac e 2 w eeks after visit 4 will be referred to as â€œvisit 4aâ€).Footnote revised for applicability to Stage 1 of study. At screening and baseline , measurements will be done in At screening, measurements will be done in triplicate. The Footnote revised for applicability to"
179,page_179,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 179Original text with changes shown New wording Reason/Justification for change triplicate. The mean of the 3 measurements will be used to determine study eligibil ity. Single measurements will be performed at all other in clinic visits.mean of the 3 measurements will be used to determine study eligibility. Stage 1 of s tudy. General Revisions to Table 2 (Stage 2): During Stage 2, Uunscheduled pharmacokinetic samples will be aimed to be collected in the event of relapse as defined per the studyâ€™s relapse criteria, any serious adverse event, patient withdrawal, and/or the need for potential TV -46000 depot excision. Every effort should be made to obtain the additional pharmacokinetic sample at the closest time possible to the occurrence of the event.During Stage 2, unscheduled pharmacokinetic samples will be aimed to be collected in the event of relapse as defined per the studyâ€™s relapse criteria, any serious adverse event, patient withdraw al, and/or the need for potential TV -46000 depot excision. Every effort should be made to obtain the additional pharmacokinetic sampl e at the closest time possible to the occurrence of the event.Revised to clarify that unscheduled PK samples do not need to be collected during Stage 1, and this is relevant only for Stage 2. [Not applicable] In Table 2, an â€œXâ€ was added to denote a urin e Î²-HCG test will be performed at the baseline visit, in addition to the serum Î² -HCG.For consistency with Section 7.4.2.2. which states that a urine test will be performed prior to every study drug administration, and since the serum result may not be available that day prior to dosing. l. Urine Î² HCG (dipstick) will be performed at all visits where study drug is administered (prior to study drug administration). A negative result must be obtained before study study drug is administered done prior to each study drug administration, except screening and baseline, where serum Î² HCG tests are performed .l. Urine Î² HCG (dipstick) test will be performed at all visits where study drug is administered (prior to study drug administration). A negative result must b e obtained before study study drug is administered.Clarification regarding urine pregnancy testing during Stage 2. n.This assessment will be performed every 12 weeks. As of Visit 9, inclusive, this assessment will be conducted every 12 weeks thereafter (Visits 12, 15, 18, and so on).n. As of Visit 9, inclusive, this assessment will be conducted every 12 weeks thereafter (Visits 12, 15, 18, and so on).Footnote revised and elaborated for clarification regarding timing of certain assessments during Stage 2. p. Blood for biomarker analyses will be collected as follows: 6 mL for serum, 6 mL for plasma, and 6.52.5mL for PAXgene RNA.p. Blood for biomarker analyses will be collected as follows: 6 mL for serum, 6 mL for plasma, and 2.5 mL for PAXgene RNA.Correction per laboratory manual. [Not applicable] s. Another pharmacokinetic sample will be collected from adolescent patients at a supplementary in -clinic visit at Week 14 (2 Weeks after Visit 9). If it is not possible to take the sample at this visit, it may be taken 2 weeks after another in -clinic visit. T wo additional samples, 3 w eeks New footnote regarding pharmacokinetic sampling in adolescents."
180,page_180,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 180Original text with changes shown New wording Reason/Justification for change and 1 w eek post -injection, respectively, may be taken at the sponsor's discretion. 4. SELECTION AND WITHDRAWAL OF PATIENTS 4.1. Patient Inclusion Criteria c. [Revision 1] The patient has provided w ritten informed consent and is competent to do so. For adolescent patients, written informed consent has been provided by each patientâ€™s parent or legal guardian, and written assent has been provided by each patient. c. [Revision 1] The patient has provided w ritten informed consent and is competent to do so. For adolescent patients, written informed consent has been provided by each patientâ€™s parent or legal guardian, and w ritten assent has been provided by each patient.Criterion revised to allow enrollment of adolescent patients in the study. j. [Revision 1] The patient is a male or female of any ethnic origin, 18 13 through 65 years of age at screening.j. [Revision 1] The patient is a male or female of any ethnic origin, 13 through 65 years of age at screening.Criterion revised to allow enrollm ent of adolescent patients in the study per regulatory input. k. [Revision 1] The patient has a body mass index between 18.0 and 38.0 kg/m2, inclusive, at screening. For adolescent patients, the BMI should be at least in the 50th percentile for age and ge nder and must not exceed 38.0 kg/m2.k. [Revision 1] The patient has a body mass index between 18.0 and 38.0 kg/m2, inclusive, at screening. For adolescent patients, the BMI should be at least in the 50th percentile for age and gender and must not exceed 38.0 kg/m2.Criterion revised to allow enrollment of adolescent patients in the study. m. [Revision 1] Wom en of childbearing potential (see Appendix E) and sexually- active female adolescents must agree not to try to become pregnant, and, unless they have exclusively same -sex partners, must agree to use a highly effective method of contraception, and agree to continue use of this method beginning 1 month before the first administration of study drugs and for the duration of the study and for 120 days after t he last injection of study drug.m. [Revision 1] Wom en of childbearing potential (see Appendix E) and sexually -active female adolescents must agree not to try to become pregnant, and, unless they have exclusively same- sex partners, must agree to use a high ly effective method of contraception, and agree to continue use of this method beginning 1 month before the first administration of study drugs and for the duration of the study and for 120 days after the last injection of study drug.Criterion revised to allow enrollment of adolescent patients in the study. n. The patient, if adult or adolescent male, is surgically sterile, or, if capable of producing offspring, has exclusively same -sex partners or is currently using an approved method of birth control and agrees to the continued use of this method for the duration of the study (and for 120 days after the last dose of study drug). Male patients with sex partners who are w omen of childbearing potential (see Appendix E) must use condoms even if surgically sterile. In addition, male n. The patient, if adult or adolescent male, is surgically sterile, or, if capable of producing offspring, has exclusively same- sex partners or is currently using an approved method of birth control and agrees to the continued use of this method for the duration of the study (and for 120 days after the last dose of study drug). Male patients with sex partners who are w omen of childbearing potential (see Appendix E) must use condoms even if Clarification following enrollment option of adolescent patients in the study."
181,page_181,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 181Original text with changes shown New wording Reason/Justification for change patients may not donate sperm for the duration of the study and for 120 days after taking the study drug.surgically sterile. In additi on, male patients may not donate sperm for the duration of the study and for 120 days after taking the study drug. 4.2. Patient Exclusion Criteria d. [Revision 1] The patient has a positive serology for human immunodeficiency virus (HIV) -1, HIV -2, hepatitis B surface antigen, and/or hepatitis C. If serology is positive for hepatitis C but the RNA test is negative, and the patient has no history of liver disease, en rollment will be considered following discussion between the investigator and the medical monitor as needed.d. [Revision 1] The patient has a positive serology for human immunodeficiency virus (HIV) -1, HIV -2, hepatitis B surface antigen, and/or hepatitis C. If serology is positive for hepatitis C but the RNA test is negative, and the patient has no history of liver disease, enrollment will be considered following discussion betw een the investigator and the medical monitor as needed.Clarification regarding patient enrollment in case of positive hepatitis C serology result. k. The patient has clinically significant findings in biochemistry, hematology, ECG, or urinalysis results. ï‚·If the patient has a prolonged QTcF interval (defined as a QTcF interval of > 450 m sec for males and >470 msec for females) at screening andorbaseline, calculated as the mean of the triplicate ECG measurements, eligibility will be decided on a case- by-case basis following discussion betw een the investigator and the sponsor. k. The patient has clinically significant findings in biochemistry, hematology, ECG, or urinalysis results. ï‚·If the patient has a prolonged QTcF interval (defined as a QTcF interval of >450 msec for males and >470 msec for females) at screening or baseline , calculated as the mean of the triplicate ECG measurements, eligibility will be decided on a case- by-case basis following discussion between the investigator and the sponsor.To clarify that discussion should take place in case of QTcF prolongation at eit her time point. 4.3.3. Pharm acokinetic Sampling in Case of Patient Withdrawal Note: Withdraw al under the above criteria (see Section 4.3.2.) w ill be discussed by the investigator and the sponsor. For patients who withdraw from the study, every effort will be made tofollow safety after withdrawal, including pharmacokinetic sampling when applicable, unless consent is withdrawn.Note: Withdraw al under the above c riteria (see Section 4.3.2.) w ill be discussed by the investigator and the sponsor. For patients who withdraw from the study, every effort will be made to follow safety after withdrawal, including pharmacokinetic sampling when applicable, unless consent is withdrawn.Correction of typos in text. 5.TREATMENTS 5.1.1.1 Starting Dose and Dose Levels In general, TV -46000 will be administered to theadult patients in the abdomen (except as indicated below ) by sc injection, at intervals of q1m or q2m, at a dose equivalent to oral risperidone 2 to 5 mg/day on which they were stabilized In general, TV -46000 will be administered to patients in the abdomen (except as indicated below ) by sc injection, at intervals of q1m or q2m, at a dose equivalent to oral risperidone 2 to 5 mg/day on which they were stabilized in Clarifications regarding administration of TV -46000."
182,page_182,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 182Original text with changes shown New wording Reason/Justification for change in Stage 1 , per the conversion table below (Table 3). The maximal dose administered will be equivalent to an oral risperidone dose of 5 mg/day. Patients that require a stabilization dose below 2 mg/day will not be randomized in the study. Also, as a precautionary measure, adolescent patients that will require a stabilization dose of more than 4 mg during the stabilization stage will not be randomi zed. Several investigational centers may be pre selected by the sponsor (based on the centersâ€™ capabilities, sponsor's considerations, and prior clinical experience with injectable medication) for injection of study drug in the back of the upper arm , instead of the abdomen , to all or some of the enrolled patients at these sites (approximately 20% of the study patient population). Stage 1, per the conversion table below (Table 3 ). The maximal dose administered will be equivalent to an oral risperidone dose of 5 mg/day. Patients that require a stabilization dose below 2 mg/day will not be randomized in the study. Also, as a precautionary measure, adolescent patients that will require a stabilization dose of more than 4 mg during the stabilization stage will not be randomized. Sever al investigational centers may be selected by the sponsor (based on the centersâ€™ capabilities, sponsor's considerations, and prior clinical experience with injectable medication) for injection of study drug in the back of the upper arm, instead of the abdo men, to all or some of the enrolled patients at these sites (approximately 20% of the study patient population).To allow for greater flexibility. 5.1.2. Placebo Investigational Medicinal Product . 5.2.1. Storage and Security The investigator or designee must confirm appropriate temperature conditions have been maintained for all IMPs medicinal products received, and any discrepancies must be reported and resolved before their use of the IMPs . â€¦ Oral risperidone is to be stored and securely locked according to the storage conditions specified in the package insert (RISPERIDONE tablets, Teva Pharmaceuticals, US PI ).The investigator or designee must confirm appropriate temperature conditions have been maintained fo r all medicinal products received, and any discrepancies must be reported and resolved before their use. â€¦ Since it is not considered an IMP, the sentence on oral risperidone storage was moved to Section 5.4. 5.2.3. Accountability Used and partially used IMP (test or placebo) w ill be destroyed by the study center. Unused IMP (test or placebo) w ill be Unused I MP (test or placebo) All test or placebo IMP supplies (used, partially- used, and unused) will be returned to the sponsor or its designee according to All test or placebo IMP supplies (used, partially -used, and unused) will be returned to the sponsor or its designee according to local and national regulations and the siteâ€™s standard operating procedures (SOPs), follow ing writt en authorization from the sponsor.Clarification that all IMP w ill be returned to the sponsor. Correction of text duplication."
183,page_183,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 183Original text with changes shown New wording Reason/Justification for change local and national regulations and the site's standard operating procedures (SOPs), follow ing written auth orization from the sponsor. 5.3. Justification for Dose of Test Investigational Medicinal Product â€¦ Based on the pharmacokinetic performance and the safety profile of TV -46000 in Study TV46000 -SAD -10055 and the population pharmacokinetic model -derived simulations, it is expected that TV -46000 provides sufficient coverage throughout 28 and 56 days in 4 doses equivalent to 2-, 3-, 4-, and 5 -mg oral risperidone based on total active moiety (Table 3). Adolescent patients will receive a maximal dose of TV -46000 equivalent to 4 mg oral risperidone.â€¦ Based on the pharm acokinetic performance and the safety profile of TV -46000 in Study TV46000 -SAD -10055 and the population pharmacokinetic model-derived simulations, it is expected that TV- 46000 provides sufficient coverage throughout 28 and 56 days in 4 doses ) equivalent to 2 -, 3-, 4-, and 5 -mg oral risperidone based on total active moiety (Table 3). Adolescent patients will receive a maximal dose of TV -46000 equivalent to 4 mg oral risperidone.Clarificati on regarding maximal dose of TV -46000 for adolescents. 5.4. Other Medicinal Products/Non -Investigational Medicinal Products In the US, Ooral risperidone tablets for stabilization (Table 4) will be a commercial product supplied by the study center. In Bul garia, oral risperidone for stabilization (Table 4) will be a commercial product supplied centrally by the sponsor. The brand name of the oral risperidone supplied w ill be recorded on the source documentation. Oral risperidone is to be stored and securely locked according to the storage conditions specified in the package insert (RISPERIDONE tablets, Teva Pharmaceuticals, US PI) manufacturerâ€™s Summary of Product Characteristics (SmPC). In the US, oral risperidone for stabilization (Table 4) w ill be a commercial product supplied by the study center. In Bulgaria, oral risperidone for stabilization (Table 4) w ill be a commercial product supplied centrally by the sponsor. The brand name of the oral risperidone supplied w ill be recorded on the source documentati on. Oral risperidone is to be stored according to the manufacturerâ€™s Summary of Product Characteristics (SmPC). Correction for consistency with Table 4; all forms of oral risperidone are allow ed. Clarification regarding oral risperidone sourcing. Since it is not considered an IMP, the sentence on oral risperidone storage was moved from Section 5.2.1 to this section and revised to encompass storage conditions for all forms of oral risperidone. 5.5 Treatm ent After the End of the Study When the study ends, eligible patients may be offered the opportunity to enter an extension study to assess the long - term safety and tolerability of extended -release risperidone. This potential extension study is beyond the scope of this protocol. A separate protocol will issued for the extension study as applicable.When the study ends, eligible patients may be offered the opportunity to enter an extension study to assess the long - term safety and tolerability of extended -release risperidone. This extension study is beyond the scope of this protocol. A separate protocol w ill issued for the extension study as applicable.Preparations for the feasibility and conduct of the extension study have begun."
184,page_184,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 184Original text with changes shown New wording Reason/Justification for change 5.7. Prior and Concom itant Medication or Therapy Enrolled patients not already on oral risperidone or injectable risperidone (RISPERDAL CONSTA, Janssen Pharmaceuticals, US PI) and on any antipsychotic (other than clozapine), will be converted to oral risperidone during Stage 1 of the study. The patients should start taking their oral risperidone beginning from Visit 2. However, they will be allowed to receive their down -titrated other antipsychotic medication together with a low dose of risperidone for the purpose of conversion only, and for as short a du ration as possible. The previous antipsychotic must be completely stopped within four weeks of visit 2. It is highly preferable that the patients be transitioned to oral risperidone during the allowed screening period after eligibility has been established . â€¦ The follow ing medications will be prohibited during this study: ï‚·antipsychotics other than the study treatments oExcept during the conversion and stabilization stage (Stage 1), and only if required for conversion from the previous antipsychotics to ora l risperidone . â€¦Allowed rescue medications will include zolpidem or diphenhydramine for insomnia; benztropine, trihexyphenidyl, or diphenhydramine for EPS; and propranolol and benzodiazepines for akathisia. In addition, use of lorazepam (up to 6 mg/day) is permitted on an as needed basis for indications other than akathisia (anxiety etc.). Use in this context must be limited to no more than 72 consecutive hours, and lorazepam should not be taken within 8 hours of rating scale assessment.Enrolled patients n ot already on oral risperidone or injectable risperidone (RISPERDAL CONSTA, Janssen Pharm aceuticals, US PI) and on any antipsychotic (other than clozapine), w ill be converted to oral risperidone during Stage 1 of the study. The patients should start taking their oral risperidone beginning from Visit 2. How ever, they will be allowed to receive their dow n- titrated other antipsychotic medication together with a low dose of risperidone for the purpose of conversion only, and for as short a duration as possible. The previous antipsychotic must be completely stopped w ithin four weeks of visit 2. It is highly preferable that the patients be transitioned to oral risperidone during the allowed screening period after eligibility has been established. The follow ing medications will be prohibited during this study: ï‚·antipsychotics other than the study treatments oExcept during the conversion and stabilization stage (Stage 1 ), and only if required for conversion from the previous antipsychotics to oral risperidone. â€¦ Allow ed rescue medications will include zolpidem or diphenhydramine for insomnia; benztropine, trihexyphenidyl, or diphenhydramine for EPS; and propranolol and benzodiazepines for akathisia. In addition, use of lorazepam (up to 6 mg/day) is permitted on an as needed basis for indications other than akathisia (anxiety etc.). Use in this context must be limited to no more than 72 consecutive hours, and lorazepam should not be taken within 8 hours of rating scale assessment.Clarification regarding conversion of patients to oral risperidone and benzodiazepine use. Additional clarification regarding use of lorazepam. 5.8. Procedures for Monitoring Patient Com pliance In Stage 1, A patient with total compliance of less than 80% A patient with total compliance of less than 80% in Stage 1 Com pliance will be measured for"
185,page_185,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 185Original text with changes shown New wording Reason/Justification for change in Stage 1 (measured on Visits 2, 3, 4, and 5) will be considered noncompliant. will be considered noncompliant. the overall stabilization period. 5.9. Randomization and Blinding In the event of an em ergency (ie, where knowledge of the study drug assignment is needed to make treatment decisions for the patient), the treatment group and dose to which the patient has been allocated can be determined by accessing the IRT system. All investigational center s will be provided w ith details on how to access the system for code breaking at the start of the study. The m edical monitor or equivalent should be consulted before unblinding, whenever possible. The Medical Monitor or equivalent should be notified follow ing unblinding. Any unblinding of the IMP performed by the investigator must be recorded in the source documents.In the event of an emergency (ie, where knowledge of the study drug assignment is needed to make treatment decisions for the patient), the tre atment group and dose to which the patient has been allocated can be determined by accessing the IRT system. All investigational centers will be provided w ith details on how to access the system for code breaking at the start of the study. The Medical Moni tor or equivalent should be notified following unblinding. Any unblinding of the IMP performed by the investigator must be recorded in the source documents.Clarification per updated sponsor template to enhance patient safety and ensure that the patientâ€™s needs are first addressed. 5.10.2 Blinding and Unblinding In case of a serious adverse event, pregnancy, or in cases when knowledge of the IMP assignment is needed to make treatment decisions, the investigator may unblind the patientâ€™s IMP assignment as deem ed necessary, mainly in emergency situations. Individual randomization codes, indicating the IMP assignment for each randomized patient, will be available to the investigator(s) or pharmacist(s) at each investigational center via the IRT, both via tele phone and internet. If possible, the sponsor should be notified of the event before breaking of the code. If this is not possible, the sponsor should be notified immediately afterwards, and the patientâ€™s IMP assignment should not be given. Breaking of the randomization treatment code can alw ays be performed by the investigational centers investigator without prior approval by the sponsor ; however, the sponsor should be notified following the breaking of the treatment code. The patient's IMP assignment should not be revealed to the sponsor.In case of a serious adverse event, pregnancy, or in cases when knowledge of the IMP assignment is needed to make treatment decisions, the investigator may unblind the patientâ€™s IMP assignment as deemed necessary, mainly i n emergency situations. Individual randomization codes, indicating the IMP assignment for each randomized patient, will be available to the investigator(s) or pharmacist(s) at each investigational center via the IRT, both via telephone and internet. Breaki ng of the treatment code can alw ays be performed by the investigator w ithout prior approval by the sponsor; how ever, the sponsor should be notified following the breaking of the treatment code. The patient's IMP assignment should not be revealed to the sponsor.Clarification per updated sponsor template to enhance patient safety and ensure that the patientâ€™s needs are first addressed. 5.10.3. Data Monitoring Committee The IDMC w ill perform 1 formal interim analysis of efficacy The IDMC w ill perform 1 formal interim analysis of Clarification."
186,page_186,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 186Original text with changes shown New wording Reason/Justification for change in this study (when the number of events observed reaches 60% of the planned 207 relapse events in the ITT analysis set [Section 3.4] 3.4). efficacy in this study (when the number of events observed reach es 60% of the planned 207 relapse events in the ITT analysis set [Section 3.4]). 6. ASSESSMENT OF EFFICACY 6.2.2.1 Schizophrenia Quality of Life Scale (SQLS) The Schizophrenia Quality of Life Scale (SQLS) will be administered to adult patients only at the time points specified in Table 1 and Table 2 , and is used to capture quality of life.The Schizophrenia Quality of Life Scale (SQLS) will be administered to adult patients only at the time points specified in Table 1 and Table 2, and is used to capture quality of life.Clarification in which patient population this scale will be assessed. Cross -link created to new tab le of assessments. 6.2.2.2. 5- Level EuroQol Five Dimensions Questionnaire (EQ -5D-5L) The 5 -Level EuroQol Five Dimensions Questionnaire (EQ- 5D-5L) will be administered to adult patients only at the time points specified in Table 1 and Table 2 , and is a st andardized questionnaire that assesses overall state of health.The 5 -Level EuroQol Five Dimensions Questionnaire (EQ- 5D-5L) will be administered to adult patients only at the time points specified in Table 1 and Table 2, and is a standardized questionnair e that assesses overall state of health.Clarification in which patient population this scale will be assessed. Cross -link created to new table of assessments. 6.2.3. Drug Attitudes Inventory 10 -item Version (DAI -10)"
187,page_187,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 187Original text with changes shown New wording Reason/Justification for change The Drug Attitudes Inventory 10 -item version (DAI -10) w ill be administered to adult patients only at the time points specified in Table 1 and Table 2 , and measures subjective responses and attitudes toward maintenance of antipsychotic drug therapy that may affect compliance.The Drug Attitudes Inventory 10 -item version (DAI -10) will be administered to adult patients only at the time points specified in Table 1 and Table 2 , and measures subjective responses and attitudes tow ard m aintenance of antipsychotic d rug therapy that may affect compliance.Clarification in which patient population this scale will be assessed. Cross -link created to new table of assessments. 6.2.4. Personal and Social Perform ance Scale (PSP) The Personal and Social Performance Scale (P SP) w ill be administered to adult patients only at the time points specified in Table 1 and Table 2 , and is a clinician -rated instrument that measures personal and social functioning in patients with schizophrenia ( Morosini et al 2000 ).The scale consists of 100 items The PSP is a 100 -point single -item rating scale, divided in to10 equal intervals. The Personal and Social Performance Scale (PSP) w ill be administered to adult patients only at the time points specified in Table 1 and Table 2, and is a clinician -rated instrument that measures personal and social functioning in patients with schizophrenia ( Morosini et al 2000 ). The PSP is a 100 -point single -item rating scale, divided into 10 equal intervals.Clarification in which patient population this scale will be assessed. Cross -link created to new table of assessments. Correction of PSP scale description. 6.2.5. Healthcare Resource Utilization Healthcare resource utilization w ill be assessed for both adult and adolescent patients approximately every 3 months (at the time points specified in Table 1 and Table 2 ) for hospitalizations, emergency room (ER) visits, and outpatient visits (ie, not including protocol -mandated outpatient visits).Healthcare resource utilizatio n will be assessed for both adult and adolescent patients approximately every 3 months (at the time points specified in Table 1 and Table 2) for hospitalizations, emergency room (ER) visits, and outpatient visits (ie, not including protocol -mandated outpat ient visits).Clarificatin in which patient population this scale will be assessed. Cross -link created to new table of assessments. 7. ASSESSMENT OF SAFETY 7.4. Clinical Laboratory Tests Table 67Header: Hematology and coagulation Table 7 Header: Hematology Correction; coagulation samples are not collected in this study. 7.4.1. Serum Chemistry, Hematology and Urinalysis Clinical laboratory tests (serum chemistry, hematology and coagulation , and urinalysis) will be performed at the time points de tailed in Table 1 and Table 2 . Clinical laboratory tests (serum chemistry, hematology, and urinalysis) will be performed at the time points detailed in Table 1 and Table 2.Correction; coagulation samples are not collected in this study. 7.4.2.2. Hum an Chorionic Gonadotropin Tests A FSH test will be performed at the screening visit for any female who has been without menses for at least 12 months to confirm post -menopausal status. Women may be allowed A FSH test will be performed at the screening visit for any female who ha s been without menses for at least 12 months to confirm post -menopausal status. Women may be Clarification for whom the FSH test should be performed."
188,page_188,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 188Original text with changes shown New wording Reason/Justification for change not to use contraceptives during the study if they h ad no menses for at least 12 months (without an alternative medical cause) and the FSH concentration is above 35 U/L. A serum beta human chorionic gonadotropin (Î² -HCG) test will be performed for all women at screening, baseline, and the follow -up/exit visits (see Table 1 and Table 2 ). At baseline, both a serum and a urine Î² -HCG test will be performed. Urine Î² -HCG (dipstick) test will be performed at all visits where study drug is administered (prior to study drug administration). A negative result must be obtained prior to study drug administration.allow ed not to use contraceptives during the study if they had no menses for at least 12 months (without an alternative medical cause) and the FSH concentration is above 35 U/L. A serum beta human chorionic gonadotropin (Î² -HCG) test will be performed for all women at screening, baseline, and the follow -up/exit visits (see Table 1 and Table 2). At baseline, both a serum and a urine Î² -HCG test will be performed. Urine Î²-HCG (dipstick) test will be performed at all visits where study drug is administered (prior to study drug administration). A negative result must be obtained prior to study drug administration.At the baseline visit, both types of pregnancy tests will be performed since the serum result may not be available that day prior to dosing. Clarification that a negative result must be obtained before study drug is administered. 7.4.2.3. Urine Drug Screen A urine drug screen will be performed at the time points specified in Table 1 and Table 2 . The urine drug screen detects the presence of drugs of abuse, including amphetamine, barbiturates, benzodiazepines, cocaine, opiates, and tetrahydrocannabinol. Substance use disorder is exclusionary and will preclude the patient from enrollment/randomization. However, if per the investigatorâ€™s judgment, a patient does not meet the criteria for substance use disorder, a Apositive result for any of the above drugs or their metabolites, w ithout medical explanation, will preclude the patient from randomization/enrollment or continued participation in the study . be discussed on a case- by-case basis between the site, the Medical Monitor and the sponsor to determine the patientâ€™s eligibility, based on the information available. The patients should be advised that use of these substances should be avoided during the study.A urine drug screen will be performed at the time points specified in Table 1and Table 2 . The urine drug screen detects the presence of drugs of abuse, including amphetamine, barbiturates, benzodiazepines, cocaine, opiates, and tetrahydrocannabinol. Substance use disorder is exclusionary and w ill preclude the patient from enrollment/randomization. How ever, if per the investigatorâ€™s judgment, a patient does not meet the criteria for substance use disorder, a positive result for any of the above drugs or their metabolites, w ithout medical explanation, will be discussed on a case -by-case basis betw een the si te, the Medical Monitor and the sponsor to determine the patientâ€™s eligibility, based on the information available. The patients should be advised that use of these substances should be avoided during the study.Clarification regarding a positive urine dru g screen result due to the high prevlalence of recreational and medical use of various substances in this patient population. 7.9.1. Colum bia Suicide Severity Rating Scale (C -SSRS) The C -SSRS is a semi structured interview that captures the occurrence, s everity, and frequency of suicide -related thoughts and behaviors (Posner et al 2011). The interview and rating for the C -SSRS iswill be conducted completed by TheC-SSRS is a semi structured interview that captures the occurrence, severity, and frequency of suicide -related thoughts and behaviors (Posner et al 2011). The interview and rating for the C -SSRS will be rater specifically trained Corrected per Clar ification Letter 01 (June2018). Any rater who meets the scale authorâ€™s requirements may conduct the rating following"
189,page_189,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 189Original text with changes shown New wording Reason/Justification for change a licensed clinician rater specifically trained to rate the scale (per the minimum requirements o utlined by the scale author), regardless of education level, who has appropriate clinical trial experience with C -SSRS administration specifically trained to rate the scale, after review and approval by the Teva clinical project physician or designee. to rate the scale (per th e minimum requirements outlined by the scale author), regardless of education level, who has appropriate clinical trial experience with C -SSRS administration, after review and approval by the Teva clinical project physician or designee. approval from the Sponsor or designee. 8. ASSESSMENT OF PHARMACOKINETICS/PHARMACODYNAMICS/BIOMARKERS/PHARMACOGENOMICS 8.1. Pharm acokineti c Assessment Blood samples will be collected from all patients for quantitation of the plasma concentrations of risperidone, 9 - OH-risperidone, and total active moiety (sum of risperidone and 9 -OHrisperidone) at weeks -12, -10, -8, and -4 in Stage 1, at ba seline, q4w in Stage 2, and at the follow -up/exit visits. In case the patient is on a twice -daily (bid) oral risperidone dosing regimen, the patient can take the first out of the 2 daily oral doses at the clinic with a PK assessment taken within an hour pr ior to dosing, and the second dose can be taken at home in the afternoon/evening, per the patientâ€™s convenience at approximately the same hour every day. During Stage 2 of the study, blood samples for PK assessment will be taken within an hour prior to sc dose administration. Another pharmacokinetic sample will be collected from adolescent patients only at Week 14 (2 weeks after Visit 9 [Week 12]), approximately after steady state is reached. It is highly preferable to collect the sample at Week 14. However, if this is not poss ible, it may be collected 2 weeks after another in -clinic visit. Up to 2 additional samples may also be collected from adolescent patients at Week 15 and Week 13 (3 weeks and 1 week post -injection, respectively) at the sponsor's discretion. This may be co nsidered, for example, if few adolescent patients will be enrolled. The additional samples, if taken following another in -clinic visit, will be collected at the same intervals. If more than 1 additional sample is taken, they do not need to be collected aft er the same injection (ie, Blood samples will be collected from all patients for quantitation of the plasma concentrations of risperidone, 9 - OH-risperidone, and total active moiety (sum of risperidone and 9 -OHrisperidone) at w eeks -12, -10, -8, and -4 in Stage 1, at baseline, q4w in Stage 2, and at the follow -up/exit visits. In case the patient is on a twice -daily (bid) oral risperidone dosing regimen, the patient can take the first out of the 2 daily oral doses at the clinic with a PK assessment taken within an hour prior to dosing, and the second dose can be taken at home in the afterno on/evening, per the patientâ€™s convenience at approximately the same hour every day. During Stage 2 of the study, blood samples for PK assessment will be taken within an hour prior to sc dose administration. Another pharmacokinetic sample w ill be collected from adolescent patients only at Week 14 (2 w eeks after Visit 9 [Week 12]), approximately after steady state is reached. It is highly preferable to collect the sample at Week 14. How ever, if this is not possible, it may be collected 2 weeks after another i n-clinic visit. Up to 2 additional samples may also be collected from adolescent patients at Week 15 and Week 13 (3 w eeks and 1 week post -injection, respectively) at the sponsor's discretion. This may be considered, for example, if few adolescent patients will be enrolled. The additional samples, if taken following another in -clinic visit, will be collected at the same intervals. If more than 1 additional Clarification regarding oral risperidone dosing and collection of pharmacokinetic samples during Stage 1 of the study. New text describing collection of additional pharmacokinetic samples from adolescents to further characterize the PK profile in this patient population. Clarification that unscheduled pharmacokinetic samples are relevant for Stage 2 of the st udy."
190,page_190,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 190Original text with changes shown New wording Reason/Justification for change 1 sample can be taken 3 weeks after Visit X and another can be taken 1 week after Visit Y). Thus, up to 3 additional pharmacokinetic samples may be taken from adolescent patients at supplementary in -clinic visits (without dosing ) at varying time intervals following sc dose administration. â€¦ During Stage 2, u Unscheduled pharmacokinetic samples will be aimed to be collected in the event of relapse as defined per the study's relapse criteria, any serious adverse event, patient withdrawal, and/or the need for potential TV -46000 depot excision. Every effort should be made to obtain the additional pharmacokinetic sample at the closest time possible to the occurrence of the event.sample is taken, they do not need to be collected after the same injection (ie, 1 sample can be taken 3 weeks after Visit X and another can be taken 1 w eek after Visit Y). Thus, up to 3 additional pharmacokinetic samples may be taken from adolescent patients at supplementary in -clinic visits (without dosing) at varying time intervals following sc dose admi nistration. â€¦ During Stage 2, unscheduled pharmacokinetic samples will be aimed to be collected in the event of relapse as defined per the study's relapse criteria, any serious adverse event, patient withdraw al, and/or the need for potential TV -46000 depo t excision. Every effort should be made to obtain the additional pharmacokinetic sample at the closest time possible to the occurrence of the event. 9. STATISTICS 9.1. Sample Size and Power Considerations Median time to impending relapse w as observed to be 7months in the placebo group in a similarly designed study (Kane et al 2012 ). Assuming a similar placebo effect in this study, as well as a hazard ratio of 1.82 (placebo vs TV- 46000), at a 2 -sided alpha of 0.025 0.05, and randomization ratio of 1:1:1 (q1m:q2m:placebo), a total of 207 relapse events will need to be observed during Stage 2 of the study for thethe ITT analysis set (adult patient s) in the 3 treatment groups (combined) to have a statistical power of approximately 90% ( East 6 [Version 6.3] manual, 2014 ). The sample size rationale is based on the adult patients. There is no estimation of the sample size in the adolescent population, and their number is not known at this time. Assuming an accrual time of 6 months and a maximal treatment duration during the double- blind stage of approximately 13 months, approximately 139 adult patients will need to be randomized to each treatment group for a total of 417 adult patients randomized. Assuming that 30% of the patients enrolled in Stage 1 w ill not be randomized to the Median time to impending relapse w as observed to be 7months in the placebo group in a similarly designed study (Kane et al 2012). Assuming a similar placebo effect in this study, as well as a hazard ratio of 1.82 (p lacebo vs TV-46000), at a 2 -sided alpha of 0.05, and randomization ratio of 1:1:1 (q1m:q2m:placebo), a total of 207 relapse events will need to be observed during Stage 2 of the study for the ITT analysis set (adult patients) in the 3 treatment groups (com bined) to have a statistical power of approximately 90% (East 6 [Version 6.3] manual, 2014). The sample size rationale is based on the adult patients. There is no estimation of the sample size in the adolescent population, and their number is not known at this time. Assuming an accrual time of 6 months and a maximal treatment duration during the double- blind stage of approximately 13 months, approximately 139 adult patients will need to be randomized to each treatment group for a total of 417 adult patients randomized. Assuming that 30% of the patients enrolled in Stage 1 w ill Correction of typo. Additional details provided regarding the expected sample size in the adult and adolescent populations."
191,page_191,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 191Original text with changes shown New wording Reason/Justification for change double- blind phase (Stage 2), a total of 596 adult patients will need to be enrolled into Stage 1. As an event -driven study, d epending on the actual recruitment rate and percentage of patients who are enrolled in Stage 1 and are randomized to Stage 2, it may be possible to randomize more than 417 adult patients, as long as Stage 2 of the study ends when the number of relapse even ts in the ITT analysis set reaches 207.not be randomized to the double -blind phase (Stage 2), a total of 596 adult patients will need to be enrolled into Stage 1. As an event -driven study, depending on the actual recruitmen t rate and percentage of patients who are enrolled in Stage 1 and are randomized to Stage 2, it may be possible to randomize more than 417 adult patients, as long as Stage 2 of the study ends when the number of relapse events in the ITT analysis set reache s 207. 9.2.2. Intent -toTreat Analysis Set The intent -to-treat (ITT) analysis set will include all adult patients randomized during the double -blind maintenance stage (Stage 2), regardless if they have received treatment or not. In the ITT analysis set, treatment will be assigned based on the treatment to which patients were randomized, regardless of which treatment they actuall y received.The intent -to-treat (ITT) analysis set will include adult patients randomized during the double- blind maintenance stage (Stage 2), regardless if they have received treatment or not. In the ITT analysis set, treatment will be assigned based on t he treatment to which patients were randomized, regardless of which treatment they actually received.Clarification; the ITT analysis set is defined for adult patients only. 9.2.3. Extended Intent -toTreat Analysis Set [Not applicable] The extended intent -to-treat (eITT) analysis set will include all patients (adults and adolescents) randomized to the double -blind maintenance stage (Stage 2), regardless if they have received treatment or not. In the ITT analysis set, treatment will be assigned based on the treatment to which patients were randomized, regardless of which treatment they actually received.Newly -created sub -section and text to define this analysis set due to the option of adolescent enrollment. 9.4. Study Population The eITT analysis set (Section 9.2) w ill be used for all study population summaries of the double- blind treatment stage unless otherwise specified. Summaries will be presented by treatment group and for all patients. The primary analysis will be conducted on the ITT analysi s set, the first key secondary endpoint will be conducted on the complete eITT analysis set and the second key secondary endpoint will be conducted on the adolescent subsetof the eITT analysis set. The analysis set on which analysis for other end -points will be conducted will be specified on a case -by-case basis. The The eITT analysis set (Section 9.2) w illbe used for all study population summaries of the double -blind treatment stage unless otherwise specified. Summaries will be presented by treatment group and for all patients. The primary analysis will be conducted on the ITT analysis set, the first key s econdary endpoint will be conducted on the complete eITT analysis set and the second key secondary endpoint will be conducted on the adolescent subset of the eITT analysis set. The analysis set on which analysis for other end -points will be conducted w ill be specified on a case- by-case basis. The enrolled patients set will be used Clarification regarding the endpoints and corresponding analysis sets with the ne wly- introduced option of adolescent enrollment."
192,page_192,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 192Original text with changes shown New wording Reason/Justification for change enrolled patients set will be used for data summaries before the double- blind treatment stage.for data summaries before the double -blind treatment stage. 9.4.1. Patient Disposition Data from patients screened and enrolled in Stage 1; patients who were enrolled in Stage 1 but not randomized for the double- blind stage and reason for not randomized; patients who were randomized; patients who were r andomized but not treated; patients in the ITT, patients in the eITT ,PP, safety, and pharmacokinetics analysis sets; patients who completed the study; and patients who withdrew from the study will be summarized using descriptive statistics. Data from pati ents who withdrew from the study will also be summarized by reason for withdraw al using descriptive statistics. Adolescent patient disposition may be summarized separately, if applicable.Data from patients screened and enrolled in Stage 1; patients who were enrolled in Stage 1 but not randomized for the double -blind stage and reason for not randomized; patients who were randomized; patients who were randomized but not treated; patients in the ITT, patients in the eITT , PP, safety, and pharmacokinetics analysis sets; patients who completed the study; and patients who withdrew from the study will be summarized using descriptive statistics. Data from patients who withdrew from the study will also be summarized by reason for withdrawal using descriptive st atistics. Adolescent patient disposition may be summarized separately, if applicable.Clarification regarding analysis sets used. 9.4.2. Dem ographic and Baseline Characteristics Treatment groups will be compared for all continuous variables, using an analysis of variance (ANOVA) with treatment group and investigational center as factors. The categorical variables of patient sex and race w ill be summarized using the descriptive statistics for each variable category. Missing categories will be presented if necessary. Treatment groups will be compared for all categorical variables using a Pearson's chi -squared test (or Fisher's exact test if cell sizes are too small). The ITT analysis set, the eITT analysis set, and the eITT subset of adolescents will be use d for the summaries. The ITT analysis set, the eITT analysis set, as well as the eITT subset of adolescents will be used for the summaries. The analysis methods will be detailed in the Statistical Analysis Plan. New text to clarify subsets used in the a nalysis. 9.5.1. Prim ary Endpoint â€¦ -an increase in any of the following 4 individual PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of â‰¥ >4and an absolute .. -an increase in any of the following 4 individual PANSS items: conceptual disorganization, halluci natory behavior, suspiciousness, and unusual thought content, to a score of >4 and an Correction of typos for consistency with other protocol sections."
193,page_193,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 193Original text with changes shown New wording Reason/Justification for change increase of > â‰¥4on the combined score of these 4PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content) since randomizationabsolute increase of â‰¥4 on the combined score of these 4 PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content) sin ce randomization 9.5.2. Key Secondary Endpoints [Not applicable] The key secondary endpoints are: 1. time to impending relapse (as defined under the primary objective) in the eITT analysis set), and 2. time to impending relapse in adolescent patients with schizophrenia. NOTE: The assessment of time to impending relapse in adolescent patients is pending randomization of at least 10 adolescent patients with clinically sufficient exposure.Newly -added sub -section defining the introduced key secondary endpoints. 9.5.3. Secondary Endpoints [Not applicable] The eITT analysis set (Section 9.2) w ill be used for all summaries in this section, unless otherwise specified. For the endpoints that are evaluted only in the adult population, the analysis will be conducted on the ITT analysis set . [Previously Section 9.5.2.] New text to clarify subsets used in the analysis. 9.5.4.2. 5 -Level EuroQol Five Dimensions Questionnaire The change from baseline to endpoint in total score w ill be calculated. The change from baseline to each visit and to endpoint in each of the EQ -5D-5L domains will be calculated.The change from baseline to each visit and to endpoint in each of the EQ- 5D-5L domains will be calculated.Correction since there is no ""total score"" in this scale. 9.5.4.6. CGI -I Score at Endpoint"
194,page_194,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 194Original text with changes shown New wording Reason/Justification for change The change from baseline to endpoint in total score w ill be calculated. CGI-I at endpoint will be analyzed.CGI-I at endpoint will be analyzed. Correction since there is no ""total score"" in this scale. 9.5.5. Planned Method of Analysis The ITT analysis set (Section 9.2.2) will be used for all efficacy analyses. Summaries will be presented by treatment group. Analysis that will be conducted on the eITT analysis set or on the adolescent patient subset of the eITT will be described below.The ITT analysis set (Section 9.2.2) will be used for all efficacy analyses. Summaries will be presented by treatment group. Analysis that w ill be conducted on the eITT analysis set or on the adolescent patient subset of the eITT w ill be described below .Re-numbering of section (instead of 9.5.4). Clarification. 9.5.5.2. Sensitivity Analysis A sensitivity analysis will be conducted to assess the impact of large intervals between the previous assessment and the assessment when the first relapse w as observed via the interval censoring method . If the interval is â‰¥1.5 times the protocol planned as sessment interval length, then the patient will be censored at the previous assessment visit. Sensitivity analysis will also be conducted by classifying dropouts (for reasons other than relapse) as relapse events instead of censoring. The PP analysis set w ill also be used to assess the primary efficacy variable. A sensitivity analysis to assess the impact of dropouts (for reasons other than relapse) will be conducted as well. Details will be provided in the statistical analysis plan. Senstivity analysis wil l be conducted on the ITT analysis set.A sensitivity analysis will be conducted to assess the impact of large intervals between the previous assessment and the assessment when the first relapse w as observed. Sensitivity analysis will also be conducted by classifying dropouts (for reasons other than relapse) as relapse events instead of censoring. The PP analysis set will also be used to assess the primary efficacy variable. Details will be provided in the statistical analysis plan. Senstivity analysis willbe conducted on the ITT analysis set.Section number changed from 9.5.4.2. due to addition of key secondary enpoints. Introduction of the interval censoring method instead of the previous description of method of sensitivity to the large inter assessment intervals. Deletion of redundant reference to dropout sensitivity analysis (mentioned 2 sentences before). Clarification regarding patient subset analyzed. 9.5.5.3. Subgroup Analysis Additional s Subgroup analysis for the primary endpoint, including region, will be described in the statistical analysis plan.Additional subgroup analysis for the primary endpoint, including region, will be described in the statistical analysis plan.Clarification. 9.5.5.4. Key Secondary Analyses [Not applicable[] 9.5.5.4.1. Key Secondary Analysis 1 Time to impending relapse in adult and adolescent patients will be assessed similarly to the Primary Efficacy Analysis using the eITT Analysis Set (Section 9.2.2. ). The Cox proportional hazard model w ill include patient age group New sub-section describing the analysis of the newly -introduced key secondary endpoints."
195,page_195,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 195Original text with changes shown New wording Reason/Justification for change (if applicable) along with treatment, and the aforementioned stratification variables as the factors. The details about the T ype I statistical error control will be discussed in Section 9.6 . 9.5.5.4.1. Key Secondary Analysis 1 Time to impending relapse in adolescent patients will be assessed if the number of randomized patients will be at least 10 w ith clinically sufficient exposure. The method will be similar to the Primary Efficacy Analysis, but will use the adolescent patients subset. The deta ils about the Type I statistical error control will be discussed in Section 9.6. 9.5.5.5. Secondary Efficacy Analysis [Not applicable] The eITT analysis set (Section 9.2) w ill be used for all summaries in this section, unless otherwise specified.[Previously Section 9.5.4.4] Information added regarding the analysis set to be used. 9.5.5.6. .[Previously Section 9.5.4.5] 9.6. Multiple Com parisons and Multiplicity"
196,page_196,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 196Original text with changes shown New wording Reason/Justification for change There w ill be 1 interim analysis when the number of events observed reaches 60% of the planned 207 relapse events (125 events) in the ITT analysis set . At this interim analysis, both primary efficacy tests will be tested at a 2-sided alpha of 0.0101. If both tests are significant at the interim analysis, the study may be stopped. If only 1 primary efficacy test (or none) is significant at the interim analysis, the study will continue until the required number of relapse events are observed. â€¦ Type -I error will be further controlled for the 2 key secondary endpoints by employing the hierarchical approach. Secondary endpoint #1 will be analyzed only in case the2 primary efficacy endpoints have p -value less than or equal to alpha o f 0.0464. In that case, key secondary endpoint #1 will be tested for the 2 dosing regimens using the same approach. Namely, tests for the 2 dosing regimens will be conducted with 2 -sided alphas of 0.0464; if one of the comparisons for the key secondary end point #1 is not significant at a 2 -sided alpha of 0.0464, the other will be tested at 2 -sided alpha of 0.0464 divided by 2. If secondary endpoint #1 is successful on both dosing regimens against placebo, and there are at least 10 adolescent patients in t he study with clinically sufficient exposure, then the 2 dosing regimens in the adolescent study population will be tested against placebo in the same way as described for the primary efficacy endpoint and key secondary endpoint #1. There w ill be 1 interi m analysis when the number of events observed reaches 60% of the planned 207 relapse events (125 events) in the ITT analysis set. At this interim analysis, both primary efficacy tests will be tested at a 2 - sided alpha of 0.0101. If both tests are significant at the interim analysis, the study may be stopped. If only 1 primary efficacy test (or none) is significant at the interim analysis, the study will continue until the required number of relapse events are observed. â€¦ Type-I error w ill be further control led for the 2 key secondary endpoints by employing the hierarchical approach. Secondary endpoint #1 w ill be analyzed only in case the2 primary efficacy endpoints have p -value less than or equal to alpha of 0.0464. In that case, key secondary endpoint #1 w ill be tested for the 2 dosing regimens using the same approach. Namely, tests for the 2 dosing regimens will be conducted with 2 -sided alphas of 0.0464; if one of the comparisons for the key secondary endpoint #1 is not significant at a 2 -sided alpha of 0. 0464, the other will be tested at 2 -sided alpha of 0.0464 divided by 2. If secondary endpoint #1 is successful on both dosing regimens against placebo, and there are at least 10 adolescent patients in the study with clinically sufficient exposure, then t he 2 dosing regimens in the adolescent study population will be tested against placebo in the same way as described for the primary efficacy endpoint and key secondary endpoint #1.Clarification. Details regarding T ype I error control for the newly -introd uced key secondary endpoints are provided. 9.7. Safety Analysis Allowed rescue medications will include zolpidem or diphenhydramine for insomnia; benztropine, trihexyphenidyl, or diphenhydramine for EPS; and propranolol and benzodiazepines for akathisia. Descriptive statistics for Descriptive statistics for allowed rescue medications (see Section 5.75.7 ) will be presented by treatment group. Safety outcomes, including changes from baseline in EPS scale scores (BARS, AIMS, and SAS) and CDSS during Details of the resc ue medication were deleted since not relvant here. Cross -reference to concomitant medication section was created for"
197,page_197,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 197Original text with changes shown New wording Reason/Justification for change allowed rescue medications (see Sectio n 5.7 )will be presented by treatment group. Safety outcomes, including changes from baseline in EPS scale scores (BARS, AIMS, and SAS) and CDSS during Stage 2, will be presented using descriptive statistics and/or ANCOVA, with treatment and stratification variables as factors and baseline as a covariate (LOCF will be used) by treatment group . Adjustment to stratification factors may be conducted as appropriate. â€¦ Selected safety data will also be presented by site of injection (abdomen vs arm) and by age group (adolescents [ages 13 - 17] and adults [18 years of age and above]), as applicable . Separate summaries for adolescent patients may be presented separately for some analyses, as applicable and will be described in the Statist ical Analysis Plan.Stage 2, will be presented using descriptive statistics by treatment group. Adjustment to stratification factors may be conducted as appropriate. â€¦ Selected safety data will also be presented by site of injection (abdomen vs arm) and by age group (adolescents [ages 13 -17] and adults [18 years of age and above]), as applicable. Separate summaries for adolescent patients may be presented separately for some analyses, as applicable and will be described in the Statistical Analysis Plan.clarity. The safety analysis method(s) will be detailed in the Statistical Analysis Plan. Newly -introduced text regarding adolescent data. 9.8. Tolerability Analysis All-cause discontinuation rates and discontinuation rates due to adverse events (dropout rates) will be calculated as the number of patients who withdrew early for all reasons, and the number of patients who withdrew early due to adverse events, respective ly, divided by number of patients in each treatment group, and will be analyzed presented using descriptive statistics.All-cause discontinuation rates and discontinuation rates due to adverse events (dropout rates) w ill be calculated as the number of pati ents who withdrew early for all reasons, and the number of patients who w ithdrew early due to adverse events, respectively, divided by number of patients in each treatment group, and will be presented using descriptive statistics.Correction. [Not applicable] Separate summaries for adolescent patients may be presented separately for some analyses, as applicable and will be described in the Statistical Analysis Plan.Newly -introduced text regarding adolescent data. 9.9. Pharm acokinetic Analysis All concentration data will be summarized by age subset (adult, adolescent), treatment (q1m, q2m or oral), dose and All concentration data will be summarized by age subset (adult, adolescent), treatment (q1m, q2m or oral), dose and Clarifications regarding the pharmacokinetic modeling and"
198,page_198,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 198Original text with changes shown New wording Reason/Justification for change visit using descriptive statistics (n, mean, standard deviation, median, minimum, geometric mean, and coefficient of variation). Drug concent rations over time [C(t)] reported by age subset, time (visit) and treatment will be presented for risperidone, 9 -OH-risperidone, and total active moiety (sum of risperidone and 9 -OH-risperidone). Additional pharmacokinetic parameters may be determined if data permit s(see Section 2.2). In addition, the pharmacokinetics of TV -46000 (and if data permit s, also of oral risperidone) will be evaluated using a population pharmacokinetics approach. Importantly, pharmacokinetic concentration analysis and population pharmacokinetics analysis independent pharmacokinetic modeling and population -based modeling analysis will take place during the study conduct, while maintaining the blind, as will be described in the pharmacokinetics analysis plan.visit using descriptive statistics (n, mean, standard deviation, median, minimum, geometric mean, and coefficient of variatio n). Drug concentrations over time [C(t)] reported by age subset, time (visit) and treatment will be presented for risperidone, 9 -OH-risperidone, and total active moiety (sum of risperidone and 9-OH-risperidone). Additional pharmacokinetic parameters may be determined if data permit (see Section 2.2). In addition, the pharmacokinetics of TV -46000 (and if data permit, also of oral risperidone) will be evaluated using a population pharmacokinetics approach. Importantly, independent pharmacokinetic mod eling and population -based modeling analysis will take place during the study conduct, while maintaining the blind, as will be described in the pharmacokinetics analysis plan.analysis. 9.13. Plann ed Interim Analysis There w ill be 1 formal interim analysis when the number of events observed in the ITT analysis set reaches 60% of the planned 207 relapse events (125 events in adult patients).There w ill be 1 formal interim analysis when the number of events observed in the ITT analysis set reaches 60% of the planned 207 relapse events (125 events in adult patients).Clarification. 15. REFERENCES [Not applicable] Asarnow R, Brown W, Strandburg R. Children with a schizophrenic disorder: neurobehavioral studies. Eur Arch Psychiatry Clin Neurosci. 1995;245:70 -9. Bo S, Haahr UH. Early -onset psychosis and child and adolescent schizophrenia. Scandinavian J Child Adolescent Psychiatry and Ps ychology 2016;4(1):1 -3. Ferrin M, Gosney H, Marconi A, Rey JM. Using Newly -added references on diagnostics and treatment of schizophrenia in the pediatric patient population."
199,page_199,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 199Original text with changes shown New wording Reason/Justification for change antipsychotic medication for the treatment of schizophrenia in children and adolescents. In Rey JM (ed), IACAPAP e- Textbook of Child and Adolescent Mental Health. Geneva: International As sociation for Child and Adolescent Psychiatry and Allied Professions 2016. Hollis C. Adult outcomes of child -and adolescent -onset schizophrenia: diagnostic stability and predictive validity. Am J Psychiatry 2000;157(10):1652 -9. Lytle S, McVoy M, Sajatovi c M. Long -acting injectable antipsychotics in children and adolescents. J Child Adolesc Psychopharmacol. 2017;27(1): 2 -9. Pogge DL, Singer MB, Harvey PD. Rates and predictors of adherence with atypical antipsychotic medication: a follow -up study of adoles cent inpatients. J Child Adolesc Psychopharmacol. 2005;15(6):901 -12. Rapoport J, Addington A, Frangou S. The neurodevelopmental model of schizophrenia: what can very early onset cases tell us? Curr Psychiatry Rep. 2005;7:81 â€“2. Weinberger D, Harrison PJ (Ed s.) Schizophrenia. 3rd ed. Hoboken, NJ: Wiley -Blackwell; 2011. Yazdi K, Unterlass G, Kemmler G, et al. Factors influencing adherence in children and adolescents treated with antipsychotics or antidepressants. Prim Care Com panion J Clin Psychiatry 2008;10( 2):160 -1. Lindenmayer JP, Czobor P, Alphs L, Nathan AM, Anand R, Islam Z. et al. The InterSePT scale for suicidal thinking reliability and validity. Schizophr Res. 2003;63(1 â€“2):161 â€“ 170. 19.Lindenmayer JP, Czobor P, Alphs L, Nathan AM, Anand R, Islam Z. et al. The InterSePT scale for suicidal thinking reliability and validity. Schizophr Res. 2003;63(1 â€“2):161 â€“ 70. Correction; the reference appears on pg 161 -170 of the journal. APPENDIX A . CLINICAL LABORATORIES AND OTHER DEPARTMENTS AND INSTITUTIONS Legal Representative of the Sponsor in the European Union Senior Director, Head of European Regulatory Affairs Legal Representative of the Sponsor in the European UnionThis reflects a change in responsibilities at Teva; introduced in Local Am 01 for Bulgaria."
200,page_200,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 200Original text with changes shown New wording Reason/Justification for change Graf-Arco -Str. 3 89079 Ulm Germ any Tel.: + Email: Graf-Arco -Str.3 89079 Ulm Germ any Telephone: E-mail: [Not applicable] Medical Monitor: Medical Director ICON PLC Mobile: + Addition of the medical monitor contact details to the protocol. Electronic Data Capture: Medidata Solutions Worldwide 350 Hudson Street New York, NY 10014 ICON Clinical Research Services 123 Smith Street Farmingdale, NY 11735 United StatesElectronic Data Capture: ICON Clinical Research Services 123 Smith Street Farmingdale, NY 11735 United StatesCorrection. The service is sub - contracted to and managed by ICON. APPENDIX B. STUDY PROCEDURES AND ASSESSMENTS BY VISIT Procedures for Screening (Visit 1, Week -16+4 weeks) â€¦ ï‚·functional measures (Personal and Social Performance Scale [PSP]) â€“for adult patients only ï‚·Schizophrenia Quality of Life Scale (SQLS) â€“for adult patients only ï‚·5-Level EuroQol Five Dimensions Questionnaire (EQ - 5D-5L) â€“for adult patients only ï‚·Calgary Depression Scale for Schizophrenia (CDSS) ï‚·healthcare resource utilization â€“forall patientsProcedures for Screening (Visit 1, Week -16+4 weeks) â€¦ ï‚·functional measures (Personal and Social Performance Scale [PSP]) â€“for adult patients only ï‚·Schizophrenia Quality of Life Scale (SQLS) â€“for adult patients only ï‚·5-Level EuroQol Five Dimensions Questionnaire (EQ - 5D-5L) â€“for adult patients only ï‚·Calgary Depression Scale for Schizophrenia (CDSS) ï‚·healthcare resource utilization â€“for all patientsClarification regarding which patient population(s) will be analyzed for the quality of life and healthcare resource utilization endpoints. This change affects the other sub - sections in this appendix in which these scales are mentioned."
201,page_201,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 201Original text with changes shown New wording Reason/Justification for change ï‚·Drug Attitudes Inventory 10 -item version (DAI -10) â€“for adult patients only â€¦ï‚·Drug Attitudes Inventory 10 -item version (DAI -10) â€“ for adult patients only â€¦ Procedures During Double -blind Maintenance Stage Administration of Investigational Medicinal Product (Baseline [Visit 6, Day 1 Â±3 days]) â€¦ ï‚·12-lead electrocardiography (in triplicate) ï‚·serum Î² -HCG tests (for w omen of childbearing potential) ï‚·urine Î² -HCG tests (for women of childbearing potential) ï‚·PANSS ï‚·CGI-S â€¦ ï‚·questions to assess ease of study drug administration â€“to be performed only in the event that prefilled syringes become available during the study ( assessed during 3 in - clinic visits for each patient) â€¦Procedures During Double -blind Maintenance Stage Administration of Investigational Medicinal Product (Baseline [Visit 6, Day 1 Â±3 days]) â€¦ ï‚·12-lead electrocardiography (in triplicate) ï‚·serum Î² -HCG tests (for w omen of childbearing potential) ï‚·urine Î² -HCG tests (for w omen of childbearing potential) ï‚·PANSS ï‚·CGI-S â€¦ ï‚·questions to assess ease of study drug administration â€“ to be performed only in the event that prefilled syringes become available during the study (assessed during 3 in -clinic visits for each patient) â€¦Addition of urine pregnancy test at the baseline visit. Clarification regarding which patient population(s) will be analyzed for the quality of life and healthcare resource utilization endpoints. Clarification; assessment of ease of study drug administr ation will only be performed for the first 3 visits for each patient after introduction of the PFS. oThis change is also relevant for sub -section d (Visit 7) and sub -section e (Visit 8) d. Stage 2: Relapse Prevention (Visit 7, Week 4Â±3 days) ï‚·questions to assess ease of study drug administration â€“to be perform ed only in the event that prefilled syringes becom e available during the study (assessed during 3 in-clinic visits for each patient)d. Stage 2: Relapse Prevention (Visit 7, Week 4Â±3 day s) ï‚·questions to assess ease of study drug administration â€“ to be perform ed only in the event that prefilled syringes become available during the study (assessed during 3 in -clinic visits for each patient)Clarification [Not applicable] f. Stage 2: Relapse Prevention (Visit 9, Week 12Â±3 days) The follow ing procedures and assessments will be performed at visit 9: ï‚·inquiry of concomitant medication ï‚·vital sign measurement ï‚·urine Î² -HCG test (for w omen of childbearing potential)Newly -introduced text outlining Visit 9 procedures due to the time points for quality of life and healthcare utilization scales."
202,page_202,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 202Original text with changes shown New wording Reason/Justification for change ï‚·PANSS ï‚·CGI-I ï‚·CGI-S ï‚·CGI-SS ï‚·AIMS ï‚·BARS ï‚·SAS ï‚·C-SSRS ï‚·PSP -and every 12 weeks thereafter (for adult patients only) ï‚·SQLS -and every 12 weeks thereafter (for adult patients only) ï‚·EQ-5D-5L -and every 12 weeks thereafter (for adult patients only) ï‚·CDSS ï‚·healthcare resource utilization -and every 12 weeks thereafter (for all patients) ï‚·blood samples for plasma drug concentration -will be taken within an hour prior to dosing ï‚·TV-46000 q1m/placebo administration â€“for patients randomized to those treatment groups ï‚·questions to assess ease of study drug administration â€“ to be performed only in the event that prefilled syringes become available during the study (assessed during 3 in -clinic visits for each patient) ï‚·adverse event inquiry (including serious adverse event reporting , injection site -related events including pain ) ï‚·inquiry about alchohol consumption and illicit drug use since previous visit NOTE: Patients will continue study visits and assessments as detailed above (ie, the same assessments performed at visits 7 and 8 w ill be repeated at visits 9 and 10, respectively). NOTE: Patients will continue study visits and assessments as detailed above (ie, the same assessments performed at visits 7 and 8 w ill be repeated at visits 9 and 10, Clarification regarding the repetition of the in -clinic visits (detailed in Table 2)."
203,page_203,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 203Original text with changes shown New wording Reason/Justification for change How ever, note that functional measures (PSP, SQLS, and EQ-5D-5L) and the health care resource utilization will be performed every 12 w eeks as of Visit 9, inclusive. Thus, the 24 week series from Visit 7 to Visit 12c (Visits 13 - 18c, Visits 19 -24c, etc) repeats until patient completion of the study, relapse or early termination. Anothe r pharmacokinetic sample will be collected from adolescent patients only at Week 14 (2 weeks after Visit 9 [Week 12]). It is highly preferable to collect the sample at Week 14. However, if this is not possible, it may be collected 2 weeks after another in -clinic visit. Up to 2 additional samples may also be collected from adolescent patients at Week 15 and Week 13 (3 weeks and 1 week post -injection, respectively) at the sponsor's discretion. The additional samples, if taken following another in -clinic visit, will be collected at the same intervals. If more than one additional sample is taken, they do not need to be collected after the same injection (ie, one sample can be taken 3 weeks after Visit X and another can be taken 1 week after visit Y). respectively). However, note that functional measures (PSP, SQLS, and EQ- 5D-5L) and the healthcare resource utilization will be performed every 12 w eeks. Thus, the 24 week series from Visit 7 to Visit 12c (Visits 13-18c, Visits 19 -24c, etc) repeats until patient completion of the study, relapse or early termination. Another pharmacokinetic sample w illbe collected from adolescent patients only at Week 14 (2 w eeks after Visit 9 [Week 12]). It is highly preferable to collect the sample at Week 14. How ever, if this is not possible, it may be collected 2 w eeks after another in -clinic visit. Up to 2 additi onal samples may also be collected from adolescent patients at Week 15 and Week 13 (3 w eeks and 1 week post -injection, respectively) at the sponsor's discretion. The additional samples, if taken following another in -clinic visit, will be collected at the s ame intervals. If more than one additional sample is taken, they do not need to be collected after the same injection (ie, one sample can be taken 3 weeks after Visit X and another can be taken 1 w eek after visit Y). Newly -added text detailing the additional PK sampling in adolescents. Stage 2: Relapse Prevention (Visit 9, Week 12Â±3 days) (orEarly Term ination (ET) Visit/End -of-Treatm ent Visit (EoT) ) The follow ing pro cedures and assessments will be performed at visit 9 orat the ET/EoT visit: ï‚·urine drug screen â€“will be perform ed if this is the patientâ€™s ET/EoT visit ï‚·inquiry of concomitant medication ï‚·full physical examination, including weight â€“will be perform ed if this is the patientâ€™s ET/EoT visit ï‚·vital sign measurement ï‚·urine Î² -HCG test (for w omen of childbearing potential) ï‚·PANSS ï‚·CGI-SStage 2: Early Termination (ET) Visit/End -of- Treatm ent Visit (EoT) The follow ing procedures and assessments will be performed at the ET/EoT visit: ï‚·urine drug screen ï‚·inquiry of concomitant medication ï‚·full physical examination, including we ight ï‚·vital sign measurement ï‚·urine Î² -HCG test (for w omen of childbearing potential) ï‚·PANSS ï‚·CGI-S ï‚·CGI-I ï‚·CGI-SSThe ET/EoT visit is now depicted as a separate visit, and therefore the clarifying comments are redundant. Clarification regarding the number of events at the end of the study. Clarification regarding performance of an ECG at this visit."
204,page_204,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 204Original text with changes shown New wording Reason/Justification for change ï‚·CGI-I ï‚·CGI-SS ï‚·AIMS ï‚·BARS ï‚·SAS ï‚·C-SSRS ï‚·PSP -will be perform ed if this is the patientâ€™s ET/EoT visit for adult patients only ï‚·SQLS -will be performed if this is the patientâ€™s ET/ EoT visit -for adult patients only ï‚·EQ-5D-5L -will be perform ed if this is the patientâ€™s ET/EoT visit -for adult patients only ï‚·CDSS ï‚·healthcare resource utilization â€“and every 12 weeks thereafter (will also be perform ed if this is the patientâ€™s ET/EoT visit) -for all patients ï‚·DAI-10 â€“will be perform ed if this is the patientâ€™s ET/EoT visit for adult patients only ï‚·blood sample for biomarker analysis â€“will be perform ed if this is the patientâ€™s ET/ EoT visit ï‚·blood samples for plasma drug concentration -will be taken within an hour prior to dosing ï‚·TV-46000 q1m/placebo administration â€“for patients randomized to those treatment groups study drug administration (for patients randomized to all treatment groups) . ï‚·questions to assess ease of study drug administration â€“to be performed only in the event that prefilled syringes become available ( in total if this is one of the 3 visits in which it is assessed ) ï‚·adverse event inquiry (including serious adverse event reporting , injection site -related events including pain ) ï‚·inquiry about alchohol consumption and illicit drug use ï‚·AIMS ï‚·BARS ï‚·SAS ï‚·C-SSRS ï‚·PSP -for adult patients only ï‚·SQLS -for adult patients only ï‚·EQ-5D-5L -for adult patients only ï‚·CDSS ï‚·healthcare resource utilization â€“ for all patients ï‚·DAI-10 -for adult patients only ï‚·blood sample for biomarker analysis ï‚·blood samples for plasma drug concentration -will be taken within an hour prior to dosing ï‚·study drug administration (for patients randomized to all treatment groups). ï‚·questions to assess ease of study drug administration â€“ to be perform ed only in the event that prefilled syringes become available (if this is one of the 3 visits in which it is assessed ) ï‚·adverse event inquiry (including serious adverse event reporting , injection site -related events including pain ) ï‚·inquiry about alchohol consumption and illicit drug use since previous visit Note: The double -blind maintenance stage will be variable in duration, with patients continuing until they experienc e a relapse event and complete all end -of-study assessments; meet 1 or more of the study discontinuation or w ithdrawal criteria; or remain relapse- free during the double -blind phase until the study is terminated for efficacy at the interim analysis or beca use 207 relapse events are recorded in the study in the ITT analysis set. Note: If per the investigator's judgement, the patient is at"
205,page_205,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 205Original text with changes shown New wording Reason/Justification for change since previous visit Note: The double -blind maintenance stage will be variable in duration, with patients continuing until they experience a relapse event and complete all end -of-study assessments; meet 1 or more of the study discontinuation or w ithdrawal criteria; or remain relapse- free during the double -blind phase until the study is terminated for efficacy at the interim analysis or because 20 7 relapse events are recorded in the study in the ITT analysis set. Note: If per the investigator's judgement, the patient is at risk of not appearing to 1 or both of the follow -up visits, the investigator may also complete the unscheduled visit form andperform an ECG.risk of not appearing to 1 or both of the follow -up visits, the investigator may also complete the unscheduled visit form and perform an ECG. Unscheduled Visits During Stage 2, Uunscheduled pharmacokinetic samples will be aimed to be collected in the event of relapse as defined per the studyâ€™s relapse criteria, any serious adverse event, patient withdrawal, and/or the need for potential TV -46000 depot excision. Every effort should be made to obtain the additional pharmacokinetic sample at the closest time possible to the occurrence of the event.Unscheduled Visits During Stage 2, unscheduled pharmacokinetic samples will be aimed to be col lected in the event of relapse as defined per the studyâ€™s relapse criteria, any serious adverse event, patient withdraw al, and/or the need for potential TV -46000 depot excision. Every effort should be made to obtain the additional pharmacokinetic sample at the closest time possible to the occurrence of the event.Clarification; relevant only to Stage 2 of study. APPENDIX D. ETHICS Informed Consent and Assent The investigator, or a qualified person designated by the investigator, should fully inform the patient (and the parent/legally acceptable representative, as applicable) of all pertinent aspects of the study, including the written information approved by t he Independent Ethics Committee/Institutional Review Board (IEC/IRB). All written and oral information about the study will be provided in a language as nontechnical as practical to be understood by the patient and the parent/legally acceptable representat ive, as applicable . The patient and the parent/legally acceptable representative, as applicable, should be given ample time Informed Consent and Assent The investigator, or a qualified person designated by the investigator, should fully inform the patient (and the parent/legally acceptable representative, as applicable) of all pertinent aspects of the study, including the written information approved by the Independent Ethics Committee/Institutional Review Board ( IEC/IRB). All written and oral information about the study will be provided in a language as nontechnical as practical to be understood by the patient and the parent/legally acceptable representative, as applicable. The patient and the parent/legally accep table representative, as applicable, Verbiage regarding assent was added following the introduction of the possibility to enroll adolescent patients in the study."
206,page_206,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 206Original text with changes shown New wording Reason/Justification for change and opportunity to inquire about details of the study and to decide whether or not to participate in the study. The above should be detailed in the source documents. â€¦ For adolescent patients, a personally signed and dated informed consent form will be provided by the parent/legally acceptable representative, and a signed and dated assent form will be provided by each patient before a ny study specific procedures or assessments are done and after the aims, methods, anticipated benefits, and potential hazards are explained according to IEC/IRB requirements. The forms will be signed and dated also by the person who conducted the informed consent discussion. The investigator will keep the original informed consent and assent forms, and copies will be given to the patients (and the parent/legally acceptable representative). It will also be explained to the patients (and the parent/legally ac ceptable representative) that they are free to refuse participation in the study and free to withdraw from the study at any time without prejudice to future treatment.should be given ample time and opportunity to inquire about details of the study and to decide whether or not to participate in the study. The above should be detailed in the source documents. â€¦ For adolescent patients, a personally signed and dated informed consent form will be provided by the parent/legally acceptable representative, and a signed and dated assent form will be provided by each patient before any study specific procedures or assessments are done and after the aims, methods, anticipated benefits, and potential hazards are explained according to IEC/IRB requirements. The forms will be signed and dated also by the person who conducted the informed consent discussion. The investigator will keep the original informed consent and assent forms, and copies will be given to the patients (and the parent/legally acceptable representative). It w ill also be explained to the patients (and the parent/legally acceptable representative) that they are free to refuse partic ipation in the study and free to withdraw from the study at any time without prejudice to future treatment. APPENDIX G. LIST OF P ROHIBITED MEDICATIONS â€¦ Moreover, the use of the following medications is prohibited throughout the study: ï‚·risperidone (except when given according to the study protocol) ï‚·antipsychotics other than the study treatments oExcept during the conversion and stabilization stage (Stage 1), and only if required for conversion from the previous antipsychotics to oral risperidone ï‚·dopamine reuptake inhibitors or prescription psychostimulants within 30 days prior to first oral risperidone doseâ€¦ Moreover, the use of the following medications is prohibited throughout the study: ï‚·risperidone (except when given according to the study protocol) ï‚·antipsychotics other than the study treatments oExcept during the conversion and stabilization stage (Stage 1), and only if required for conversion from the previous antipsychotics to oral risperidone ï‚·dopamine reuptake inhibitors or prescription psychostimulants within 30 days prio r to first oral Clarification regarding use of antipsychotics during Stage 1 of the study; for consistency with Section 5.7."
207,page_207,Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 207Original text with changes shown New wording Reason/Justification for change ï‚·opiates or opiate- containing analgesics within 14 days prior to first oral risperidone dose medicationsrisperidone dose ï‚·opiates or opiate- containing analgesics within 14 days prior to first oral risperidone dose medications .
208,page_208,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 208Original text with changes shown New wording Reason/Justification for change Pharmacogen etics6 1d6 Virology 9 1 9 Total 37.553.5 4045 217297 (309 for adolescents) aSerum pregnancy test to be performed for w omen of childbearing potential only. bUp to 3 additional samples will be collected from adolescent patients. bcBiomarker blood samples will be collected as follows: 6 mL each for plasma and serum, and 6.52.5mL for RNA (PAXgene). dA blood sample for pharmacogenetic analysis will be collected at baseline or any visit thereafter, unless the patient declines testing or local regulations prohibit testing.Pharmacogene tics6 1d6 Virology 9 1 9 Total 53.5 45 297 (309 for adolescen ts) aSerum pregnancy test to be performed for w omen of childbearing potential only. bUp to 3 additional samples will be collected from adolescent patients. cBiomarker blood samples will be collected as follow s: 6 mL each for plasma and serum, and 2.5 mL for RNA (PAXgene). dA blood sample for pharmacogenetic analysis will be collected at baseline o r any visit thereafter, unless the patient declines testing or local regulations prohibit testing."
209,page_209,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 209Original text with changes shown New wording Reason/Justification for change APPENDIX J. PHARMACOGENETIC ASSESSMENTS A blood sample (6 mL) for pharm acogenetic assessment will be collected from all patients who signed the informed consent for pharmacogenetic assessments at the time point detailed in Table 1 Table 2 . Genetic variability in the metabolizer gene, cytochrome P4 50 2D6 (CYP2D6) , will be evaluated for an association with drug concentrations of TV- 46000 and oral risperidone. A blood sample (6 mL) for pharmacogenetic assessment will be collected from all patients who signed the informed consent for pharmacogenetic assessments at the time p oint detailed in Table 2. Genetic variability in the metabolizer gene, cytochrome P4 50 2D6 (CYP2D6) , will be evaluated for an association with drug concentrations of TV- 46000 and oral risperidone. Table of Assessments has been divided into 2 to reflect St age 1 and Stage 2; therefore, the cross -link was corrected to appropriate table."
210,page_210,Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 21016.7. Letter of Clarification 01 (26 June 2018)
211,page_211,Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 211
212,page_212,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 21216.8. Local Amendment 01 for Bulgaria (Dated 28 May 2018) The primary reason for this local amendment is to allow inclusion of Bulgarian investigational centers and patients in this study . The amended protocol was submitted as part of the Clinical Trial Authoriz ation (CTA) Application in Bulgaria. To adhere with local regulations, the European Union Drug Regulating Authorities Clinical Trials (EudraCT) number has been added to the protocol. A few additional revisions have been made to clarify various aspects of the planned study conduct in this country . The revisions listed below have been made to the protocol and protocol s ynopsis, as appropriate, and are considered non -substantial and administrative by the Teva Authorized Representative. A comparison table sho wing the changes from the Protocol with Revision 01 to the L ocal Amendment 01 for Bulgaria is provided below. Previous text with changes indicated is presented in the column titled â€œOriginal text with changes shown,â€ and the final text is presented in the column titled ""New wording"". Revised or new text is shown in bold italics and deletions are shown with strike -throughs."
213,page_213,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 213Changes to the P rotocol Original text with changes shown New wording Reason/Justification for change TITLE PAGE (Other sections affected by this change: Investigator Agreem ent; Coordinating Investigator Agreement) Clinical Study Protocol with Revision Local Am 01for BulgariaClinical Study Protocol with Local Am 01for BulgariaTo denote the country -specific local amendment. EudraCT number: Not applicable 2018 -001619 -65EudraCT number: 2018 -001619 -65 Number added for study conduct in EU. AMENDMENT HISTORY [Not applicable] AMENDMENT HISTORY The protocol for Study TV46000 -CNS -30072 (original protocol dated 14 December 2017) has been amended and reissued as follows: Local Amendment 01 for Bulgaria28May 2018 (6patients enrolled to date) Protocol with Revision 0115 February 2018 (0patients enrolled to date) The Summary of Changes to the Protocol includes the corresponding reason/justification for each change and is provided in Section 16.This page w as added in the amendment for tracking history. LIST OF ABBREVIATIONS [Not applicable]SmPC = Summary of Product CharacteristicsNewly -added abbreviation. 3.STUDY DESIGN 3.2. Planned Number of Patients and Countries Approximately 795 patients will be screened to achieve enrollment of approximately 596 patients in Stage 1 , including approximately 57 patients in Bulgaria . The number of randomized patients in Stage 2 is planned to be approximately 417, including approximately 40 patients in Approximately 795 patients will be screened to achieve enrollment of approximately 596 patients in Stage 1, including approximately 57 patients in Bulgaria. The number of randomized patients in Stage 2 is planned to be approximately 417, including Information added regarding study projection in Bulgaria."
214,page_214,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 214Original text with changes shown New wording Reason/Justification for change Bulgaria. Details on the definition of evaluable patients and determination of the sample size are given in Section 9.1. The study is planned to be conducted in approximately 80 investigational centers in North America and possibly other regions (eg, Bulgaria) as well.approximately 40 patients in Bulgaria. Details on the definition of evaluable patients and determination of the sample size are given in Section 9.1. The study is planned to be conducted in approximately 80investigational centers in North America and possib ly other regions (eg, Bulgaria) as well. 5.TREATMENTS 5.2.1. Storage and Security The investigator or designee must confirm appropriate temperature conditions have been maintained for all IMPs medicinal products received, and any discrepancies must be reported and resolved before their use of the IMPs . â€¦ Oral risperidone is to be stored and securely locked according tothe storage conditions specified in the package insert (RISPERIDONE tablets, Teva Pharmaceuticals, US PI ).The investigator or designee must confirm appropriate temperature conditions have been maintained for all medicinal products received, and any discrepancies must be reported and resolved before their use. â€¦ Since it is not considered an IMP, the sentence on oral risperidone storage was moved to Section 5.4. 5.2.3. Accountability Used and partially used IMP (test or placebo) w ill be destroyed by the study center. Unused and partially used IMP (test or placebo) w ill be Unused IMP (test or placebo) will be returned to the sponsor or its designee according to local and national regulations and the siteâ€™s standard operating procedures (SOPs), follow ing w ritten authorization from the sponsor.Unused and partially used IMP (test or placebo) w ill be returned to the sponsor or its designee according to local and national regulations a nd the siteâ€™s standard operating procedures (SOPs), following written authorization from the sponsor.Clarification that the IMP w ill be returned to the sponsor. Correction of text duplication. 5.4. Other Medicinal Products/Non -Investigational Medicinal Products Oral risperidone tablets for stabilization (Table 4) w ill be a commercial product supplied centrally by the study center the sponsor . The brand name of the oral risperidone supplied will be recorded on the source documentation. Oral risperidone is to be stored and securely locked according to the storage conditions specified in the package insert ( RISPERIDONE tablets, Teva Pharmaceuticals, US PI ) manufacturerâ€™s Summary of Product Characteristics (SmPC) . Oral risperidone for stabilization (Table 4) w ill be a commercial product supplied centrally by the sponsor. The brand name of the oral risperidone supplied w ill be recorded on the source documentation. Oral risperidone is to be stored according to the man ufacturerâ€™s Summary of Product Characteristics (SmPC). Correction for consistency with Table 4; all forms of oral risperidone are allow ed. In Bulgaria, oral risperidone will be sourced by the sponsor. Since it is not considered an IMP, the sentence on oral risperidone storage was moved from Section 5.2.1 to this section and revised to encompass storage conditions for all"
215,page_215,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 215Original text with changes shown New wording Reason/Justification for change forms of oral risperidone. 9. STATISTICS 9.5.1. Prim ary Endpoint â€¦ - an increase in any of the following 4 individual PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content, to a score of â‰¥ >4and an absolute increase of > â‰¥4on the combined score of these 4PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content) since randomization.. -an increase in any of the following 4 individual PANSS items: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thoug ht content, to a score of >4 and an absolute increase of â‰¥4 on the combined score of these 4 PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content) since randomizationCorrection of typos for consisten cy with other protocol sections. APPENDIX A . CLINICAL LABORATORIES AND OTHER DEPARTMENTS AND INSTITUTIONS Legal Representative of the Sponsor in the European Union Merckle GmbH Graf-Arco -Str. 3 89079 Ulm Germ any Tel. Email: Legal Representative of the Sponsor in the European Union Merckle GmbH Graf-Arco -Str.3 89079 Ulm Germ any Telephone: E-mail: This reflects a change in responsibilities at Teva."
216,page_216,Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 21616.9. Protocol with Revision 01(Dated 15 February 2018) The Clinical Study Protocol with Revision 01 includes updates to the original protocol dated 14 December 2017.
217,page_217,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 217APPENDIX A.CLINICAL LABORATORIE S AND OTHER DEPARTMENTS AND INST ITUTIONS Sponsorâ€™s Authorized Representative Vice President, Therapeutic Area Head, Neurology and Psychiatry Specialty Clinical Development Teva Branded Pharmaceutical Products R&D, Inc. Tel Cell: Legal Representative of the Sponsor in the European UnionMerckle GmbH Graf-Arco -Str.3 89079 Ulm Germ any Telephone E-mail: Sponsorâ€™s Medical Expert/Contact Point designated by the Sponsor for Further Inform ation on the StudyTeva Branded Pharmaceutical Products R&D, Inc. Tel: Cell: Email: Study Principal Investigator Professor of Psychiatry, Neurology and Neuroscience; Chairman, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Tel: Email: Medical MonitorsFor US: Medical Director ICON PLC Mobile: For Bulgaria: ) Medical Director ICON PLC Mobile: Sponsorâ€™s Representative of Global Patient Safety and Pharm acovigilance For serious adverse events: Send by email to the local safety officer/contract research organization. The email address will be provided in the serious adverse event report form. In the event of difficulty transmitting the form, contact the sponsorâ€™s study personnel identified above for further instruction.Director, Safety Physician Global Patient Safety and Pharmacovigilance Teva Pharmaceutical Industries,"
218,page_218,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 218Contra ct Research OrganizationICON Clinical Research Services 123 Smith Street Farm ingdale, NY 11735 United States Central Clinical LaboratoryICON Clinical Research Services 123 Smith Street Farm ingdale, NY 11735 United States Rater Training for Clinical Scales and Utilization MeasuresSignant Health (formerly Bracket) 575 E. Sw edesford Road, Ste 200 Wayne, PA 19087 United States Electronic Data CaptureICON Clinical Research Services 123 Smith Street Farm ingdale, NY 11735 United States Central Electrocardiogram EvaluationeResearch Technology, Inc 1818 Market Street #1000 Philadelphia, PA, 19103 United States Interactive Response TechnologyICON Clinical Research Services 123 Smith Street Farm ingdale, NY 11735 United States Bioassay and Pharm acokinetic Sample AnalysisTeva Pharmaceutical Works P. Ltd. Co. (TPW) Bioanalytical Laboratory Pallagi St. 13 Debrecen 4042 Hungary"
219,page_219,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 219APPENDIX B.STUDY PROCEDURES AND ASSES SMENTS BY VISIT 1. Procedures for Screening (Visit 1, Week -16+4 weeks) The screening visit (visit 1) will take place not more than 4 weeks before Stage 1 (visits 2, 3, 4, and 5) . The following procedures will be performed at visit 1: ï‚·obtain written informed consent before an y stud y-related procedures are performed ï‚·review medical and ps ychiatric history ï‚·Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 5th Edition ï‚·review prior medication history ï‚·review inclusion and exclusion criteria ï‚·clinical laboratory tests (serum chemistry , hematology , and urinaly sis) ï‚·virology and th yroid screening tests ï‚·urine drug screen ï‚·inquiry about concomitant medication ï‚·full phy sical examination (including height and weight) ï‚·vital sign measurements ï‚·12-lead electrocardiography (in triplicate) ï‚·serum beta human chorionic gonadotropin (Î²- HCG) pregnancy test (for women of childbearing potential) ï‚·Positive and Negative Syndrome Scale (PANSS) ï‚·Clinical Global I mpression of Severit y (CGI -S) ï‚·Clinical Global I mpression -Severit y of Suicidality (CGI -SS) ï‚·Abnormal Involuntary Movement Scale (AIMS) ï‚·Barnes Akathisia Rating Scale (BARS) ï‚·Simpson -Angus Scale (SAS) ï‚·Columbia Suicide Severity Rating Scale (C -SSRS) ï‚·functional measures (Personal and Social Performance Scale [PSP]) â€“ for adult patients only ï‚·Schizophrenia Quality of L ife Scale (SQLS) â€“for adu lt patients only ï‚·5-Level EuroQol Five Dimensions Questionnaire (EQ-5D- 5L) â€“ for adult patients only ï‚·Calgary Depression Scale for Schizophrenia (CDSS)"
220,page_220,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 220ï‚·healthcare resource utilization â€“ for all patients ï‚·Drug Attitudes Inventory 10- item version (DAI -10) â€“for adult patients only ï‚·inquiry about adverse events (including serious adverse event reporting ) ï‚·inquiry about alchohol consumption and illicit drug use 2.Procedures Before Administration of Investigational Medicinal Product (Stage 1:Oral Conversion and Stabilization Stage) a.Stage 1: Oral Conversion and Stabilization (Visit 2, Week -12Â±3 days; Visit 3, Week -10Â±3 days; Visit 4, Week - 8Â±3days; and Visit 5, Week - 4Â±3days) The following procedures will be performed at visits 2, 3, 4, and 5 (unless otherwise specified): ï‚·clinical laboratory tests (serum chemistry , hematology , and urinaly sis) â€“ at visit 4 only ï‚·inquiry of concomitant medication ï‚·full phy sical examination, including weight -at visit 2 only ï‚·vital sign measurement ï‚·urine Î² -HCG test (for women of chi ldbearing potential) ï‚·PANSS ï‚·Clinical Global I mpression â€“Improvement (CGI -I) ï‚·Clinical Global I mpression of Severit y (CGI -S) ï‚·CGI-SS ï‚·AIMS ï‚·BARS ï‚·SAS ï‚·C-SSRS ï‚·CDSS ï‚·blood samples for plasma drug concentration -will be taken within an hour prior to dosing ï‚·oral risperidone dispensing (for qd intake) ï‚·inquiry about adverse events (including serious adverse event reporting) ï‚·dosage review and adjustment ï‚·inquiry about alchohol consumption and illicit drug use since previous visit b.Stage 1: Oral Conversion and Stabilization (Telephone Contacts [Visit 4a, Week -6Â±3 days and Visit 5a, Week -2Â±3days])"
221,page_221,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 221The following procedures and assessments will be performed at visits 4a and 5a (telephone contacts): ï‚·inquiry about pregnancy status (for women of childbearing potential) ï‚·C-SSRS ï‚·adverse event inquiry (including serious adverse event reporting) ï‚·inquiry about alchohol consumption and illicit drug use since previous visit ï‚·brief set of clinical questions to detect psy chotic sy mptoms â€“ the specific questions asked will be at the di scretion of the investigator. A list of suggested questions will be provided to the investigator. Procedures During Double -blind Maintenance Stage Administration of Investigational Medicinal Product (Baseline [Visit 6, Day 1 Â±3 days]) The following procedu res will be performed at visit 6: ï‚·review inclusion and exclusion criteria (including randomization- specific criteria) ï‚·clinical laboratory tests (serum chemistry , hematology , and urinaly sis) ï‚·urine drug screen ï‚·inquiry of concomitant medication ï‚·full phy sical examination (including weight) ï‚·vital sign measurement ï‚·12-lead electrocardiography (in triplicate) ï‚·serum Î² -HCG tests (for women of childbearing potential) ï‚·urine Î² -HCG tests (for women of childbearing potential) ï‚·PANSS ï‚·CGI-S ï‚·CGI-SS ï‚·AIMS ï‚·BARS ï‚·SAS ï‚·C-SSRS ï‚·PSP â€“for adult patients only ï‚·SQL Sâ€“for adult patients only ï‚·EQ-5D -5L â€“for adult patients only ï‚·CDSS ï‚·healthcare resource utilization"
222,page_222,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 222ï‚·DAI-10 â€“ for adult patients only ï‚·blood sample for pharmacogenetic anal ysis, unless the patient declines testing or local regulations prohibit testing. ï‚·blood sample for biomarker anal ysis, unless the patient declines testing or local regulations prohibit testing. ï‚·assessment of stability (based on the defined criteria) ï‚·randomization ï‚·blood samples for plasma drug concentration -will be taken within an hour prior to dosing ï‚·TV-46000 every month (q1m)/placebo administration â€“for patients randomized to those treatment groups ï‚·TV-46000 every 2 months (q2m) administration â€“ for patients randomized to that treatment group ï‚·questions to assess ease of study drug administration â€“ to be performed only in the event that prefilled syringes become available during the study (assessed during 3 in-clinic visits for each patient). ï‚·inquiry about adverse events (including serious adverse event r eporting , injection site-related events including pain ) ï‚·inquiry about alchohol consumption and illicit drug use since previous visit Procedures During Double -blind Maintenance Stage Administration of Investigational Medicinal Product (Stage 2: Relapse Prev ention) c.Stage 2: Relapse Prevention (Visit 6a, Week 1Â±3days; Visit 6b, Week 2Â±3 days; and Visit 6c, Week 3Â±3 days [Telephone Contacts]) (Visit 7a, Week 5Â±3days; Visit 7b, Week 6Â±3 days; and Visit 7c, Week 7Â±3 days [Telephone Contacts], 8a - 8c, 9a- 9c, etc.) Note: Telephone contacts will occur weekly between in- clinic visits during the double -blind maintenance stage (Stage 2) (see Table 2). These contacts will be referred to by the previous visit number and a letter (for example, the telephone contacts that take place 1, 2, and 3 weeks after visit 6 will be referred to as â€œvis it 6a,â€ â€œvisit 6b,â€ and â€œvisit 6c,â€ respectivel y). The following procedures and assessments will be performed at visits 6a, 6b, and 6c (telephone contacts) and the other telephone contacts between the in -clinic visits: ï‚·inquiry about pregnancy status (for women of childbearing potential) ï‚·C-SSRS ï‚·adverse event inquiry (including serious adverse event reporting , injection site -related events including pain ) ï‚·inquiry about alchohol consumption and illicit drug use since previous visit"
223,page_223,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 223ï‚·brief set of clinical questions to detect psy chotic sy mptoms â€“ the specific questions asked will be at the discretion of the investigator. A list of suggested questions will be provided to the investigator. Psychiatric adverse events or suspicion of psy chiatric deterioration as a result of the telephone contact will trigger an invitation to the patient to an unscheduled visit where psychiatric scales will be administered to rule out an impending relapse at the discretion of the investigator. d.Stage 2: Relapse Prevention (Visit 7,Week 4Â±3days) The following procedures and assessments will be performed at visit 7: ï‚·inquiry of concomitant medication ï‚·vital sign measurement ï‚·urine Î² -HCG test (for women of childbearing potential) ï‚·PANSS ï‚·CGI-I ï‚·CGI-S ï‚·CGI-SS ï‚·AIMS ï‚·BARS ï‚·SAS ï‚·C-SSRS ï‚·CDSS ï‚·blood samples for plasma drug concentration -will be taken within an hour prior to dosing ï‚·"
224,page_224,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 224ï‚·vital sign measurement ï‚·12-lead electrocardiography ï‚·urine Î² -HCG test (for women of childbearing potential) ï‚·PANSS ï‚·CGI-I ï‚·CGI-S ï‚·CGI-SS ï‚·AIMS ï‚·BARS ï‚·SAS ï‚·C-SSRS ï‚·PSP â€“for adult patients only ï‚·SQL S â€“for adult patients only ï‚·EQ-5D -5L â€“for adult patients only ï‚·CDSS ï‚·blood samples for plasma drug concentration -will be taken within an hour prior to dosing ï‚·TV-46000 q1m/placebo administration â€“ for patients randomized to those treatment groups ï‚·TV-46000 q2m administration â€“ for p atients randomized to that treatment group ï‚·questions to assess ease of study drug administration â€“ to be performed only in the event that prefilled syringes become available during the study (assessed during 3 in-clinic visits for each patient) ï‚·adverse eve nt inquiry (including serious adverse event reporting , injection site -related events including pain ) ï‚·inquiry about alchohol consumption and illicit drug use since previous visit f.Stage 2: Relapse Prevention (Visit 9, Week 12Â±3 days) The following procedures and assessments will be performed at visit 9: ï‚·inquiry of concomitant medication ï‚·vital sign measurement ï‚·urine Î² -HCG test (for women of childbearing potential) ï‚·PANSS ï‚·CGI-I"
225,page_225,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 225ï‚·CGI-S ï‚·CGI-SS ï‚·AIMS ï‚·BARS ï‚·SAS ï‚·C-SSRS ï‚·PSP -and every 12 weeks thereafter (for adult patients only) ï‚·SQL S -and every 12 weeks thereafter (for adult patients only) ï‚·EQ-5D- 5L -and every 12 weeks thereafter (for adult patients only) ï‚·CDSS ï‚·healthcare resource utilization - and every 12 weeks thereafter ï‚·blood samples for plasma drug concentrati on -will be taken within an hour prior to dosing ï‚·TV-46000 q1m/placebo administration â€“ for patients randomized to those treatment groups ï‚·questions to assess ease of study drug administration â€“ to be performed only in the event that prefilled syringes bec ome available during the study (assessed during 3 in-clinic visits for each patient) ï‚·adverse event inquiry (including serious adverse event reporting , injection site -related events including pain ) ï‚·inquiry about alchohol consumption and illicit drug use sin ce previous visit NOTE: Patients will continue study visits and assessments as detailed above (ie, the same assessments performed at visits 7 and 8 will be repeated at visits 9 and 10, respectivel y). However, note that functional measures (PSP, SQLS, and E Q- 5D-5L) and the healthcare resource utilization will be performed every 12 weeks after visit 9. Thus, the 24 week series from Visit 7 to Visit 12c (Visits 13 -18c, Visits 19 -24c, etc) repeats until patient completion of the study , relapse or earl y termina tion. Another pharmacokinetic sample will be collected from adolescent patients only at Week 14 (2 weeks after Visit 9 [Week 12]). It is highl y preferable to collect the sample at Week 14. However, if this is not possible, it may be collected 2 weeks after another in -clinic visit. Up to 2 additional samples may also be collected from adolescent patients at Week 15 and Week 13 (3 weeks and 1 week post -injection, respectively ) at the sponsor's discretion. The additional samples, if taken following another in -clinic visit, will be collected at the same intervals. If more than 1 additional sample is taken, they do not need to be collected after the same injection (ie, 1 sample can be taken 3 weeks after Visit X and another can be taken 1 week after Visit Y) . g. Stage 2: Early Termination (ET) Visit/End-of-Treatment Visit (EoT)"
226,page_226,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 226The following procedures and assessments will be performed at the ET/EoT visit: ï‚·urine drug screen ï‚·inquiry of concomitant medication ï‚·full phy sical examination, including weight ï‚·vital sign measurement ï‚·urine Î² -HCG test (for women of childbearing potential) ï‚·PANSS ï‚·CGI-S ï‚·CGI-I ï‚·CGI-SS ï‚·AIMS ï‚·BARS ï‚·SAS ï‚·C-SSRS ï‚·PSP â€“for adult patients only ï‚·SQL S â€“for adult patients only ï‚·EQ-5D- 5L â€“for adult patients only ï‚·CDSS ï‚·healthcare resource utilization â€“ ï‚·DAI-10 â€“ for adult patients only ï‚·blood sample for biomarker anal ysis, unless the patient declines testing or local regulations prohibit testing. ï‚·blood samples for plasma drug concentration -will be taken within an hour prior to dosing ï‚·study drug admini stration (for patients randomized to all treatment groups) -This is applicable onl y for the EoT visit, not the ET visit. ï‚·questions to assess ease of study drug administration â€“ to be performed only in the event that prefilled syringes become available ( i f this is 1 of the 3 visits in which it is assessed) ï‚·adverse event inquiry (including serious adverse event reporting , injection site -related events including pain ) ï‚·inquiry about alchohol consumption and illicit drug use since previous visit"
227,page_227,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 227Note: The doub le-blind maintenance stage will be variable in duration, with patients continuing until they experience a relapse event and complete all end -of-study assessments; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse -free a t the time of study termination. Note: If per the investigator's judgement, the patient is at risk of not appearing to 1 or both of the follow -up visits, the investigator may also complete the unscheduled visit form and perform an ECG. Follow -up/Exit Peri od (Follow -up Visit 1 [4 weeks after last dosing visit] and Follow -up Visit 2 [8 weeks after the last dosing visit, End -of-Study (EoS) Visit]) The following procedures and assessments will be performed at follow -up visit 1 and follow -up visit 2: ï‚·clinical laboratory tests (serum chemistry , hematology , and urinaly sis) ï‚·inquiry of concomitant medication ï‚·full phy sical examination (including weight) ï‚·vital sign measurement ï‚·12-lead electrocardiography ï‚·serum Î² -HCG tests (for women of childbearing potential) ï‚·PANSS ï‚·CGI-I ï‚·CGI-S ï‚·CGI-SS ï‚·AIMS ï‚·BARS ï‚·SAS ï‚·C-SSRS ï‚·PSP -at Follow -up Visit 2 only ï‚·SQL S -at Follow- up Visit 2 only ï‚·EQ- 5D-5L -at Follow- up Visit 2 only ï‚·CDSS ï‚·healthcare resource utilization - at Follow- up Visit 2 only ï‚·DAI-10 - at Follow -up Visit 2 only ï‚·blood sample for biomarker anal ysis, unless the patient declines testing or local regulations prohibit testing. ï‚·blood samples for plasma drug concentration"
228,page_228,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 228ï‚·adverse event inquiry (including serious adverse event reporting , injection site -related events including pain ) ï‚·inquiry about alchohol consumption and illicit drug use since previous visit Note: Eligible patients who choose to enter the long term TV46000 -CNS -30078 extension study will not need to complete the follow -up/exit visits in this study . Unscheduled V isits An unscheduled visit may be performed at any time during the study as deemed necessary by the investigator (eg, in case of psy chiatric adverse events or suspicion of a ps ychiatric deterioration). The date and reason for the unscheduled visit will be recorded on the CRF as well as an y other data obtained from procedures and assessments. Procedures performed during unscheduled visits will include the following: ï‚·concomitant medication review; ï‚·inquiry about changes in use of alcohol and illicit drugs ï‚·vital sign measurements ï‚·adverse event inquiry (including serious adverse event reporting , injection site -related events including pain ) ï‚·C-SSRS (""Since L ast Visit"" version) (if visit scheduled to assess psy chiatric adverse events) ï‚·PANSS and review of relaps e criteria Other procedures may be performed at the discretion of the investigator. In addition, to reduce patient burden and to avoid unnecessary data collection, the investigator will have discretion in determining whether the aforementioned procedures (which are currentl y marked in Table 1and Table 2as mandatory ) actually need to be performed during the unscheduled visit in the case that: (i) the unscheduled visit is one of multiple in-clinic visits, that are de emed necessary in close proximity (2 or more visits within 1 week), and (ii) when the visit is for administrative purposes (eg, reconsenting) or clinical reasons (eg, repeat laboratory sample collection for reasons unrelated to an adverse event or impending/current relapse), and notdue to a potential relapse or a change in the patient's medical status per clinical judgement . Notwithstanding, it is hereby emphasized that the above refers only to unscheduled visits, and not to any other scheduled in- clinic visits or telephone contacts. During Stage 2, unscheduled pharmacokinetic samples will be aimed to be collected in the event of relapse as defined per the study â€™s relapse criteria, any serious adverse event, patient withdrawal, and/or the need for potential TV- 46000 depot excision. Every effort should be made to obtain the additio nal pharmacokinetic sample at the closest time possible to the occurrence of the event."
229,page_229,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 229APPENDIX C.QUALITY CONTROL AND QUALITY ASSURANCE Protocol Amendments and Protocol Deviations Protocol Amendments No changes from the final approved (signed) protocol will be initi ated without the prior written approval or favorable opinion of a written amendment by the Independent Ethics Committee/I nstitutional Review Board (IEC/I RB) and national and local competent authorities (CAs), as applicable , except when necessary to address immediate safety concerns to the patients or when the change involves only nonsubstantial logistics or administration. The principal investigator at each investigational center, the coordinating investigator (if applicable), and the sponsor will sign the protocol amendment. Protocol Deviations A protocol deviation is defined as an y change, divergence, or departure from the study design or procedures defined in the protocol. I mportant protocol deviations are a subset of protocol deviations that might signif icantly affect the completeness, accuracy , and/or reliability of the study data or that might significantl y affect a subject's rights, safet y, or well -being. For example, important protocol deviations might include enrolling subjects in violation of key eligibility criteria designed to ensure a specific subject population or failing to collect data necessary to interpret primary endpoints, as these may compromise the scientific value of the trial. All protocol deviations will be reported to the responsible IEC/IRB, as required. When an important protocol deviation is reported, the sponsor will determine whether to discontinue the patient from the study or permit the patient to continue in the study, with documented approval from the medical expert. The decis ion will be based on ensuring the safety of the patient and preserving the integrit y of the study. A noncompliant patient may continue taking the stud y treatment only if this does not jeopardize the patientâ€™s safety . The sponsor will assess each protocol d eviation and decide whether any of these noncompliances should be reported to the Regulatory Authorit y as a serious breach of Good Clinical Practice ( GCP) and the protocol. Changes in the inclusion and exclusion criteria of the protocol are notprospectivel y granted b y the sponsor. If the investigational center personnel learn that a patient who did not meet protocol inclusion and exclusion criteria was entered in a study , they must immediately inform the sponsor of the protocol deviation. A dev iation from the eligibility criteria will alway s result in study drug discontinuation in case the patient has not been dosed. In case a patient who was wrongly randomized has already started taking the study drug, a risk/benefit evaluation has to take plac e, and a strong clinical justification must be provided in case the patient is not withdrawn from the study drug. If such patient has alread y completed the study or has withdrawn early, no action will be taken, but the deviation will be recorded. For COVID -19 updates, refer to Appendix N. Information to Study Personnel The investigator is responsible for giving information about the study to all personnel members involved in the study or in any element of patient management, both before starting the study and"
230,page_230,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 230during the course of the study (eg, when new personnel become involved). The investigator must ensure that all stud y personnel are qualified b y education, experience, and training to perform their specific task. These study personnel members must be listed on the investigational center authorization form, which includes a clear description of each personnel memberâ€™s responsibilities. This list must be updated throughout the study , as necessary . The study monitor is responsible for explaining the protocol to all study personnel, including the investigator, and for ensuring they comply with the protocol. Study Monitoring To ensure compliance with GCP g uidelines, the study monitor or representative is responsible for ensuring that patients have signed the informed consent form and the study is conducted according to applicable Standard Operating Procedures (SOPs), the protocol, and other written instruct ions and regulatory guidelines. The study monitor is the primary association between the sponsor and the investigator. The main responsibilities of the study monitor(s) are to visit the investigator before, during, and after the study to ensure adherence t o the protocol, that all data are correctl y and completely recorded and reported, and that informed consent is obtained and recorded for all patients before they participate in the study and when changes to the consent form are warranted, in accordance wit h IEC/IRB approvals. The study monitor(s) will contact the investigator and visit the investigational center according to the monitoring plan. The study monitor will be permitted to review and verify the various records (CRFs and other pertinent source data records, including specific electronic source document relating to the study ) to verify adherence to the protocol and to ensure the completeness, consistency, and accuracy of the data being recorded. As part of the supervision of study progress, other sponsor personnel may , on request, accompan y the study monitor on visits to the investigational center. The investigator and assisting personnel must agree to cooperate with the study monitor to resolve any problems, errors, or possible misunderstandings con cerning the findings detected during the course of these monitoring visits or provided in follow- up written communication. For COVID -19 updates, refer to A ppendix N. Audit and Inspection The sponsor may audit the investigational center to evaluate study conduct and compliance with protocols, SOPs, GCP guidelines, and applicable regulatory requirements. The sponsorâ€™s Global Clinical Quality Assurance, i ndependent of Global Specialty Development, is responsible for determining the need for (and timing of) an investigational center audit. The investigator must accept that CAs and sponsor representatives may conduct inspections and audits to verify complian ce with GCP guidelines."
231,page_231,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 231APPENDIX D.ETHICS Informed Consent and Assent The investigator, or a qualified person designated by the investigator, should fully inform the patient (and the parent/legall y acceptable representative, as applicable) of all pertinent aspects of the study , including the written information approved by the Independent Ethics Committee/I nstitutional Review Board (IEC/I RB). All written and oral information about the study will be provided in a language as nontechnical as practical to be understood b y the patient and the parent/legally acceptable representative, as applicable. The patient and the parent/legally acceptable representative, as applicable, should be given ample time and opportunity to inquire about details of the study and to decide wheth er or not to participate in the study . The above should be detailed in the source documents. Written informed consent will be obtained from each patient before any study specific procedures or assessments are done and after the aims, methods, anticipated b enefits, and potential hazards are explained. The patientâ€™s willingness to participate in the study will be documented in the informed consent form (I CF), which will be signed and personall y dated b y the patient and by the person who conducted the informed consent discussion. The investigator will keep the original ICFs, and copies will be given to the patients. It will also be explained to the patients that the patient is free to refuse participation in the study and free to withdraw from the study at an y time without prejudice to future treatment. For adolescent patients, a personally signed and dated informed consent form will be provided by the parent/legall y acceptable representative, and a signed and dated assent form will be provided b y each patient before an y stud y specific procedures or assessments are done and after the aims, methods, anticipated benefits, and potential hazards are explained according to IEC/IRB requirements. The forms will be signed and dated also b y the person who conducted the informed consent discussion. The investigator will keep the original informed consent and assent forms, and copies will be given to the patients (and the parent/legall y acceptable representative). It will also be explained to the patients (and the parent/le gally acceptable representative) that they are free to refuse participation in the study and free to withdraw from the study at any time without prejudice to future treatment. Competent Authorities and Independent Ethics Committees/Institutional Review Boa rds Before this study starts, the protocol will be submitted to the national competent authority (CA) and to the respective IEC/I RB for review. As required, the study will not start at a given investigational center before the IEC/IRB and CA (as applicable) for the investigational center give written approval or a favorable opinion. Confidentiality Regarding Study Patients The investigator must ensure that the privacy of the patients, including their identity and all personal medical information, will be maintained at all times. I n case report forms (CRFs) and other documents or image material submitted to the sponsor, patients will be identified not by their names, but b y an identification number."
232,page_232,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 232Personal medical information may be reviewed for t he purpose of patient safet y or for verify ing data in the source and the CRF. This review may be conducted b y the study monitor, properly authorized persons on behalf of the sponsor, Global Quality Assurance, or CAs. Personal medical information will alway s be treated as confidential. Registration of the Clinical Study In compliance with national and local regulations and in accordance with Teva standard procedures, this clinical study will be registered on trials registry websites."
233,page_233,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 233APPENDIX E. BIRTH CONTROL METHODS AN D PREGNANCY TESTING Contraception recommendations and pregnancy testing should encompass all investigational medicinal product (IMPs) as well as non -IMPs, eg, background therap y, and the measures to be followed should be based on the medicinal product with highest risk. Assessment of likelihood of possible interaction between IMP or concomitant medications and hormonal contraception should be conducted. Hormonal contraception may be susceptible to interaction with the IMP, which may reduce the efficacy of the contraception method, eg, cytochrome P4504A inducers. In case of suspected interaction, hormonal contraceptive alone may not be sufficient. In the absence of clinical pharmacokinetic interaction study data in IMPs with demonstrated or suspected human te ratogenicity /fetotoxicity , recommendation for use of hormonal contraceptives should be thoroughl y justified by the sponsor. Additional contraceptive methods, including supplementary barrier methods, may be considered. Women/girls of childbearing potential are defined as: ï‚·not surgically (documented hy sterectomy , bilateral oophorectomy, or bilateral salpingectomy ) or congenitally sterile ï‚·not postmenopausal Postmenopausal women are defined as: ï‚·1year postmenopausal (no menses for 12 months without an alternati ve medical cause plus an increased concentration of follicle stimulating hormone [FSH] of more than 35 U/L) in women not using hormonal contraception or hormonal replacement therap y Recommendations for application of birth control methods: ï‚·IMP with possibl e human teratogenicit y/fetotoxicity ï€­Highl y effective method of contraception ï€­Contraception during treatment and until the end of relevant sy stemic exposure ï€­Additional pregnancy testing to be considered; as a minimum, at the end of relevant s ystemic exposur e ï€­In each case of delayed menstrual period (over 1 month between menstruations) confirmation of absence of pregnancy is strongly recommended. This recommendation also applies to women of childbearing potential with infrequent or irregular menstrual cycles. Description of highly effective birth control methods: Highl y effective birth control methods are methods that can achieve a failure rate of less than 1% per year when used consistently and correctly . Such methods include the following: ï‚·Combined estrogen and progestogen hormonal contraception (oral, intravaginal, transdermal) associated with inhibition of ovulation; these should be initiated at least"
234,page_234,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 2347days (for I MPs without suspected teratogenicit y/genotoxicity ) and 1 month (for IMPs pot entially teratogenic/genotoxic) before the first dose of IMP. ï‚·Progestogen -only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation; these should be initiated at least 7 days (for IMPs without suspected teratogenicity /genotoxicity ) and 1 month (for IMPs potentially teratogenic/genotoxic) before the first dose of IMP. ï‚·Intrauterine device and intrauterine hormone-releasing s ystem need to be in place at least 2 months before screening. ï‚·Bilateral tubal occlus ion ï‚·Vasectomized partner provided that he is the sole sexual partner and has received medical assessment of the surgical process ï‚·Sexual abstinence is only considered a highl y effective method if defined as refraining from heterosexual intercourse in the de fined period. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifesty le of the patient. ï‚·Periodic abstinence (eg, calendar, ovulation, sy mptothermal, post -ovulation met hods), declaration of abstinence for the duration of a study, and withdrawal are not acceptable methods of contraception (according to Medicines and Healthcare Products Regulatory Agency , MHRA). Male contraception: Male patients must alway s use a condom. Vasectomy: Use of contraceptive methods applies also to vasectomized men, because of the risk associated with transfer of a drug via seminal fluid. Pregnant female partners of male study participants: Male study participants must use condoms during intercou rse if their female partners are pregnant."
235,page_235,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 235APPENDIX F.LOST TO FOLLOW-UP A patient will be considered lost to follow -up if he/she repeatedl y fails to return for scheduled visits and is unable to be contacted b y the investigational center. The following actions must be taken if a patient fails to return to the investigational center for a required stud y visit: ï‚·The investigational center must attempt to contact the patient and/or caregiver and reschedule the missed visit as soon as possible and counsel the patient on the importance of maintaining the assigned visit schedule and ascertain whether or not the patient wishes to and/or should continue in the study . ï‚·In cases in which the patient is deemed lost to follow- up, the investigator or designee must make every effort to regain contact with the patient and/or caregiver (where possible, 3 telephone calls and, if necessary , a certified letter to the patientâ€™s last known mailing address or local equivalent methods). These contact attempts should be documented in the patientâ€™ s medical record. ï‚·Should the patient and/or caregiver continue to be unreachable, he/she will be considered to have withdrawn from the study with a primary reason of â€œlost to follow -up.â€ For COVID -19 updates, refer to Appendix N."
236,page_236,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 236APPENDIX G.LIST OF PROHIBITED M EDICATIONS List of Prohibited Medications Affecting Cytochrome P450 A partial list of drugs that are either strong/moderate inhibitors of cy tochrome P450 (CYP) 2D6 or strong inducers of CYP3A4 and/or P -glycoprotein (P -gp) are presented below: Table 9: List of Prohibited Medications Affecting Cytochrome P450 Therapeutic class Strong and m oderate CYP2D6 inhibitorsaStrong CYP3A4 and/or P -gp inducersb Anti-arrhythmics Quinidine, dronedarone AntidepressantscFluoxetine, paroxetine , duloxetine Kinase inhibitors Dacom itinib Recreational drugs/ psychostimulantsEcstasy Calcimimetic agents Cinacalcet Protease inhibitors Tipranavir/ritonavir Antifungals Terbinafine Monoamine oxidase inhibitors Moclobemide Beta 3 -adrenoreceptor agonists Mirabegron Fusion inhibitors AMD070 Glucosylceramide synthase inhibitorsEliglustat Anti-emetics Rolapitant Antibiotics Rifampin, rifabutin Antineoplastics Mitotane Antilipemics Avasimibe Anticonvulsants Phenytoin, carbamazepine, phenobarbital Anti-androgens Enzalutamide Dopamine -Norepinephrine reuptake inhibitorsBupropion Others Lumacaftor Herbal medications St Johnâ€™s Wort aThe use of strong or moderate inhibitors of CYP2D6 is prohibited w ithin 14 days or 5 half -lives (whichever occurs last) prior to first oral risperidone dose and throughout the study. bThe use of strong inducers of CYP3A4 and/or P -glycoprotein is prohibited within 30 days prior to first oral risperidone dose and throughout the study. cThese antidepressants are permitted if the patient was on a stable dose for at least 3 months prior to screening (no dose changes or new administrations will be permitted during the study). CYP2D6=cytochrome P450 2D6; CYP3A4=cytochrome P450 3A4; P-gp=P -glycoprotein."
237,page_237,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 237Moreover, the use of the following medications is prohibited throughout the study : ï‚·risperidone (except when given according to the study protocol) ï‚·antipsy chotics other than the study treatments ï€­Except during the conversion and stabilization stage (Stage 1 ), and only if required for conversion from the previous antips ychotics to oral risperidone. ï‚·dopamine reuptake inhibitors or prescription psy chostimulants within 30 day s prior to first oral risperidone dose ï‚·opiates or opiate -containing analgesics within 14 day s prior to first oral risperidone dose medications In addition to those listed above, medications that may be expected to significantly interfere with the metabolism or excretion of risperidone and/or 9-O H risperidone, may be associated with a significant drug interaction with risperidone, or may pose a significant risk to patientsâ€™ participation in the study (eg, chloroquine, which is a QTc prolongator) are prohibited."
238,page_238,Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 238
239,page_239,Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 239
240,page_240,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 240APPENDIX J.PHARMACOGENETIC ASSESSMENTS A blood sample (6 mL) for pharmacogenetic assessment will be coll ected from all patients who signed the informed consent for pharmacogenetic assessments at the time point detailed in Table 2, unless the patient declines testing or local regulations prohibit testing. All blood tubes will be labeled with the patient code number . If required by local regulations, following DNA extraction from the pharmacogenetic blood sample, the DNA sample will be labeled with a new code (ie, double coding). . The candidate genes may be related to pharmacokinetics, safet y features, drug mec hanism of action, schizophrenia, or related diseases. The final list of genes that will be investigated will be selected at a later stage before the anal ysis to allow for updating with the latest scientific evidence. Genetic anal ysis could also include seq uencing of the whole genome, if warranted. The planned pharmacogenetic anal ysis and results of other potential genetic factors will be detailed in a separate document. Pharmacogenetic assessment will be performed only for investigations related to schizop hrenia, related diseases, or various aspects of understanding response to the test drug or related drugs (other antips ychotics). Details on processes for collection and shipment of these samples can be found in the procedural manual."
241,page_241,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 241APPENDIX K.PRODUCT COMPLAINTS Clinical Product Complaints A clinical product complaint is defined as a problem or potential problem with the phy sical quality or characteristics of clinical investigational medicinal product (IMP) supplies or clinical device supplies used in a clinical res earch stud y sponsored b y Teva. Examples of a product complaint include, but are not limited to: ï‚·suspected contamination ï‚·questionable stability (eg, color change, flaking, crumbling, etc) ï‚·defective components ï‚·missing or extra units (eg, primary container is received at the investigational center with more or less than the designated number of units inside) ï‚·incorrect packaging or incorrect or missing labeling/labels ï‚·unexpected or unanticipated taste or odor, or both ï‚·device not working correctly or appears defective in some manner ï‚·excessive force to inject Each investigational center will be responsible for reporting a possible clinical product complaint by completing the product complaint form provided by Teva and emailing it to clinical.productcomplaints@t evapharm.com within 48 hours of becoming aware of the issue. For complaints involving a device or other retrievable item, it is required that the device (or item) be sent back to the sponsor for investigative testing whenever possible. For complaints invol ving an IMP, all relevant samples (eg, the remainder of the patientâ€™s IMP supply ) should be sent back to the sponsor for investigative testing whenever possible. 1. Product Complaint Information Needed from the Investigational Center In the event that the pro duct complaint form cannot be completed, the investigator will provide the following information, as available: ï‚·investigational center number and principal investigator name ï‚·name, phone number, and address of the source of the complaint ï‚·clinical protocol n umber ï‚·patient identifier (patient study number) and corresponding visit numbers, if applicable ï‚·product name and strength for open -label studies ï‚·patient number, bottle, and kit numbers (if applicable) for double -blind or open -label studies ï‚·product available for return (y es/no)"
242,page_242,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 242ï‚·product was taken or used according to protocol (y es/no) ï‚·description or nature of complaint ï‚·associated serious adverse event (y es/no) ï‚·clinical supplies unblinded (for blinded studies) [yes/no] ï‚·date and name of person receiving the comp laint Note: Reporting a product complaint must not be delay ed even if not all the required information can be obtained immediately . Known information must be reported immediately . The sponsor will collaborate with the investigator to obtain an y outstanding information. Handling of Investigational Medicinal Product(s) at the Investigational Center(s) The investigator is responsible for retaining the product in question in a location separate from the investigatorâ€™s clinical study supplies. The sponsor may request that the investigator return the product for further evaluation and/or anal ysis. If this is necessary , the clinical study monitor or designee will provide the information needed for returning the IMP. If it is determined that the investigational cent er must return all I MP, the sponsor will provide the information needed to handle the return. The integrity of the randomization code and corresponding blinded clinical supplies will be maintained whenever possible. A serious adverse event or the potential for a product quality problem existing bey ond the scope of the complaint may be a reason to unblind the clinical supplies for an affected patient. Adverse Events or Serious Adverse Events Associated with a Product Complaint If there is an adverse event or serious adverse event due to product complaint, the protocol should be followed for recording and reporting (Section 7.1.2 and Section 7.1.5.3 of the protocol , respectivel y). Documenting a Product Complaint The investigator will record in the source documentation a description of the product complaint and an y actions taken to resolve the complaint and to preserve the safety of the patient. Once the complaint has been investigated by the sponsor and the invest igator, if necessary , an event closure letter may be sent to the investigational center where the complaint originated or to all investigational centers using the product. Medical device incidents, including those resulting from malfunctions of the device, must be detected, documented, and reported b y the investigator throughout the study."
243,page_243,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 243APPENDIX L.DATA MANAGEMENT AND RECORD KEEPING Direct Access to Source Data and Documents All patient data must have supportive original source documentation in the medical records, or equivalent, before they are transcribed to the case report form (CRF). Data may not be recorded directly on the CRF and considered as source data unless the sponsor provides written instructions specify ing which data are permitted to be recorded directl y to the CRF. If data are processed from other institutions or by other means (eg, clinical laboratory , central image center, electronic diary data), the results will be sent to the investigational center, where they will be retained but not transcribed to the CRF, unless otherwise noted in the protocol. These data may also be sent electronically to the sponsor (or organization performing data management). The medical experts, study monitors, auditors, Independent Ethics Committee/I nstitutional Review Board (IEC/I RB), and inspectors from competent authority (CA) (or their agents) will be given direct access to source data and documents (eg, medical charts/records, laboratory test results, printouts, videotapes) for source data verification, provided that pat ient confidentiality is maintained in accordance with national and local requirements. The investigator must maintain the original records (ie, source documents) of each patientâ€™s dat a at all times. The investigator must maintain a confidential patient ide ntification list that allows the unambiguous identification of each patient. Data Collection Data will be collected using CRFs that are specifically designed for this study . The data collected on the CRFs will be captured in a clinical data management s ystem (CDMS) that meets the technical requirements described in 21 Code of Federal Regulations Part11 (USA) and documents of other concerned CAs. Before using the CDMS, it will be fully validated, and all users will receive training on the s ystem and study -specific training. After they are trained, users will be provided with individual sy stem access rights. Data will be collected at the investigational center by appropriatel y designated and trained personnel, and CRFs must be completed for each patient who p rovided informed consent. Patient identity should not be discernible from the data provided on the CRF. If data are processed from other sources (eg, central laboratory, bioanal ytical laboratory , central image center, electronic diary data, electronic patient -reported outcome [ePRO] tablet), these data will be sent to the investigational center, where they will be retained but not transcribed to the CRF, unless otherwise noted in the protocol. These data may also be sent electronicall y to the sponsor (or or ganization performing data management). All patient data must have supportive original source documentation in the medical records, or equivalent, before they are transcribed to the CRF. Data may not be recorded directly on the CRF and considered as source data unless the sponsor provides written instructions specify ing which data are permitted to be recorded directly to the CRF."
244,page_244,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 244For patients who enter a study but do not meet entry criteria, at a minimum, data for screening failure reason, demography , and adverse events from the time of informed consent will be entered in the CRF. Data Quality C ontrol Data Management is responsible for the accuracy , quality , completeness, and internal consistency of the data from this study . Oversight will be carried out as described in the sponsorâ€™s Standard Operating Procedures (SOPs) for clinical studies. Day -to-day data management tasks for this study are delegated to a contract organization, and these functions may be carried out as described in the SOPs for clinical st udies at that organization. These SOPs will be reviewed b y the sponsor before the start of data management activities. Data will be verified b y the study monitor using the data source and reviewed by Data Management using both automated logical checks and manual review. Data identified as erroneous or data that are missing will be referred to the investigational center for resolution through data queries. Any necessary changes will be made in the clinical database, and data review and validation procedures will be repeated as needed. Data from external sources will be compared with the information available in the CDMS and an y discrepancies will be queried. Applicable terms will be coded according to the coding conventions for this study . At the conclusion o f the study , the CDMS and all other study data will be locked to further additions or corrections. Locking the stud y data represents the acknowledgement that all data have been captured and confirmed as accurate. All data collected will be approved by the investigator at the investigational center. This approval acknowledges the investigatorâ€™s review and acceptance of the data as being complete and accurate. Archiving of Case Report Forms and Source Documents Sponsor Responsibilities The original CRFs will be archived b y the sponsor. I nvestigational center -specific CRFs will be provided to the respective investigational centers for archiving. Investigator Responsibilities The investigator must maintain all written and electronic records, accounts, not es, rep orts, and data related to the study and any additional records required to be maintained under country , state/province, or national and local laws, including, but not limited to : ï‚·full case histories ï‚·signed informed consent forms ï‚·patient identification lists ï‚·CRFs for each patient on a per -visit basis ï‚·data from other sources (eg, central laboratory , bioanal ytical laboratory , central image center, electronic diary ) ï‚·safet y reports ï‚·financial disclosure reports/forms"
245,page_245,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 245ï‚·reports of receipt, use, and disposition of the IMPs ï‚·copies of all correspondence with sponsor, the IEC/I RB, and an y CA The investigator will retain all records related to the study and any additional records required, as indicated b y the protocol and according to applicable laws and regulations, un til the contract research organization or sponsor notifies the institution in writing that records may be destro yed. If, after 25 years from study completion, or earlier in the case of the investigational center closing or going out of business, the invest igator reasonabl y determines that study record retention has become unduly burdensome, and the sponsor has not provided written notification of destruction, then the investigator may submit a written request to the sponsor at least 60 days before an y plann ed disposition of study records. After receipt of such request, the sponsor may make arrangements for appropriate archival or disposition, including requiring that the investigator deliver such records to the sponsor. The investigator shall notify the spon sor of any accidental loss or destruction of study records."
246,page_246,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 246APPENDIX M.PUBLICATION POLICY All unpublished information given to the investigator by the sponsor shall not be published or disclosed to a third part y without the prior written consent of the sponsor. The r esults of this study may be published or presented at scientific meetings. If this is foreseen, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission. This allows the sponsor to protect proprietary information and to provide comments. The sponsor will comply with the requirements for publication of study results: â€œRecommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journalsâ€ (www.I CMJE.org). Publication of the results wi ll occur in a timely manner according to applicable regulations. I n accordance with standard editorial and ethical practice, the sponsor will generally support publication of multicenter studies only in their entiret y and not as individual investigational center data. In this case, a coordinating investigator will be designated b y mutual agreement. Authorship will be determined by mutual agreement and in line with I nternational Committee of Medical Journal Editors authorship requirements: ï‚·substantial contri butions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work ï‚·drafting the work or revising it criticall y for important intellectual content ï‚·final approval of the version to be published ï‚·agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrit y of an y part of the work are appropriately investigated and resolved The publications committee established b y the sponsor will oversee this process. Additional publications may follow. Policies regarding the publication of the study results are defined in the financial agreement. No patent applications based on the results of the study may be made by the investigator nor may assistance be given to any third party to make such an application without the written authorization of the sponsor."
247,page_247,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 247APPENDIX N.MANAGEMENT OF STUDY ACTIVITIES DURING COVID -19 This appendix is to address the modification set- up in study conduct during the outbreak of the Coronavirus disease 20 19 (COVID -19) pandemic. The changes will be effective for the period of the COVID- 19 pandemic and when the situation at specific sites/countries allow s the return to regular study activities, this appendix will be void for those countries/site s. The follow ing sections of the protocol are affected: Section 3.1. General Study Design and Study Schematic Diagram; Section 3.5. Schedule of Study Procedures and Assessments In the event of an emergency situation (eg, the Coronavirus disease 2019 [ COVID -19] pandemi c), in case a patient cannot return to the clinic for the scheduled visits (eg, due to quarantine, isolation, patient's concern, or closure of the site clinic), remote assessment of efficacy and safet y scales via TC and/or videoconference (VC), with VC being the preferred method, may be allowed. The results of the scale rating will be directly entered into the eCRF per the usual process;o therwise, subject status should be NOT COMPL ETED DUE TO: 'Other' 'COVID -19 logistical reasons prevented patient's continuation in the study '. Ifthe patient does not continue in the study due to site closure, the subject status should be NOT COMPL ETED DUE TO: 'Other' 'COVID -19 logistical reasons prevented patient's continuation in the study '. In the event that a patient completes the oral stabilization stage (Stage 1) but cannot come to the site for the baseline visit for randomization (eg, due to quarantine, isolation, patient's concern or closure of the site clinic), it may be possible to extend the duration of Stage 1 on a case -by-case basis, following discussion between the investigator and the sponsor stud y physician. In addition, the test and placebo IMP (as applicable) may be administered according to the schedule outlined in the protocol by unblinded study personne l, or home care service providers trained according to study specifications, via visits to the patient's place of residence. The patient's consent to the home visit will be collected in advance, where possible, by phone and documented in the patientâ€™s char t. The IMP will be transported, prepared , and administered in a blinded fashion per the conditions specified in the pharmacy manual and the injection instructions , provided that proper barrier precautions can be effectivel y implemented to minimize any risk of exposure, and that site staff follow CDC guidelines and local health authority procedures . Modifications to other procedures and assessments (ECG, lab sample collection, pharmacokinetic sampling, etc) will be performed per implemented contingency measures according to sponsor instructions and the corresponding manual. For example, if central lab samples cannot be collected for safet y assessments, sites may have patients visit a local reference lab to perform the assessments. At-home nursing visits may be used to perform safet y assessments such as ECG, laboratory sample collection, vital signs, an d nursing assessments to determine an y new adverse events."
248,page_248,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 248These measures will be implemented on a case- by-case basis, and onl y when and where they are warranted due to the emergency situation. Preferably , the original protocol instructions willbe follow ed whenever the new instructions are not required. Section 5.1.1. Test Investigational Medicinal Product; Section 5.1.2. Placebo Investigational Medicinal Product; Table 4. Investigational Medicinal Products Used in the Study; Section 5.2.1. Storage and Security; Section 5.2.3 Accountability Any IMP trans ported for home administration will be returned to the clinic to maintain accountability .Used s yringes will be disposed of immediately after administration in accordance with site (or the group homeâ€™s) SOP. Section 5.9. Randomization and Blinding In the event of an emergency situation (eg, COVID -19 pandemic), in case off- site IMP administration is warranted, the IMP will be transported, prepared , and administered in a blinded fashion per the conditions specified in the pharmacy manual and the injection in structions, provided that proper barrier precautions can be effectivel y implemented to minimize any risk of exposure ,and that site staff follow CDC guidelines and local health authority procedures . Section 6. Assessment of Efficacy In the event of an eme rgency situation (eg, the COVID -19 pandemic), in case a patient cannot return to the clinic for the scheduled visits (eg, due to quarantine, isolation, patient's concern, or closure of the site clinic), remote assessment of efficacy scales via TC and/or VC , with VC being the preferred method, may be allowed. The results of the scale rating will be directl y entered into the eCRF per the usual process. These measures will be implemented on a case- by-case basis, and onl y when and where they are warranted due to the emergency situation. Preferably , the original protocol instructions willbe followed whenever the new instructions are not required. Section 7. Assessment of Safety In the event of an emergency situation (eg, the COVID -19 pandemic), in case a patient cannot return to the clinic for the scheduled visits (eg, due to quarantine, isolation, patient's concern, or closure of the site clinic), remote a ssessment of safety scales (as well as inquiries regarding adverse events and use of concomitant medication) via TC and/or VC, with VC being the preferred method, may be allowed. The results of the scale rating will be directl y entered into the eCRF per the usual process. Modifications to other procedures and assessments (ECG, lab sample collection, pharmacokinetic sampling, etc) will be performed per implemented contingency measures according to sponsor instructions and the corresponding manual. These m easures will be implemented on a case -by-case basis, and onl y when and where they are warranted due to the emergency situation. Preferably , the original protocol instructions will be followed whenever the new instructions are not required."
249,page_249,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 249Section 7.4. Cli nical Laboratory Tests If central lab samples cannot be collected for safety assessments, sites may have a home nursing visit to collect the required samples or have patients visit a local reference lab to perform the assessments. Section 7.6. Vital Signs; 7.7. Electrocardiography At-home nursing visits may be used to perform safety assessments such as ECG, vital signs, and nursing assessments to determine an y new adverse events. Section 8.1. Pharmacokinetic Assessment If pharmacokinetic samples cannot be c ollected due to limitations in ability to carry out the procedure, an at -home nursing vendor or site personnel could perform the sample collection, processing and shipment to the CRO (I CON) central lab via appropriate courier. The samples should be collect ed and processed as described in supporting documentation provided to the vendor or site nurses as applicable. Section 9.5.4.2. Sensitivity Analysis Sensitivity and supplementary anal yses will be conducted to evaluate the impact of the change to remote monitoring (VC visits) and the impact of the COVID -19 pandemic on the impending relapse and rating scales. The anal ysis will include subgroup anal ysis (eg, pre, during and post COVID -19 pandemic outbreak, where each patient will be classified into one of t he levels), a multivariate model (eg ,Cox model with time dependent covariate for COVID -19), and/or imputation methodology for patients' attrition due to the COVID -19 pandemic ,as appropriate and if data permit. Details of the supplementary and sensitivity analyses will be presented in the statistical analy sis plan or addendum thereof, following a blinded review meeting prior to database lock. Section 10. Quality Control and Quality Assurance Deviations from the study conduct due to emergency situations (eg, the COVID -19 pandemic), including implemented contingency measures and their impact ( eg, patient discontinuation from treatment with investigational product and/or study, alternative procedures used to collect critical safet y and/or efficacy data, etc ), will be described in the appropriate sections of the CSR as applicable. Appendix C. Quality Control and Quality Assurance Protocol Deviations Deviations from the study conduct due to emergency situations (eg, the COVID -19 pandemic), including implemented contingency measures and their impact ( eg, patient discontinuation from treatment with investigational product and/or study, alternative procedures used to collect critical safet y and/or efficacy data, etc) , will be described in the appropriate sections of the CSR as applicable. Study Monitoring In case of an emergency situation (eg, the COVID -19 pandemic), monitors may not be able to access the investigational centers for on -site visits in a timely manner. A remote monitoring risk mitigation plan will be utilized for sites where on -site monitoring visits are not permitted due to"
250,page_250,"Placebo- Controlled Study â€“Schizophrenia Clinical Study Protocol with Amendment 03 Study TV46000- CNS -30072 250an increased public health risk, in accordance with I RB approval . Details are provided in the monitoring plan. Appendix F. Lost to Follow- Up In case of an emergency situation (eg, COVID -19 pandemic), ifa patient cannot return to the clinic for the scheduled visits, home visits may take place to mitigate the possibility of being lost to follow up. NOTE: Appendix G. List of Prohibited Medications/ Section 5.7. Prior and Concomitant Medication or Therapy Although not an operational modification per se, this is to notify that chloroquine, which is a QTc prolongator, was added to the text as an example of a prohibited medication that may pose a significant risk to patient participation in the study (see also separate entry in summary of changes). â€œIn addition to those listed above, medications that may be expected to significantly interfere with the metabolis m or excretion of risperidone and/or 9 -OH risperidone, may be associated with a significant drug interaction with risperidone, or may pose a significant risk to patientsâ€™ participation in the study (eg, chloroquine, which is a QTc prolongator) are prohibit ed.â€"
